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ABSTRACT 
 
The field of prenatal screening and diagnosis has developed rapidly over the past half-
century, enabling possibilities for detecting anomalies in reproduction that were never before 
contemplated. A simple blood sample can aid in the identification of several conditions in the 
fetus early in the pregnancy. If a fetus is found to be affected by Down syndrome, anencephalus, 
spina bifida, or Edward's syndrome, a decision must then be made whether to continue or 
terminate the pregnancy. As prenatal screening becomes increasingly commonplace and part of 
routine maternal care, researchers are faced with the challenge of understanding its effects at the 
level of the population and monitoring trends over time. Greater uptake of prenatal screening, 
when followed by prenatal diagnosis and termination, has important implications for both 
congenital anomaly surveillance and infant and fetal mortality indicators. Research in Canada 
suggests that this practice has led to reductions in the congenital-anomaly specific infant 
mortality rate and increases in the stillbirth rate.(1, 2)  
 The current study is a population-based, epidemiological exploration of demographic 
predictors of maternal serum screening (MSS) and amniocentesis uptake, with special attention 
to variations in birth outcomes resulting from different patterns of use. To accomplish our 
objectives, multiple data sources (vital statistics, hospital and physician services, cytogenetic and 
MSS laboratory information) were compiled to create a comprehensive maternal-fetal-infant 
dataset. Data spanned a six-year period (2000-2005) and involved 93,171 pregnancies. A binary 
logistic regression analysis found that First Nations status, rural-urban health region of residence, 
maternal age group, and year of test all significantly predicted MSS use. Uptake was lower in 
women living in a rural health region, First Nations women, and those under 30 years of age. The 
study dataset identified ninety-four terminations of pregnancy following detection of a fetal 
anomaly (TOPFA), which led to a lower live birth prevalence of infants with Down syndrome, 
Trisomy 18, and anencephalus. While a significant increasing trend was observed for the overall 
infant mortality rate in Saskatchewan between 2001-2005, a clear trend in one direction or the 
other could not be seen in regards to infant deaths due to congenital anomaly. 
 First Nations status and maternal age were important predictors of both MSS and 
amniocentesis testing, and appeared to influence the decision to continue or terminate an affected 
pregnancy. The fact that First Nations women were less likely to screen (9.6% vs. 28.4%) and to 
have diagnostic follow-up testing (18.5% vs. 33.5%), meant that they were less likely to obtain a 
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prenatal diagnosis when the fetus had a chromosomal anomaly compared to other women (8.3% 
vs. 27.0%). This resulted in a lower TOPFA rate compare to the rest of the population (0.64 vs. 
1.34, per 1,000 pregnancies, respectively) and a smaller difference between the live birth 
prevalence and incidence of Down syndrome and Trisomy 18 for First Nations women. 
 Women under 30 years of age were much less likely to receive a prenatal diagnosis when 
a chromosomal anomaly was present (18.4% vs. 31.8%). While risk for a chromosomal anomaly 
is considerably lower for younger mothers, 53.5% of all pregnancies with chromosomal 
anomalies and 40.7% of DS pregnancies belonged to this group.   
 Consistent with other studies pregnancy termination rates following a prenatal congenital 
anomaly diagnosis are high (eg. 74.1% of prenatally diagnosed Down syndrome or Trisomy 18 
cases), but these rates may be misleading in that they are based on women who chose to proceed 
to prenatal diagnosis. The fact that two-thirds (67.3%) of Saskatchewan women who received an 
increased-risk result declined amniocentesis, helps to put this finding into context.  
Strong surveillance systems and reasonable access to research datasets will be an on-
going challenge for the province of Saskatchewan and should be viewed as a priority. 
Pregnancies and congenital anomalies are two particularly challenging outcomes to study in the 
absence of perinatal and congenital anomaly surveillance systems. Still pregnancies that never 
reach term must be accounted for, in order to describe the true state of maternal-fetal-infant 
health and to study its determinants. While our study was able to identify some interesting trends 
and patterns, it is only a snapshot in time. Key to the production of useful surveillance and 
evaluation is timely information. The current system is not timely, nor is it user-friendly for 
researchers, health regions or governments. Data compilation for the current study was a 
gruelling and cumbersome process taking more than five years to complete. A provincial 
overhaul is warranted in both the mechanism by which researchers access data and in the 
handling of data. The Better Outcomes Registry & Network (BORN) in Ontario is an innovative 
perinatal and congenital anomaly surveillance system worthy of modelling.(3)  
Academic papers in non-ethics' journals typically focus on the technical or programmatic 
aspects of screening and do not effectively alert the reader to the complex and profound moral 
dilemmas raised by the practice. A discussion of ethics was felt necessary to ensure a well-
rounded portrayal of the issue, putting findings into context and helping to ensure their moral 
relevance did not remain hidden behind the scientific complexities. Here I lay out the themes of 
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the major arguments in a descriptive manner, recognizing that volumes have been written on the 
ethics of both screening and abortion. A major ethical tension arising within the context of 
population based prenatal screening is the tension between community morality and the principle 
of respect for personal autonomy. Prenatal screening and selective termination have been framed 
as a purely private or medical matter, thereby deemphasizing the social context in which the 
practice has materialized and the importance of community values. I consider how a broader 
sociological perspective, one that takes into account the relevance of community values and 
limitations of the clinical encounter, could inform key practice and policy issues involving 
prenatal screening. It is my position that the community's voice must be invited to the 
conversation and public engagement processes should occur prior to any additional expansion in 
programming. I end with a look at how the community’s voice might be better heard on key 
issues, even those issues that at first glance seem to be the problems of individuals. As Rayna 
Rapp (2000) (4) poignantly observed, women today are 'moral pioneers' not by choice, but by 
necessity. 
By elucidating the effects of prenatal screening and the extent of the practice of selective 
termination in the province, the true occurrence of important categories of congenital anomalies 
in our province can be observed. Without this knowledge it is very difficult to identify real 
increases or decreases in fetal and infant mortality over time as the etiologies are complex. 
Evidence suggests a large and increasing impact of TOPFA on population-based birth and 
mortality statistics nationally, whereas in Saskatchewan the effect appears to be less pronounced. 
Appreciation of the intervening effect of new reproductive technologies will be increasingly 
important to accurate surveillance, research, and evaluation as this field continues to expand. 
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DEFINITIONS 
 
Congenital anomaly - An abnormality of structure, function or body metabolism that is present  
   at birth (even if not diagnosed until later in life) and results in physical or  
   mental disability.
1
  
 
Gestation   - Development of the fetus from the first day of the last period until birth,  
   40 weeks.
2
 
 
Infant mortality - Death in the first year of life (0-364 days)
3
 
 
Live birth   - "... the complete expulsion or extraction from the mother, irrespective of  
   the duration of the pregnancy, of a product of conception in which, after  
   the expulsion or extraction, there is breathing, beating of the heart,   
   pulsation of the umbilical cord or unmistakable movement of voluntary  
   muscle, whether or not the umbilical cord is cut or the placenta is   
   attached."
4
  
 
Medical abortion  - A medical procedure (whether by drugs or surgery) meant to destroy the 
   fetus or embryo. Also referred to as a termination of pregnancy, or   
   therapeutic, surgical or induced abortion.  
 
Neonatal  - First 27 days after birth
3
 
 
Postneonatal   - 28 to 364 days after birth
3
 
 
Prenatal   - Before birth
2
  
 
Spontaneous  - A clinically recognized natural pregnancy loss before the fetus is 20 
abortion                      weeks or weighs 500 grams.
5
   
 
Stillbirth  -  "...the complete expulsion or extraction from the mother after at least 20  
   weeks' pregnancy, or after attaining a weight of at least 500 grams, of a  
   product of conception in which, after the expulsion or extraction, there is  
   no breathing, beating of the heart, pulsation of the umbilical cord or  
   unmistakable movement of voluntary muscle."
2
   
 
Termination of  - A medical abortion performed because of a known or suspected   
pregnancy for condition posing serious threats to the quality of life of the child 
fetal anomaly  and/or undesirable to the mother.
                                               
1 March of Dimes Resource Center. Birth Defects. 1998. (Available www.modimes.org). 
2 Tiran D. (1997). Midwives’ Dictionary. (9th ED). London, UK: Bailliere Tindall.  
3 Public Health Agency of Canada. Canadian Perinatal Health Report - 2008 Edition. Ottawa 2008. 
4 Vital Statistics Act, 1995, Saskatchewan Government. (Available at 
http://www.qp.gov.sk.ca/documents/English/Statutes/Statutes/V7-21.pdf). 
5 Regan L, Ral R. Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet 
Gynaecol 2000;14(5):839. 
 1 
 
CHAPTER 1: INTRODUCTION 
 
1.0 Introduction 
 The field of prenatal screening and diagnosis has developed rapidly over the past half-
century, enabling possibilities for detecting anomalies in reproduction that were never before 
contemplated. Technology has made it possible to test a blood sample and identify several 
conditions in the fetus early in the pregnancy. Given more information about the health status of 
the fetus, women are able to make decisions not available to them in the past, including whether 
to continue or terminate pregnancies
6
 affected by congenital anomalies. These new choices, and 
the act of choosing, are fraught with ethical and moral dilemmas. As prenatal screening becomes 
increasingly commonplace and part of routine maternal care, researchers are faced with the 
challenge of understanding its effects at the level of the population and monitoring trends over 
time. Greater uptake of prenatal screening, when followed by prenatal diagnosis and termination, 
has important implications for congenital anomaly (CA) surveillance and the interpretation of 
infant and fetal mortality outcomes. Pregnancies that never reach term must be counted in order 
to describe the true state of maternal-fetal-infant health and to study its determinants.  
The national live-birth prevalence of important categories of congenital anomalies 
(including Down syndrome, hypoplastic left heart syndrome, neural tube defects, and limb 
reduction defects) have either declined or stabilized since the late 1980s.(5) Prenatal screening 
and the termination of pregnancies diagnosed with a CA have been shown in some countries to 
be responsible for this stabilization (6-10); however, little is known about its impact throughout 
Canada. To date, the published literature in Canada has examined the connection between 
prenatal diagnosis and the prevalence of neural tube defects in British Columbia and Ontario.(11, 
12) Investigations by Liu, Wen, Joseph, and Kramer et al (1999-2002, 2013) (1, 2, 13-16) have 
also elucidated the relationship between pregnancy terminations following prenatal detection of 
an anomaly and trends in infant and fetal mortality. There is, however, a need for more research 
in Canada to examine the population impact of prenatal screening and diagnosis, across 
provinces and across population sub-groups. In particular, studies have not been able to directly 
link birth outcomes to information on prenatal screening and diagnosis, and reliance on birth and 
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 Termination of pregnancy is synonymous with therapeutic, surgical or medical abortion, or induced abortion.  
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death certificate data invariably leads to undercounting of pregnancy termination for reasons of a 
CA (1).  
When delivered as intended, prenatal screening is optional and each adequately informed 
woman either accepts or declines testing from their physician or midwife. The reasons for 
choosing to screen or not to screen are as complex as each individual, but also depend on many 
cultural, programmatic and system-level factors.(7, 17, 18) As such, rates of uptake of prenatal 
screening vary widely by geographic location and correlate to client and physician characterist ics 
and value systems. The fact that uptake differs across populations means that follow-up 
diagnostic testing and ultimately, termination of pregnancies for fetal anomaly
7
 (hereafter 
abbreviated to TOPFA), will both occur at differential rates. It is these differences that may 
result in variations in key population health indicators like the infant and perinatal mortality rates 
and CA birth rates; all of which provide us with important information about infant and maternal 
health and the broader determinants of health of society as a whole.  
The current dissertation research is unique in that to my knowledge it is one of the first 
instances within Canada to undertake a comprehensive examination of the direct link between 
prenatal screening uptake and outcomes at the population level, including the birth prevalence of 
major categories of CAs and infant and fetal mortality rates. The prevalence of screening at the 
population level is related to a number of factors, including access to services, physicians` 
support and knowledge of screening, and women's values, educational backgrounds, level of real 
and perceived risk, and culture.(4, 19-32) The outcomes are therefore hypothesized to vary 
according to geography, age, and ethnic group. Similar variations in mortality and CA birth 
prevalence are also anticipated.  
In recent years the infant mortality rate (IMR) has come under greater scrutiny because 
technological changes and methodological limitations threaten its utility as a global indicator of 
health and wellbeing.(33-36) Such limitations may have even severed its connections to the 
broader determinants of health. Gortmaker and Wise (1997) argue health care technologies (eg. 
neonatal intensive care services and surfactant therapy) have "altered traditional pathways of 
social influence [and] plead for recognition among infant mortality specialists [for] an 
opportunity to expand their disciplinary embrace to include the social forces that shape both the 
dimensions of medical progress and differential access to the fruits of this technical struggle".(34 
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p.158) Three main factors have led to the challenges around comparability of IMR across 
populations. First, an important methodological limitation relates to differences in birth 
registration practices across countries; second, a health system’s ability to deliver and sustain 
very low birth weight and pre-term infants may increase the pool of infants with a high mortality 
risk; and third, prenatal screening and selective termination reduces the number of high-risk 
infants, albeit inconsistently, across population sub-groups and different countries.(13-16, 33, 
36-38) All of these factors have the potential to modify the IMR, and sometimes, counterbalance 
one another. Consider the historically elevated IMR in the Aboriginal population. How much of 
the variation is due to the social determinants of health (eg. income, education, lower use of 
preventative health care) and how much is due to lower acceptance of prenatal screening by 
Aboriginal women and the subsequent lower rates of termination of pregnancy for fetal anomaly 
are important questions to parse through. While the causes of IMR are said to be strongly linked 
to factors affecting the health of entire populations, such as economic development, living 
conditions, social wellbeing, and environment (39), not enough attention has been given to its 
strong link to prenatal screening and the selective termination of pregnancies with congenital 
anomalies. The 2005 United Nations’ Human Development Report goes as far as to state: “No 
indicator captures the divergence in human development opportunity more powerfully than child 
mortality".(40 p.4) Though customarily acclaimed as a critical population health indicator, doubt 
has been cast on the utility of IMR in cross-national comparisons, leading to second guessing its 
inclusion in key national health indicator reporting.(41) An important step is to better understand 
the IMR-prenatal screening link. 
Insights into the determinants of infant and fetal mortality through research will help to 
better guide practice and policy making, which together can lead to improved overall health and 
wellbeing. By elucidating the effects of prenatal screening and the extent of the practice of 
selective termination, the true prevalence of CAs in our province will be made known. Without 
this knowledge we are not able to track real increases or decreases in CAs and sufficiently 
interpret trends in infant mortality over time. Answers to these research questions are crucial for 
accurate surveillance, research, and evaluation in our province.  
Outside of ethics' journals, much of the peer-reviewed literature on the topics of prenatal 
screening and termination of pregnancy for fetal anomaly offers the impression that there is 
nothing morally contentious being discussed. By using medical terminology and phrasing, 
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researchers present the topic in a way that masks the many layers of moral complexity inherent 
in these practices. This is not necessarily intentional, but rather a function of the publication 
process and its disciplinary focus, strict space limits, complexity of the issue, and a lack of 
familiarity with the philosophy and ethics of science. Nonetheless, ethical considerations are a 
significant and indivisible aspect of prenatal screening, and as a result, the current project will 
bring to light some of the thorny ethical questions posed by pregnancy termination of affected 
fetuses. In doing so it presents a more comprehensive analysis of prenatal screening than before, 
which typically has focused on either epidemiological aspects or ethical aspects, but not both. 
Attention will be given to both the broader questions surrounding prenatal screening and 
connected to the more practical dilemmas confronting physicians, women and their families.  
 
1.1 Study Objectives and Null Hypotheses for Quantifiable Outcomes 
 When conceptualizing the link between prenatal screening and population health 
outcomes, one must keep in mind the cascade of events potentially set in motion by the initial 
offer for screening by the physician or midwife. This process includes a series of decision steps, 
which may ultimately contribute to a different pregnancy outcome. The objectives for this study, 
similarly, follow a logic, starting with the investigation of factors that influence the decision to 
have the screening test, then diagnosis. When a diagnosis is made the next decision step is 
whether to terminate the pregnancy or continue; a step in the pathway that has important 
ramifications for the live birth rate of congenital anomalies (those subject to prenatal diagnosis), 
as well as for indicators of fetal and infant death. Each decision point in this pathway will be 
analyzed through the lens of person- and place-specific factors that may contribute to the 
outcome of interest.   
 My primary study objectives and their accompanying null hypotheses are as follows:  
1. To examine the relationship between mother's region of residence, Registered Indian 
status, and age and utilization of prenatal screening and diagnosis.  
 Ho: Uptake of MSS and follow-up diagnostic testing does not vary by mother's health 
region of residence, Registered Indian Status, or age group.  
2. To study variations in pregnancy terminations for fetal anomaly by mothers' region of 
residence, Registered Indian status, and age.  
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 Ho: Pregnancy terminations for congenital anomaly do not vary by mother's health 
region of residence, Registered Indian Status, or age group. 
3. To determine if terminations of pregnancy for fetal anomaly have resulted in decreases in 
the number of live births with congenital anomalies between 2000-2005 that are screenable 
by the MSS program, in particular, chromosomal anomalies. 
Ho: The live birth prevalence rates of Down syndrome and trisomy 18 have not changed 
between 2000-2005 as a result of terminations of pregnancy prenatally-identified through 
the Saskatchewan MSS program.   
4. To determine if terminations of pregnancy for fetal anomaly have resulted in decreases in 
the stillbirth rate, the neonatal mortality rate, the congenital anomaly-specific infant 
mortality rate, or the overall infant mortality rate between 2001-2005.  
Ho: The number of terminations of pregnancy for fetal anomaly has not changed the 
annual stillbirth, neonatal mortality, CA-specific infant mortality, or crude infant mortality 
rates between 2001-2005.  
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CHAPTER 2: LITERATURE REVIEW 
 
2.0 Prenatal Screening  
 Prenatal screening has evolved considerably since the 1970s when maternal age was the 
only means available to identify pregnancies at increased risk for CA. At that time, women over 
the age of 35 could be offered amniocentesis; a procedure that is now known to carry a risk of 
miscarriage of 1 in 200 to 1 in 100, after adjusting for factors such as gestational age.(42) 
Prenatal screening was introduced with the hope of reducing the need for invasive testing 
(amniocentesis) and could also be used by women who might not otherwise opt for screening 
and would therefore lead to increased case ascertainment during the prenatal period. In the late 
1980's alpha fetoprotein (AFP) in maternal blood was just starting to be used to predict neural 
tube defects in select Canadian sites.(43) By the late 1990's and early 2000's, the ""triple marker" 
screen became the tool routinely used. The name reflected its ability to integrate measures of 
three blood serum levels: beta chorionic gonadotrophin (hCG), unconjugated estriol (uE3), and 
AFP.(44)  
 As newer tests are being integrated into existing screening programs, the triple test has 
been largely replaced. Some of the newer screens include: the quadruple test, where dimeric 
inhibin A is added to AFP, hCG, and uE3 markers; nuchal translucency (NT) measurement 
where the nuchal fold (a marker for aneuploidy) is measured using ultrasound between 11-14 
weeks; first trimester screening (FTS) where a NT measurement is combined with two maternal 
serum markers – hCG and Pregnancy Associated Plasma Protein A (PAPP-A); and integrated 
prenatal screening (IPS) where a NT measurement is combined with PAPP-A and second 
trimester MSS.(45, 46) Each test performs differently in terms of its detection and false-positive 
rates, with the newer tests performing better (on average) than the triple test. Further evolution of 
prenatal screening has resulted in a shift in the timing from the second to the first trimester. 
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Table 2.1 Prenatal screening modalities by time frame of introduction, conditions 
detectable and detection rate* 
Time frame  Test Name Methodology Conditions detected Performance 
(detection 
rate)† 
1970s Maternal age > 35 
years 
Amniocentesis is offered 
to all women over age 35 
Most major 
chromosomal 
problems; many 
genetic disorders 
30%-40% 
1980s Alpha fetoprotein 
(AFP) testing 
AFP Neural tube defects 
(NTD), Down 
syndrome (DS), 
Trisomy 18 (T18) 
Women < 35: 
85% NTDs, 
60% DS, 60% 
T18.  
1990s – 
2000s 
Triple marker test human chorionic 
gonadotrophin (hCG), 
unconjugated estriol 
(uE3), and AFP 
NTD, DS, T18 65%-75% 
2000s Quadruple test Dimeric inhibin A + 
hCG, uE3, AFP 
NTD, DS, T18 80%-90% 
Mid-2000s First trimester 
screening 
Nuchal translucency (NT) 
(an ultrasound 
measurement of the 
nuchal fold taken 
between 11-14 weeks) 
DS 70% 
Maternal serum markers - 
Pregnancy Associated 
Plasma Protein A (PAPP-
A) and ß-hCG 
NTD, DS, T18 60% 
NT + maternal serum 
markers ß-hCG and 
PAPP-A 
NTD, DS, T18 80% - 90% 
late-2000s Combined first and 
second trimester 
screening 
(integrated) 
NT + PAPP-A and 
second trimester MSSϮ 
NTD, DS, T18 95% 
Integrated maternal 
serum screening†  
NTD, DS, T18 85% 
Stepwise sequential 
maternal serum 
screeningǂ 
NTD, DS, T18 80% 
* Coory MD, Roselli T, Carroll HJ. Antenatal care implications of population-based trends in Down syndrome birth 
rates by rurality and antenatal care provider, Queensland, 1990-2004. The Medical journal of Australia. 2007 Mar 
5;186(5):230-4.(46) †Screening is done in both the first and second trimesters, but a single risk estimate is reported 
to the expectant mother only in the second trimester.ǂ Screening is done in both the first and second trimesters, and 
results of the first trimester are reported to the mother so she can act on them at the time. The detection rate depends 
on the sequence of tests used (an indicative figure is given here). 
† At a false-positive rate of 5%. 
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 The shift from age-based screening to population-based screening is an important one in 
the field's history. The former practice of offering amniocentesis only to women over the age of 
35 allowed for the detection of up to 30-40% of all Down syndrome (DS) cases in the 
population.(47) By extending the offer of screening to all pregnant mothers, there is the potential 
to capture 85% or more of DS cases. In 2007, the Society of Obstetricians and Gynecologists of 
Canada (SOGC) modified its previous guideline to reflect this move towards a population-based 
approach and now recommends that all women be offered be offered maternal serum 
screening.(48) It is not yet known what impact expanded screening has had on the occurrence of 
these three conditions as far as numbers of children being born into the Canadian population. If 
one looks at the case of Tay-Sachs disease, the introduction of prenatal screening almost three 
decades ago has led to an estimated 90% decrease in the condition in Jewish populations in the 
United States and Canada.(49) Because Tay-Sachs is an always fatal neurodegenerative disease, 
the impact of screening is likely much greater than would be expected with the three conditions 
targeted through MSS.  
Only a handful of conditions are routinely screened for during the prenatal period in 
Canada - Down syndrome, neural tube defects; and trisomy 18. It is important to note that while 
only a small number of conditions can be screened for, many more can be diagnosed through 
prenatal diagnosis, which is conducted through either amniocentesis or chorionic villus sampling 
(CVS). The number of genetic conditions that can be diagnosed prenatally grew from 
approximately 100 in 1993 to more than 1000 today.(50, 51) Cystic fibrosis (CF) screening is the 
newest condition for which a screening test has been developed, however in this case screening 
starts with the parents. Parents are offered screening for CF through a blood test, and if both are 
positive, then amniocentesis is offered. At present, the SOGC has recommended against 
population-based carrier screening for CF for all parents, but recommends offering screening 
only to parents believed to be at higher-risk.(52) While we do not know how many parents are 
screened for CF in Canada, 20 percent of pregnant women receiving prenatal care in the United 
States are screened for cystic fibrosis.(53) Another parameter of interest for some parents is fetal 
gender. The practice of aborting female fetuses is well-established in countries like India and 
China where male children are more highly valued and there are growing concerns about 
prenatal sex selection in the US and Canada. While viewed as morally reprehensible by most 
practitioners, and addressed by the SOGC in a recent policy statement declaring its non-support 
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for termination of pregnancy on the basis of gender (54), there is evidence that prenatal sex 
selection is occurring in Canada (55, 56).  
The SOGC statement reads:  
“The Society of Obstetricians and Gynaecologists of Canada believes that medical 
technologies and/or testing for the sole purpose of gender identification in pregnancy 
should not be used to accommodate societal preferences. Testing may include but not be 
limited to diagnostic imaging, maternal biochemical testing, chorionic villous sampling, 
amniocentesis, and any pre-implantation genetic testing. Sex identification with the intent 
of minimizing genetic transmission of disease is generally well supported internationally, 
but measures that perpetrate discrimination are condemned. The SOGC does not support 
termination of pregnancy on the basis of gender.”(54 p.909) 
In countries where sex selection abortion is common, the male to female ratio is increasingly 
skewed and analysis by Statistics Canada has found this very phenomenon in Canadian cities 
with high immigrant populations.(55-58) It seems the long-awaited genomic era has arrived, 
accompanied by its impenetrable moral, social and legal controversies.  
Attempts to enact legislation governing assisted reproductive technologies in Canada 
have been unsuccessful, leaving most of the conversation to happen in academic journals and 
ethical concerns to be managed through the guidelines and policies of professional 
organizations.(59) There is a curious lack of public discourse around prenatal screening and 
which conditions are acceptable for screening. Instead, professional bodies are leading the 
charge. These are the organizations whose members are responsible for delivering testing and 
performing termination of pregnancies, and therefore could be argued to have a vested interest in 
the normalization of prenatal screening and diagnosis. At the very least, they represent one 
particular viewpoint out of a multitude of voices that need to be heard, but have not yet been 
engaged. One explanation for the lack of public engagement is the contextual and psychological 
proximity between prenatal screening/diagnosis to fiercely debated topics including abortion, 
treatment of people with disabilities, eugenics, and limits to individual autonomy. Instead, the 
responsibility for such decisions has rested almost entirely on physicians and pregnant 
women.(4) Inevitable advances in genetics and screening techniques are likely to cultivate 
further moral, ethical and legal dilemmas about what limitations society ought to impose.   
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2.0.1 Maternal Serum Screening 
 Maternal Serum Screening (MSS) is a cluster of prenatal screening methods used to 
identify pregnant women whose fetuses have a greater likelihood of congenital anomalies and 
offer these women follow-up diagnostic testing. The term itself is often used to refer to the 'triple 
screen', but can be used more generally when speaking about prenatal screening programs that 
utilize many of the screening techniques previously described. By measuring the concentration 
of markers in maternal blood, an estimate is produced that tells each woman their probability of 
giving birth to an infant with any of these three conditions.(44) Since MSS is a screen and not a 
diagnostic test, women with results above the cut-off ("increased-risk") must undergo follow-up 
testing, such as a detailed ultrasound or a more invasive amniocentesis, to know for certain.   
 MSS generates probability estimates by comparing each woman’s test result to the norms 
for the population. An estimate is calculated for each patient based on maternal age and the 
trivariate Gaussian frequency distributions from affected and unaffected pregnancies.(60, 61) Put 
another way, an individual woman’s test result is compared to the values expected for women 
with normal pregnancies of the same gestational age, maternal age, ethnic background, diabetes 
status, body weight and parity. Other factors such as smoking and previous false positive 
findings may also affect test results, but are not always controlled for in every screening 
program. It is important to note that an increased-risk result in one laboratory will not necessarily 
be an increased-risk result in another due to different population norms. In Saskatchewan, up 
until mid-2009, the triple test was the primary screening technique offered throughout the 
province. This particular test is offered between 15 and 20 weeks gestation, but the ideal time to 
sample is between 16 and 18 weeks. Recently the provincial MSS program has added several 
techniques, including first trimester and integrated screens.   
Several studies have been conducted looking at the once popular triple test and have 
shown differences in its performance across settings. The age, race and general health of 
pregnant women differ in each population in ways that affect the test's performance or its ability 
to accurately detect fetal anomalies.(60) Therefore it is vital that evaluations are done 
specifically looking at the population in which the screening program is being implemented. 
Studies have shown the triple test to have detection rates in the range of 48% - 91% (median 
71%), with false-positive rates between 3% and 35% (median 5.6%), depending on the cut-off 
level used by the laboratory and the proportion of tests where the gestational age is confirmed by 
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ultrasound.(6, 10, 44, 61-77) Accurate gestational dating is a crucial factor in test performance 
(78), but can be a challenge in rural settings where this service is not always offered. Detection 
rates for the triple test rise, on average, from 59% without gestational dating to 69% with these 
scans.(67) In Britain, differences in age distributions across health districts led to significant 
variations in test performance, which means that a greater proportion of women in some districts 
would receive increased-risk results and be referred for an amniocentesis, even though all were 
offered the same test using the same risk cut-off level.(60) Studies have also shown detection 
rates to vary by as much as 39% between women age 35 and over and women under age 35, with 
false-positive rates being as much as 38% higher in women age 35 and over.(62, 66, 71, 72) The 
positive predictive value of screening is lower in populations where the prevalence of disease is 
lower (79), such as in younger women.  
  While the sensitivity and specificity of MSS varies according to both patient 
characteristics and the condition being screened, the overall high rate of false-positives is a 
concern for pregnant women and physicians. It is estimated that anywhere from 1 in 10 to 1 in 20 
women being tested will receive an increased-risk result.(5) In reality, only 1-2% of women 
receiving an increased risk result will have a fetus affected by DS, NTD, or trisomy 18. 
Therefore women undergoing amniocentesis due to such results may be putting their pregnancies 
at-risk based on a mistaken indication of their personal risk; a fact that limits the usefulness of 
MSS testing in the clinical setting, especially for pregnant women who are mainly seeking 
assurance of their babies health (80).  
 MSS is voluntary and women are given the choice to accept or decline testing, and as a 
result, studies have found the uptake of MSS varies by maternal age, residence and ethnicity (62, 
63, 81) Religious beliefs and education also appear to impact women’s acceptance of prenatal 
screening.(82) The influence of socioeconomic factors on screening utilization are less well-
understood. However, the uptake and offer of prenatal serum screening was found to be lower in 
mothers with lower education levels living in northern Ireland; in contrast, no differences in the 
offer or uptake of other prenatal screening tests was observed.(83) Due to a lack of evaluation 
and research, it is not known to what extent ethnicity, religion or other factors affect test 
utilization by pregnant women in Canada.  
In Canada, prenatal serum screening, in one form or another, is offered by most provinces 
including British Columbia, Alberta (1991), Manitoba (1999), Quebec, Ontario (1993), Nova 
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Scotia, and Newfoundland. Once performed only on an ad hoc basis in Saskatchewan, MSS 
became available to all pregnant women throughout the province in May of 2001. Prior to its 
introduction, there was no coordinating body for prenatal testing throughout the province. 
Modeled after the Ontario MSS program, the Saskatchewan MSS program allows for the 
Provincial Laboratory in Regina to receive and examine all blood samples and return results to 
physicians. In addition, the program is responsible for the distribution of educational materials to 
physicians. The Saskatchewan MSS program underwent a process evaluation looking at program 
uptake and overall test performance for the purposes of program evaluation and planning. The 
current dissertation project built upon a similar dataset compiled for the MSS Evaluation (i.e. 
laboratory and cytogenetic data linked to hospital birth outcomes); however, my dissertation 
dataset has been expanded to include all pregnancy losses, stillbirths, births and deaths during a 
five-year time period. The value of adding all pregnancy outcomes is that it enables the 
evaluation of population effects, while the former is limited to the sub-group of women who 
were screened. 
 The literature indicates that the performance of MSS programs vary widely.(44, 62, 69, 
70, 73, 77) The success of a population-based screening initiative may be largely affected by the 
social, demographic, environmental, and cultural characteristics of the population it serves. In 
Saskatchewan, there are certain unique circumstances that can be studied to gain a better 
understanding of people's use of prenatal screening tests, including the large aboriginal 
population, the rural nature of the province coupled with more limited health services in rural 
and remote centres, and the traditionally low uptake of prenatal diagnostic technologies. From a 
health services perspective, there are questions around the delivery of the program, which will 
help to determine its effectiveness, suitability, and accessibility in the province. From a 
population health perspective, there is the question of the screening program's impact at the level 
of the population and differential uptake along social, economic, and cultural lines. Very few 
prenatal screening programs, Saskatchewan’s included, have been evaluated for an impact at the 
population level, which presents an opportunity to gain a better understanding of the factors 
affecting program performance at the level of the population.   
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2.0.2 A Population Health Lens 
Drawing from the population health philosophy, there is a basic question of the screening 
program’s impact at the level of the population. As a strategic training fellow in the CIHR-
funded Community and Population Health Research (CPHR) training program, students are 
encouraged to adopt a population health focus within their research. In the document Taking 
Action on Population Health (1998), the Health Promotion and Programs Branch of Health 
Canada emphasized that one guiding principle of a population health approach is “an increased 
focus on health outcomes and on determining the degree of change that can actually be attributed 
to our work.”(84 p.1) Kindig and Stoddard (2003) also advocate “for the inclusion of outcomes 
and distributional considerations if a population health approach is to be useful in policy 
making” and contend, “without such a framework, advocacy and financial incentives can 
proceed independently of their impact.”(85 p.382) This research fits well within a population 
health framework and is designed to contribute to the understanding of prenatal screening in this 
context. Aside from the quantitative component, the population health perspective challenges 
this research to go beyond the clinical, technical and individual ethical issues posed by prenatal 
screening, to incorporate a broader sociological lens.    
 
2.1 Congenital Anomalies 
 The term “congenital anomaly” is used to describe an abnormality of structure or 
function present at birth.(86) Other synonymous terms may include: birth defects, congenital 
malformations, and congenital abnormalities. In 2004, 4.8% of Canadian children were born with 
a CA, although estimates at birth depend on the inclusion criteria and ascertainment methods 
used by each region.(37) Congenital anomalies encompass a range of conditions in the fetus that 
vary markedly in their clinical picture and prognosis, even for infants with identical diagnoses. 
For most CAs, the causes are unknown. It is estimated that approximately 15%-25% are due to 
genetic conditions (chromosomal and single gene causes), 8%-12% to environmental factors 
(maternal-related conditions, drug or chemical exposures), 20-25% to multifactorial inheritance, 
and causes for the remaining 40%-60% are unknown.(87) The most common types of CAs in 
Canada are musculoskeletal anomalies, congenital heart defects, and urinary system 
anomalies.(5) Over the past two decades fewer infants are dying as a result of CAs, however, 
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they still remain an important cause of infant mortality.
8
 In 2004, congenital anomalies were 
responsible for 23.6% of all deaths in infants under the age of one year.(37)  
 
2.1.1 Screenable Conditions 
Maternal Serum Screening (MSS) is able to detect, with varying degrees of sensitivity 
and specificity, three categories of congenital anomalies: Down syndrome, neural tube defects, 
and trisomy 18. Other congenital anomalies, such as limb reduction and congenital heart defects, 
can be detected by specialized ultrasound during the second trimester. Below is a brief 
introduction to these three groups of screenable conditions.  
Down syndrome (DS), also known as trisomy 21, occurs in approximately 1 in 800 live 
births in Canada and its risk increases with advancing maternal age (5). Significant variations in 
mental abilities, behavior and physical development exist between individuals with DS; each 
person has their own unique personality, capabilities and talents.(88) Most people with DS will 
have mild to moderate developmental delays, but fewer than 10% fall into the severe category. In 
terms of health conditions, it is estimated that 40% of individuals with DS will have a cardiac 
anomaly.(5) Advances in health care have led to substantial reductions in early life mortality risk 
and much greater survival overall. More than 90% of infants born with DS will survive to one 
year of age and 85% to at least age 10.(5) Life expectancy of people with DS is approximately 
55 years, depending on the individual and other medical conditions.(88) In recent decades, 
people living with DS are increasingly participating in the workforce, attending post-secondary 
school and even getting married.  
Considerable variation in the rate of DS exists across Canadian provinces and European 
countries, with rates in 2001 – 2004 (combined) ranging from 10.4 per 10,000 total births in 
Quebec, to 14.0 per 10,000 births in Saskatchewan, to 21.7 per 10,000 births in Prince Edward 
Island.(8, 37) Very little is known about the etiology of DS, other than the risk of having an 
affected child increases with age. Despite the fact that risk increases with age and the average 
age of mothers has dramatically increased in the last two decades, national rates of DS-affected 
live births remain relatively unchanged.(5) Evidence suggests that the live birth prevalence of 
Down syndrome has remained stable as a result of increased detection and termination of 
                                               
8 This fact may reflect increased use of prenatal screening/ diagnosis and pregnancy termination; an important focus 
of this research.  
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affected pregnancies.(6-8, 10) To date, very little has been published on CA rates and trends in 
Saskatchewan, including on DS.  
Trisomy 18, or Edward's syndrome, is a chromosomal anomaly occurring in about 1 out 
of every 3,000 live births.(89) It is three times more common in girls than boys and is caused by 
an extra copy of chromosome 18. While it is a generally a very severe condition with marked and 
fatal co-conditions, the severity varies across cases. Some of the more commonly observed 
characteristics include heart defects, kidney abnormalities, omphalocele, esophageal atresia, 
clenched hands, delayed growth and developmental delays. Most infants with this condition die 
before birth, and of those surviving, an estimated 10% live longer than one year. Only about 10 
people with trisomy 18 have been documented to live into the teenage years. Much of the 
prenatal screening outcomes research has focused on DS or neural tube defects, however this 
study will also consider trisomy 18.  
Neural tube defects (NTD) are among the most common types of CA and involve 
malformations of the central nervous system.(1) Neural tube defects were the first screenable 
category of CA. Anencephalus, spina bifida, and encephalocele are all types of NTD, however, 
they vary quite notably in severity. The number of infant deaths due to NTD dropped 
dramatically in Canada between 1989 and 1999, from 11.1 per 10,000 total births to 5.6, with 
prenatal screening and selective termination being the most likely explanation.(5) While research 
has found that folic acid has a strong protective effect  - if taken early enough in the pregnancy it 
can prevent up to 75% of cases – a national survey done in 1998 found limited awareness about 
its benefits among women of childbearing years.(90) As a result, in 1998, Canada implemented 
mandatory fortification of enriched flour and uncooked cereal grains with folic acid. Recent 
research has shown that this initiative has led to substantial reductions in the incidence of 
NTDs.(91-93) 
 
2.1.2 Other Categories of Congenital Anomalies not Screenable by MSS 
Most CAs cannot be screened for using a simple blood test, but some conditions are 
detected through ultrasound, which is really another form of prenatal screening. Examples of this 
include congenital heart defects, oral clefts, and limb reduction defects.  
The most common category of CA is congenital heart defects (CHD), which occur in 
approximately 1 in 100 – 150 newborns.(5) Improvements in diagnosis and surgical treatment 
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have dramatically improved the prognosis of children with CHD by substantially reducing 
childhood mortality and morbidity. Still CHD is one of the most common causes of death due to 
CA in Canada. Similar to DS, older maternal age is a known risk factor, as well as paternal age. 
Evidence has also shown folic acid to be protective of CHDs.(94) In terms of detection, CHD is 
initially recognized through detailed ultrasound screening and followed-up by fetal 
echocardiography.(5) Over half of all severe CHDs are detectable when high-risk pregnancies 
are targeted; a rate typically lower than the three conditions screened through MSS. Rates of 
CHD in Canada rose from 1989 to 1999 from 82 per 10,000 total births (live and still births) to 
104.(5) Increasing rates are thought to be partly the result of improved diagnostic capabilities 
(increase case ascertainment) and potentially to the shift in maternal age distribution. National 
data does not reflect the number of cases terminated following prenatal detection. 
Orofacial clefting is another relatively common CA in Canada and is an important cause 
of child morbidity. Oral clefts are difficult to diagnose prenatally through ultrasound screening, 
which is the only method currently available.(5) Prenatal screening therefore has a very limited 
impact on prevalence rates and only detects cases where there is another associated CA. Having 
said that, most pregnancies that are terminated would not be terminated for an oral cleft only, but 
the fetus would typically have a cleft in addition to other CAs. Birth prevalence of cleft lip (CL), 
cleft lip with cleft palate (CL/P), and cleft palate (CP) vary across provinces and ethnic groups. 
One Saskatchewan investigation found the live birth prevalence of oral facial clefts to be higher 
in First Nations mothers.(95) From 1989 to 1999 the national total birth rate (including 
stillbirths, but not terminations) has remained quite stable.(5)  
Lastly, limb reduction defects (LRD) are a rare form of CA characterized by total or 
partial absence of an arm or leg or part thereof.(5) Thalidomide is the most commonly known 
risk factor for LRD, but otherwise very little is known about their etiology. The rates of LRD 
declined significantly over time in Canada, from 4.8 per 10,000 total births in 1989 to 3.7 per 
10,000 births in 1999.(5) Serious LRDs can be detected prenatally by second trimester 
ultrasound, with a detection rate between 20-60% depending on the type of defect and if there is 
another CA present.(1) Prenatal screening, when followed by selective termination for CA, has 
been shown to reduce the birth prevalence of LRD. For instance, statistics found 12.9 per 10,000 
total births in Alberta had a LRD; a figure that increased to 14.1 per 10,000 when terminations 
were included.(1) 
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2.2 Termination of pregnancy for fetal anomaly and surveillance  
 Studies have shown that a significant proportion of pregnancies confirmed to have a CA 
through prenatal screening and/or diagnosis are terminated (table 2.2).(6, 11, 71, 96-100) The 
rate at which terminations for this reason occur will determine the population health impact, as 
measured by CA birth prevalence and infant and fetal mortality rates. Studies have shown that 
the occurrence of TOPFA has been shown to vary across geographically and according to the 
type of anomaly detected. In the case of Down syndrome, the proportion of prenatally diagnosed 
cases terminated was very high in countries like France (99.5%) (1997-1998) and Hawaii 
(84.0%) (1987-1996), while lower in Atlanta (26.4%) (1994-199) and Britain (43.7%) (1991-
1999).(71, 97, 100, 101) The uptake of prenatal screening has remained low (less than 25%) in 
the Netherlands, however the rate of TOPFA appears to have offset the effect of increasing 
maternal age on national DS rates. Less is known about trends in TOPFA for various anomalies, 
however terminations of prenatally identified DS cases in South Australia increased from 7.1% 
in 1982 to 75% in 1996.(6) Geographical variations in TOPFA were evident.  
 Not a great deal is known about variations within Canada or the exact proportion of total 
pregnancies with DS or other CA types that have been terminated. A dated estimate by the Royal 
Commission on New Reproductive Technologies, back in 1993, estimated that 5% of fetuses 
with a CA were prenatally detected and 80% of these pregnancies were terminated.(102) A more 
recently published study in British Columbia (2006) found that out of the 124 prenatally detected 
cases of NTDs between 1997-1999, 73% were terminated.(11) As a result, the three-year NTD 
birth incidence fell by 60% from 1.16/1000 to 0.47/1000. Nova Scotia experienced a notable 
increase in the proportion of total NTD cases resulting in a TOPFA (49.2% in 1991-1994 to 
73.5% in 1998-2000), although the number of cases diagnosed prenatally was not reported.(91) 
Those women who continue down the prenatal screening pathway in search of a definitive 
diagnosis will almost certainly have differing views on the practice of TOPFA (25, 80, 103), 
which explains the characteristically high rate of pregnancy termination following prenatal 
diagnosis. A high percentage of fetuses that are prenatally diagnosed with a CA and then 
terminated may have a relatively small impact on the overall population of infants born with CA, 
if the numbers opting for screening and diagnosis are small. Where the practice is bound to have 
the greatest population impact is in settings where screening rates are high, test sensitivity is 
high, and TOPFA is common. More research is necessary in Canada to determine the magnitude 
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of impact that pregnancy terminations have on CA live birth trends, and if differences can be 
found across population sub-groups. 
 
Table 2.2 Percent of congenital anomalies diagnosed during pregnancy and percent 
terminated--by research study, date, region, and congenital anomaly type 
Authors Time 
Period 
Region Congenital 
Anomaly 
type 
Findings 
Chan et al (104) 1966-
1991 
South Australia Neural tube 
defects 
Live birth prevalence declined by 5.1% each 
year, with an 84% decrease from 1966 to 
1991 (2.29/1000 live births and 0.35/1000 
live births, respectively). Of all identified 
cases, 27.8% resulted in a pregnancy 
termination (35.3% of anencephaly cases; 
22.1% of spina bifida cases). In women 
undergoing AFP screening or mid-trimester 
ultrasound, 99.0% of anencephaly and 
75.7% of spina bifida cases were detected.  
Cragan et al (105) 1985-
1994 
Arkansas (1985-
89), California 
(1989-1991), 
Georgia (1990-91), 
Hawaii (1988-
1994), Iowa (1985-
1990), South 
Carolina (1992-93) 
Anencephaly 
or spina bifida 
The proportion of total NTD cases that were 
terminated ranged from 9% in Arkansas to 
42% in Atlanta and Hawaii. In Atlanta, the 
percentage of NTD-affected pregnancies 
terminated was higher among white women. 
In Hawaii, the proportion of pregnancies that 
were terminated was higher among Asian 
women.  
Forrester et al (100) 1987-
1996 
Hawaii Ten selected 
anomalies 
The following proportion of selected 
anomalies were prenatally diagnosed: 
anencephalus (87%), encephalocele (83%), 
gastroschisis (76%), spina bifida (62%), 
trisomy 18 (61%), omphalocele (60%), 
Down syndrome (43%), trisomy 13 (40%), 
cleft lip (14%), and cleft palate (0%). The 
proportion of pregnancies terminated after 
prenatal diagnosis:  anencephalus (83.1%), 
encephalocele (54.3%), spina bifida (48.3%), 
trisomy 18 (68.3%), Down syndrome 
(84.0%), and trisomy 13 (62.5%). 
Roberts et al (106) 1990-
1991 
Atlanta, GA Neural tube 
defects 
87 NTD cases were identified and 28 of 
those pregnancies were terminated (32.2%). 
The birth prevalence rate was 0.77/1,000 live 
births. The incidence rate was 1.13/1.000 
live births. The proportion of cases that were 
terminated was higher for women aged 35 
and over compared to those less than 35 
years (RR=5.10; 95% CI 3.14-8.28), and 
lower for black women compared to white 
women (RR=0.33, 95% CI 0.16-0.66). 
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Authors Time 
Period 
Region Congenital 
Anomaly 
type 
Findings 
Siffel et al(101) 1990-
1999 
Atlanta, GA Down 
syndrome 
The birth prevalence of Down syndrome was 
10.1  per 10,000 live births from 1994-99. 
The incidence was 15.3 per 10,000 births 
during the same period. Of 526 identified 
cases, 139 (26.4%) were terminated. 
Rankin et al (97) 1991-
1999 
Five British regions All anomalies 
combined 
Out of all cases, termination of pregnancies 
occurred in 43.7% of Down syndrome cases; 
81.3% of neural tube defects cases; 16.6% of 
limb reduction defects; 65.8% of trisomy 18 
cases. 
Royal Commission 
New Reproductive 
Technologies (102) 
1993 Canada All anomalies 
combined 
Out of the 5% of prenatally-diagnosed 
congenital anomaly cases, 80% were 
terminated. 
Crider et al (107) 1994-
2003 
Atlantic, GA Trisomy 13 
and trisomy 18 
70.8% of trisomy 13 and 76.1% of trisomy 
18 cases were diagnosed prenatally. Of 
prenatally diagnosed cases, 60.8% of 
trisomy 13 and 59.7% of trisomy 18 cases 
were terminated. The rate of prenatal 
diagnostic testing was lower in non-Hispanic 
black women for both trisomy 13 (OR 0.24, 
95% CI 0.08-0.78) and trisomy 18 (OR 0.32, 
95% CI 0.14-0.69).    
Van Allen et al (11) 1997-
1999 
British Columbia Neural tube 
defects 
124 out of 144 neural tube defect cases 
(86.1%) were diagnosed prenatally. Out of 
124 prenatally-diagnosed neural tube defect 
cases, 73% were terminated.  
Gameren-
Oosterom et 
al(108) 
1997-
2007 
Netherlands  The mean incidence of Down syndrome was 
14.57 per 10,000 births, of which 85% were 
live births. Live birth prevalence remained 
unchanged (p=0.385 for trend), despite an 
increase in mean maternal age (p<0.001). 
Pregnancy terminations could not be directly 
captured, however, an increasing trend in the 
proportion of DS births before 24 weeks was 
observed (p=0.011). 
Zlotogora et al 
(99) 
1999-
2000 
Israel Neural tube 
defects 
90% of anencephaly cases among Jewish 
women were terminated compared to 59% 
among non-Jewish women. 73% of spina 
bifida cases among Jewish women were 
terminated during pregnancy compared to 
43% among non-Jewish women.  The birth 
prevalence of NTDs was higher among non-
Jews (anencephaly 3.6/ 10,000 live births, 
spina bifida 5.9/10,000) than among Jews 
(anencephaly 1/10,000 live births, spina 
bifida 1.4/10,000 live births). 
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Authors Time 
Period 
Region Congenital 
Anomaly 
type 
Findings 
Cheffins et al (6) 2000 South Australia Down 
syndrome 
Terminations of prenatally-diagnosed Down 
syndrome cases increased from 7.1% in 
1982 to 75% in 1996. 
 
Muller et al (71) 2002 France Down 
syndrome 
Of 54,321 patients with an increased-risk 
screening result in 1997 and 1998, 95% had 
follow-up diagnostic testing. 623 out of 626 
(99.5%) of prenatally- diagnosed Down 
syndrome cases were terminated.  
Boyd et al (109) 2002- 
2004 
12 European 
countries 
Down 
syndrome and 
neural tube 
defects 
Down syndrome cases: Out of all prenatally 
diagnosed cases, the termination rate ranged 
from 73% - 100% (mean=88%) across 12 
countries. When all CA were taken together 
(prenatally diagnosed and not), the 
termination rate ranged from 31% - 87% 
(mean=60%). Neural tube defect cases: Out 
of all prenatally diagnosed cases, the 
termination rate ranged from 0% -100% 
(mean=88%) across 12 countries. When all 
CA were taken together (prenatally 
diagnosed and not), the termination rate 
ranged from 0% - 92% (mean=77%). 
Loane et al (8) 1990-
2009 
13 European 
countries 
Down 
syndrome, 
Trisomy 18, 
and Trisomy 
13 
Proportion of all cases diagnosed prenatally 
ranged from less than 10% in Ireland to 
~85% in France and Switzerland. Mode of 
diagnosis (ie. ultrasound, serum 
screening/combined screening, or invasive 
diagnostic testing) varied considerably by 
country. The pregnancy termination rates for 
congenital anomalies were highest in France 
(77.3% of all cases combined, not only those 
prenatally detected) and lowest in Ireland 
and Malta (0%).  
Smith et al (98) 1998-
2007 
East Midlands and 
South Yorkshire 
regions of England 
Nine selected 
congenital 
anomalies with 
poor 
prognoses 
86% of affected fetuses were prenatally 
detected and diagnosis did not vary over 
time or by level of deprivation. The 
pregnancy termination rates for congenital 
anomalies were lower in the most deprived 
areas (63%) than in the least deprived (79%). 
The proportion of pregnancies terminated 
after prenatal diagnosis were as follows: 
anencephaly (88%), spina bifida (78%), 
hypoplastic left heart (56%), diaphragmatic 
hernia (29%), trisomy 18 (81%), trisomy 13 
(83%). 
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2.2.1 Calculating the Birth Prevalence of Congenital Anomalies  
When examining the occurrence of CAs in a given population, the live or total birth rate 
is often the statistic reported. Both are incomplete in so far as they do not capture all cases of 
CAs in the numerator and the denominator (refer to Table 2.3 below). The rate reported typically 
depends on the data that is available. In settings where a CA surveillance system is in place, CAs 
in the majority of pregnancies are captured, including terminations. This enables reporting on all 
CAs in live births, stillbirths, and terminations of pregnancy, which is the current gold standard. 
Using this information the birth incidence can be reported. Having said that, all CA rate 
calculations exclude from the denominator elective medical abortions that are not specifically for 
reasons of CA; a calculation that could lead to either over- or underestimates (depending on the 
CA risk of this population). The most important point here is that accurate CA surveillance 
requires as complete capture of all pregnancies as possible – something that is a challenge for 
jurisdictions that do not have high-functioning, well-designed CA surveillance systems.  
Table 2.3 Methods for calculating congenital anomaly prevalence 
Indicator Numerator Denominator Limitations 
Live CA birth 
prevalence 
Live births with a CA  All live births Excludes stillbirths + TOPFA  
Total CA birth 
prevalence 
Live births with a CA + 
stillbirths with a CA  
All live + stillbirths Excludes TOPFA 
CA incidence Live births with a CA+ 
stillbirths with a CA+ 
TOPFA 
Live + stillbirths + 
TOPFA 
Only includes TOPFA in the 
numerator and denominator and 
excludes abortions for non-CA-
related reasons 
 
Studies have shown that decreases in the birth prevalence of CAs disappear or decrease 
when termination data are included in the analysis.(6, 8, 10, 110) This observation has significant 
implications for CA surveillance, especially when rates often only reflect live births or live and 
stillbirths combined. If true increases and decreases cannot be identified with confidence, 
research into the etiology of different CA types and tracking risk profiles of different populations 
will not be possible. The accurate and complete reporting of CAs is important to surveillance of 
birth outcomes and to the program and policy context surrounding screening programs and fetal-
maternal health research.  
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2.2.2 Trends in neural tube defects and Down syndrome 
Neural tube defects are commonly cited conditions where decreases in the birth 
prevalence have been observed nationally and internationally, but trends have been difficult to 
explain. In 1994, recommendations regarding folic acid supplementation (through vitamins) were 
introduced, then followed by a national policy on the mandatory fortification of grains products 
in November of 1998.(91) Initially increased folic acid consumption was presumed to be 
responsible for observed NTD reductions in Canada, but prenatal screening also became more 
common during this timeframe and soon became a competing explanation. A study by Van Allen 
et al (2006) in British Columbia found that declines in NTD birth rates between 1997-1999 were 
primarily attributable to prenatal screening and terminations.(11) Pregnancy termination 
following prenatal diagnosis reduced the three-year NTD incidence by 60% from 1.16/1000 to 
0.47/1000. Later research revealed a more mixed picture however, when it comes to explaining 
declining NTD birth trends. In fact, it is not an either-or scenario, but rather both factors have 
played a role in reducing NTD birth rates. A study in Nova Scotia clearly illustrated a trend in 
falling NTD incidence owing to folic acid fortification– from 2.55 per 1000 births in the 
prefortification period (1991-1994) and 2.61 per 1000 births in the supplementation period 
(1995-1997), down to 1.17 per 1,000 births in the post-fortification period (1998-2000)(91); 
representing a 54% decrease over the 10-year period. These estimates included live births, 
stillbirths and termination of fetuses with an NTD. It is interesting to note the difference in 
calculated rates when terminations of pregnancy are excluded (done for illustration purposes), 
which is not an uncommon presentation of data in many jurisdictions. The 10-year NTD average 
incidence rate was 2.22 per 1,000 births when terminations were included and 0.89 per 1,000 
when terminations were excluded; a 60% decrease over the time period. Therefore pregnancy 
terminations had a slightly greater impact on the birth prevalence of NTDs than folic acid 
fortification. In addition, when the rates exclude pregnancy termination data, the trending looks 
quite different and would have led to the erroneous conclusion that folic acid supplementation 
alone precipitated a 40% reduction in NTDs. Looking at the unchanged rates (when termination 
data was included: 2.55 vs. 2.61 per 1,000 births), this was not the case. Further evidence in 
support of folic acid fortification followed with a seven-province study spanning 1993 to 2002 
that found a 46% reduction in NTD incidence (1.58 per 1,000 births pre-fortification to 0.86 
during the full-fortification period, including termination of pregnancies for fetal anomaly).(93) 
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The magnitude of decrease was proportional to the prefortification baseline rate in each province, 
meaning that provinces with higher baseline rates like the Newfoundland and Labrador saw 
steeper declines than those with lower rates like British Columbia (a rate difference of 3.8 vs. 
0.21 per 1,000 births, respectively). Geographical differences almost disappeared after 
fortification began. Similarly, a study done in the United States found that regional variations in 
the rates of NTDs were reduced or eliminated when pregnancy termination data was used in the 
analysis.(110) 
 
Figure 2.1 Birth prevalence of neural tube defects in Nova Scotia by folic acid fortification 
and supplementation period, with and without terminated neural tube defect pregnancies*  
 
* Recalculated rates based on published figures from Persad VL, Van den Hof MC, Dube JM, Zimmer P. 
Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ 2002 Aug 6;167(3):241-5. 
 
While NTD rates have been on the decline, DS rates in Canada remain stable despite a 
dramatic shift in the maternal age distribution (See figure 2.2 below).(5) Maternal age is a well-
established DS risk factor, with risk increasing incrementally up until age 35, then more sharply 
(see table 2.4 below).(111-113) Data on the birth incidence of DS in Alberta (1990-1998) show 
slightly different risk estimates than Bray et al's (1998) meta-analysis of nine published datasets 
(111), but portray a clear rate increase with maternal age.(5) Even though age is currently the 
only well-identified risk for DS, many cases occur in women younger than 35, reflecting the 
greater fertility of this group. Between 1980 and 2011, the proportion of women aged 30 and 
over who gave birth in Canada went from 21.5% to 51.2%.(5, 114) Saskatchewan has 
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experienced an increase in the proportion of births to mothers in this age group, however, they 
account for a much lower proportion of births. For instance, in 2011, 36.1% of live births in 
Saskatchewan were to women aged 30 and over compared to 51.2% nationally.(114) It is 
expected that an increase in live DS births would accompany such a large increase in the risk 
profile of Canadian mothers, however it did not (see Figure 2.3 below).  
 
Figure 2.2 Age-specific live birth rates among females aged 20 – 44 years, Canada, 1962, 
1982, 2004*† 
 
*Public Health Agency of Canada, 2008. Canadian Perinatal Health Report - 2008 Edition. Ottawa. † Statistics 
Canada, 2006. Births. Catalogue no. 84F0210XIE 
 
Table 2.4 Estimated Down syndrome birth incidence by maternal age*† 
Multi-centre study Alberta 
Maternal age Odds  Rate per 1,000 Maternal age Rate per 1,000 % of total DS cases  
16 1 in 1493 0.67 < 20 0.48 3.2 
20 1 in 1445 0.69 20 – 24 0.67 12.5 
25 1 in 1259 0.79 25 – 29  0.72 21.1 
30 1 in 821 1.22 30 – 34 1.27 30.9 
35 1 in 336 2.97 35 – 39 2.83 24.0 
40 1 in 97 10.15 40 - 44 6.30 6.9 
45 1 in 25 38.89 > 45 42.9 1.5 
50 1 in 6 142.13    
*Health Canada, 2002. Congenital anomalies in Canada - A perinatal health report, 2002. Ottawa: Minister of Public 
Works and Government Services Canada. †Bray I, Wright DE, Davies C, Hook EB. Joint estimation of Down 
syndrome risk and ascertainment rates: a meta-analysis of nine published data sets. Prenatal diagnosis. 1998 
Jan;18(1):9-20.  
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Figure 2.3 Down syndrome rates and fertility rates for females aged 35-49 years, Canada, 
1989 – 2006*†  
 
* Public Health Agency of Canada, 2008. Canadian Perinatal Health Report - 2008 Edition. Ottawa. 
 
A similar phenomenon can be seen internationally in other developed countries. For 
instance, in Paris from 1981 - 2000 the proportion of women aged 35 and over giving birth 
increased markedly (11.1% to 26.1%); a trend that was accompanied by a rise in the DS 
incidence by 5% per year. Despite the substantial increase in the number of births to older 
mothers, the live birth prevalence of DS dropped 3% each year from 1981 to 2000, with a 
maternal age-adjusted decrease of 13% each year.(10) Accordingly the live birth prevalence fell 
from an estimated 10 to 5 cases per 10,000 births over the two decades, while the true birth 
incidence (terminations included) rose from 11 cases per 10,000 births in 1981 to 40 DS cases 
per 10,000 births in the late-90s. Interestingly, the proportion of DS cases diagnosed prenatally 
increased nine-times in women under the age of 38 (9.5% to 84.9%), and also increased in 
women aged 38 and over (59.1% to 95.4%). In general, the percentage of DS cases diagnosed 
prenatally in Paris is very high. Taken together, Khoshnood et al (2000) concluded that the shift 
towards screening women of all ages and France's national screening policy have had a 
substantial impact on prenatal detection and live DS birth rates in that country.(10) A study 
examining the population of France between 1997-1998 observed that 95% of women that 
received an increased-risk MSS result had follow-up diagnostic testing, with 99.5% terminating 
their pregnancy after receiving confirmation of Down syndrome.(71)  
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Similar trends have been observed in other countries. In South Australia use of maternal 
serum screening for Down's syndrome increased from 17% when introduced in 1991 to 76% of 
women who gave birth in 1996. Between 1982 to 1996 the overall birth prevalence of DS fell by 
60% from 1.05 to 0.42 per 1,000 live births, in spite of a notable rise in maternal age.(6) As was 
the case in France, the drop in DS cases could be explained by an increase in the termination of 
pregnancies known to be affected by DS – from 7.1% of all cases detected in the population in 
1982-86 to 75% in 1996. Most of this increase was found to be due to increased maternal serum 
screening use among younger women.(6) Neighbouring Queensland Australia also experienced a 
substantial drop in maternal age-adjusted rates of DS births from 2000 to 2004.(46) Interestingly, 
reductions in DS total prevalence were most pronounced in mothers receiving prenatal care from 
private obstetricians  (-27.5%) and urban-residing mothers (-14.3%), as compared to rural-
residing mothers (0.0%) or those receiving prenatal care from public hospitals (+2.9%).  
 
Figure 2.4 Down syndrome, neural tube defect, and congenital heart defect rates, Canada, 
1989 - 2006* 
* Public Health Agency of Canada, Congenital Anomaly Surveillance System, 2012. Congenital anomaly 
national prevalence data, 1989-2006. Ottawa. 
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2.2.3 Data challenges in the ascertainment of pregnancy terminations for fetal 
anomaly 
While there is reasonable evidence that the termination of affected pregnancies is 
responsible for declines in CA rates, particularly those amenable to screening, the shortage of 
Canadian research in this area limits what can be said about this relationship. Little is known 
about the magnitude of the impact that variations in screening/ diagnosis/ termination have on 
CA rates regionally and for different sub-groups (eg. those under and over age 35, Registered 
Indian compared to other women). In addition, the potential for undercounting TOPFA is 
significant and the relationship between screening uptake and population outcomes is largely 
unknown. There are three main reasons: (1) inability of traditional data systems to account for all 
CAs that are diagnosed prenatally and then terminated; (2) difficulties associated with the cross-
linkage of screening and diagnostic information and birth outcome data; and (3) lack of 
published reporting on the topic. In most provinces without a CA surveillance system, like 
Saskatchewan, data on pregnancy termination is mainly captured by hospital separations in the 
Discharge Abstract Database (DAD), however detailed diagnostic data is not available on fetuses 
where an anomaly was detected.
9
 As a result, the DAD must be linked with diagnostic data, 
typically held by cytogenetic laboratories and clinics. At the national level, the Canadian 
Congenital Anomalies Surveillance System (CCASS) faces noteworthy challenges that prevent 
accurate reporting of CA incidence. In the 2002 report, Congenital Anomalies in Canada, Health 
Canada notes that "one of the most significant limitations [of the CCASS] is the inability to 
monitor the impact of prenatal diagnosis on the birth prevalence of selected congenital anomalies 
... directly limit[ing] an assessment of primary and secondary preventive strategies."(5 p.xiv) 
This is due to the fact that most jurisdictions do not report pregnancy losses with a gestational 
age less than 20 weeks (the criteria for stillbirth), which include earlier TOPFAs. The result is an 
underestimation of CA incidence, particularly for screenable conditions, and limited ability to 
interpret temporal and geographical patterns. Furthermore, cases that are diagnosed outside the 
hospital and those diagnosed in-hospital longer than 30 days after birth are also missed. The 
latter is due to the fact that CIHI no longer shares birth dates with CCASS, therefore follow-up 
of each infant was reduced from one-year to 30 days starting in 2001.(37) 
                                               
9 ICD-9 code 655and ICD-10-CA code O35 are most specific for neural tube defects (eg. O35.00 for fetal 
anencephaly), but are insufficient for the identification of cases of fetal Down syndrome (O35.1 chromosomal 
anomaly) or congenital heart defects (O35.9 fetal abnormality and damage, unspecified).   
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2.3 Infant Mortality Rates 
The infant mortality rate (IMR), defined as the number of deaths in children under the 
age of one year per 1,000 live births in a calendar year, is a sensitive measure of population 
health in both developed and developing countries.(39) A well-established and often cited 
measure of wellbeing in society, the IMR is a reflection of a population's health, mortality, and 
health care system. In the Canadian Perinatal Health Report (2003), Shi Wu Wen states that 
"infant mortality has been considered the single most comprehensive measure of health in a 
society.”(115 p.89) It has traditionally been viewed as a population health indicator that is 
responsive to structural factors such as economic development, sanitation, nutrition, inequality 
and environment.(39) Furthermore, it captures the health status of maternal and child populations 
and the multitude of factors that determine survival in the first year of life, including prenatal and 
postnatal nutrition, drug and tobacco use, medical care, and immunizations. While some have 
questioned the utility of the IMR as a measure of broader wellbeing, Reidpath and Allotey 
(2003) found a very high correlation between the disability adjusted life expectancy, a frequently 
used population health measure, and IMR in 180 countries.(39) An earlier study utilizing 
worldwide data on infant mortality from the United Nations demonstrated that the Human 
Development Index (HDI), and all of its individual components including life expectancy, 
literacy, and per capita gross domestic product, is a very powerful predictor of infant mortality 
rates.(116) The HDI accounted for 85-92% of the variance in infant mortality rates. This 
reinforces the IMR's ability to detect factors not only related to health in early life but also to the 
health of the entire population.  
 
2.3.1 Infant mortality in Canada and Saskatchewan 
 Canada has experienced dramatic declines in infant death over the past century.(117) 
Despite its remarkable progress, Canada still has high rates in comparison to other Organization 
for Economic Co-operation and Development (OECD) countries. Canada’s relative ranking on 
IMR fell to a ranking of 15
th
 place
 
out of 17 peer countries in 2006.(118) An important limitation 
to international comparisons is the lack of standardization of live birth and stillbirth registrations, 
which undermines the ability to compare fetal and infant mortality rates.(36) Within Canada, the 
IMR varies considerably across provinces and territories, with Saskatchewan having the highest 
rate in 2009 (see Figure 2.5).(119) 
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Figure 2.5 Crude infant mortality rates by province and Canada, 2009* 
 
*Statistics Canada, CANSIM. Infant mortality rates by province and territory. Table 102-0504  
  
 Historically Saskatchewan has had one of the highest rates in the country. In recent years, 
Saskatchewan and Manitoba, and more recently Newfoundland and Labrador, have vied for this 
notorious distinction (figure 2.6).   
Figure 2.6 Infant mortality rates by province, Canada, 2003-2009*
 
 *Statistics Canada, CANSIM. Infant mortality rates by province and territory. Table 102-0504  
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 Within the province, rates vary widely across health regions from as low as 3.7 deaths per 
1,000 live births in the Cypress Health Region to as high as 11.4 and 15.3 in the Mamawetan 
Churchill and Athabasca Health Regions in 2001-05 (five-year averages).(120) Differences in 
social, economic and health care environments across health regions may explain some of this 
variation, but exact causal factors have not been fully explored.  
Aboriginal ancestry and income are two interrelated risk factors that have been identified 
as impacting infant mortality. Disparities across ethnic and socioeconomic populations provide 
important insights into the nature and magnitude of inequity in our society. In Canada, the IMR 
among Aboriginal peoples has been reported as being twice as high as the rest of the population 
for the past century.(38, 121) Interestingly, however, statistics released from the First Nations 
and Inuit Health Branch (FNIHB) in 2000 noted a drop to 6.4 per 1,000 live births as compared 
to the national rate of 5.3 per 1,000 live births.(122) Similar to inconsistencies internationally in 
the documentation of births, evidence suggests underreporting of infant and fetal death in 
Aboriginal populations have an impact on IMR statistics, in particular for births at the borderline 
of viability.(123) A recent study done by the Joint Working Group on First Nations, Indian, 
Inuit, and Métis Infant Mortality disputes the IMR reported by FNIHB and concludes that 
available information demonstrates persistent and sizeable disparities.(38) Specifically, it found 
infant mortality rates in First Nations (Status Indians on-reserve), Status Indians living off-
reserve and Inuit were 1.7 to more than 4 times higher than the overall Canadian and/or non-
Aboriginal rates. The greatest disparity in infant mortality appeared during the postneonatal 
period, where death is often attributed to congenital conditions, sudden infant death syndrome, 
and infections. It has been hypothesized that some of the difference in IMRs across Aboriginal 
and non-Aboriginal populations is attributable to inadequate prenatal care, however, it is unclear 
what impact improved access to earlier prenatal care would have on infant mortality. Smylie 
(124) credits socioeconomic inequities as the source of the disparity, along with the distances 
needed to travel to receive adequate maternity care. Ethnic disparities in the United States have 
persisted in spite of improvements in prenatal care utilization by black and Hispanic 
women.(125)  
Accurate documentation of Aboriginal ethnicity and capture of all births in this 
population is paramount to valid and reliable IMRs for Aboriginal populations in Canada.  
Following work done by the Joint Working Group on First Nations, Indian, Inuit, and Métis 
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Infant Mortality, Smylie, Fell, and Ohlsson (2010) comment on the need for better 
standardization and further research on this topic:  
“The calculation of accurate IMRs for Aboriginal populations in Canada is 
complicated by the lack of uniform and consistently available information regarding First 
Nations, Indian, Inuit, and Métis identity in Canadian birth and death registration databases. 
Our efforts at systematic review of the existing literature were limited by the paucity of 
publications in this area. There is a pressing need for more scholarly work, including the call 
for a more standardized approach to the collection of First Nations, Indian, Inuit and Métis 
birth and death data in the provinces and territories, particularly for non-Status Indians and 
Métis.”(38, p.147)  
The current research will help to broaden our understanding of infant mortality in Registered  
Indian populations in Saskatchewan and will shed light on the uptake and impact of prenatal 
screening and intervention in this population sub-group.   
Despite the fact that significant progress has been made in Aboriginal peoples’ overall 
health status, Aboriginal infant mortality rates remain higher than those for the rest of the 
Canadian population.(38) Elevated death rates in Aboriginal infants may be explained by 
socioeconomic risk factors, including poor housing conditions, communicable diseases, lower 
utilization of prenatal and medical care services, chronic disease, lifestyle factors (higher rates of 
obesity and smoking), and less frequent incorporation of preventative measures.(120, 125) One 
Canadian study documented an income gradient in an urban setting with the highest income 
levels having the lowest IMR and the lowest income levels having the highest IMR.(126) Given 
that both Aboriginal adults and children disproportionately experience poverty and low income 
in Canada, socioeconomic circumstances certainly will play some role in the higher mortality 
risk among Aboriginal infants, but the exact mechanism responsible for this association is not 
known. Differences in IMR across population sub-groups cannot be adequately explored without 
accounting for competing explanations such as uptake of prenatal screening and selective 
termination. Prenatal screening and pregnancy termination for fetal anomalies are believed to be 
much less common in Aboriginal women, while risk for some CAs to be higher; a difference that 
may explain disparities in infant death. No research has been done yet exploring the link between 
pregnancy termination for congenital anomaly and IMR with special attention to Aboriginal 
populations.  
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2.3.2 Reproductive Technologies and Congenital Anomaly-Specific Infant 
Mortality 
 If lower rates of infant death are partially or largely explainable by increased prenatal 
screening/diagnosis and selective terminations, it is important that this link is well-understood. A 
body of research has begun to establish a clearer relationship between TOPFA and rates of fetal, 
neonatal, and infant mortality.(2, 14, 15, 98) Still studies have yet to establish TOPFA as a 
definitive cause of lowered rates of overall infant mortality, quantified its impact, or suggested 
what the rate would be if new reproductive technologies and pregnancy termination for this 
reason were not available. The quantification of impact will be necessary if we are to restore 
IMRs ability to reflect the true realities of populations. As Gortmaker & Wise (1997) explain, 
"mechanisms that traditionally defined infant mortality as a 'social mirror' (127) have been 
altered appreciably by rapid innovations in health services technology.”(34 p.148) Such 
innovations, when accessed differentially by population sub-groups, have the ability to create or 
exacerbate apparent disparities in health indicators.  
Pregnant women in Saskatchewan have traditionally been less inclined to utilize 
reproductive technologies and elective abortions.(102, 128) For instance, it is estimated that 
more than one in five pregnancies was terminated nationally in 2006, while one in eight was 
terminated in Saskatchewan.(128)
10
 This apparent preference towards non-intervention could in 
fact explain the historically higher infant mortality rates – a central hypothesis of this research.11 
The decline observed nationally over the past three decades has been due, in part, to fewer 
infants dying from congenital anomalies, and there is evidence to point to TOPFA as the cause 
(1, 13-15, 37). A more nuanced understanding of this link is important to our understanding of 
regional variations and trends in prenatal testing and intervention. 
                                               
10 The Therapeutic Abortion Survey has notable limitations and the national figures provided are underestimates of 
the actual rate of induced abortions nationally. Some respondents, representing significant portions of the Canadian 
population, withhold their information. Since 2003, no information has been collected on Canadian residents who 
obtain an abortion outside of Canada. The figures also only include those abortions that occur either in hospital or 
clinic, and do not include other types of abortions (eg. pharmacological abortions).129. Canadian Institute for 
Health Information. Update to the Privacy Impact Assessment of the Therapeutic Abortions Database, 2003. March, 
2011. In Saskatchewan, all information on therapeutic abortions occurring in hospitals is submitted. No abortions 
occur in clinics in Saskatchewan, therefore the provincial estimate is expected to be a better representation of the 
true incidence.   
11 It is also possible that factors other than personal values/preferences have contributed to the lower rate of 
abortions in Saskatchewan, such as low access. This possibility is discussed further in the discussion chapter. 
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Figure 2.7 Ratio of induced abortions per 100 live births, Saskatchewan and Canada, 1990 
– 2006*  
 
*Statistics Canada. Induced abortions in hospitals and clinics, by area of residence of patient, Canada, provinces and 
territories, annual. CANSIM table 106-9013. 
The primary causes of infant death have changed somewhat over time and are different 
for developing and developed countries. The history of infant death in Canada is not an 
uncomplicated one. Here congenital anomalies and immaturity have been the leading causes of 
death – accounting for approximately 55% of deaths in 2004.(37) One-quarter of infant deaths in 
Canada were due to CAs alone. Five year earlier CAs were the number one cause of infant death. 
While the national IMR has been in steady decline since the early 1960s, rates leveled out 
between 1991 and 1995, then dropped significantly in 1996 and 1997 despite increasing 
registration of births less than 500 grams.(15) The gains of 1991 – 1997 were mainly attributed 
to fewer SIDS deaths and deaths due to immaturity. Against the backdrop of these changes in 
infant mortality risk, the congenital anomaly-specific IMR in Canada steadily declined each year 
from 2.53 per 1,000 live births in 1985 to 1.06 per 1000 live births in 2005 (see figure 2.9).(130) 
Other developed countries have witnessed similar drops in CA-specific IMRs over the last two 
decades.(1, 131) 
Studies by Wen, Liu, Joseph, Kramer et al have made significant contributions to the 
broader understanding of infant and fetal mortality trends due to congenital anomalies in 
Canada.(1, 2, 13-15) One of the earliest studies, by Wen et al (14) in 1999, found large 
interprovincial variations in infant mortality caused by cardiovascular system anomalies and 
anencephaly, whereas no variation was observed across provinces for chromosomal anomalies. 
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Infant mortality rates due to CA were also generally higher in Newfoundland, Saskatchewan and 
Alberta (1990-1995). This early piece of research, however, had two key shortcomings that call 
into question the inferences made. First, data on basic risk exposure (maternal age, in particular) 
was not available for analysis, which also varies by region. Because maternal age cannot be 
accounted for as an explanatory variable, it may be that some provinces have older maternal 
populations and therefore higher rates of particular CA types, which could alone increase the 
number of infants dying from a CA. Second, the results are purely correlational as the study was 
descriptive and did not explore causal links between prenatal screening, selective termination 
and cause-specific or overall IMR.  
Using live birth and death databases for several Canadian provinces/territories (Ontario, 
Newfoundland, and British Columbia were excluded), Wen et al (13) analyzed trends in infant 
mortality due to congenital anomalies between 1981-83 and 1993-95. The researchers identified 
reductions in many major CA categories, but noted that the magnitude of decrease varied 
according to CA type. Decreases were largest for anencephaly (pre-folic acid supplementation 
and fortification), spina bifida, and digestive system, musculoskeletal, and cardiovascular 
anomalies.(13) An interesting discovery was that the proportion of infant deaths due to 
chromosomal anomalies, some of which are detectable through prenatal screening, rose from 
7.5% (1981-83) to 13.0% (1993-1995); the authors point to increasing maternal age as a potential 
explanation. Infant deaths due to respiratory and urinary system anomalies did not show a 
significant decline, which makes sense given that these CA types are difficult to detect 
prenatally. Provinces and territories without widespread access to a provincial prenatal screening 
programs (at the time) were observed to have higher rates of infant deaths due to CA. For 
instance, compared with the province of Quebec, congenital anomaly-attributed infant mortality 
was statistically significantly higher in Newfoundland, Saskatchewan, and Alberta. These 
changes in cause-specific CA infant mortality strengthen the inference that prenatal screening 
and termination of pregnancies for CA are together responsible for observed declines and 
variations in IMR.  
A 2002 study by Liu et al (15) found that the lowered IMR observed nationally in 1996 
and 1997 was preceded by a rise in early fetal deaths (20-21 weeks) due to pregnancy 
termination or CA, suggesting a shift in the timing of death from infancy to the perinatal period. 
Both fetal death due to CA and fetal death due to pregnancy termination at 20 to 21 weeks 
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increased substantially between 1991-1998  (94% and 578%, respectively). It could also be seen 
that provinces and territories with higher rates of fetal death due to pregnancy termination and/or 
congenital anomalies at 20-23 weeks gestation had lower CA-specific IMR.(15) For example, in 
Saskatchewan the fetal death rate due to pregnancy termination/ congenital anomalies at 20 to 23 
weeks' gestation was 16.7 per 100,000 fetuses at risk with a CA-specific IMR of 2.57 per 1000 
live births, as compared to Nova Scotia where the fetal death rate was 131.4 per 100,000 fetuses 
at risk and the CA-specific IMR was 1.35 per 1000 live births. While this association was most 
evident for provinces like Saskatchewan, Newfoundland, Manitoba and Nova Scotia, it was 
questionable for Quebec, New Brunswick, and Prince Edward Island. Unless one simultaneously 
considers the incidence of fatal anomalies in each population, it is difficult to interpret aggregate 
trends. For instance, provinces with lower rates of neural tube defects will generally have a lower 
cause-specific IMR, as well as lower rates of fetal death due to pregnancy termination and/or CA 
for this reason. High rates of fetal death due to pregnancy termination, on the other hand, could 
theoretically reflect more terminations for Down syndrome, but this condition does not 
contribute significantly to death during the first year. Ideally, future studies can be designed to 
differentiate between pregnancy termination and etiological factors when examining the reasons 
for CA-related IMR.(15) While the study by Liu et al represents the most convincing piece of 
research on the TOPFA-IMR link to date, it utilized live birth and stillbirth databases only and 
provinces were not using a standard definition of stillbirth during the study period (1991-98), 
which means that a portion of pregnancy terminations for CA would have been missed. Because 
terminations of pregnancies for CA are often carried out before 20 weeks gestation, many cases 
would not be captured through the stillbirth data. An Australian study found that 79% of 
pregnancy terminations for CA were done before 20 weeks gestation.(131) In addition, while 
fetal deaths due to CA/termination were captured in the Liu et al (2002) study, identification of 
the reason for pregnancy termination (ie. CA type) was not possible.(15) While TOPFA was 
clearly a factor in the lower rates of infant deaths observed in some provinces, differences may 
have been due in part to maternal age distributions, other risk factors, or importantly, greater 
prenatal detection rates and therefore more fetal deaths being attributed to a CA. This is a 
challenge with grouping fetal deaths due to CA and TOPFA, and exemplifies the importance of 
having linked data on prenatal diagnosis and other demographics. Liu and his colleagues (2002) 
predicted that with the shift towards first-trimester screening and greater access to prenatal 
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diagnosis in rural communities, terminations of pregnancy for CAs would increase and 
subsequently CA-specific IMRs would decline further.(15) To adequately monitor and account 
for this mode of  intervention, our data systems must be designed to accurately capture earlier 
terminations of pregnancy and work will need to be ongoing as prenatal screening/diagnosis 
practice continues to evolve. 
Outside of Canada, Australia has witnessed a similar phenomenon where infant mortality 
rates due to CAs went from 4.36 per 1000 births in 1980-84 to 2.75 per 1000 births in 1995-
98.(131) Bourke et al (2005) conducted one of the only studies designed to estimate the effect of 
pregnancy terminations for CA on mortality rates to one year of age over two decades (1980-
1998).
12
 Utilizing linked data from the Western Australian Birth Defects Registry, the proportion 
of pregnancy terminations for CA that would have resulted in a death before one year of age was 
estimated and adjusted death rates calculated. Experimenting with two new approaches for 
modeling this impact (in addition to the standard crude rate calculation), the researchers found 
significant differences in mortality rates to age one after adjusting for terminations of pregnancy 
for CA. The methods yielded important differences, showing changes ranging from a 37% 
reduction in mortality rates to age one to an 11% increase. Model one (1980-1998) and two 
(1980-84) calculated the proportion of births affected by a CA that resulted in a death by age 
one. These proportions were multiplied by the number of terminations in each CA category to 
estimate additional mortality to age one. Using an expert case review approach (model three), 
approximately half of the observed reduction in all-cause mortality to one year could be 
explained by the increase of terminations of pregnancy for CA.(102) Australia's supposed 
success in reducing mortality among CA live-born infants (to one year of age) was almost halved 
in the case of nervous system defects and increased substantially for chromosomal defects.   
 
 
 
 
 
 
 
                                               
12 Mortality rate to one year of age is different from the infant mortality rate in that it includes perinatal (stillbirths 
>=400 grams or of >= 20 weeks and live births dying within 28 days) and postneonatal (29 – 365 days) deaths. The 
advantage of this approach is that no time of death needs to be ascribed, in so far as determining the likelihood that 
each pregnancy termination might have resulted in a stillbirth, neonatal, or postneonatal death.  
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Figure 2.8 CA-specific mortality rates to age one, four methods to rate calculation, 
percentage change over two time periods (1980-84 and 1995-98), Australia*  
 * Bourke J, Bower C, Blair E, Charles A, Knuiman M. The effect of terminations of pregnancy for fetal 
abnormalities on trends in mortality to one year of age in Western Australia. Diatr Perinat Epidemiol. 2005 
Jul;19(4):284-93. 
  
 In Saskatchewan congenital anomaly surveillance is poor. There is no provincial CA 
surveillance system in place, although Saskatoon Health Region implemented a pilot system, and 
the only provincial statistics publicly reported on CAs pertain to CA-related infant mortality. 
Changes in infant mortality due to CAs occurred somewhat sporadically from 1985-2005, 
although a general downward trend can be seen. From 1998-2005, the rate declined from 2.35 to 
1.59 per 1,000 live births (-32.3%), which represented a larger decrease than the period from 
1985-1998 (-12%). Overall, the CA-specific IMR in Saskatchewan decreased by 46% between 
1985 and 2004, compared to a national decline of 58%. The Saskatchewan rate was also notably 
higher than the Canadian rates over time, including the most recent years. This data alone 
provides additional support for the TOPFA–IMR link, however lowered rates in Saskatchewan 
might have been due to other factors including fewer CA-affected pregnancies (eg. younger 
population of mothers, preconception preventive measures), improved medical care, and 
differences in the number of low birth weight births. Moreover the factors driving the 
Saskatchewan trends could differ from those observed nationally.  
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Figure 2.9 CA-specific infant mortality rates, Canada and Saskatchewan, 1985-2005* 
 
* Public Health Agency of Canada, Congenital Anomaly Surveillance System, 2012. Congenital anomaly 
national prevalence data, 1989-2006. Ottawa. 
 
2.4 Predictors of Uptake of Prenatal Screening  
Some women accept maternal serum screening (MSS) while others do not. Differences in 
patient characteristics, preferences, values, or some other structural barriers to MSS may explain 
variations in uptake. Evidence shows that personal characteristics such as maternal age, religious 
background, ethnicity, and geographic location all impact MSS utilization to some extent. In an 
audit of four East London hospitals, maternal age and ethnicity both significantly predicted 
uptake of MSS for Down’s syndrome.(63) Women aged 37 or over at the time of delivery had 
the lowest uptake of serum screening, but were more likely to bypass serum screening and go 
directly to amniocentesis. Uptake of MSS in London was also higher among Caucasian (84%) 
women as compared to Bangladeshi (42%), Indian (74%) and Pakistani (75%) women (69). 
Religious background also appears to influence women’s decisions. In one study conducted in 
Israel, Sher et al. (2002) found that substantially more non-religious women underwent prenatal 
diagnostic testing compared with more traditional, orthodox (religious), or ultra-orthodox 
women.(82) Shohat (2003) found use of MSS to be lower in the non-Jewish population, with the 
overall uptake of 20% remaining stable from 1996 through 2000 in Israel.(132) It is not known if 
ethnicity or religion is a factor in the decision-making of pregnant women in Canada. In fact, 
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there are no published studies that stratify MSS uptake for different ethnic groups within Canada 
or look at other predictors of uptake. Still there is the perception by Saskatchewan physicians 
that Aboriginal women in the province accept MSS less often than non-Aboriginal women.(32) 
Uptake of prenatal screening has increased over time in many regions, although 
utilization can still vary widely within the same community. For instance, in London from 1990 - 
1999 uptake ranged from 45-80% across hospitals.(63) Here in Canada, an Ontario study found 
an overall uptake of 48%, with rates being as high as 60% in Toronto and below 20% in 
Northern Ontario.(70) The same was seen in British Columbia where 45% of all pregnancies 
were screened in 2005, but rates varied from 84% in Vancouver to 29% in Vancouver Island and 
28% for the rest of the province.(133) Nationally, Manitoba had the highest reported rate of 
uptake at 60% in 2006 whereas Saskatchewan and Newfoundland and Labrador had the lowest at 
just over 20%.(80, 134, 135) In 2006, uptake in Ontario sat at 63% and at 49% in BC.(133, 136) 
MSS experienced a dramatic increase in popularity in South Australia over a relatively short 
amount of time, rates jumping from 17% in 1991 to 75% in 1996.(25) In a study in France 
(1997-98), Muller et al (2002) found that 65% of all pregnant women in that country had 
MSS.(71) 
 
Figure 2.10 Maternal serum screening (all modalities), select provinces, Canada, 2006  
 
The way in which MSS is offered by each health system and provider characteristics have 
been shown to have some impact on utilization rates, however the relationship is not 
straightforward. Dormandy et al (2002) found a higher uptake of screening in hospitals in one 
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health region in England where serum screening was offered as part of the routine prenatal check 
as compared to those where a separate visit was required.(137) However, the type of screening 
test offered and whether or not a reminder notice was sent showed no effect. In Canada, research 
has shown that female physicians (compared to male) and obstetricians (compared to family 
physicians) were more likely to report offering screening to all patients.(21, 32) 
Statistics on MSS uptake are made up of several groups of women including: those who 
accept, those who refuse (either directly to their care professional or by not presenting for the 
blood work), women who were never offered testing, and women presenting too late in their 
pregnancy for medical care and were therefore ineligible for screening. Research on this topic is 
extensive, spanning many countries, population sub-groups and three decades, and has identified 
several common themes about why or why not women have screening done. Reasons for 
screening included: to gain knowledge about the health of the fetus; being at increased risk of 
having a child with DS; did not know they could refuse screening; favourable characteristics of 
the screening test; trust in care professionals to offer only important tests.(25, 26, 30, 138, 139) 
Reasons for declining included: unfavourable characteristics of the screening test (eg. high false-
positive rate; cannot detect all cases); not necessary/ personal risk perceived to be low; would not 
make a difference in the management of the pregnancy; opposition to abortion; anxiety/ 
uncertainty (and concerns about the impact of this stress on the baby); risk of fetal loss and harm 
during invasive follow-up testing; opposition to the medicalization of pregnancy; acceptance of / 
knowing persons with disabilities.(23-25) 
 Some women who receive “increased risk” serum screening results will decide to 
follow-up with prenatal diagnostic testing and some will not, depending on many factors relating 
to the mother’s risk profile and values and preferences. Alberman et al (2003) found that more 
women under age 35 with a positive MSS result had prenatal diagnostic testing as compared to 
women aged 35 and over (58% and 41%); whereas a greater proportion of women aged 35 and 
older with a negative MSS result chose to have a diagnostic test (9% and 0.3%).(63) One study 
in Connecticut (1996) found that even though advances in screening had occurred, the proportion 
of DS cases detected during a 12-year period had not changed.(62) Ultimately, the decision to 
choose follow-up testing is based on a number of factors and appears to vary by geography and 
across population sub-groups (similar to prenatal serum screening). The overall impact of 
screening on CA detection requires uptake by a significant proportion of the population, test 
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sensitivity, and the decision to follow-up increased-risk results with diagnostic testing. To date, 
no studies have been published in Canada tracing uptake through the pathway from prenatal 
screen offer to acceptance of prenatal diagnosis and pregnancy outcome.  
Women’s decision to accept or reject testing does not necessarily offer much about her 
value and preferences or rationale. Based on the literature, a plethora of factors can play a role in 
uptake. For many women the goal of screening is to rule out any problems and receive 
reassurance of the baby’s health, rather to intervene through abortion.(25, 80) By examining 
patterns of uptake of screening, diagnosis and pregnancy termination, some insights may be 
gained about the delivery and acceptance of new emerging reproductive technologies. However, 
more qualitative study and surveys will need to be done with Saskatchewan women themselves 
in order to know the exact reasons for choosing to screen or not to screen. 
Differences in prenatal detection and termination of pregnancies affected by CAs have 
been shown to create disparities across socioeconomic and geographic groupings. One 
population-based study in Paris, France found that maternal occupation and place of origin had 
significant effects on the likelihood of a prenatal diagnosis of Down syndrome and on 
continuation of pregnancy after DS diagnosis.(31) Women in lower-status occupations were 
more than twice as likely, after controlling for age, to deliver a live-born infant with DS as 
women in the highest-status occupational category. This finding is consistent with research that 
has shown socioeconomic disparities in use of medical services generally, and prenatal testing in 
particular, in several countries.(34, 140-147) Khoshnood et al (2006) were the first to show that 
differences in the uptake of prenatal diagnostic testing by socioeconomic groups resulted in 
differences in live-birth DS prevalence; a finding that is due to the fact that women of lower SES 
were less likely to opt for screening/ diagnosis and were less likely to terminate a pregnancy 
when diagnosed with DS.(31) The study also found no difference in age-adjusted DS risk for 
women of different socioeconomic backgrounds. France has an active national policy targeting 
increased access to prenatal screening and a culture that favours pregnancy termination, which 
have together led to overall reductions in the live-birth prevalence of DS, perhaps making it a 
special case. A more recent study by Smith et al (2011) using data from the United Kingdom 
Fetal Anomaly Screening Program found that while antenatal detection rates were similar for 
pregnant women from different deprivation areas, the rates of TOPFA were lower in women 
from more deprived areas compared to those from less.(98) Differences in TOPFA led to 
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sizeable differences between deprivations areas in the live birth rate of CAs and neonatal 
mortality associated with nine of the anomalies studied. These observed disparities mean that 
families with fewer resources are more often taking on the responsibility for caring for, and 
advocating for, children with special needs. 
 
2.5 Gaps in current research and surveillance 
The greatest impediment to basic CA surveillance in Canada is the inability to accurately 
capture termination of pregnancies for CA, and the resulting underestimation of CA, which 
prevents systematic investigation of risk factors and trends in maternal, perinatal, and infant 
health. A strong national CA surveillance system would require the bringing together of data 
from multiple sources, which is complex and requires committed resources. The Canadian 
Congenital Anomaly Surveillance System (CCASS), the national surveillance database, does not 
capture data on early terminations of pregnancy for CA or those that occurred outside a hospital 
or other important risk factor information.
13
 While it provides good quality information on CA 
live births and stillbirths, a significant proportion of CA pregnancies are spontaneously lost or 
terminated and therefore missed. According to Meschino (2007), a well-developed and 
functional CA surveillance system is integral to understanding the effectiveness of interventions 
(diagnosis, medical and surgical); helping to determine prognostic factors for many CA types; 
enabling us to better research CA etiology and tracking risk factor prevalence; and for exploring 
the impact of mode, timing, and location of delivery on morbidity and mortality of infants born 
with CAs.(148) Back in 2002, Alberta and Newfoundland were the only programs that collected 
elective pregnancy terminations less than 20 weeks and Newfoundland only captured those that 
are NTD-related.(5) In recent years investments have been made in provincial surveillance 
systems to enhance capacity for population-based reporting and data sharing agreements are in 
place (or underway) to enable many provinces/territories to contribute data to the CCASS. A 
standardized approach to collecting data across provinces (and even within provinces, as is the 
case in Saskatchewan) is necessary to render comparable statistics, addressing many of the 
limitations described.  
                                               
13 The CCASS is testing the linkage between mother and baby records and extending follow-up to two years. This 
linkage will provide data on  maternal age, health conditions (diabetes, asthma), and drug usage (when recorded on 
the hospital record) (personal communication, Jocelyn Rouleau, Public Health Agency of Canada).  
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 An estimated one in every five pregnancies in Canada was terminated in 2006.(128) Yet 
this population of pregnancies is routinely excluded from consideration when reporting 
provincial, national and international statistics on fetal mortality. Another important concern is 
that the Therapeutic Abortion Database/ Survey, the only source of abortion data nationally, has 
several data quality concerns that undermine its validity and reliability. Specifically, the data has 
incomplete demographic information; excludes out-of-country procedures after 2003; potentially 
double counts some records due to lack of identifiers; and several larger Canadian clinics have 
opted not to submit abortion data at all.(128) In addition, since 1999 Ontario has altered its 
method of capturing abortions and this has resulted in underestimates of about 5.4% each year 
provincially and 1% nationally. These are significant, and often underappreciated, omissions in 
the data used to conduct maternal and perinatal surveillance. 
 Another well-documented, although not-well-understood, challenge is the relatively 
common occurrence of spontaneous abortions (or "miscarriage"). Few surveillance systems 
worldwide track this pregnancy outcome, which may be due to the significant portion of cases 
that occur outside hospital and their uncertain significance as far as maternal and fetal/infant 
health. Typically spontaneous abortion is used as an outcome in itself, since testing of the fetus 
to identify causes is rare, and where known, is often not documented in hospital or physician 
databases. Still, spontaneous abortion, if used as part of an intentional surveillance program, can 
be used as a marker for teratogens in the environment, recognizing that many anomalies that 
appear among spontaneous abortions never or rarely appear in live births and the majority of 
anomalous conceptions are found in such cases.(149) Despite the lack of information available 
on this type of pregnancy outcome, many fetuses with a congenital anomaly are lost early. One 
study examining outcomes for 538 fetuses prenatally-diagnosed with trisomy 13 or 18 found that 
between 12 weeks gestation and term many ended in spontaneous abortion or stillbirth (49% and 
72%, respectively).(150) In the case of CA surveillance and research, natural fetal loss (including 
both spontaneous abortion and stillbirth) and elective medical abortions are crucial to our 
understanding of the true occurrence of these outcomes.  
  
 2.5.1 A need for improved indicators 
 The advent of new prenatal screening technologies has the potential to mask real changes 
in infant and fetal death, thereby globally affecting these indicators. A solution proposed by both 
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Davidson et al. (2005) and van der Pal-de Bruin et al. (2002) is the use of “natural” or “adjusted” 
indicators of perinatal death.(151, 152) Specifically, terminations of pregnancy for fetal anomaly 
can 'artificially' reduce perinatal and infant mortality rates and give the illusion that progress has 
been made on etiological factors. An adjusted indicator could estimate mortality rates, under the 
hypothetical scenario that no TOPFA were performed.    
 The importance of revealing the natural IMR is that it offers a truer depiction of progress 
(or decline) in improving the social, economic, and health care environments that sustain and 
promote wellbeing of the population and for which the health and survival of infants is a key 
marker. As noted earlier, IMR is a valuable indicator of the health of the entire population. In 
terms of policy and surveillance, the lack of an adjusted IMR prevents decision-makers from 
accurately assessing the performance and policies of federal, provincial and regional/ community 
programs and broader health initiatives. It also leaves the door open for speculation that yearly 
fluctuations are due mostly or partly to prenatal screening and selective termination, without any 
definitive evidence to support or to dispute such a claim. It is unclear then if Saskatchewan’s 
poor overall performance, as far as infant mortality, is the result of lower or declining quality of 
the social determinants of health or if it is linked to its historically lower uptake of prenatal 
screening and diagnosis as compared to other provinces. If the latter is the most responsible 
explanation, then the greater acceptance of prenatal screening and higher rates of termination of 
pregnancy for fetal anomaly in other provinces must not be mistaken for higher-quality social, 
economic, and health care environments which are the real determinants of lower IMR. In sum, 
the lack of clear understanding of the determinants of infant mortality in Saskatchewan blunts 
discussions around this topic and compromises the IMR’s potential as a key indicator of a 
society’s health-promoting circumstances.  
 Research has been done looking at changes in perinatal mortality (PMR) as a result of 
termination of fetuses with CAs. Van der Pal-de Bruin et al (2002) estimated the impact of 
prenatal terminations on the PMR using a calculated lethality for each CA in the hypothetical 
case that no pregnancy termination had been performed and was expressed in the natural 
PMR.(152) The study found large differences between European countries and regions in terms 
of the number of termination of pregnancies for CAs. The differences between the reported and 
natural PMR varied between 3.7 and 14.1 per 10,000 live and stillbirths. The difference was 
greater in regions where prenatal screening was more common. Here the emphasis on infant 
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mortality is largely due to the importance placed on the IMR as a global health indicator, as it is 
a much-more widely used indicator of general societal health and wellbeing. It is often used in 
health planning, evaluation, community research, and policy development.(34, 39, 41, 153) If a 
measure (ie. a TOPFA-adjusted IMR) could be developed that takes into consideration the 
population of vulnerable fetuses that have been removed by means of abortion, many of which 
would have been born alive, the validity and utility of the IMR would be strengthened. Ideally, 
the end result would be a single figure that is relatable in both policy and research contexts.  
 
2.6 Ethics 
 Ethical inquiry has been incorporated into the current research for three reasons: (1) 
questions of ethics are valuable because they are socially relevant and intimately linked to the 
practice of selectively terminating pregnancies with CA; (2) the academic literature on prenatal 
screening often sidesteps the issues of ethics, addressing them separately as opposed to 
considering the interconnectedness of concepts; and (3) no ethical framework exists for future 
decision-making and policy around prenatal screening in Saskatchewan or Canada. An 
environmental scan (2002) was conducted on behalf of the CIHR Institutes’ of Genetics and 
Health Services and Policy Research Joint Planning and Policy Committee on Health Services in 
Genetics.(154) The report commented on some of the shortcomings of research and policy-
planning documents to date. “Many of the reports identified were theoretical or discursive in 
nature and varied in scope from highly specific to very general. The majority were rather 
general, and some focused on a particular issue or set of issues concerning genetics 'in society'. 
Most identified issues and concerns but few went beyond this in any useful way.”(154) 
Alternatively, the committee developed a list of key questions on health services in genetics. In 
particular, there were questions concerning the impact of genetic testing and related health 
services on people and their families, society, health care providers, funders and industry, with 
attention to the broad range of factors that might modify such impact. The expectation for the 
current research is that it will go beyond describing the key ethical dilemmas around prenatal 
screening to offer some insights into how providers and policymakers might deal with such 
issues, whether or not a broader social consensus can be reached.  
Despite its contentious nature, very little public dialogue has occurred around prenatal 
screening in Canada. The deeper one delves into the policy landscape, the more one recognizes 
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the need for greater engagement of a variety of affected stakeholders. Many have called attention 
to the widening gap between genetic advances and reproductive screening/diagnostic 
technologies and their application in clinical practice, yet not enough has been done on the policy 
front to attend to such disconnects. At the practice level, prenatal screening has raised concerns 
about everything from inadequate provider knowledge and education, lack of informed consent, 
lack of access to and inadequacy of genetic counseling, and poor test performance, to disparities 
in access and utilization between different groups of women. In terms of broader policy creation, 
there are questions about the limits of screening, its ethical basis and eugenic potential, 
implications for those living with disabilities, the question of personhood and the moral 
significance of the fetus, as well as who is driving the technology - mothers or industry or 
experts. There is an ever-widening gap between genetic knowledge and society's capacity to 
think through these new possibilities, but the need is growing for this type of thinking and a more 
applied ethics approach.  
Emerging are the fields of Public Health Genetics and Community Genetics where 
numerous theories have been postulated about ways in which the gap between clinical medicine 
and public health interventions can be bridged.(155) However, debating the practicalities of 
implementing genetic medicine at the population level may be somewhat premature. What must 
be considered first, and articulated, is the foundation that these decisions ought to be based upon. 
Values are a critical building block of the 'translational highway' hoping to link clinical and 
public health genetics, and in fact, values must set the foundation.(155) In the United States, the 
National Human Genome Research Institute currently supports a scholarly program on the 
ethical, legal and social implications (ELSI) of genetics research. ELSI inquiry examines the 
values underlying the use of new genetic technology, ideally before it is in use. In 1999, the 
ELSI program was expanded to specifically address issues arising when genetics is used to 
advance the public's health; the results was Public Health ELSI (PHELSI). While there is some 
dialogue amongst Canadian ethics scholars on the social, legal, and ethical ramifications of 
prenatal screening, there is no parallel program in this country or mechanism for knowledge 
translation between new research and scholarship and decision-making.  
Currently there are not any real limitations or laws setting parameters around termination 
of pregnancies, and a pivotal question arises: whose values will guide decisions about which 
terminations are morally acceptable, socially desirable and legally permissible? Arguably, 
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prenatal screening presents another case of science leading us and we are racing to catch up. 
Some have argued that the issue has quite successfully been framed as a purely private or 
medical matter, where the focus is on procedural solutions when substantive debate is actually 
what is required.(156) In Canada today, the Society of Obstetrics and Gynecologists of Canada 
(SOGC) along with the Prenatal Diagnosis Committee of the Canadian College of Medical 
Geneticists (CCMG) provide guidelines and recommendations on prenatal screening and 
diagnosis for practitioners.(52, 54, 157) However, some might argue that organizations whose 
professional bodies have a vested interest in promoting the uptake and spread of this technology 
and associated interventions should not be taking the lead on writing the best practice guidelines, 
or at minimum, that the views of those living with disabilities and intended users (women) 
should also be represented in such guidelines. In the absence of legislation or policies at the 
national or provincial level to guide current or future practice, there is a rather disjointed and 
vague decision-making landscape. However, legislation and public health policy can offer a 
variety of safeguards against potential misuses.(155) It is this lack of coherence and leadership 
that puts our society at risk for morally objectionable practices and increases the risk for an 
uninformed public to watch as a new reality around birth and genetics is fashioned and 
normalized. 
Prenatal screening and termination of pregnancy for fetal anomaly continue to occur as 
though they are 'normal', or at least acceptable personal decisions, thereby demanding little 
attention. A better answer, it will be argued, is that the Canadian public is educated and 
consulted in a meaningful and deliberate way, where multiple voices guide public policy on 
these fundamental and monumental questions. On the face of it, Canadian society supports 
public participation and community involvement, yet the public has been left out of this key 
policy issue. Where prenatal screening is described in both academic and lay publications, the 
ethical issues raised are often given token recognition or left out entirely, unless debate occurs 
within a forum that specifically engages ethical issues. Up until recently, there has been no 
concrete attempt, or even plan, for engaging Canadians around discussions of values and morals. 
Questions of ethics have been broached in a limited way on broad topics relating to 
biotechnology through the Canadian Biotechnology Strategy, but prenatal screening was omitted 
from inquiry.(158) If not addressed, select groups of experts will carry on making all decisions 
about new and existing screening technologies for the whole of society. Ethical discussions will 
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continue to be restricted to the individual and the clinical encounter, where the historical roots 
and societal implication of this practice are decontextualized. Prenatal screening as it exists 
today, and as it is imagined for tomorrow, sets parameters around which human lives are 
optional and as such warrants a more open, encompassing, and transparent debate. The active 
engagement of an informed public will be essential if the positive potential of genomics is to be 
realized, while minimizing social harms.(155) 
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CHAPTER 3: METHODOLOGY 
 
3.0 Study Design 
In studying the relationship between maternal serum screening, pregnancy termination 
for CA, and live CA birth rates and infant mortality rates, multiple data sources were combined 
to create a comprehensive maternal-fetal-infant database. Most of the data spanned a six-year 
period (2000-2005) and individual level variables were drawn from the following sources: the 
provincial health administrative databases (hospital and physician services, person registry), 
provincial laboratory MSS data file, Vital Statistics, and cytogenetic laboratory data from the 
Saskatoon and Regina Qu'Appelle Health Regions. The study is a population-based, 
retrospective, cohort study. Saskatchewan women with a documented pregnancy were grouped 
either as exposed (i.e. those who underwent MSS) or unexposed (i.e. those who did not have 
MSS) and followed for a period of time to determine the incidence of prenatal diagnostic testing, 
TOPFA, and live born infants with congenital anomalies. In this context, prenatal screening/ 
diagnosis 'exposure' can involve three different tests (serum screening, ultrasound, and 
amniocentesis) and is best thought of as a pathway rather than a one-time event.  
 
3.1 Study Population 
The population-based cohort for this study includes all female residents, eligible for 
Saskatchewan Health benefits coverage, who either delivered a baby (live or stillborn), 
experienced a fetal loss (spontaneous abortion) or had a pregnancy termination (medical or 
therapeutic abortion) between January 1, 2000 and December 31, 2005, inclusive. Each woman 
was followed until her exit date from the cohort, which was the earliest of one of the following: 
pregnancy termination, fetal loss, stillbirth
14
 or live birth
15
. Women were identified using the 
                                               
14
 Stillbirth is defined under The Vital Statistics Act, 2009 for the purpose of registering stillbirths in the Province of 
Saskatchewan as follows: "Stillbirth means the complete expulsion or extraction from the mother after at least 20 
weeks' pregnancy, or after attaining a weight of at least 500 grams, of a product of conception in which, after the 
expulsion or extraction, there is no breathing, beating of the heart, pulsation of the umbilical cord or unmistakable 
movement of voluntary muscle." (p. 8, Vital Statistics Act, 1995, Saskatchewan Government; 
http://www.qp.gov.sk.ca/documents/English/Statutes/Statutes/V7-21.pdf)  
15
 Live birth is defined under The Vital Statistics Act, 2009 for the purpose of registering live births in the Province 
of Saskatchewan as follows: “Live birth means the complete expulsion or extraction from the mother, irrespective of 
the duration of the pregnancy, of a product of conception in which, after the expulsion or extraction, there is 
breathing, beating of the heart, pulsation of the umbilical cord or unmistakable movement of voluntary 
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Vital Statistics live birth and stillbirth data, person registry, hospital separation, and physician 
services files as described below (See Appendix A). To link infant and mother records, each 
mother's health services number (HSN) was matched to the person registry system to obtain the 
family number, which was then used to obtain the infant's HSN.
16
 In cases where the mother's 
HSN was not recorded on the birth registration record or where the infant's HSN was not found 
by this method, an iterative process of name, sex and date of birth matching was done to link 
moms and babies. All live born infants were followed for up to one year after their birth in order 
to capture all deaths in the first year of life (for IMR calculation) and to ensure high case 
ascertainment for all CA types.  
 
3.1.1 Identification of births  
Saskatchewan Health beneficiaries who delivered a live born or stillborn baby in 
Saskatchewan between January 1, 2000 and December 31, 2005 were identified using the Vital 
Statistics birth registration file. Vital Statistics birth and stillbirth registration data for out-of-
province births and stillbirths to Saskatchewan residents were included where the data were 
available. Adoptions at birth were excluded because it is not possible to link the baby with 
his/her birth mother. However, the number of these instances would be relatively small. From 
1999 to 2003, public adoptions dropped from 66 to approximately 20 per year.(159)  
 
3.1.2 Identification of abortions  
Saskatchewan Health beneficiaries who had a spontaneous, medical or "other" abortion 
during the study period of January 1, 2000 and December 31, 2005 were identified using hospital 
separation and physician services data. Spontaneous abortion subjects were identified as female 
Saskatchewan Health beneficiaries who had one or more physician service or hospital separation 
record with any of the following diagnostic or fee-for-service codes during the study period: 
ICD-9 code ICD-10-CA code Fee-for-Service code 
632 - missed abortion O02.1 - missed abortion 350P - spontaneous abortion 
634.x- spontaneous abortion O03.x - spontaneous abortion  
 
                                                                                                                                                       
muscle, whether or not the umbilical cord is cut or the placenta is attached." (p. 6, Vital Statistics Act, 1995, 
Saskatchewan Government; http://www.qp.gov.sk.ca/documents/English/Statutes/Statutes/V7-21.pdf) 
16Records are only created for live and stillbirths, not for spontaneous or medical abortions. The exception is when a 
medical abortion is performed at or after 20 weeks or if the fetus weighed 500 grams or more.  
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 Up until 2001/02 hospital services diagnoses in Saskatchewan were reported according to 
the International Classification of Diseases, Ninth Revision (ICD-9) coding scheme and 
procedures were coded according to the Canadian Classification of Diagnostic, Therapeutic and 
Surgical Procedures (CCP) guidelines. In April 2002, all hospitals transitioned to using the 
International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, 
Canada (ICD-10-CA) guidelines, and procedures were recorded using the Canadian 
Classification of Health Interventions (CCI) coding scheme. While not all hospitals switched 
over at once, the extraction software used to identify codes is able to search for both ICD-9 and 
ICD-10-CA codes at the same time. Physician services data were coded using three-digit ICD-9 
codes for the whole study period.  
Elective abortion subjects were identified as female Saskatchewan Health beneficiaries 
who had one or more hospital separation record with any of the following ICD-9 or ICD-10-CA 
diagnostic codes during the study period. In Saskatchewan, medical abortions are performed as 
day surgery or inpatient procedures in a hospital; no Saskatchewan physician clinics performed 
medical abortions during the study period. Subjects who had a medical abortion in Saskatchewan 
were, therefore, identified only through the hospital separation data using the ICD-9 or ICD-10-
CA codes listed below. Subjects who had a medical abortion outside Saskatchewan, on the other 
hand, were identified using both hospital separation data (using the codes listed below) and 
physician services data. Physician services data with the following ICD-9 and/or fee-for-service 
codes were used only to identify medical abortions performed outside Saskatchewan.  
ICD-9 code ICD-10-CA code Fee-for-Service code 
635.x - legally induced abortion O04.x - medical abortion 50P - therapeutic abortion - 
first trimester 
  250P - medical abortion - 
second trimester 
 
Within the International Classification for Diseases, there is a category for other 
abortion. Upon further examination, it appears that this code captures instances of self-inflicted 
abortions or spontaneous abortions following amniocentesis or trauma (eg. car accident). 
Because this category may include abortions relating to amniocentesis, these cases were included 
in the database and were matched against cytogenetic testing data to determine if these were 
pregnancy losses relating to prenatal diagnosis. Subjects having this type of abortion were 
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identified as female Saskatchewan Health beneficiaries who had one or more physician services 
or hospital separation records with any of the following diagnostic codes during the study period: 
ICD-9 code ICD-10-CA code Fee-for-Service code 
636.x - illegally induced 
abortion 
O05.x - other abortion n/a 
637.x - unspecified abortion   
 
The three types of abortion events (i.e., spontaneous, medical and other) were identified 
separately, then combined into a single “abortion event file” (see description below), and finally 
merged into the study`s Maternal-Fetal-Infant database. Spontaneous (SA), medical (MA) and 
other (OA) abortion records from the physician services and hospital separation data were 
processed separately using a “90-day rule” to collapse records into MA, SA, and OA episodes. 
The 90-day rule was applied as follows: if a woman had two or more physician service and/or 
hospital separation records for a given type of abortion within 90 days of each other, the record 
with the earliest service date was identified as the index date and all records for the same type of 
abortion (MA, SA, or OA) within 90 days following the index date were considered part of the 
same episode.  
The resulting three abortion episode files (i.e., one file each for SA, MA and OA 
episodes) were then combined into a single abortion event file using a 90 day rule to collapse 
overlapping episodes. In these cases, flags on the subject file indicate that one or more abortion 
episode types were identified in the 90 day period following the “index abortion event”. Flags 
identify the type of abortion, number of days after the index date and data source (physician 
service record vs. hospital separation record). These steps were determined to be the best 
possible approach to limiting the number of events missed, duplicated, or avoiding 
misclassification. Upon closer analysis of the three abortion categories and their occurrence in 
the data, the decision was made to rely primarily on the "index abortion event" and to also err on 
the side of over-inclusion of medical abortion cases, which meant recoding the index event if the 
second or third record was a medical abortion. Specifically, where there were both medical and 
spontaneous abortions codes or a medical and other abortion code (for one woman within 90 
days), the diagnosis of a medical abortion was assumed to be correct. It appears that the category 
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"other abortion" may be used in error by physician clinics and most often likely relates to a 
spontaneous abortion.
17
 
 
3.1.3 Study definition of medical abortion 
For the purposes of the current study, the ascertainment of medical abortion cases was 
somewhat broader than the definition used by the National Therapeutic Abortion Database 
(CIHI). While the ICD diagnostic codes and CCP/ CCI procedure codes used to identify cases 
were nearly identical, the presence of a diagnostic code was used solely to identify abortions in 
the current study and a procedure code was not required. The type of intervention (eg. surgical, 
pharmaceutical) was not pertinent to the study hypotheses and reliance on diagnostic codes was 
meant to cast the net wider and detect more cases. In addition, the actual intervention or abortion 
procedure does not always occur on the same day as the completed abortion (eg. some women 
must present several times for induction, and are sent home, before the abortion is actually 
completed). Procedure codes were, however, extracted from the hospital and physician data and 
available for cross-matching. For the termination of pregnancy for fetal anomaly (TOPFA) cases, 
93.6% (88/ 94) of abortion events had a matching medical abortion procedure code
18
. In 
addition, CIHI excludes hospital records where the specified intervention was cancelled, 
abandoned, performed previously or out of hospital; the current study did not make these 
exclusions, which could have resulted in a greater number of overlapping episodes, however, the 
impact of this on case ascertainment is expected to be small and will have benefits for capture of 
events.  
Another methodological difference between the Therapeutic Abortion database (CIHI) 
and the current study is that CIHI retains the first abortion record (index event) and excludes all 
other codes of interest within 28 days, while here 90 days was used. The Manitoba Centre for 
Health Policy used 14 days. Here 90 days was seen to be a reasonable window given the healing 
time required (following a pregnancy loss or birth) before a subsequent pregnancy can occur and 
the time it takes for a woman to confirm a subsequent pregnancy. The likelihood is low that a 
                                               
17The Manitoba Centre for Health Policy (MCHP) concurred with this assessment in their own work. Their 
recommendation was to consider omitting this code, however, it appears it is used much less often in Manitoba 
(perhaps partly because they were not using physician claims data in the work referenced, only inpatient 
hospitalizations). 
18 A limitation in the coding was the omission of three CCP procedure codes (used prior to 2001/02) and the 
grouping of another in a separate procedure group under "other obstetric-related procedures". This may account for 
the 6.4% without a procedure code (n=6).  
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unique, new pregnancy could be conceived, with the woman presenting for care at hospital or 
physician office for a second loss within 90 days of the first loss or pregnancy. In the extremely 
unlikely event that a second pregnancy was erroneously grouped with a previous pregnancy (and 
therefore misclassified), the effect on the independent and dependent variables should be 
negligible given that medical abortions following quickly after spontaneous abortions (or vice 
versa) would not have been eligible for maternal serum screening or diagnosis.    
Looking at the index medical abortion cases in Table 3.1, there were 11,391 cases in total 
during the study period, with 372 of these cases having an “other” abortion code within 90 days 
(345, or 93%, of which were from physician data) and 644 having a spontaneous abortion code 
within 90 days (563, or 87%, of which were from physician data) that occurred within 90 days. 
For all medical abortion index cases, the woman was classified in the study as having a medical 
abortion. However, for the spontaneous and other abortion index cases where a medical abortion 
code followed within 90 days, the woman was reclassified as having a medical abortion (n=134; 
122 of which were identified from the hospital data). This decision is largely due to lower 
confidence in the spontaneous and other abortion codes, and the fact that most of the overlapping 
medical abortion codes were identified in the hospital data, which is a more valid and reliable 
dataset as compared to physician services data.  
 
Table 3.1 Type of abortion according to source of identification (physician services versus 
hospital file) and event order (index, second and third), 2000-2005 (pooled), Saskatchewan 
 N 
(from physician services/ from hospital file) 
 
 
 
Index Abortion event  Second abortion event 
 
Third abortion event 
 
Medical abortion 11391 (1103 / 10288) 280 - other (269 / 11) 
625 - spontaneous (549 / 76) 
92 - other (76 / 16) 
19 - spontaneous (14/ 5) 
Spontaneous 
abortion  
8724 (3652 / 5072) 62 - medical (9 / 53) 
2980 - other (2723 / 257) 
5 - medical (1/ 4) 
8 - other (8/ 0) 
Other or 
unspecified 
abortion  
3087 (2911 / 176) 67 - medical (2 / 65) 
624 - spontaneous (319 / 305) 
5 - spontaneous (4/ 1) 
 
3.2 Data Sources 
 As described, there were five sources from which data were drawn for the current study. 
Vital Statistics birth and death registration data was used to identify live and stillbirths, as well as 
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infant deaths within the first year of life and causes of death. Data from inpatient hospital visits 
and day surgeries were used to capture pregnancy events such as medical and spontaneous 
abortions, as well as diagnoses. Physician services (or claims) data were scanned for fee-for-
service and diagnostic codes (Table 3.3-3.4). Cytogenetics lab data reported laboratory results 
for amniocentesis tests for women from the study entry date to the exit date plus 90 days. The 
Provincial Laboratory provided a data file on all laboratory results for MSS tests completed 
between May 1, 2001 (program implementation) and March 31, 2005. When compiling the 
service data (ie. laboratory tests and physician services) for each subject, records were included 
when the service date fell within the study entry date and exit date. Vital Statistics, hospital, and 
physician services data were available for all six years of the study, while Cytogenetics data from 
Regina Qu'Appelle and MSS laboratory data were not (Table 3.2).  
 
Table 3.2. Data inclusion by data source and year
 
  
 3.2.1 Creation of the Maternal-Fetal-Infant dataset 
A comprehensive master file, the Maternal-Fetal-Infant dataset, was created using two 
subject files for women: one file relating to women who had birth events (live or stillbirths) and 
one file relating to women who had abortion events (spontaneous, medical or other) during the 
study period. Note that a woman may be included in the study more than once (e.g. for two or 
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more births, stillbirths, or abortion events). Women included in the study for more than one 
pregnancy had different study identification numbers assigned for each event to further protect 
confidentiality. For women, the study entry date was the latter of January 1, 2000 or health 
coverage initiation date up to December 31, 2005. Women exited the study on the date of the live 
birth, stillbirth, or abortion event. A baby subject file containing demographic and birth or 
stillbirth information for the live born and stillborn infants was also created. For babies, they 
enter the study on the date of their birth and are followed-up to either the date of death, date of 
emigration from the province, or one year after birth. For women, hospital separation, physician 
services, and MSS test data were compiled for the period of time they are included in the study. 
Amniocentesis data from the Cytogenetic Laboratories in the Saskatoon and Regina Qu’Appelle 
Health Regions was available from January 1, 2001 to December 31, 2005 and from October 1, 
2001 to December 31, 2005, respectively. Amniocentesis data from Regina Qu'Appelle is 
missing from January through September of 2001 because cytogenetic testing was out-sourced to 
a lab in British Columbia during this time frame and data could not be located for this study. A 
flag was included on the mother’s subject file to indicate a mother’s Registered Indian status.19 
Mother's health region of residence was based on her home address as of December 31st of the 
year of the subject’s study exit date. For babies, hospital separation, physician services and Vital 
Statistics data were compiled for the period beginning on the date of birth and ending on their 
study exit date. For babies whose study exit is due to death, all recorded causes of death were 
extracted from the Vital Statistics death registration file. In addition to deaths that occur in 
Saskatchewan, this file contains all deaths of Saskatchewan residents that occur in Alberta. If the 
death occurred in Alberta, the record will report underlying cause of death only. The database 
also includes a file derived from reciprocal billing hospital separation records, which reports fact 
and date of death for deaths of Saskatchewan Health beneficiaries occurring in hospitals outside 
Saskatchewan and Alberta.  
 
 3.2.2 Dataset strengths  
Data collected through the provincial health databases will enable the study hypotheses 
outlined in Chapter 1 to be explored in detail. In general, this will include an examination of the 
                                               
19 For the current study, the Registered Indian flag is based on information in the Person Registry System. In the 
Person Registry, Registered Indians are those Saskatchewan Health beneficiaries registered under Section 6 of the 
Indian Act and assigned a ten-digit number in the Indian Registry and who self-identify to Saskatchewan Health.  
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screening program’s general performance (detection rate, positive and negative predictive value, 
false-positive rate); outcomes of positive screening results (follow-up with amniocentesis, 
termination of pregnancy for fetal anomaly, and pregnancy loss due to invasive testing); 
distribution of MSS uptake across the province, over time, by ethnicity, age, and 
rural/remote/urban geographies; trends in the incidence and birth prevalence (live and total) of 
CA categories over time; and changes in infant and fetal mortality (overall and CA-specific). 
Because the dataset captures nearly most pregnancies, prenatal screening tests, and prenatal 
interventions for residents of Saskatchewan, the Maternal-Fetal-Infant database provides a 
unique opportunity for a population-based study of this nature. The linking of cytogenetic, 
laboratory, Vital Statistics, hospital, and physician data strengthens inferences that can be made 
regarding the causal pathway leading from prenatal screening through to pregnancy termination 
for CAs, which is a limitation of other research in this field. Equally important, the data captures 
pregnancy terminations and spontaneous losses at less than 20 weeks gestation where a CA was 
diagnosed using amniocentesis; a population missing from the Canadian Congenital Anomaly 
Surveillance System (CCASS) and omitted from several key studies on this topic.(5) 
 
3.3 Study Variables 
Diagnoses of interest were reported for both women and their babies by specific codes or 
a grouping of related codes. Table 3.3 below outlines some of the key variables and diagnostic 
codes used to capture the presence or absence of each condition (for more detail see Appendix 
B). Table 3.4 outlines the procedure codes used to capture relevant variables. Both hospital and 
physician databases were used to identify procedures of interest, therefore fee-for-service codes 
were identified in addition to CCP and CCI codes. 
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Table 3.3 ICD-9 and ICD-10-CA diagnostic codes of interest for infants and women 
Category ICD-9* ICD-10-CA 
Infants   
Severe neural tube defects: Anencephalus, 
craniorachischisis, iniencephaly, encephalocele 
740.x, 742.0 Q00-Q01.x 
Spina bifida (with or without hydrocephalus) 741.x Q05.x 
Down's syndrome - Trisomy 21 758.0 Q90.0-Q90.2; Q90.9 
Edwards' syndrome - Trisomy 18  758.2 Q91.0-Q91.3 
Congenital heart defects  745-747.x Q20-Q28.x 
Congenital malformations of genital organs 752.x Q50-Q56.x 
All other congenital anomalies of nervous system 742.1-742.9 Q02-Q04.x, Q06.x, Q07.x 
All other chromosomal anomalies 758.1, 758.3-758.9 Q91.4-Q99.x 
All other congenital anomalies 743-744.x, 748-
751.x, 753-757.x, 
759.x 
Q10-Q19.x, Q30-Q45.x, 
Q60-Q89.x 
Other conditions originating in the perinatal 
period - termination of pregnancy, fetus and 
newborn 
779.6 P96.4 
Fetus and newborn affected by other maternal 
complications of pregnancy - spontaneous 
abortion, fetus 
761.8 P01.8 
Stillbirth  P95 
Women   
Stillbirth 656.4, V27.1, V27.3, 
V27.4, V27.6, V27.7 
O36.42, O36.43, O36.49, 
Z37.1, Z37.3-Z37.4, 
Z37.6-Z37.7x 
Non-viable pregnancy 630, 631, 633 O00.x, O01.x, O02.0, 
O02.8 - O02.9 
Spontaneous abortion (miscarriage) 632, 634.x O02.1, O03.x 
Medical abortion 635.x O04.x 
Other abortion 636.x, 637.x O05.x 
Failed attempted abortion 638 O07.x 
Continuing pregnancy after abortion or 
intrauterine death of one fetus or more 
 O31.1, O31.2 
Antenatal screening & abnormal findings† V26.3, V28.0-V28.2, 
V28.8-V28.9, V83-
V84.x 
O28.x, Z36.x, Z31.5 
* Four digit ICD-9 codes are only available on the hospital file; physician file has only three digit 
diagnoses. Therefore, on the physician file, four digit codes were grouped (e.g., ICD-9 758.0 and 758.2 into 'all 
other chromosomal anomalies'; 761.8 and 779.6 into 'perinatal conditions'; 656.4 into 'all other pregnancy/childbirth 
complications'). † ICD-9 codes - flag that screening was done; ICD-10-CA codes - flag for abnormal findings..  
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Table 3.4 Hospital procedure codes and fee-for-service physician billing codes 
Category CCP CCI FSC 
Women    
Stillbirth   241P 
Spontaneous abortion   350P 
Ectopic gestation removal 81.21, 86.3 5.CA.93.^^ 48P, 248P 
Medical abortion 86.4x, 87-87.2x 5.CA.88.^^, 5.CA.89.^^, 
5.CA.90.^^ 
50P, 250P 
Surgical repair of Fetus 87.56 5.FG-5.FM.^^ n/a 
Amniocentesis 87.3 5.AB.02.^^ 57P, 58P, 59P, 
44W 
Other diagnostic procedures 
related to pregnancy 
  40W, 47W, 48W, 
41W, 45W, 46W, 
446W, 50W 
Women and infants    
Genetic assessment n/a n/a 5G, 7G, 9G, 11G, 
13G, 38G, 39G, 
40G, 50G 
 
3.3.1 Identifying terminations of pregnancy for fetal anomaly (TOPFA) 
Once data linkage was complete and the Maternal-Fetal-Infant database constructed, a 
new variable was created that captures terminations of pregnancy following a CA diagnosis 
(TOPFA). Identification of TOPFA cases was done by matching abortion status against 
amniocentesis testing and maternal serum screening, along with ICD codes on the hospital 
record. That is, TOPFAs were classified in situations where the mother either had MSS testing or 
amniocentesis prior to a medical abortion, to differentiate elective abortions from those done in 
response to a definite or probable diagnosis. The rationale is that women who have elective 
abortions would rarely, if ever, investigate their pregnancy for CAs. Due to the fact that medical 
abortions sometimes resulted in live or stillbirths, a more qualitative line-by-line review of the 
data was completed to look at all information available on each pregnancy.  
Of the 94 pregnancies terminated following a CA diagnosis during the 6-year study 
period: 25 had medical abortion codes and an accompanying stillbirth record; 56 had medical 
abortion codes; ten had medical abortion codes and an accompanying live birth record; two were 
live births with a termination of fetus/newborn code; and two had multiple abortion codes 
(including spontaneous abortion codes on the hospital file and medical and other abortion codes 
on the physician file; both had amniocentesis tests). It is important to note that a fetus terminated 
by means of a medical abortion can meet the definition of a stillbirth or live birth under the Vital 
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Statistics Registration Act.
20
 In the case of administrative datasets, the mothers will have a code 
for a medical abortion and there will also be a stillbirth or live birth record for the infant. Any 
abortion that results in a fetus that breaths or has a heartbeat, or where the abortion takes places 
at 20 weeks or when the fetus weighs 500 grams or more, must be registered as a birth under the 
Saskatchewan Vital Statistics Registration Act. Out of the 94 pregnancies resulting in a TOPFA, 
eight had termination of pregnancy, fetus, and newborn codes (P96.4 or 779.6). In all of the 
TOPFA cases the medical abortion code was the most responsible diagnosis at discharge (ie. not 
secondary, pre-admit comorbidity, post-admit comorbidity or optional).   
 
 3.3.2 Identification of congenital anomaly diagnosis using hospital and physician 
data 
 The current study drew from multiple data sources in order to best capture all CAs 
diagnosed in the pregnancy population. Because Saskatchewan does not have a provincial CA 
surveillance system, the administrative health databases were necessary for CA identification. 
Congenital anomaly diagnoses are mandatory codes that are entered into the hospital services file 
for inpatient hospitalizations (including following deliveries on the newborn's record) and day 
surgeries using standardized, international classification systems including the International 
Classification of Diseases 9th and 10th versions (Canadian). The Saskatchewan Medical Services 
files capture information about each patient visit to a physician`s office where one fee-for-
service code and one ICD-9 diagnostic code is captured.
21
 Bringing together information from 
multiple data sources enabled more complete case ascertainment, much like CA surveillance 
systems rely on the same, varied sources of information. Table 3.5 presents the results of a kappa 
analysis. Perfect agreement is not expected, nor desirable, given that physician services data was 
used in hopes of enhancing case ascertainment. Interpretation of the kappa values is as follows: 
poor (<0.20), fair (0.21 – 0.40), moderate (0.41 – 0.60), good (0.61 – 0.80), and very good (0.81 
– 1.00).(160) All values were significant at the p<.05 level. The highest level of agreement can 
be seen between hospital and physician data for anencephalus/ encephalocele and circulatory 
system defects, where agreement was very good and good. Kappa values for spina bifida and 
congenital malformations of the genital organs demonstrate moderate agreement. Fair agreement 
was found for CAs involving the nervous system, chromosomal anomalies and other anomalies. 
                                               
20See footnote 14 and 15 for the definition of live and stillbirths in the province of Saskatchewan.  
21 Visits to salaried physicians and those on alternate payment schemes who do not shadow bill are not captured in 
the data.  
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It is worth acknowledging that kappa is an imperfect measure due to its reliance on the 
prevalence of cases in each category.(160)  Nonetheless, it is commonly used and seems to be 
the most appropriate approach for judging agreement. There were diagnoses where agreement 
could not be assessed (ie. Down syndrome). The coding of Down syndrome in physician records 
is such that cases could not be separated out from other chromosomal anomalies.
22
 In the case of 
anencephalus, the condition is highly fatal and one would not expect cases to be seen in the 
community. In total, 3975 instances of CA were diagnosed in the physician data that would not 
have been picked up using hospital data alone; this represents 41.5% of total CAs identified in 
the study population.  
Table 3.5 Total CA diagnosed in hospital separation and physician billing data, agreement 
between data sources, Saskatchewan, 2000-2005 
CA type Cases 
diagnosed in 
hospital data 
Cases 
diagnosed in  
physician 
data 
Additional 
cases diagnosed 
in physician 
data 
Total 
cases 
Kappa  P-value 
Down syndrome 97 ** 0 97 -  
Spina bifida 24 63 45 69 .414 .000 
Anencephalus / 
encephalocele 
10 ** 1 11 .991 .000 
Trisomy 18 9 ** 0 9 -  
Circulatory 1400 1611 624 2024 .648 .000 
Genital 537 538 294 831 .450 .000 
Nervous 221 230 169 390 .268 .000 
Chromosomal 62 165 132 194 .290 .000 
Other 3248 4158 2710 5958 .358 .000 
Total 5608 6766 3975 9583   
** Figures suppressed < 5 
 
3.4 Canadian Institute for Health Information (CIHI) aggregate data request 
 Two codes are available in the ICD-9 and ICD-10-CA system that help to identify a 
TOPFA. These include: ICD-9 code 655 (known or suspected fetal abnormality affecting 
management of mother) and ICD-10-CA code 035 (maternal care for known or suspected fetal 
abnormality and damage). When one of these codes is coupled with a code for a medical 
                                               
22
In the medical services data, diagnoses are reported using only three digit (as opposed to four digit, as in the 
hospital file) ICD-9 codes. Therefore, on the physician file, this resulted in conditions such as encephalocele code 
742.0 being grouped in "all other anomalies of the nervous system" (rather than with anencephalus) and Trisomy 21 
(Down Syndrome) code 758.0 and Trisomy 18 code 758.2 being grouped into "all other chromosomal anomalies". 
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abortion a TOPFA is detected. The dataset for the current study did not contain the O35/655 
codes, which is a noted limitation
23
. In an effort to address this information gap, and to validate 
the study dataset, a request for aggregate data from CIHI's data holdings was made (Appendix 
B). The request included all O35/655 codes co-occurring in the same episode as a medical 
abortion performed as an inpatient or day surgery admission, between 2000-2010, for all 
Saskatchewan residents cared for in any Canadian hospital. Data were drawn from the Discharge 
Abstract Database/ Hospital Morbidity Database (hospital inpatient) and the National 
Ambulatory Care Reporting System (day surgery). Gestational age of the fetus at the time of 
abortion was reported according to the following groupings: <11 weeks, 12-14 weeks, 15-19 
weeks, and 20 weeks or more. If several abstracts for one patient met the selection criteria and 
occurred within 28 days, only the first one was retained to avoid counting the same termination 
of pregnancy multiple times. 
3.5 Software  
 Both SPSS (version 17.0 and 21.0) and SAS (Enterprise Guide 4.1) were used for 
statistical data analysis. Microsoft Excel (2007) was used to create tables and figures.  
 
3.6 Data analysis 
 3.6.1 Descriptive analysis  
Descriptive analysis covered three general topic areas: (1) sample characteristics and 
pregnancy outcomes; (2) program performance indicators, (3) uptake of MSS and prenatal 
diagnostic testing; and (4) fetal and infant mortality rates. Examination of program-level 
indicators is useful to our understanding about the cause-and-effect relationship between prenatal 
screening/diagnosis and population outcomes. Most measures were further broken down 
according to urban/rural region, mother's age group, and Registered Indian status in order to 
further explore the contribution of these factors to the diagnostic pathway. Documenting the 
pathway between prenatal screening, follow-up prenatal diagnosis, and pregnancy termination 
for CA is an important component to establishing a link between the MSS program and birth 
outcomes. Figure 3.1 illustrates the prenatal screening-diagnosis pathway when using the  triple 
marker screen. Table 3.7 below outlines the indicators of interest for each area of inquiry. 
                                               
23 During the initial request these codes were grouped into a 'pregnancy/childbirth complication' category in error. A 
request was made to the Ministry of Health to have these codes separated out, but it was denied.  
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Figure 3.1 Prenatal screening-diagnosis pathway 
 
 
Table 3.6. Areas of analysis and related indicators  
Program Performance MSS and Amniocentesis 
Uptake 
Population Outcomes 
Detection rate (by screen category*) 
False-positive rate (by screen category*) 
Positive and negative predictive value (by 
screen category*) 
% dated via ultrasound 
Amniocentesis uptake  
CAs diagnosed by amniocentesis 
Pregnancy loss rate associated with 
amniocentesis 
% of pregnancies diagnosed with a fetal 
anomaly terminated 
% utilization by 
geography, year of test, 
age group, and Registered 
Indian Status. 
CA live birth prevalence 
CA total birth prevalence 
CA incidence 
Crude IMR 
CA-specific IMR 
Regular stillbirth rate 
Spontaneous stillbirth rate 
CA-specific neonatal 
mortality rate 
* Down syndrome, Trisomy 18, neural tube defect 
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 When studying CAs, prevalence has often been used as the measure of disease frequency 
instead of incidence.(5) This is largely because of the significant number of CA cases that go 
undetected due to early pregnancy loss, and in many jurisdictions, termination of CA-affected 
pregnancies. Case ascertainment in the current study is the highest that could be expected in a 
population-based study utilizing administrative health data, but information on the CA-status of 
spontaneous and elective abortions are still unknown. As described earlier (Chapter 2), there are 
three commonly used ways to calculate birth prevalence – live births only ("live birth 
prevalence"), live and stillbirths ("total birth prevalence"), or live and stillbirths and terminations 
of pregnancy for fetal anomaly ("birth incidence"). Despite the fact that some CA cases will be 
missed due to early pregnancy loss, the term "birth incidence" will be used over birth prevalence 
when describing results to denote the more complete inclusion of all possible known CA cases. 
Even with most diseases in children or adults, we often use the term incidence to describe all 
new cases in a given time period, recognizing that a certain percentage of cases always go 
undetected. Individuals may have more than one CA, therefore when calculating overall CA 
incidence and death due to CA, infants and fetuses with multiple CAs will be counted as one. 
However, when calculating the prevalence of specific CA types, infants with multiple CAs will 
be counted for each type of CA they are affected by. 
 
 3.6.2 Binary logistic regression analysis 
   3.6.2.1 Covariate identification for multivariate analysis 
 Bivariate analysis was used to determine which variables to include in the multivariate 
models. According to the standard approach, any variable with a p-value equal to or less than 
0.25 would be included in multivariable analysis. Pearson’s chi-square test was used. Outcome 
variables were dichotomous – 'presence or absence of MSS testing' and 'amniocentesis 
performed - yes or  no'. It is important to note that findings cannot account for the effects of age 
and other relevant factors, hence they were simply correlated with the outcomes and cannot 
indicate causal relationships. Bivariate analysis was only used for selecting statistically 
significant variables to be included in model building and multivariate analysis. 
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  3.6.2.2 Model building strategy  
 Hosmer and Lemeshow’s model building strategy was used to explore predictors of MSS 
uptake and amniocentesis testing.(161) In order to fit a best model for each, backward stepwise 
elimination was carried out manually using the ‘enter’ method. First, all relevant independent 
variables were entered into the model. These included factors that were significant (p<.25) in 
bivariate analysis and other biologically or clinically important factors. After fitting a model with 
all significant covariates, variables that were removed earlier from the model were re-entered to 
ensure they did not add to the model. The result was a main effects model where significant 
(p<.05) predictors remained. Next, all possible interaction terms were entered into the model 
one-at-a-time. The interaction terms were retained if the Wald statistic was significant at the 
p<.05 level. Confounding was assessed by comparing the ß values of important predictors in the 
reduced main effects model to those in a model including the potential confounder. A change 
greater than 20% in ß values between models was an indication of confounding, and hence the 
confounder would be retained in the model. Once the final model was constructed, it was 
assessed for goodness of fit using the likelihood ratio test.(162) Discriminative performance was 
assessed using the concordance (or c) statistic, which equals the area under the receiver operating 
characteristic (ROC) curve in the case of dichotomous outcomes.(163, 164) The c-statistic ranges 
from zero to one, with a value of one representing perfect prediction and a value of 0.5 
representing chance prediction. A value between 0.7 and 0.8 is thought to demonstrate 
acceptable predictive performance. The Brier score was used to indicate overall model 
performance or calibration. Scores range from zero to one, with a lower score indicating less 
prediction error.(165) A value less than 0.25 represents an acceptable prediction error.  
 Pregnancies resulting in a live or stillbirth or those that were terminated for fetal anomaly 
(TOPFA) were included in a binary regression analysis to explore predictors of MSS uptake and 
prenatal diagnostic testing, while elective medical or spontaneous abortions were excluded. 
Spontaneous and medical abortions were excluded from this portion of the analysis due to the 
very low rate of uptake in pregnancies with such outcomes. The rationale for omitting these 
outcomes is based on the assumption that women with unwanted pregnancies are very unlikely to 
screen (figure 4.4) and therefore would create bias in the sample and a confounding effect that 
would complicate interpretation. Spontaneous abortions, by definition, occur early and testing is 
not offered until 15 weeks. It would have been ideal to include those spontaneous abortions that 
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qualified for screening (15-19 weeks), but information on gestational age for abortions was not 
available. Similarly, elective medical abortions are typically performed because a baby is not 
wanted (regardless of their CA status), therefore it stands to reason that very few of these women 
would want to know more about the fetuses' health. Due to the fact that month of pregnancy was 
not reported in the study dataset and MSS screening data was incomplete for 2001 and 2005, 
only a subset of pregnancies could be used for the current analysis (2002-2004). Nevertheless, a 
total of 35,527 pregnancies remained for analysis.  
   
 3.6.3 Infant mortality analysis 
 Analysis of infant deaths during the first year of life was undertaken to better understand 
the connection between the provincial MSS program, selective abortions and congenital anomaly 
trends in live born infants and as a cause of infant deaths. Cause of death information was 
obtained from the Vital Statistics death registration data. The Vital Statistics database includes 
all deaths that occur in Saskatchewan and deaths of Saskatchewan residents that occur in 
Alberta. If the death occurred in Alberta, the record reported the underlying cause of death only 
(i.e., multiple causes of death are not identified). The database also includes a file derived from 
reciprocal billing hospital separation records, which reports fact and date of death for deaths of 
Saskatchewan Health beneficiaries occurring in hospitals outside Saskatchewan and Alberta. 
The reasons for infant deaths were analyzed according to underlying (or primary) cause, as well 
as multiple (or contributing) causes. The World Health Organization defines underlying cause of 
death as "the disease or injury which initiated the train of events leading directly to death, or the 
circumstances of the accident or violence which produced the fatal injury.”(166 p.763) 
Information on other diseases or conditions leading to death are also important. On the Vital 
Statistics death registration file, up to 20 multiple causes may be reported for each case. Multiple 
causes are ". . .all those diseases, morbid conditions or injuries which either resulted in or 
contributed to death and the circumstances of the accident or violence which produced any such 
injuries.(166 p.763) For the current research, cause of death information was grouped according 
to the study's diagnostic categories, including CA (by type), conditions arising in the perinatal 
period, and 'other'. Perinatal conditions include complications of the placenta or umbilical cord, 
intrauterine hypoxia, and birth asphyxia. Conditions such as respiratory distress syndrome, SIDS, 
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infectious disease, cancer and unintentional and intentional injuries are captured in the 'other' 
category.  
 
 3.6.4 Assessing trends 
 Trends in both CA prevalence and incidence and infant and fetal mortality (figure 3.2) 
were assessed in a primarily descriptive manner, paired with the average annual percent change 
and chi-square test for trend. The average annual percent change allows one to see if the rate is 
increasing or decreasing and the magnitude of the change. The formula for average annual 
percent change is: 
 
In order to test for statistically significant trends, the chi-square test for trend was calculated 
using Epi InfoTM
 
(version 7.1.2). When working with rare events, and hence small numbers, the 
direction and size of differences (and their associated clinical and public health significance) 
may be viewed as important independent from their statistical significance.    
 
 3.6.5 Tests of difference 
 To assess the statistical significance of a change in rate or of the difference between two 
rates (eg. between two population subgroups), the standard error of the difference between the 
two rates was calculated.(167)  
 
where p1 and p2 are the two rates to be compared (expressed as proportions) and q is 1-p.  
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Figure 3.2 Components of fetal-infant mortality (115) 
 
 
3.7 Study Ethics Approval 
Formal ethics approval for this research was obtained from the Behavioural Research 
Ethics Board at the University of Saskatchewan (REB#B05-189) (Appendix C). The Data 
Access Review Committee (DARC) at the Ministry of Health reviewed the data request for 
issues related to confidentiality and privacy; approval was received April 2007. Operational 
approval was received from the Saskatoon Health Region for the use of cytogenetic laboratory 
data. All data was compiled by the staff at the Epidemiology and Research Unit at the Ministry 
of Health and subsequently de-identified such that the variables released for analyses off-site 
would not reasonably be expected to enable the identification of users or service providers.  
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CHAPTER 4: RESULTS 
4.1 Descriptive Analysis 
 4.1.1 Characteristics of pregnancies in study population 
 A total of 93,171 pregnancy events were captured during the study period, involving 
more than 94,165 fetuses and infants.
24
 Women may have been included in the study more than 
once, but multiple pregnancies were not linked, in order to better protect confidentiality. Using a 
variable that identified the number of times each woman was included in the study, it could be 
seen that there were 61,060 unique women: 37,308 (61.1%) women had one pregnancy included 
in the study; 17,154 (28.1%) had two; 5125 (8.4%) had three; and 1473 (2.4%) had four or more 
pregnancies included in the study.  
 Characteristics of the study population are presented in table 4.1. The majority of women 
were 34 years or younger (88.9%), however given the large study population, there were still 
10,343 women aged 35 and over (11.1%). In terms of geographic location, women were spread 
across the province with 20.0% living in southern health regions (Cypress, Five Hills, Heartland, 
Sun Country, and Sunrise); 23.8% in Regina Qu'Appelle; 27.5% in Saskatoon; and 26.6% in 
northern health regions (Athabasca, Keewatin Yatthe, Kelsey Trail, Mamawetan, Prairie North, 
and Prince Albert Parkland). An estimated 21.7% of all pregnancies occurred in women of 
Registered Indian status.  
 The geographic distribution of births was slightly higher in the north (27.5%) and lower 
in the south (20.5%), which is consistent with the higher fertility rate in Aboriginal women and a 
somewhat older population in the south. A different geographic dispersal was seen for medical 
abortions, with almost two-thirds (63.7%) being performed on women who lived in the 
Saskatoon or Regina Qu'Appelle health regions. The proportion of elective medical abortions in 
First Nations
25
 women was slightly lower than the overall proportion of pregnancies in this 
population (19.6% v. 21.7%, respectively; p=0.0001). Looking at cases of medical abortion 
where a fetal anomaly was diagnosed (TOPFA), few (12.8%) involved mothers of Registered 
Indian status. 
 
                                               
24 Information on plurality was only available for births not spontaneous or medical abortions, therefore this figure is 
an underestimate. 
25 The term First Nations will be used interchangeably with the term Registered Indian, recognizing that while all 
Registered Indian women are First Nations women, not all First Nations women are identified as such in this study 
(eg. Métis, Inuit). 
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Table 4.1 Demographic characteristics, by pregnancy outcome, Saskatchewan, 2000-2005 
(n= 93,171) 
n (%) 
 
All 
pregnancies 
n=93,171        
Live or 
Stillbirths             
n=70454 
Medical 
abortions 
n=11,295 
Spontaneous 
/ other 
abortions 
n= 11,328 
Termination 
of pregnancy 
for fetal 
anomaly 
n=94 
Health Region of 
residence 
     
Southern regions 
Regina Qu'Appelle 
Saskatoon 
Northern 
Regina Qu'Appelle & 
Saskatoon
 ţ
 
All rural regions
 ţ
  
Unknown/ suppressed 
ţ
 
18648 (20.0) 
22150 (23.8) 
25607 (27.5) 
24799(26.6) 
838 (0.9) 
 
868 (0.9) 
261 (0.3) 
14465 (20.5) 
15712 (22.3) 
18964 (26.9) 
19401 (27.5) 
819 (1.2) 
 
851 (1.2) 
242 (0.3) 
1843 (16.3) 
3668 (32.5) 
3528 (31.2) 
2251 (19.9) 
- 
 
- 
5 (0) 
2324 (20.5) 
2759 (24.4) 
3097 (27.3) 
3134 (27.7) 
- 
 
- 
14 (0.1) 
16 (17.0) 
11 (11.7) 
18 (19.1) 
13 (13.8) 
19 (20.2) 
 
17 (18.1) 
- 
 Registered Indian  
Status of mother 
     
Yes 
No 
20197 (21.7) 
72974 (78.3) 
15611 (22.2) 
54843 (77.8) 
2218 (19.6) 
9077 (80.4) 
2356 (20.8) 
8972 (79.2) 
12 (12.8) 
82 (87.2) 
Age group of mother      
Under 25 years 
25-29 years 
30-34 years 
35 years and over 
35554  (38.2) 
27960  (30.0) 
19314  (20.7) 
10343 (11.1) 
24924 (35.4) 
22511 (32.0) 
15717 (22.3) 
7302 (10.4) 
6865 (60.8) 
2358 (20.9) 
1150 (10.2) 
922 (8.2) 
3747 (33.1) 
3063 (27.0) 
2424 ( 21.4) 
2094 (18.5) 
18 (19.1) 
28 (29.8) 
23 (24.5) 
25 (26.6) 
ţ  
For stillbirth events or where the baby died during the first year of life and for multiple pregnancies, RHAs were 
grouped more broadly; the two urban health regions (Regina Qu'Appelle and Saskatoon) were grouped into one and 
all other, rural regions into a second. Health region of residence was also suppressed for infants born with 
anencephalus/encephalocele, Down syndrome, trisomy 18 or spina bifida and for triplet pregnancies; these were 
grouped into the unknown category. Year of birth was suppressed for multiple pregnancies and where one or more 
baby had a diagnosis of anencephalus/encephalocele, Down syndrome, trisomy 18 or spina bifida and triplet 
pregnancies. 
 
 Table 4.2 enables a closer look at the distribution of pregnancy outcomes according to 
mother's age. More pregnancies in women aged 25-34 resulted in a birth than those in women 
who were younger or older. The proportion of medical abortions was highest in the 24 years and 
under age group with 19.3% of all identified pregnancies ended in this way, accounting for 
60.8% of all abortions provincially during this time period. Medical abortion was least frequently 
seen in the 30-34 age group (6.0%). The reverse was true for TOPFAs, where the rate increased 
steadily with age. Medical abortion after a CA diagnosis was more common amongst the oldest 
age group (35 years and above), double the rate seen for women aged 30-34 (0.24% vs. 0.12%, 
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respectively). Spontaneous abortions were also twice as common in women aged 35 and over as 
compared to the youngest group (20.2% vs. 10.5%, respectively).  
 Differences across health regions and geographic groupings are of interest in so far as 
they suggest variations in access to health services, the health of the population, and potentially, 
value systems. A slightly higher percentage of pregnancies in the southern and northern regions 
of the province resulted in a birth than those in the urban regions. A contributing factor was the 
higher rate of elective medical abortions near cities. The percent of pregnancies in the rural north 
or south that ended by medical abortion was lower (9.1% and 9.9%, respectively) than women 
living in Saskatoon (13.8%) or Regina (16.6%). Rates of spontaneous abortions were similar 
across the regions. The higher rate of TOPFA in the 'Regina Qu'Appelle and Saskatoon' health 
regions (combined) and 'all rural regions' categories is due to the fact that, to protect 
confidentiality, the Ministry of Health suppressed the mother's health region of residence for 
twin or triplet pregnancies and those where a diagnosis of Down Syndrome, Edward's Syndrome, 
or neural tube defect was made. 
 Spontaneous and elective medical abortions were slightly less common in First Nations 
women when compared to the rest of the population, but there was not an appreciable difference. 
While TOPFAs were relatively uncommon events, they were almost twice as common in non-RI 
women as in RI women (0.11% vs. 0.06%, respectively).  
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Table 4.2 Number and rate per 100 pregnancies, by pregnancy outcome, according to 
women's characteristics, Saskatchewan, 2000-2005 (n=93,171) 
 
 
n (%) 
All 
pregnancies 
Live or 
Stillbirths 
Medical 
abortions 
Spontaneous 
/other 
abortions 
Termination 
of pregnancy 
for fetal 
anomaly 
Age group of 
mother 
     
24 years & under 35554 24924 (70.1) 6865 (19.3) 3747 (10.5) 18 (0.05) 
25-29 years 27960 22511 (80.5) 2358 (8.4) 3063 (11.0) 28 (0.10) 
30-34 years 19314 15717 (81.4) 1150 (6.0) 2424 (12.6) 23 (0.12) 
35 years and over 10343 7302 (70.6) 922 (8.9) 2094 (20.2) 25 (0.24) 
Health region of 
residence 
     
Southern regions 18648 14465 (77.6) 1843 (9.9) 2324 (12.5) 16 (0.09) 
Regina Qu'Appelle 22150 15712 (70.9) 3668 (16.6) 2759 (12.5) 11 (0.05) 
Saskatoon 25607 18964 (74.1) 3528 (13.8) 3097 (12.1) 18 (0.07) 
Northern regions 24799 19401 (78.2) 2251 (9.1) 3134 (12.6) 13 (0.05) 
RQHR/SHR 838 819 (97.7)   19 (2.3) 
All rural regions 868 851 (98.0)   17 (2.0) 
Suppressed 261 242 (92.7) 5 (1.9) 14 (5.4) - 
Registered Indian 
Status of mother 
     
Yes 20197 15611 (77.3) 2218 (11.0) 2356 (11.7) 12 (0.06) 
No 72974 54843 (75.2) 9077 (12.4) 8972 (12.3) 82 (0.11) 
 4.1.2 Birth outcome trends 
 The number of women experiencing a pregnancy each year remained quite stable across 
the study period (mean = 15,528). Table 4.3 provides data on the frequency of pregnancy 
outcomes (stillbirths, live births, spontaneous abortions, medical abortions, other abortions, and 
termination of pregnancy for fetal anomaly) from 2000 - 2005. The number of live and stillbirths 
varied slightly from year-to-year, with no discernible trend. Terminations of pregnancy for 
reasons of a fetal anomaly increased from two cases in 2000 to 20 in 2005. Spontaneous 
abortions declined from 2001-2003, then increased in 2004-05 to levels similar to 2000. The 
proportion of pregnancies ended by medical abortion was similar across all years (mean=1882/ 
year). 
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4.3 Pregnancy outcomes, number and percent of fetuses/infants according to outcome, 
annual, Saskatchewan, 2000-2005 (n= 94,165)*  
Year Stillbirth Live 
birth 
TOPFA Spontaneous 
abortion 
Medical 
abortion 
Other 
abortion 
Total 
fetuses/  
infants 
2000 68 (0.43) 11939 
(75.6) 
2 (0.01) 1426 (9.0) 1878 
(11.9) 
487 (3.1) 15794 
2001 77 (0.49) 12018 
(76.3) 
7 (0.04) 1342 (8.5) 1857 
(11.8) 
452 (2.9) 15755 
2002 83 (0.54) 11610 
(75.8) 
19 (0.12) 1321 (8.6) 1812 
(11.8) 
476 (3.1) 15325 
2003 67  (0.43) 11834 
(75.7) 
23 (0.15) 1339 (8.6) 1854 
(11.9) 
520 (3.3) 15642 
2004 80 (0.50) 11844 
(74.7) 
24 (0.15) 1410 (8.9) 1952 
(12.3) 
539 (3.4) 15856 
2005 68 (0.43) 11815 
(74.8) 
20 (0.13) 1478 (9.4) 1889 
(12.0) 
533 (3.4) 15793 
Suppressed ** 0 0 0 0 0 0 
Total 444 (0.47) 71060 
(75.5) 
95 (0.10) 8316 (8.8) 11243 
(11.9) 
3007 (3.2) 94165 
*Data was only available on plurality (or number of infants per pregnancy) for births and not abortions. ** Figure 
suppressed < 5. 
 
Figure 4.1 Live births and total pregnancies, Saskatchewan, 2000-2005 
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Figure 4.2 Pregnancy losses, Saskatchewan, 2000-2005 
 
 
 4.1.3 Characteristics of infants and fetuses in study population  
 Table 4.4 below provides information on the characteristics of both live and stillborn 
infants included in the study. Ideally, similar information would have been available for fetuses 
lost to spontaneous and medical abortion, however, data was not extracted from the 
'Reproductive Abstract' portion of the DAD record and therefore information on gestational age, 
and plurality was not available. Of the 71,448 infants live born or stillborn, 48.9% of infants 
were female and 51.1% were male. Most were full-term (90.8%), singleton (94.5%) births. Birth 
weights were not normally distributed, with just 1.3% and 5.7% falling into the very low 
(<1500g) and low (<2500g) birth weight categories.  
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Table 4.4 Characteristics live or stillborn infants (n= 71448), Saskatchewan* 
 Live or 
Stillbirths                        
n (%) 
Baby Sex  
Female 
Male 
34971 (48.9) 
36476 (51.1) 
Plurality  
Single 
Twins 
Triplets 
Missing 
67534 (94.5) 
1779 (2.5) 
84 (0.1) 
2051 (2.9) 
Gestational age at birth  
0-14 weeks 
15-20 weeks 
21-27 weeks 
28-33 weeks 
34-36 weeks 
37-41 weeks 
42 weeks+ 
Missing 
** (0.0) 
28 (0.0) 
435 (0.6) 
1192 (1.7) 
3609 (5.1) 
63833 (89.3) 
1067 (1.5) 
1283 (1.8) 
Birth weight  
500 grams 
500-999 grams 
1000- 1499 grams 
1500- 2499 grams 
2500- 3999 grams 
4000+ grams 
Missing 
125 (0.2) 
340 (0.5) 
408 (0.6) 
3175 (4.4) 
55331 (77.4) 
11294 (15.8) 
775 (1.1) 
*Excludes TOPFA that were live born or stillborn 
** Figure suppressed < 5 
 While Canadian statistics are showing significant trends towards delayed childbirth (37), 
the age distribution of Saskatchewan mothers who gave birth between the years 2000-2005 saw 
little change. The percent of mothers 30 years and over with a live birth increased from 31.4% in 
2000 to 33.1% in 2005; all of the increase could be seen in the 30-34 age group. Nationally, this 
figure increased from 45.6% in 2000 to 48.9% in 2005, with increases in all age groups between 
30-49 years.(114) The most recent estimate from Statistics Canada show this figure increased to 
52.1% in 2011. 
 Figure 4.3 illustrates outcomes across the pregnancy continuum until one year of life, 
alongside the timing of prenatal screening options and diagnostic testing. In essence, a full cohort 
of pregnancies conceived will diminish in size due to a variety of natural and human initiated 
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factors that put fetuses at-risk of death. For the purposes of the study, loss-to-follow-up was 
shown too. From 2000-2005, there were 93,171 pregnancies identified (94,165 fetuses/ infants) 
through the Saskatchewan Ministry of Health's databases. Spontaneous abortions and stillbirths 
are two forms of unintended or natural pregnancy loss that affected 11,772 pregnancies (12.5%). 
Elective medical abortions and terminations of pregnancy for congenital anomaly ("intended 
pregnancy loss") collectively ended another 11,390 (12.1%). Three-quarters (75.4%) of all 
fetuses were born alive. Of these live births, 97.1% survived to one year of age, 0.6% died, and 
the outcome was unknown for the remaining 2.3% that were lost to follow-up. 
 
Figure 4.3 Pregnancy continuum from conception to age one, by intervention status and 
outcome, 2000-2005 (pooled)  
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            4.1.4 Maternal Serum Screening Program   
  4.1.4.1 Test performance 
 Understanding the impact of the MSS program on commonly-used population health 
indicators is central to this research. As such, it is important to cultivate a better understanding of 
test performance and factors that predict uptake. Tables 4.5-4.7 below present the false positive, 
positive and negative predictive value, true positive, and detection rates for each of the three 
screenable conditions. All women in the study having a MSS test during the study period were 
included in these calculations. Uptake of MSS is explored in the section that follows.  
 A total of 9,791 pregnancies were screened for Down syndrome during this time period, 
of which, 745 had a result above cut-off. Of the 745 women screening-positive, 16 cases of 
Down syndrome were diagnosed. The false positive (type I error) rate was 7.5%. The detection 
rate was 69.6%, meaning that almost one out of every three cases of Down syndrome were 
missed during screening. Based on the positive predictive value, among women who received an 
increased risk result only 2.2% actually were carrying a fetus with Down syndrome. Based on 
the negative predictive value, among women who received a decreased risk result 99.9% did not 
have an affected fetus. 
Table 4.5  Screening performance for Down Syndrome* 
 Down syndrome 
diagnosed 
False 
positive 
rate 
Detection 
rate 
Positive 
predictive 
value 
Negative 
predictive 
value 
Screening result Yes No 7.5% 69.6% 2.2% 99.9% 
Negative 7 9039 
Positive 16 729 
* This crosstab excludes ~ 74 cases of abortion after the DS screen (10 positive and 64 negative screens) as these 
cases did not have outcome data. Of the 64 negative-screens, 44 were spontaneous abortions and 20 were medical 
abortions presumed to be TOPFAs. Of the 10 positive-screens, 8 were spontaneous abortions and 2 were medical 
abortions presumed to be TOPFAs. If we assumed that all TOPFA involved DS-affected fetuses, which is unlikely 
as 9 out of the 20 TOPFA cases screened positive for an NTD, the detection rate would be 37.2%, the negative 
predictive value would be 99.7%, and the false-positive rate and positive predictive value would remain unchanged. 
 
  There were 10,152 screening tests completed for the detection of neural tube defects. Of 
the 147 women screening at increased-risk, less than 5 cases were confirmed. Due to the missing 
information on NTD diagnoses, measures of test performance were not calculated. An apparently 
low detection rate would have been an artefact of the data, as many instances of NTD fetuses are 
lost before birth (whether by spontaneous abortion or termination), and could not be captured 
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due the absence of ultrasound diagnostic information and diagnostic coding of stillbirths (see 
Limitation section in Discussion Chapter for detailed discussion).  
Table 4.6  Screening performance for Neural Tube Defect*  
 Neural tube 
defect diagnosed 
False 
positive rate 
False 
negative 
rate 
True 
positive 
rate 
Detection 
rate 
Screening result Yes No - - - - 
Negative 12 9993 
Positive ** 144 
* The above data includes  non-terminated pregnancies only. Cases of abortion were omitted (109 in total, of which 
77 were negative and 32 were positive). Of the 77 screen-negative cases, 48 were spontaneous abortions and 29 
were medical abortions presumed to be TOPFAs. Of the 32 screen-positive cases, 18 were spontaneous abortions 
and 14 were medical abortions presumed to be TOPFAs. ** Figure suppressed < 5. 
 
 There were 9,783 screening tests completed for the detection of trisomy 18. Of the 33 
women receiving an increased risk result, less than 5 cases had documented diagnoses. Out of 6 
cases of trisomy 18 diagnosed in the screening population, less than 5 cases were detected during 
screening resulting in a 66.7% detection rate. The false positive rate was very low (0.30%). 
Based on the positive predictive value, among women who received an increased risk result 
12.1% actually were carrying a fetus with trisomy 18. Based on the negative predictive value, 
among women who received a decreased risk result 99.9% did not have an affected fetus. 
 
Table 4.7  Screening performance for trisomy 18* 
 Trisomy 18 
diagnosed 
False 
positive 
rate 
Detection 
rate 
Positive 
predictive 
value 
Negative 
predictive 
value 
Screening result Yes No 0.30% 66.7% 12.1% 99.9% 
Negative ** 9748 
Positive ** 29 
*There were 54 cases of apparent abortions omitted because of lack of outcome data, of which 32 were negative and 
22 were positive. Of the 32 negative, 22 were spontaneous abortions and 10 were medical abortions presumed to be 
TOPFA. Of the 22 positive screens, 19 were spontaneous abortions and another 3 were medical abortions presumed 
to be TOPFA. ** Figure suppressed < 5. 
 
 Accurate gestational dating is important to the accuracy of serum screening and can 
significantly lower the false-positive rate (168). Out of the 10, 657 women who had MSS during 
the study, 2501 (23.5%) had their pregnancy dated using ultrasound. Dating ultrasound is not 
available to all communities in Saskatchewan and may account for the lower rate.  
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  4.1.4.2 Maternal serum screening uptake 
 Table 4.8 reports basic frequencies for study subjects who had MSS during their 
pregnancy. Screening spanned all age categories, but those in the 25-34 year group accounted for 
more than half of all screens (58.7%). A large percent of tests were drawn from women living in 
either Saskatoon or Regina Qu'Appelle health regions (62.2%) and the majority were not of 
Registered Indian status (91.3%). The annual volume of screens increased from 2001-2004. The 
MSS program was launched part way through 2001 (in May), only partly explaining the lower 
numbers for that year. The Maternal-Infant-Fetal dataset contained MSS data up to March 31st 
of 2005, therefore tests for the latter part of the year were not captured, explaining fewer tests 
that year (n=830). Sixty-three twin pregnancies had MSS, accounting for a very small portion of 
tested pregnancies (0.5%). Of the 10,657 women having MSS, 702 (6.6%) followed-up with an 
amniocentesis. The vast majority of screened pregnancies resulted in a live birth (98.1%).  
 
Table 4.8 Demographic characteristics, women having MSS, Saskatchewan, 2001-2005 
(n=10,657) 
 MSS tested pregnancies 
Mother's age group 
Under 25 years 
25-29 years 
30-34 years 
35 years and more 
 
2387 (22.4) 
3353 (31.5) 
2897 (27.2) 
2020 (19.0) 
Health region of residence 
Southern 
Regina Qu'Appelle  
Saskatoon 
Northern 
Regina Qu'Appelle/ Saskatoon 
Rural regions 
 
2549 (23.9) 
3481 (32.7) 
3040 (28.5) 
1357 (12.7) 
110 (1.0) 
85 (0.8) 
Registered Indian Status 
No 
Yes 
 
 9730 (91.3) 
       927 (8.7) 
Year of specimen collection 
2001 
2002 
2003 
2004 
2005 
Missing 
 
1126 (10.6) 
2548 (23.9) 
3034 (28.5) 
3065 (28.8) 
830 (7.8) 
54 (0.5) 
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Year of birth or pregnancy loss 
2001 
2002 
2003 
2004 
2005 
Missing 
 
382 (3.6) 
2065 (19.4) 
3010 (28.2) 
3029 (28.4) 
2137 (20.1) 
34 (0.3) 
 
Plurality 
Single 
Twin 
Multiple 
Missing 
 
10377 (97.4) 
63 (0.5) 
** (0.0) 
216 (2.0) 
Amniocentesis completed 
Yes 
No 
Missing 
 
702 (6.6) 
9888 (92.8) 
67 (0.6) 
Pregnancy outcome 
Live birth 
Stillbirth 
Spontaneous abortion 
Medical abortion 
Termination of pregnancy for fetal anomaly 
 
10455 (98.1) 
65 (0.6) 
73 (0.7) 
** (0.0) 
63 (0.6) 
** Figure suppressed < 5. 
 The proportion of pregnancies having MSS testing varied according to pregnancy 
outcome. Only one pregnancy that ended in an elective medical abortion had MSS.
26
 It was also 
very rare for pregnancies that ended by spontaneous abortion to have had MSS earlier in the 
pregnancy; an expected finding given that the triple test can only be offered between 15-18 
weeks, at a time when many of these losses would have already occurred. Pregnancies that were 
aborted because of a known or suspected CA were most likely to have had MSS, with 67.0% 
(63/94) of TOPFA having had MSS. Serum screening is only but one step in the prenatal 
diagnostic continuum and it makes sense that most pregnancies where a fetus is diagnosed with 
an anomaly, then terminated, would have had MSS. 
 
 
 
                                               
26 The screening test was not processed as it was too early. There was no other codes indicating that diagnostic 
testing was performed or care codes suggesting investigation for anomalies. Hence the decision was not to designate 
as a TOPFA.   
 81 
 
Figure 4.4 Proportion of women having MSS, by pregnancy outcome category, 
Saskatchewan, 2002-2005 (pooled) 
 
 Looking at MSS uptake over the study period, figure 4.5 shows the percent of live and 
stillbirths that had MSS each year. Utilization of this screening program increased substantially 
from 2001-2002, then leveled out in 2003-2005.  
 
Figure 4.5 Proportion of live and stillbirths that had MSS, Saskatchewan, annual, 2000-
2005* 
 
* The 2001 rate is low partly because MSS was not offered until May of that year. The data was not provided in a 
way that enabled me to determine which pregnancies would have been eligible (ie. which pregnancies were between 
15-20 weeks at the time of program implementation). 
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 4.1.5 Prenatal diagnostic testing 
  4.1.5.1 Descriptives 
Cytogenetic laboratory data was obtained from the two tertiary hospitals in Saskatchewan where 
all samples, drawn for purposes of prenatal diagnostic testing, are sent. Data was available from 
January 1st 2001 - December 31st 2005 from Saskatoon's lab and from October 1st 2001 - 
December 31st 2005 from Regina's. In total, 959 pregnancies (1.0% of the study population) 
underwent prenatal diagnostic testing during this time. A large proportion of tests belonged to 
mothers living in the Saskatoon health region (41.2%), while fewer were performed on women 
from southern (15.2%) or northern (10.6%) health regions (see table 4.9). Most tests involved 
women aged 35 and over (68.6%) and women who were not of Registered Indian status (94.2%). 
The number of tests was lower in 2001 due to incomplete data from Regina's lab, but otherwise 
there was a slight decline in testing volume from 2002-2004. The lower testing number in 2005 
is an artifact of data collection, since the study only captured pregnancies that resulted in an 
outcome in 2005, therefore pregnancies tested and that came to completion in 2006 were 
omitted. Most commonly amniocenteses were carried out between 15-20 weeks gestation 
(89.4%). The most common reasons given for testing were "advanced maternal age" (50.3%) or 
an abnormal MSS result (28.3%). As far as diagnosis, 91.0% of fetuses tested did not have a 
chromosomal anomaly. Another 7.4% had either Down syndrome, trisomy 18, or another 
chromosomal anomaly (detailed diagnoses not available). Testing was inconclusive or 
discontinued in 1.6% (16) of cases.  
 
Table 4.9 Characteristics of women having prenatal diagnostic testing, Saskatchewan, 
2001-2005 (n=959)  
 n (%) 
Age group: 
24 years and under 
25-29 years 
30-34 years 
35 years and over 
 
56 (5.8) 
91 (9.5) 
154 (16.1) 
658 (68.6) 
Health region of residence: 
Southern health regions 
Regina Qu'Appelle health region 
Saskatoon health region 
Northern health regions 
Unknown or broadly grouped 
 
146 (15.2) 
241 (25.1) 
395 (41.2) 
102 (10.6) 
75 (7.8) 
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Registered Indian Status: 
No 
Yes 
 
921 (94.2%) 
57 (5.8%) 
Year of test
*
: 
2001* 
2002 
2003 
2004  
2005* 
Missing 
 
159 (16.5) 
235 (24.5) 
215 (22.4) 
204 (21.3) 
134 (14.0) 
12 (1.3) 
Parity: 
0 
1 
2 
3 
4 or more 
Missing 
 
13 (1.4) 
290 (30.2) 
309 (32.2) 
186 (19.4) 
118 (12.3) 
43 (4.5) 
Gestational age: 
12-14 weeks 
15-17 weeks 
18-20 weeks 
21-23 weeks  
24-26 weeks 
27-29 weeks 
30-32 weeks 
33 weeks and over 
Missing 
 
** (0.3) 
388 (61.6) 
175 (27.8) 
30 (4.8) 
10 (1.6) 
9 (1.4) 
7 (1.1) 
9 (1.4) 
328 
Reason for test: 
Abnormal ultrasound 
Advanced maternal age 
Abnormal MSS result 
Risk of chromosomal anomaly  
Fetal anomaly 
Intrauterine fetal death 
Other or unspecified 
 
118 (12.3) 
482 (50.3) 
271 (28.3) 
28 (2.9) 
23 (2.4) 
** (0.2) 
32 (3.3) 
Amniocentesis result: 
Trisomy 21 
Trisomy 18 
Other diagnosis 
Normal 
Inconclusive (eg. no growth, 
discontinued testing) 
 
15 (1.6) 
12 (1.3) 
43 (4.5) 
873 (91.0) 
16 (1.6) 
*2001 and 2005 figures for amniocentesis tests do not reflect all tests done in Saskatchewan for these years. Data 
from the RQHR lab went back to October 2001, which explains the lower overall number for that year. 2005 figures 
do not reflect tested pregnancies that did not result in an outcome during 2005, as our study was designed to capture 
abortions and births that occurred in 2005, not pregnancies.   
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  4.1.5.2 Testing indication 
 Over the course of the study, the primary reason women chose amniocentesis shifted 
from "advanced maternal age" to abnormal MSS result. Test indication was documented by 
obstetricians and family physicians and included in the Cytogenetics lab file. In 2001, the year 
that the MSS program was launched in the province, 74.5% of tests were performed based on 
maternal age-associated risk and just 7.5% were due to an abnormal MSS result (figure 4.6). By 
2005, advanced maternal age and abnormal MSS result accounted for an equal share of testing. 
Figure 4.7 supports this finding illustrating a notable drop in amniocentesis uptake in the oldest 
age group - from 79.5% of all tests involving mothers aged 35 and over in 2001 down to 63.2% 
in 2005. Women under age 29 accounted for an increasing proportion of amniocenteses over the 
study period (9.9% in 2001 and 20.6% in 2005). There was a slight increase in 2005 in the 
proportion of amniocenteses resulting from an abnormal ultrasound. The Cytogenetics 
Laboratory in Saskatoon was able to provide an update on amniocentesis testing in 
Saskatchewan, including the age of women being tested and the test indication. From 2006-2012, 
the proportion of testing done due to 'advanced maternal age' continued to fall (44.6% to 13.1%), 
while testing due to abnormal MSS results climbed (36.8% to 56.6%). Interesting to note is the 
increase in amniocenteses that are being performed as a result of abnormal findings during 
ultrasound. It does also appear that trends in low uptake of amniocentesis have continued as 
absolute numbers remained stable (mean=178), suggesting that the rate of TOPFA in 
Saskatchewan may be similar to the rate observed in the current study. 
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Figure 4.6 Main reason for amniocentesis, Saskatchewan, annual, 2001-2012* 
 
* A data update for 2006-2012 was provided by the Cytogenetics laboratory, Saskatoon Health Region who now 
handles all testing in the province. 
Figure 4.7 Proportion of amniocentesis by mother's age group, Saskatchewan, annual, 
2001-2005 
 
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Abnormal ultrasound 11.8 12.0 9.7 9.8 19.9 16.6 29.6 25.9 23.6 25.5 21.8 25.8 
Advanced maternal age 74.5 51.7 42.6 39.5 39.0 44.6 31.5 24.7 21.5 16.8 18.6 13.1 
Abnormal MSS result 7.5 16.5 38.9 39.5 38.2 36.8 30.2 39.5 49.7 51 54.8 56.6 
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Reason for amniocentesis testing, Saskatchewan women, 2001-2012 
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
< 25 years  5.6 3.7 5.5 5.8 8.8 7.3 11.7 9.3 9.7 6.7 7.4 7.1 
25-29 years 4.3 9.1 11.1 10.2 11.8 10.4 13.6 20.4 16.4 10.1 15.4 17.3 
30-34 years 10.6 13.2 20.3 19.9 16.2 16.1 21.6 19.1 23.6 22.1 23.4 30.5 
35+ years  79.5 74.0 63.1 64.1 63.2 66.3 53.1 51.2 50.3 61.1 53.7 45.2 
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Amniocentesis testing by mother's age group,  
Saskatchewan, annual, 2001-2012 
 86 
 
  4.1.5.3 Use of maternal serum screening prior to testing 
 The expectation is that MSS results will facilitate women's decision-making about 
whether to follow-up with an invasive, diagnostic test, thereby reducing unnecessary risk to the 
fetus. Figure 4.8-4.9 show the uptake of prenatal diagnostic testing in women between the years 
2002-2005 who had MSS and received an increased-risk result ("screen positive"), decreased-
risk result ("screen negative"), or for cases where no result was generated.
27
 Women who 
received a screen-positive result were much more likely than those who received a screen-
negative or no result to follow-up with an amniocentesis (32.7%, 3.8%, and 8.3%, respectively). 
Table 4.10 breaks the information down further for each of the three screenable conditions, 
Down syndrome, NTD, and trisomy 18. Here it can be seen that 36.8% of women who screened-
positive for DS opted for further testing, while 15.3% of women with a screen-positive for NTD 
and 32.7% of trisomy 18 did the same. Amniocentesis provides a definitive diagnosis for 
chromosomal anomalies and is a highly sensitive screening tool for NTD. Typically women who 
screen-positive for NTD are first offered high-resolution ultrasound, then amniocentesis, in order 
to obtain an amniotic AFP sample and acetyl cholinesterase measurements.(169,170) The 
amniotic fluid sample is then screened by the MSS program at the Provincial Laboratory to 
provide a risk estimate and is a highly accurate screen. Conversely, 1.3% of screen-negatives for 
DS opted for further testing, and 6.3% of NTD and 3.9% of trisomy 18 screen-negatives did the 
same.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               
27 2001 was excluded from analysis as amniocentesis data was missing from the Regina Cytogenetics Laboratory 
from January - September. 
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Figure 4.8 Amniocentesis testing by MSS uptake and screening result, all pregnancies, 
Saskatchewan, 2001-2004 
 
 
Figure 4.9 Amniocentesis uptake by screening result (all conditions combined), 
Saskatchewan, 2002-2005 (pooled) 
 
 
32.7% 
67.3% 
3.8% 
96.2% 
8.3% 
91.7% 
Amnio - Yes Amnio - No Amnio - Yes Amnio - No Amnio - Yes Amnio - No 
Increased risk + Decreased risk - No screen result 
Amniocentesis by screening result (all conditions combined), Saskatchewan, 
2002-2005 (pooled) 
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Table 4.10 Prenatal diagnostic testing according to MSS screening result, Saskatchewan, 
2002-2005 (pooled) 
Condition 
n (%) 
Screening result Amniocentesis 
Down syndrome 
 
Yes No 
Negative 118 (1.3) 8674 (98.7) 
Positive 270 (36.8) 463 (63.2) 
Neural Tube Defects Negative 607 (6.3) 9051 (93.7) 
Positive 24 (15.3) 133 (84.7) 
Trisomy 18 Negative 372 (3.9) 9079 (96.1) 
Positive 16 (32.7) 33 (67.3) 
All conditions 
combined (any) 
Negative (to all 3) 353 (3.8) 8891 (96.2) 
Positive (to any of the 3) 313 (32.7) 645 (67.3) 
No result 36 (8.3) 398 (91.7) 
 
 Figure 4.10 illustrates the moderating effect that age has on the association between MSS 
result and amniocentesis. While diagnostic testing is higher overall in mothers who received a 
screen-positive result, the uptake increases with age. Of women age 24 and under who received a 
screen-positive MSS result, 13.3% had an amniocentesis. Prenatal diagnostic testing was almost 
three times higher in the high age group (37.8%). A similar pattern could be seen for women 
who screened-negative. The rate of amniocentesis among the youngest women who received a 
screen-negative result was low (0.5%) compared to those in the 35 years and older age category 
(19.5%). 
Figure 4.10 Proportion of women having amniocentesis by mother's age group and MSS 
risk result, Saskatchewan, 2002-2005 (pooled) 
 
13.3% 
0.5% 
7.7% 
22.0% 
0.9% 
7.9% 
35.8% 
1.1% 
3.8% 
37.8% 
19.5% 
16.4% 
Increased risk + Decreased risk - No screen result 
Proportion of women having amniocentesis by mother's age group and 
MSS risk result, Saskatchewan, 2002-2005 (pooled) 
Less than 25 25-29  30-34 35 years+ 
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 Registered Indian women were much less likely to opt for amniocentesis following a 
screen-positive or screen-negative MSS result. While 33.7% of non-Registered Indian women 
had an amniocentesis after receiving an increased risk result, just 18.5% of Registered Indian 
women had follow-up diagnostic testing.  
 
Figure 4.11 Proportion of women having amniocentesis by mother's Registered Indian 
status and MSS risk result, Saskatchewan, 2002-2005 (pooled) 
 
 
 Pregnancy outcomes varied according to the diagnosis made through amniocentesis. The 
likelihood that a tested-pregnancy would result in a live birth was much higher if the result was 
"normal" than if a chromosomal anomaly was diagnosed.
28
 Out of the 873 pregnancies where no 
chromosomal anomaly was diagnosed, 825 (94.5%) were live born. In the case of fetuses 
diagnosed with Down syndrome, trisomy 18, or another chromosomal anomaly, the proportion 
of live births was considerably lower (20.0%, 16.7% and 51.1%, respectively). For 'other 
chromosomal anomalies' some of this difference could be accounted for by a higher proportion 
of stillbirths. In the case of Down syndrome and trisomy 18, however, a large proportion of 
fetuses were taken by means of a selective abortion (73.3% and 75.0%, respectively). Because 
fewer 'other chromosomal anomalies' ended in TOPFA, this allowed for more spontaneous 
stillbirth losses. 
 
 
                                               
28
 Not all data shown in table below due to small numbers. 
18.5% 
2.1% 
6.1% 
33.7% 
4.0% 
9.1% 
Increased risk + Decreased risk - No screen result 
Proportion of women having amniocentesis by Registered Indian Status 
and MSS risk result, Saskatchewan, 2002-2005 (pooled) 
Registered Indian Non-Registered Indian 
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Table 4.11 Pregnancy outcome by amniocentesis diagnosis (n=958), Saskatchewan, 2001-
2005 (pooled)
29
 
 
n (%) 
Live birth TOPFA Total 
Down syndrome and Trisomy 18 5 (18.5) 20 (74.1) 27 
Other chromosomal anomaly 22 (51.2) 8 (18.6) 43 
Normal 825 (94.5) 20 (2.3) 873 
 
4.2 Multivariate Analysis 
 Binary logistic regression was used to further explore the differences between 
pregnancies that had MSS and those that did not, and pregnancies that had amniocentesis and 
those that did not. 
  
 4.2.1 Selection of variables for inclusion: MSS model 
 Using bivariate analysis, the following factors differed (p<.25) according to MSS use: 
mother's age, health region of residence, Registered Indian status, and year that the birth, 
abortion, or MSS test occurred. Looking in more detail at the distribution of MSS users and non-
users according to each risk factor, some patterns were evident (p<.000). In terms of mother's 
age, the likelihood of having had MSS increased with age. This finding is not unexpected given 
that national guidelines up to 2007 recommended triple test screening primarily for women aged 
35 and over.(48) Only 15.7% of the youngest age group had MSS, while 43.2% of the oldest did. 
A larger proportion of pregnancies in women residing in the urban health regions had MSS 
(30.0%) compared to those in rural settings (18.3%). MSS uptake was considerably less common 
in women of Registered Indian status (9.6% vs. 28.4%, respectively). MSS uptake was lower in 
2002, during only the second year of the program, then held steady at 25.8% in 2003 and 2004. 
 
 
 
 
 
 
 
 
 
 
                                               
29
 Portions of table suppressed due to small numbers, according to Saskatchewan Ministry of Health regulations.  
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Table 4.12 Covariates and MSS Uptake, 2002-2004 
demographic 
characteristic  
No Yes Total Chi-square value 
(2-sided sig.) 
Mother's age group 
Under 25 years 
25-29 years 
30-34 years 
35 years and more 
 
10428 (84.3) 
8612 (75.7) 
5793 (71.4) 
2086 (56.8) 
 
1945 (15.7) 
2757 (24.3) 
2179 (28.6) 
1536 (43.2) 
 
12373 
11369 
8115 
3670 
 
1289.46 (.000) 
Health region of 
residence 
Rural 
Urban 
 
 
14375 (81.7) 
12526 (70.0) 
 
 
3228 (18.3) 
5379 (30.0) 
 
 
17603 
17905 
 
 
662.13 (.000) 
Registered Indian Status 
No 
Yes 
 
19755 (71.6) 
7164 (90.4) 
 
7851 (28.4) 
757 (9.6) 
 
27606 
7921 
 
1195.38 (.000) 
Year of MSS test 
2002 
2003 
2004 
 
9470(78.8) 
8703 (74.2) 
8746 (74.2) 
 
2542 (21.2) 
3024 (25.8) 
3042 (25.8) 
 
12012 
11727 
11788 
 
93.00 (.000) 
* If no MSS test, then year of birth/abortion was used. 
  
  4.2.1.1 Predictors of MSS uptake 
 The final main effects model (table 4.13) identified several predictors significant at the 
p<.05 level. When holding all other variables constant, health region of residence, age group, 
Registered Indian status, and year of MSS test remained significant predictors (p<.000) for MSS. 
As expected, the likelihood that one would have MSS increased with increasing age. Women 
belonging to the 35 years and over age group were more than three times as likely to have had 
MSS testing as compared to women in the youngest age category (OR=3.19, 95% CI 2.46-4.13). 
Non-First Nations women were more than three times as likely to screen as First Nations women 
(OR=3.26, 95% CI 2.81-3.79). The health region of residence variable was collapsed into a 
dichotomous rural-urban variable due to the difficulty placing cases broadly grouped by the 
Epidemiology, Research and Evaluation Unit (Ministry of Health) as a result of small sample 
concerns. The regression model found that women residing within Saskatoon or Regina 
Qu'Appelle Health Region boundaries were almost twice as likely to have MSS as those in rural 
or remote locales. The year that the pregnancy ended (whether by birth, stillbirth or abortion) or 
tested was shown to have a small impact on MSS uptake; women who were pregnant during the 
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latter two years were more likely to screen than those at the start of the study period, presumably 
due to increasing awareness of the screening program over time.  
 Significant interaction effects were found between age group and urban-rural region 
(p<.000); urban-rural region and Registered Indian Status (p=.004); and age and Registered 
Indian status (p=.019).  
 
Table 4.13 Final main effects model which includes variables associated with MSS uptake 
Variable (reference)  ß (S.E.) Sig. Odds Ratios 95% C.I. for Exp (ß) 
Lower               Upper 
Age group  
24 years and under (ref)  .000    
25-29 years .301 (.102) .003 1.351 1.107 1.650 
30-34 years .338 (.123) .006 1.401 1.102 1.782 
35 years and over 1.161 (.132) .000 3.193 2.467 4.133 
Registered Indian (yes) 1.182 (.077) .000 3.261 2.806 3.789 
Urban-rural region 
(rural) 
.690 (.084) .000 1.993 1.692 2.348 
Test year       
2002 (ref)  .000    
2003 .290 (.032) .000 1.337 1.256 1.423 
2004 .307 (.032) .000 1.359 1.277 1.447 
Age modified by region 
of residence  
 .000    
25-29 years*urban -.048 (.069) .485 .953 .833 1.090 
30-34 years*urban -.047 (.073) .524 .954 .827 1.102 
35 years and over*urban .419 (.089) .000 1.521 1.278 1.809 
Urban-rural region by 
Registered Indian status 
     
Urban*non-RI -.240 (.084) .004 .786 .667 .928 
Age modified by 
Registered Indian status 
 .019    
25-29 years*non-RI .080 (.103) .439 1.083 0.885 1.325 
30-34 years*non-RI .232 (.124) .061 1.262 0.990 1.608 
35 years and over*non-RI -.258 (.135) .056 0.772 0.593 1.006 
 
 4.2.1.2 Model diagnostics 
 To assess the goodness of fit of the model, the Hosmer-Lemeshow test was used. For the 
model presented in table 4.13, the chi-square statistic was 8.801 (p=0.359), showing no evidence 
of lack of fit. In addition, the likelihood ratio test was used to assess variables in the final model 
 93 
 
against those in the preliminary main effects model. The log likelihood statistic was highly 
significant (LR=99.5 chi-square, 9 degrees of freedom = 49.76, p<0.005).This indicates that the 
final model was the better, more parsimonious model. As a result, the model is acceptable. The 
final model had a c-statistic of 0.677 (95% CI: 0.670, 0.683) and a Brier score of 0.000005 
indicating acceptable discrimination and very low prediction error. 
 4.2.1.3 Interaction assessment 
 In the final model, three interaction terms (age*urban-rural region; urban-rural region*RI 
status ; and age*RI status) were found to be significant (p<.05). The predicted probabilities, 
calculated directly from the final regression model, are plotted below (figures 4.12-4.15). Error 
bars are included for each estimate providing the 95% confidence intervals. In addition, odds 
ratios for each level of effect were calculated manually to quantify the relationship (tables 4.14-
4.16).(161) 
  4.2.1.3.1 Registered Indian Status-Urban/Rural Interaction 
 Figure 4.12 shows the probability of women having MSS, according to whether they 
were Registered Indian or not and if they lived in an urban or rural health region. The probability 
of testing was higher in non-RI women living in an urban region (0.333) and lowest in RI women 
living in a rural region (0.736). Odds ratios for each level of effect were then calculated, along 
with 95% confidence intervals (table 4.12). Here it can be seen that among women living in an 
urban health region, those who were non-RI were 2.56 times more likely to have had MSS than 
those who were RI. In rural regions, the difference was greater, with non-RI women being 3.26 
times more likely to have had MSS than RI women. Looking at RI women only, the effect of 
urban region is slightly larger than it is among non-RI women (1.99 vs. 1.57, respectively).  
 
Table 4.14 Calculation of odds ratios for MSS uptake when interaction present 
Effect Among Odds Ratios 95% CI 
Urban-Rural Region*   
Urban RI Status- No 1.57 1.24 - 1.98 
Urban RI Status- Yes 1.99 1.69 - 2.35 
RI Status** 
RI Status- No Urban 2.56 2.05 - 3.20 
RI Status- No Rural 3.26 2.81 - 3.79 
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Figure 4.12 Predicted probability of women having MSS by RI status and urban-rural  
health region, 2002-2004 
 
  4.2.1.3.2 Age-urban/rural interaction 
 Women living in an urban health region had higher MSS uptake than those in rural 
regions, for all age categories. Figure 4.13 plots the predicted probabilities of women having 
MSS, according to age and whether they lived in a rural or urban health region. The difference 
between the predicted probability that urban and rural women would have MSS increased with 
age (0.074, 0.092, 0.104, and 0.235, respectively). In women aged 35 and over, 53.1% living in 
an urban region had MSS, while only 29.6% of rural women in the same age group had 
screening. Looking at the youngest age category, 19.9% of women in the urban region had MSS 
compared to 12.4% of those in rural regions. 
 While uptake was highest in the 35 years and over age group, testing was substantially 
higher in urban compared to rural regions for this age group (OR=3.03, 95% CI 2.39 - 3.85) 
(table 4.15). In urban health regions the oldest age group was 4.85 times (95% CI 3.56-6.62) 
more likely to have MSS than the youngest. In rural regions, the oldest age group was 3.19 times 
(95% CI 2.47-4.13) more likely to have MSS than the youngest.  
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Figure 4.13 Predicted probability of women having MSS by age group and rural-urban 
health region, 2002-2004 
 
 
Table 4.15 Calculation of Odds Ratios for MSS uptake when interaction present 
Effect Among Odds Ratios 95% CI 
Age group   
35 years + Rural 3.19 2.47 - 4.13 
30-34 years Rural 1.40 1.10 - 1.78 
25-29 years Rural 1.35 1.11 - 1.65 
35 years + Urban 4.85 3.56 - 6.62 
30-34 years Urban 1.34 1.01 - 1.77 
25-29 years Urban 1.29 1.01 - 1.64 
Urban-rural health region 
Urban 35 years + 3.03 2.39 - 3.85 
Urban 30-34 years 1.90 1.54 - 2.35 
Urban 25-29 years 1.90 1.53 - 2.36 
Urban 24 years & under 1.99 1.69 - 2.35 
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  4.2.1.3.3 Age-RI status interaction 
 Registered Indian status was an influential factor as far as whether or not women had 
MSS, with uptake being higher in non-RI women for all age groups (figure 4.14). The increase in 
MSS uptake with each age category was comparably small for RI women under age 35. In the 35 
years and older age group, MSS uptake was more than double in non-RI compared to RI women 
(OR= 2.52; 95% CI = 1.86-3.41) (table 4.16). The effect of non-RI status was greater in the 
younger age groups, for example, non-RI women in the 30-34 year age group were 4.11 times 
(95% CI 3.10-5.46) more likely to screen than RI women of the same age.  
 
Figure 4.14 Predicted probability of women having MSS by age group and Registered 
Indian status, 2002-2004 
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Table 4.16 Calculation of Odds Ratios for MSS uptake when interaction present 
Effect Among Odds Ratios 95% CI 
Age group   
35 years + RI status 3.19 2.47 - 4.13 
30-34 years RI status 1.40 1.10 - 1.78 
25-29 years RI status 1.35 1.10 - 1.65 
35 years + Non-RI status 2.47 2.15 - 2.83 
30-34 years Non-RI status 1.77 1.26 - 2.48 
25-29 years Non-RI status 1.46 1.10 - 1.94 
Registered Indian status 
Non-RI status 35 years + 2.52 1.86 - 3.41 
Non-RI status 30-34 years 4.11 3.10 - 5.46 
Non-RI status 25-29 years 3.53 2.84 - 4.39 
Non-RI status 24 years & under 3.26 2.81 - 3.79 
 
 Figure 4.15 plots the relationship between all three variables contained in the statistically 
significant interaction terms, simultaneously illustrating the relationship between variables 
contained in the interaction terms and MSS. Particularly interesting is the very low probability of 
screening in RI women under age 35 living in a rural region and, by comparison, the much 
higher probability for non-RI women in the an urban region.  
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Figure 4.15 Predicted probability of women having MSS by RI status, urban-rural  health 
region, and age group, 2002-2004 
 
 4.2.2 Selection of variables for inclusion: amniocentesis model 
 Table 4.17 presents chi-square analyses investigating patterns in prenatal diagnostic 
testing across geography, age groups, ethnicity, MSS testing status and result, and ultimately 
differences in pregnancy outcome for those deciding to have invasive testing. Due to missing 
data for the year 2000 and for the southern portion of the province in 2001, only pregnancies 
occurring from 2002-2005 were included in the present analysis. Amniocentesis was more than 
twice as common in urban mothers as compared to those living in a rural health region (2.6% vs. 
1.0%, p<.000). Testing rates increased significantly (p<.000) with age, with 0.3% of mothers 
under 25 years having the procedure compared to 11.8% of those aged 35 and over. 
Amniocentesis uptake was more than four times higher in women not of Registered Indian status 
compared to those who were (2.2% vs. 0.5%, respectively). Women that had MSS were more 
likely to have amniocentesis than those who did not. Looking more closely at the influence of 
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MSS result, one-third of women (33.8%) who screened-positive had diagnostic testing compared 
to only 3.4% of those who screened negative. An interesting difference could be seen across 
pregnancy outcomes, with testing rates being the lowest in  pregnancies that ended by a 
spontaneous or planned abortion (0.2% and 0.0%, respectively) and considerably higher in those 
that ended in stillbirth (7.6%). Amniocentesis is a risk factor for fetal loss and this finding will be 
examined in more detail.(171) 
 
Table 4.17 Covariates and amniocentesis testing 2002-2004 (pooled)(n=35,527),  
n (%) Amniocentesis Chi-square 
value (2-sided 
sig.) 
Yes No 
Health region of residence: 
Rural 
Urban 
 
177 (1.0) 
463 (2.6) 
 
17426 (99.0) 
17442 (97.4) 
 
125.254 (.000) 
Age group: 
24 years and under 
25-29 years 
30-34 years 
35 years and over 
 
33 (0.3) 
62 (0.5) 
113 (1.4) 
432 (11.8) 
 
12340 (99.7) 
11307 (99.5) 
8002 (98.6) 
3238 (88.2) 
 
2335.880 (.000) 
Registered Indian Status: 
No 
Yes 
 
602 (2.2) 
38 (0.5) 
 
27004 (97.8) 
7883 (99.5) 
 
100.665 (.000) 
MSS screening result: 
No MSS/ result 
Negative 
Positive 
 
129 (0.5) 
256 (3.4) 
255 (33.8) 
 
27140 (99.5) 
7248 (96.6) 
499 (66.2) 
 
4751.542 (.000) 
Pregnancy outcome: 
Live birth 
Stillbirth 
Spontaneous abortion* 
Medical abortion* 
Termination of pregnancy for fetal 
anomaly 
 
582 (1.7) 
17 (7.6) 
13 (0.2) 
** (0.0) 
41 (66.1) 
 
34659 (98.3) 
207 (92.4) 
5598 (99.8) 
5655 (100) 
21 (33.9) 
 
2102.578 (.000) 
*Excluded from the logistic regression analysis, but figures reported here for reference. ** Figure suppressed < 5 
  
  4.2.2.1 Predictors of amniocentesis uptake 
 Binary logistic regression was used to further explore the differences between 
pregnancies that had an amniocentesis and those that did not. The final main effects model (table 
4.18) identified several predictors significant at the p<.05 level. When holding all other variables 
constant, age group, Registered Indian status, urban or rural health region of residence, MSS 
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screening result, and ultimately, pregnancy outcome were all highly significant predictors of 
prenatal diagnostic testing (p<.000). Women aged 35 and over were six times more  likely to 
have testing than those aged 24 and under (OR= 6.70, 95% CI 3.03-14.84), while women 
between the ages of 25-34 were no more likely than the youngest age group to have the 
procedure. Before adding the interaction terms to the final model, non-RI women were 
significantly more likely to have testing than RI women, but the effect became non-significant in 
the final model. Women living in an urban health region were more likely to screen than those in 
rural regions. The regression model shows that women's MSS result mattered as to whether or 
not they pursued diagnostic testing. While a positive MSS result was most strongly predictive of 
testing, women who received a negative MSS result were still more likely to have testing than 
those that did not have MSS. Due to the presence of interactions in the model, the main effects 
cannot be interpreted directly from the output below.  
 Significant interaction effects were found between age group and screening status 
(p<.000); urban-rural region and screening status (p<.000); and age and Registered Indian status 
(p=.013). 
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Table 4.18 Final main effects model which includes variables that are associated with  
having amniocentesis  
 
ß (S.E.) S.E. Sig. Odds 
Ratios 
95% C.I. for Exp (ß) 
Lower               Upper 
Age group 
24 years and under (ref)   .000    
25-29 years -.638 .561 .255 .528 .176 1.586 
30-34 years -.721 .709 .309 .486 .121 1.953 
35 years and over 1.902 .406 .000 6.702 3.026 14.841 
Registered Indian (yes) -.573 .374 .125 .564 .271 1.173 
Urban-Rural region (rural) 1.114 .205 .000 3.046 2.038 4.554 
Screening status 
No MSS/ no result (ref)   .000    
Negative result 1.247 .538 .020 3.479 1.212 9.985 
Positive result 5.268 .478 .000 194.007 76.046 495.299 
Age modified by screening 
status 
  .000    
25-29 years*negative 1.260 .630 .045 3.526 1.026 12.119 
25-29 years*positive .541 .571 .343 1.718 .561 5.260 
30-34 years*negative 1.256 .624 .044 3.511 1.034 11.917 
30-34 years* positive .933 .551 .091 2.542 .863 7.491 
35 years and over*negative 1.064 .531 .045 2.899 1.024 8.206 
35 years and over* positive -2.236 .471 .000 .107 .042 .269 
Urban-rural region modified 
by screening status 
  .000    
Urban*negative -1.155 .251 .000 .315 .193 .515 
Urban*positive -.776 .272 .004 .460 .270 .784 
Age modified by Registered 
Indian status 
  .013    
25-29 years*non-RI .675 .626 .281 1.963 .575 6.699 
30-34 years*non-RI .939 .748 .209 2.558 .590 11.082 
35 years and over*non-RI 1.551 .483 .001 4.714 1.830 12.145 
   
  4.2.2.2 Model diagnostics 
 To assess the goodness of fit of the model, the Hosmer-Lemeshow test was used. For the 
model presented in table 4.18, the chi-square statistic was 5.239 (p=0.631), showing no evidence 
of lack of fit. In addition, the likelihood ratio test was used to assess variables in the final model 
against those in the preliminary main effects model. The log likelihood statistic was highly 
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significant (LR=421.447 chi-squared, 9 degrees of freedom = 240.634, p<0.005). This indicates that 
the final main effects model was the better, more parsimonious model. As a result, the model is 
acceptable. The final model had a c-statistic of 0.838 (95% CI: 0.821 - 0.856) and a Brier score 
of 0.0000021 indicating excellent discrimination and very low prediction error. 
   
 4.2.2.3 Interaction assessment 
 In the final model, three interaction terms (age*screening status; urban-rural 
region*screening status; and age*Registered Indian status) were all found to be significant 
(p<.05). The predicted probabilities, calculated directly from the final regression model, are 
plotted for selected interactions below (figures 4.16-4.18). Error bars are included for each 
estimate providing the 95% confidence intervals. The probability of having had an amniocentesis 
increased with mother's age for all three screening categories (no MSS, negative, positive), but 
was considerably higher in pregnant women that received a screen-positive result (Figure 4.16). 
The groups with the highest mean predicted probability were women aged 30-34 years and 
women aged 35 and over who screened-positive (0.389 and 0.375, respectively). Pregnant 
women living in an urban health region were more likely to have had an amniocentesis than 
those living in a rural region, for all three screening statuses (figure 4.17). Among those 
receiving a screen-positive result, urban dwellers were more likely to have follow-up testing than 
women residing in rural regions (mean predicted probability of 0.366 vs. 0.271). While 
amniocentesis testing was more prevalent overall in non-Registered Indian women compared to 
Registered Indian women, the difference could not be seen for the youngest age group, widened 
with age, and was most pronounced in those 35 years and over (Figure 4.18). Testing was 
uncommon in women under 30 years in both RI and non-RI women.   
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Figure 4.16 Predicted probability of women having amniocentesis by screening status and 
mother's age group, 2002-2004 
 
Figure 4.17 Predicted probability of women having amniocentesis by screening status and 
mother's health region of residence, 2002-2004 
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Figure 4.18 Predicted probability of women having amniocentesis by RI status and 
mother's age group, 2002-2004 
 
 
4.3 Prenatal diagnosis of chromosomal anomalies 
 Antenatal detection of CA may differ depending on the extent to which women accept 
serum screening, the sensitivity of screening (both ultrasound and serum) for various conditions, 
rates of follow-up diagnostic, and the risk profile of women choosing to continue down the 
diagnostic pathway. Registered Indian women, younger women, and those living in a rural health 
region have been shown to be less likely to pursue these options. To assess differences in 
prenatal diagnosis across populations sub-groups, table 4.19 below presents the proportion of all 
chromosomal anomalies detected during pregnancy.
30
 Prenatal detection of chromosomal 
anomalies was much lower in RI women compared to non-RI women (8.3% vs. 27.0% overall). 
Women in the 29 years and younger age group were also less likely to have received a diagnosis 
before delivery compared to those 30 years and over (18.4% and 31.8%).  
 
                                               
30 Data could not be analyzed according to rural or urban health region as this information was suppressed by the 
Ministry of Health for all conditions screenable by the MSS program.  
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Table 4.19 Number and proportion of cases prenatally diagnosed, by RI status and 
mother's age group, 2000-2005 (pooled) 
Number of cases 
diagnosed prenatally / total 
number of cases (%) 
Down Syndrome Trisomy 18 "Other" 
chromosomal 
anomaly 
Overall 
Registered Indian status (11.8) (5.3) (8.3) 
Non-Registered Indian 
status 
14/92 (15.2) 11/18 (61.1) 42/138 (30.4) 67/248 (27.0) 
29 years & under 4/44 (9.1) 3/8 (37.5) 21/100 (21.0) 28/152 (18.4) 
30 years & over 11/64 (17.2) 9/11 (81.8) 22/57 (38.6) 42/132 (31.8) 
Total 15/108 (13.9) 12/19 (63.2) 43/157 (27.4) 70/284 (24.6) 
 *When either the numerator or denominator was less than 5 both were suppressed and 
only the proportion reported.  
 
 4.3.1 Amniocentesis-related fetal loss 
 There is general agreement that amniocentesis poses additional risk to the fetus, over-
and-above the natural background risk associated with the final weeks and months of pregnancy, 
but the magnitude of excess risk has been debated.(171) The answer is important to informed 
decision making about both screening and prenatal diagnostic testing. All women with a 
pregnancy between 2002-2005 were grouped according to their amniocentesis status and 
pregnancy/birth outcomes were compared. Due to the absence of gestational age data for 
spontaneous abortions and for amniocentesis tests processed in the RQHR lab, only a crude 
assessment could be completed. The overall stillbirth rate was 2.22% (95% CI 1.3-3.5%) 
(19/854) and the total fetal loss rate was 4.0% (95% CI 2.7-5.4%) (34/869) in women having an 
amniocentesis. In those not having the procedure, the overall stillbirth rate was 0.61% (95% CI 
0.5 - 0.7%) (279/45781). The total fetal loss rate could not be calculated for non-testers due to 
the absence of gestational age; the majority of losses occur before the pregnancy would be 
eligible for amniocentesis and this figure would be highly misleading. If only considering 
stillbirths at less than 24 weeks, as some studies have done (172), the rate was 0.95% (95% CI 
0.4-1.9%) (8/843) for the amniocentesis group and 0.12% (56/45574) for the control group. 
Terminations of pregnancy for fetal anomaly were included in the denominators, as per the 
SOGC's suggestion, to ensure an accurate depiction of the true fetal loss rate.(171) 
 
4.4 Congenital anomaly birth prevalence and incidence analysis 
 As described in section 2.2.1, birth prevalence and incidence rates for congenital 
anomalies can often portray a disparate picture. The magnitude of the difference and the pattern 
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will depend on the CA and the extent to which TOPFA are occurring in the population. It will 
also, as seen below, depend on the number of TOPFA cases that are stillborn or live born, as 
these will have been captured by standard CA rate calculations (ie. those where TOPFA are not 
included). Figures 4.19-4.21 present trends in CAs detectable through the provincial MSS 
program  - anencephalus, Down syndrome, and trisomy 18. For each CA type, the live birth 
prevalence (cases diagnosed after delivery per 10,000 live births), total birth prevalence (cases 
diagnosed in stillbirths or live births per 10,000 live and stillbirths), and birth incidence (cases 
diagnosed in medical abortions or spontaneous abortions before 20 weeks gestation, stillbirths 
and live births per 10,000 live and stillbirths and early fetal losses tested by prenatal diagnosis) 
were calculated. Spontaneous and elective medical abortions were excluded from the 
denominator, unless having undergone prenatal diagnostic testing, due to the fact that their case 
status was unknown.  
 For two out of the five years studied, the live birth prevalence rate was notably lower 
than the incidence for severe NTDs (figure 4.19). During 2001 and 2002, the incidence rates 
were double the live birth prevalence rates. Overall, there was an annual average percent increase 
of 30% in the live birth prevalence of severe NTDs and 29.6% increase in the birth incidence. 
While the increases in both lines were notable, the trends were statistically non-significant 
(p=0.15 and p=0.32, respectively). Having said that, numbers were very small each year and 
therefore the power to detect a difference was low. In the case of Down syndrome, the live birth 
prevalence and incidence began to diverge in 2001, but the absolute difference between the rates 
held from 2003 onward (2.4 percentage points difference). The relative difference between the 
two rates decreased slightly between 2003 and 2005 (16.7% and 14.9%, respectively). An overall 
increasing trend was observed for Down syndrome rates in Saskatchewan, with the slope of the 
incidence line being slightly steeper than the live birth prevalence line. The average annual 
percent increase for the live birth line was 9.0% and 10.0% for the incidence line; the chi-square 
test for trend was non-significant (p=0.28) for the live birth prevalence rate and borderline non-
significant (p=0.09) for the incidence rate. The incidence and birth prevalence rates of trisomy 18 
varied considerably from year-to-year, as did the difference between the lines (figure 4.21). The 
largest difference in the live birth and incidence rates was in 2004 (0.84 vs. 4.19 per 10,000, 
respectively). The annual percent change for the live birth line was 45.3% and 83.9% for the 
incidence line, and the chi-square tests for trend were both non-significant (p=0.77 and p=0.10 
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respectively). Anencephalus, Down syndrome, and trisomy 18 all increased over the six-year 
period studied. The total birth prevalence was almost identical to the live birth prevalence in the 
case of anencephalus and Down syndrome. In the case of anencephalus, the absence of 
diagnostic data on stillbirths likely accounts for the similarly in live and total birth prevalence 
rates in the population, given the known risk for stillbirth for this outcome. It is therefore likely 
that the total birth prevalence and incidence rates are underestimates of the true occurrence of 
severe NTDs in Saskatchewan. Similarly, the absence of cytogenetic laboratory data for 2000 
and for the southern portion of the province for part of 2001 may have resulted in an 
underestimate in the birth incidence of Down syndrome and trisomy 18 for those two years. 
 
Figure 4.19 Anencephalus and similarly severe neural tube defects, comparison of live and 
total birth prevalence and incidence, annual, Saskatchewan, 2000-2005* 
 
 
 
 
 
 
 
 
2000 2001 2002 2003 2004 2005 
Live birth prevalence  0.84 0.83 0.86 1.69 2.53 2.54 
Total birth prevalence 0.83 0.83 0.86 1.68 2.52 2.53 
Birth incidence 0.83 1.65 1.71 1.67 2.51 2.52 
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Anencephalus and similarly severe neural tube defects, live and total birth 
prevalence and incidence, annual, 2000-2005 
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Figure 4.20 Down syndrome, comparison of live and total birth prevalence and incidence, 
annual, Saskatchewan, 2000-2005 
 
Figure 4.21 Trisomy 18, comparison of live and total birth prevalence and incidence, 
annual, Saskatchewan, 2000-2005 
 
2000 2001 2002 2003 2004 2005 
Live birth prevalence  11.7 12.9 14.6 14.4 16.0 16.1 
Total birth prevalence 11.7 12.9 14.6 14.4 16.0 16.9 
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Down syndrome, live and total birth prevalence and incidence,  
annual, 2000-2005 
2000 2001 2002 2003 2004 2005 
Live birth prevalence  0.84 0.83 2.58 1.69 0.84 1.69 
Total birth prevalence 0.84 0.83 2.57 2.52 2.52 2.53 
Birth incidence 0.83 0.83 4.27 2.52 4.19 3.37 
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Trisomy 18, live and total birth prevalence and incidence, annual,                  
2000-2005 
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 Diagnostic information was unavailable for conditions diagnosed by ultrasound that did 
not result in a live birth. As a result, only the live birth prevalence could be calculated for spina 
bifida and anomalies of the circulatory, genital, or nervous systems (figure 4.22). Circulatory 
system anomalies were by far the most common CA, followed by genital anomalies. While there 
were some notable year-to-year fluctuations, no clear trends could be seen. Spina bifida is a 
condition screenable by MSS and live birth prevalence rates are very likely impacted by the 
practice of TOPFA. While terminated cases could not be identified given the study limitations, 
there were 11 instances where a medical abortion was preceded by a 'positive' MSS result. These 
cases were very likely NTDs diagnosed by ultrasound, which would impact the rates of spina 
bifida and several NTDs reported here. 
 
Figure 4.22 Live birth prevalence of select types of congenital anomalies, annual, 
Saskatchewan, 2000-2005 
 
  
 4.4.1 Population rates of chromosomal anomalies by mother's characteristics 
 Live birth prevalence and incidence rates of Down syndrome, trisomy 18 and "other 
chromosomal anomalies" were calculated and reported according to mother's age and Registered 
2000 2001 2002 2003 2004 2005 
Spina bifida 11.73 6.66 8.61 11.83 9.29 10.17 
Circulatory system anomalies 262.19 297.05 304.05 256.09 281.16 310.89 
Genital system anomalies 96.33 129.81 126.61 117.48 125.8 105.89 
Nervous system anomalies 31.83 32.45 39.62 34.65 21.11 32.19 
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Indian status to further explore differences in the termination of pregnancy (figures 4.23-4.28). 
For greater stability of estimates, data were pooled for all years due to the suppression of birth 
year for Down syndrome and trisomy 18 cases. These three CA types were selected due to the 
greater confidence in case ascertainment of chromosomal anomalies, because of access to 
cytogenetic laboratory data.  Differences in the live birth and incidence rate varied according to 
CA type. For Down syndrome, the most notable difference was in the 35 years and over age 
group; the live birth prevalence was 44.2 per 10,000 live births and the incidence was 57.3 per 
10,000 total births and pregnancies undergoing prenatal diagnosis. For trisomy 18, discrepancies 
between rates began earlier and could be seen in all but the youngest age group, but the 
difference was most pronounced in the oldest age category (8.2 vs. 2.8, respectively). For "other" 
chromosomal anomalies, the difference between the rates was similar across age groups. 
 Differences were observed between the live birth prevalence and incidence of Down 
syndrome, trisomy 18 and "other" chromosomal anomalies according to Registered Indian status, 
albeit not as pronounced as those observed for maternal age. In the case of Down syndrome, the 
relative difference between live birth prevalence and birth incidence was smaller for Registered 
Indian (+5.2%) than for non-Registered Indian (+13.0%) women. Trisomy 18 incidence was 
twice the rate of live birth prevalence in non-RI women, however, no live birth cases were 
detected in the RI population and therefore a rate difference could not be calculated. Looking at 
'other chromosomal anomalies', the rate difference was larger for non-RI compared to RI women 
(17.5% vs. 4.4%, respectively). A difference potentially due to the higher rates of amniocentesis 
testing in non-RI women compared to RI women, which increases the likelihood of identifying 
other chromosomal anomalies not screened for through MSS. 
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Figure 4.23 Live birth prevalence and incidence of Down syndrome by mother's age group, 
Saskatchewan, 2000-2005 
 
 
Figure 4.24 Live birth prevalence and incidence of trisomy 18 by mother's age group, 
Saskatchewan, 2000-2005 
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2000-2005 
24 years & under 25-29 years 30-34 years 35 years & over 
Live birth prevalence 1.2 0.9 1.3 2.8 
Incidence 1.2 2.2 3.2 8.2 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
R
at
e
 p
er
 1
0
,0
0
0 
 
Live birth prevalence vs incidence, Trisomy 18, by mother's age group, 
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Figure 4.25 Live birth prevalence and incidence of "other" chromosomal anomaly by 
mother's age group, Saskatchewan, 2000-2005 
 
Figure 4.26 Live birth prevalence and incidence of Down syndrome by Registered Indian 
status, Saskatchewan, 2000-2005 
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Figure 4.27 Live birth prevalence and incidence of trisomy 18 by Registered Indian status, 
Saskatchewan, 2000-2005 
 
 
Figure 4.28 Live birth prevalence and incidence of "other" chromosomal anomaly by 
Registered Indian status, Saskatchewan, 2000-2005 
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Live birth prevalence vs incidence, "other" chromosomal anomaly, by 
Registered Indian status, 2000-2005 
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4.5 Terminations of pregnancy for reason of congenital anomaly 
 4.5.1 Descriptives 
 The focal point of the current study was the identification of selective abortions 
performed following a CA diagnosis, to study the impact of this practice on population 
outcomes, and explore characteristics of pregnancies being ended in this manner. In total, 95 
fetuses were taken by means of a TOPFA, involving 94 pregnancies. Table 4.20 presents 
information on key characteristics of these women and their fetuses. Women of all ages 
underwent TOPFA, with a somewhat higher percentage belonging to women aged 25-29 years; a 
difference that likely reflects the greater fertility of this population. Cases were split equally 
between urban and rural regions. While 21.7% of all pregnancies belonged to RI women (table 
4.1), 12.6% of TOPFAs were performed on RI women. The number of cases was higher in 2003 
- 2005 as compared to the first two years of the MSS program (2001-02). The majority of cases 
had MSS (67.4%) or amniocentesis (65.3%) earlier in the pregnancy. Of pregnancies undergoing 
amniocentesis (then followed by a TOPFA), almost one-third (32.3%) did not have a 
chromosomal anomaly, 22.6% returned no result or discontinued testing, and the remaining 
45.1% had a chromosomal anomaly. When all diagnostic information was compiled for these 
cases, the most common known or suspected diagnoses were Down syndrome (15.8%), neural 
tube defect (14.8%), and other chromosomal anomaly (10.5%). In 46.3% of TOPFAs, the CA 
type was unknown. This is largely due to the absence of stillbirth diagnostic data and O35/655 
codes from the mother's abstract. As far as timing of the abortions, selective terminations 
generally occurred later in the pregnancy than an elective abortion typically would; most were 
done between 15-23 weeks (82.1%), with 7 (10.5%) being carried out between 24-30 weeks 
gestation.  
 
Table 4.20 Terminations of pregnancy for reason of fetal anomaly,  Saskatchewan, 2001-
2005 (n=95) 
 n (%) 
Mother's age group 
Under 25 years 
25-29 years 
30-34 years 
35 years and more 
 
18 (18.9) 
29 (30.5) 
23 (24.2) 
25 (26.3) 
Health region of residence 
Urban regions 
Rural regions 
 
47 (49.5) 
48 (50.5) 
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* Unknowns are presumed to be cases where a congenital anomaly was diagnosed (or suspected) by ultrasound (eg. 
spina bifida, anencephalus,cardiac abnormalities, urinary tract anomalies). Because ultrasound data is not available 
in a format that can be easily linked with administrative health databases, this information was not available. There 
were 6 cases where a fee-for-service billing code indicated an amniocentesis was performed, but there was no record 
(and therefore no diagnosis) in the data. It is possible that these were performed out-of-province. 
**Figures suppressed <5 
  
 
 
Registered Indian Status 
No 
Yes 
 
83 (87.4) 
12 (12.6) 
Year of event 
2000 
2001 
2002 
2003 
2004 
2005 
 
**  
7 (7.4) 
19 (20.2) 
23 (24.2) 
24 (25.3) 
20 (21.1) 
Maternal Serum Screening completed 
Yes 
No 
 
64 (67.4) 
31 (32.6) 
Amniocentesis completed 
Yes 
No 
 
62 (65.3) 
33 (34.7) 
Amniocentesis diagnosis 
Trisomy 21 
Trisomy 18 
Other chromosomal anomaly 
No chromosomal anomaly 
No result/missing 
 
11 (17.7) 
9 (14.5) 
8 (12.9) 
20 (32.3) 
14 (22.6) 
Pregnancy outcome 
Live birth, followed by death 
Fetal death >=20 weeks or 500g 
Fetal death < 20 weeks or <500g 
 
12 (12.6) 
25 (26.3) 
58 (61.1) 
Confirmed or suspected diagnosis 
Down syndrome  
Neural tube defect 
Trisomy 18 
Unknown* 
Other chromosomal or congenital anomalies 
 
15 (15.8)  
14 (14.7) 
9 (9.5) 
44 (46.3) 
13 (13.7) 
Gestational age at termination 
15-20 weeks 
21-23 weeks 
24-30 weeks 
Missing 
 
45 (47.4) 
33 (34.7) 
10 (10.5) 
7 (7.4) 
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 From 2001 to 2005 there were 70 chromosomal anomalies diagnosed through 
amniocentesis. Table 4.21 below reports the proportion of prenatally diagnosed cases that were 
terminated. Overall, the proportion of trisomy 18 (75.0%, 95% CI 42.8-94.5) and Down 
syndrome (73.3%, 95% CI 44.9-92.2) pregnancies terminated was much higher than for the 
'other' chromosomal anomalies category (18.6%, 95% CI 8.4-33.4). Small numbers made 
interpretation difficult, in particular for RI women where the number of cases diagnosed during 
pregnancy was very small (<5). The number of prenatally diagnosed cases of Down syndrome 
and trisomy 18 was similarly small in younger women, making interpretation a challenge. Rate 
of TOPFA, for Down syndrome and trisomy 18 combined, was only slightly higher in women 
aged 30 and over (75.0%, 95% CI 50.9-91.3) compared to those 29 years and under (71.4%, 95% 
CI 29.0-96.3). For 'other' chromosomal anomalies, pregnancy termination was much less 
common in women aged 30 and over (33.3%, 95% CI 14.6-57.0) compared to those 29 years and 
under (4.5%, 95% CI 0.12-22.8). Data could not be reported according to urban and rural 
residence due to suppression of urban-rural status for live births with Down syndrome, neural 
tube defects, or trisomy 18. 
Table 4.21 Number of chromosomal anomalies prenatally diagnosed and terminated, by 
CA type, by mother's age, RI status, and health region of residence, Saskatchewan, 2001-
2005 (pooled) 
TOPFA/ number 
prenatally diagnosed (%) 
Down 
syndrome 
Trisomy 18 'Other' chromosomal 
anomalies 
Total 
29 years & under  5/7 (71.4) 7/21 (33.3) 12/ 28 (42.9) 
30 years & over 9/11 (81.8) 6/9 (66.7) 1/22 (4.5) 16/42 (38.1) 
Registered Indian **/** **/** 
Non-Registered Indian 10/14 (71.4) 8/11 (72.7) 8/42(19.0) 26/67 (38.8) 
Total 75.0% 73.3% 18.6% 40% 
 ** Figure suppressed < 5 
 
 Figures 4.29-4.34 present the TOPFA rates by RI status, maternal age, and urban-rural 
residence for all pregnancies
31
, enabling comparisons across subgroups. Between 2001 and 2005, 
there were 1.19 pregnancy terminations for CA per 1,000 total pregnancies for the whole of 
Saskatchewan (95% CI 0.9-1.4), with the occurrence being half as common for women of RI 
status (0.64 per 1,000 total pregnancies, 0.3-1.0) compared to non-RI women (1.34, 95% CI 1.1-
                                               
31 Note: Only pregnancies that had the potential to result in a TOPFA were included in the denominator (live births, 
stillbirths, or abortions that underwent prenatal diagnosis). 
 117 
 
1.6). The difference between RI and non-RI women narrowed over the five-year period. The 
TOPFA rate was much higher in women aged 35 and over (2.78 per 1,000 pregnancies, 95% CI 
1.8-4.1) compared to those 24 years and under (0.61 per 1,000 pregnancies, 95% CI 0.3-0.9); the 
rates rose with increasing age. Overall pregnancy terminations for fetal anomaly were more 
prevalent in women aged 30 and over from 2001-2005,  however, rates increased from 2003-
2005 in women under age 30. Rates were very similar in rural (1.44 per 1,000 pregnancies, 95% 
CI 1.0-1.9) and urban populations (1.32 per 10,000 pregnancies, 95% CI 0.9-1.7) (figure 4.33). 
 
Figure 4.29 Rate of termination of pregnancy for fetal anomaly, number per 1,000 total 
pregnancies, Registered Indian and non-Registered Indian, Saskatchewan, 2001-2005 
(pooled) 
 
Figure 4.30 Rate of termination of pregnancy for fetal anomaly, number per 1,000 total 
pregnancies, Registered Indian and non-Registered Indian, annual, Saskatchewan, 2001-
2005 
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Figure 4.31 Rate of termination of pregnancy for fetal anomaly, number per 1,000 total 
pregnancies, by age group, annual, Saskatchewan, 2001-2005 (pooled) 
 
Figure 4.32 Rate of termination of pregnancy for fetal anomaly, number per 1,000 total 
pregnancies, by age group, annual, Saskatchewan, 2001-2005 
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Figure 4.33 Rate of termination of pregnancy for fetal anomaly, number per 1,000 total 
pregnancies, by rural-urban health region of residence, Saskatchewan, 2001-2005 (pooled) 
 
 
 
Figure 4.34 Rate of termination of pregnancy for fetal anomaly, number per 1,000 total 
pregnancies, by rural-urban health region of residence, Saskatchewan, annual, 2001-2005  
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calculated for three gestational age categories. Amniocentesis data from the Regina Qu'Appelle 
Health Region did not include gestational age; therefore the current analysis is limited to 
procedures performed in Saskatoon (n=660). Similar to findings from other studies, the 
pregnancy termination rate declined with increasing gestational age (chi-square = 44.86, p<.000). 
Upon closer inspection, the majority (81.3%) of the amniocenteses performed between 12-16 
weeks were due to 'advanced maternal age', whereas abnormal ultrasound was the most common 
(83.6%) reason for having the procedure at 22 weeks or later. It must be noted that this analysis 
includes only women that received a diagnosis following amniocentesis, and not those cases 
where the anomaly was diagnosed using ultrasound only. 
Table 4.22 Pregnancy termination for chromosomal anomaly, by gestational age at 
amniocentesis, 2001-2005 
 Gestational age 
 12-16 weeks 17-21 weeks  22 weeks or later 
Number of chromosomal 
anomalies diagnosed 
12 24 8 
Number of pregnancy 
terminations 
7 10 ** 
Percent of pregnancies with 
anomaly terminated (95% CI) 
58.3%                
(27.7-84.8) 
41.7% 
(22.1-63.4) 
<20.0%* 
(0.3-52.7) 
Most common reason for 
amniocentesis (%) 
81.3% - 
advanced 
maternal age 
47.6% - positive 
MSS result 
83.6% - abnormal 
finding on 
ultrasound 
*Percent reported in general terms due to suppression of numerator   **Figure suppressed < 5  
 Earlier pregnancy terminations for reasons of a CA (< 20 weeks) that do not meet the 
legal criteria for a stillbirth or live birth are often missed when surveillance or research relies 
solely on vital statistics records. In Saskatchewan, 58 TOPFAs (61.1%) were performed prior to 
20 weeks (or before the fetus weighed 500 grams). Two sets of rates were calculated below in 
order to illustrate the difference one could expect to see if only using vital statistics records to 
identify cases (table 4.23): (1) TOPFA that resulted in a live or stillbirth (per 1,000 total births); 
and (2) all TOPFA including early terminations (per 1,000 total pregnancies).
32
 The six-year rate 
for the TOPFA-live or stillbirths was 0.5 per 1,000 total births, while the total TOPFA rate was 
1.3 per 1,000 total pregnancies. 
                                               
32 Total pregnancies includes all live and stillbirths, as well as pregnancies that underwent prenatal diagnostic 
testing. Spontaneous and other medical abortions that were not evaluated for a CA were not included in the 
denominator.  
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 Table 4.23 Pregnancy termination for chromosomal anomaly, births versus all 
pregnancies, number and rate, Saskatchewan, annual, 2000-2005 
 2000 2001 2002 2003 2004 2005 6-year 
total  
(95% CI) 
TOPFA- live or 
stillbirths 
** ** 6 7 11 11 37 
Rate per 1,000 
total births 
** ** 0.5 0.6 0.9 0.9 
0.5 
(0.4-0.7) 
TOPFA- all 
pregnancies 
** 7 19 23 24 20 95 
Rate per 1,000 
total pregnancies 
** 0.6 1.6 1.9 2.0 1.7 
1.3 
(1.1-1.6) 
** Figure suppressed < 5.  
 
 4.5.3 Comparing findings to aggregate data from the Canadian Institute for Health 
Information 
 Because the study dataset did not contain cytogenetics data for the year 2000 and part of 
2001 was missing for Regina's laboratory, it was known that some cases of TOPFA would be 
missed. In addition, diagnostic data for non-chromosomal anomalies was not available for fetal 
losses, including pregnancy terminations. A special data request was made to the Canadian 
Institute for Health Information (see Methods chapter) in order to compare the number of 
TOPFA identified from each data source, despite the fact that the DAD itself may not have had 
perfect capture of cases during this time period. From 2000-2005, the study dataset identified 95 
TOPFA cases, while the CIHI hospital data file reported 115 cases. As was expected, the largest 
difference could be seen in the year 2000 (24 cases in CIHI data vs. 2 in the study dataset), while 
agreement between the two datasets from 2001-2005 was very good. Beyond 2005, the CIHI 
data shows a slight upward trend, with rates varying year-to-year.  
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Figure 4.35 Rate of termination of pregnancy for fetal anomaly, number per 1,000 live 
births, CIHI hospital (2000-2010) data versus study dataset (2000-2005) 
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Table 4.24 Infant death descriptives, Saskatchewan, 2000-2005 (n=428) 
 n (%) 
Mother's age  
Less than 25 
25-29 years 
30-34 years 
35 years+ 
181 (42.3) 
130 (30.4) 
76 (17.8) 
41 (9.6) 
Plurality  
Twins (both died) 
Twin (sibling survived) 
Single 
Missing or suppressed 
30 (7.0) 
26 (6.1) 
347 (81.1) 
25 (5.8) 
RHA of residence  
RQHR/SHR 
Rural health region 
Suppressed 
190 (44.4) 
219 (51.2) 
19 (4.4) 
Mother's Registered Indian Status  
Yes 
No 
152 (36.2) 
266 (63.8) 
Birth weight  
500 grams or less 
500-999 grams 
1000-1499 grams 
1500-2499 grams 
2500-3999 grams 
4000+ grams 
Missing 
44 (10.3) 
119 (27.8) 
25 (5.8) 
60 (14.0) 
152 (35.5) 
20 (4.7) 
8 (1.9) 
Gestational age  
15-20 weeks 
21-25 weeks 
26-31 weeks 
32-36 weeks 
37 weeks + 
Missing 
13 (3.0) 
127 (29.7) 
60 (14.0) 
58 (13.5) 
157 (36.6) 
13 (3.0) 
Age at death  
0 days 
1-6 days 
7-27 days 
28-365 days 
153 (35.7) 
73 (17.1) 
36 (8.4) 
166 (38.8) 
Autopsy performed  
Yes 
             Used to determine cause of death 
No 
Missing 
139 (32.5) 
40 (9.3) 
231 (54.0) 
58 (13.5) 
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Year of death  
2000 
2001 
2002 
2003 
2004 
2005 
2006 
57 (13.3) 
65 (15.2) 
60 (14.0) 
71 (16.6) 
75 (17.5) 
92 (21.5) 
8 (1.9) 
 From 2000-2005, the most common cause of death for infants under age one was "other 
causes" (45.0%), as per the current study definition (table 4.25). The second most common cause 
identified was "conditions arising in the perinatal period" (34.1%). Altogether, 20.8% (n=89) of 
infants who died had a CA listed as the underlying cause of death and an additional 4.4% (n=19) 
had a CA as one of multiple causes of death, meaning that one or more CA played a role in 108 
(25.2%) infant deaths. In total, 310 of the 418 deaths (74.8%) did not identify a CA as a cause of 
death on the Vital Statistics registration. However, when taking a closer look into the hospital, 
amniocentesis, and physician services data, 72 of those 310 cases had a CA diagnosis including: 
4 infants born with anencephalus or encephalocele, 24 instances of circulatory system anomalies, 
17 with "other" CA types, and 21 with multiple anomalies. The contribution of these anomalies 
to death is unclear, but calls into question the documentation of CA as an underlying or multiple 
cause of death.  
Table 4.25 Underlying cause of death, infant deaths (under 1 year of age), Saskatchewan, 
2000-2005 (pooled) 
Diagnostic category Underlying cause of death, 
Vital Statistics 
n (%) 
Congenital anomaly 89 (20.8)  
Perinatal conditions 146 (34.1) 
Other causes* 193 (45.0) 
Total 428 
 *'Other causes' include reasons not related to congenital anomaly or conditions in the perinatal period. 
 Overall congenital anomalies claimed a significant portion of infant lives (20.8%), but the 
contribution of any one category or type of CA was very small. Infant deaths due to 
anencephalus, spina bifida, Down syndrome, or trisomy 18 could not be reported on a year-to-
year basis or even as a six-year pooled figure (for each individual category), due to the 
Ministry’s 'small cell size' policy. Between 2000-2005, there were 12 infant deaths with one of 
the 'screenable conditions' as the primary cause (ie. anencephalus, spina bifida, Down syndrome, 
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or trisomy 18).  The next most common categories of death involving a CA were: other 
chromosomal anomalies (n=8), circulatory system anomalies (n=13) and nervous system 
anomalies (n=12). A total of 44 infants died due to other types of CAs not named above.  
  
 4.6.1 Trends in infant and fetal mortality 
 The year of death was reported for all infants who died in the study population; however, 
figures for the year 2000 were an underestimate given that babies born in 1999 were not included 
in the study. As such, analyses of infant death trends were limited to 2001-2005. Figure 4.36 
illustrates trends in the crude infant, neonatal and postneonatal mortality rates across the study 
period. The infant mortality rate increased substantially during these five years, driven largely by 
an increase in postneonatal mortality from 2002-2005. The average annual percent change for the 
infant, neonatal, and postneonatal mortality rates were 10.0%, 8.5%, and 18.8%, respectively 
(chi-square test for trend p=0.01, p=0.21, and p=0.01). However, a 2005 spike in the number of 
neonatal deaths (3.4 per 1,000 live births to 4.9 per 1,000 live births) led to a 23.8% increase in 
the overall infant mortality rate above the 2004 rate. There were 58 neonatal deaths that year 
compare to the four-year preceding average of 42 deaths. Stillbirth and perinatal mortality 
(Figure 4.37) rates fluctuated year-to-year, with no clear trend observed.  
Figure 4.36 Infant, neonatal, and postneonatal mortality rates, crude, Saskatchewan, 
annual, 2001-2005 
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Figure 4.37 Perinatal mortality and stillbirth rates, crude, Saskatchewan, annual, 2001-
2005*
 
* Perinatal mortality rate was not reported for the year 2000, due to the possibility that deaths to babies born in 
December of 1999 could have been missed. Given the study methodology, stillbirth capture would not have been 
affected. 
 
 4.6.2 Trends in congenital anomaly-related infant deaths 
  A total of 89 infants died as a result of a congenital anomaly, for an overall congenital 
anomaly-specific infant mortality rate of 1.25 per 1,000 live births. In order to investigate any 
changes in the contribution of CA-related deaths to overall infant mortality during the time 
period, the crude IMR is presented alongside two variations of CA-related infant mortality rates 
(figure 4.38): (1) CA-specific IMR and, (2) IMR excluding CA-specific death. The former is 
relevant to the current research as it may fluctuate due to TOPFA, while the latter will not. The  
CA-specific IMR experienced an annual average percent change of 13.4% over the five-year 
period, but the increase was not statistically significant (chi-square test for trend, p=0.31). 
However, in 2002 there was a 42.9% decrease in this rate (0.8 infant deaths per 1,000 live births 
compared to 1.4 deaths per 1,000 live births the year prior) (p=0.17). The 'IMR excluding CA-
specific deaths' rose steadily and significantly over time from 4.0 per 1,000 live births in 2001 to 
6.1 per 1,000 live births in 2005, representing an annual average percent change of 11.3% 
(p=0.01). Both CA-related and non-CA-related causes contributed to year-to-year variations in 
the crude IMR. For instance, fewer CA-related deaths in 2002 led to a slight decline (overall) 
that year, despite more non-CA deaths. In 2005, there was an increase in the number of neonatal 
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deaths (figure 4.36) and in non-CA deaths (table 4.26).
33
 Looking at the proportion of infant 
deaths each year caused by a CA (figure 4.39), the figure varied from a high of 26.2% in 2001 to 
a low of 15.0% in 2002. The 2005 increase in the number of CA-related deaths was not apparent, 
as measured by proportion of deaths, due to the simultaneous increase in the number of non-CA 
deaths.  
 
Table 4.26 Infant deaths, by congenital anomaly and non-congenital anomaly related 
causes, numbers and rates, Saskatchewan, annual, 2001-2005 
 2001 2002 2003 2004 2005 Five-year 
total 
Total infant deaths 65 60 71 75 92 363 
Infant deaths with CA as 
underlying cause 
17 9 17 16 20 79 
Infant deaths without CA 
as underlying cause 
48 51 54 59 72 284 
Total births 12018 11611 11834 11845 11811 71058 
 
Figure 4.38 Comparison of crude infant mortality rates (crude, congenital anomaly-
specific, and excluding deaths due to congenital anomaly), Saskatchewan, annual, 2001-
2005  
 
                                               
33 A closer investigation of this finding was not possible, as our working dataset did not contain the 'death year' 
variable.  
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Figure 4.39 Proportion of infant deaths due to CA (underlying cause), Saskatchewan, 
annual, 2001-2005 
 
 
 Given that determining the role of each condition in infant deaths can be complex and 
cause-of-death investigations and documentation may vary, rates of infant death due to CA were 
calculated two ways (figure 4.40): (1) including only cases where a CA was the underlying/main 
cause; and (2) including all cases where a CA contributed to an infant's passing. The trend 
remains similar, but the rate including all CA-related deaths was higher overall (+23.1%) than 
the rate including only deaths where CAs were the main cause of death . 
Figure 4.40 Congenital anomaly-specific infant mortality rate, CA as underlying versus any 
cause, Saskatchewan, annual, 2001-2005 
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When the congenital anomaly-specific IMR is plotted alongside the TOPFA rate (figure 4.41), 
some interesting patterns can be seen. For instance, in 2001, a lower TOPFA rate (0.6 per 1,000 
pregnancies) occurred alongside higher rates of CA-related death (1.4 per 1,000 live births). By 
comparison, in 2002, the TOPFA rate increased by 166.7% and the CA-specific IMR fell by 
42.9%. The 2005 results are consistent with this pattern showing an increase in CA-specific 
mortality at the same time as the annual TOPFA rate declined. Figures for 2003 and 2004 do not 
illustrate a similar pattern, however the TOPFA rate is a crude indicator in that it does not 
portray the type of CAs being terminated. Conditions like Down syndrome and spina bifida are 
less likely to result in death during the first year, therefore the impact on the IMR will be less 
than if the fetus was affected by a serious and fatal anomaly like anencephaly.  
 
Figure 4.41 Congenital anomaly-specific infant mortality rate and termination of 
pregnancy for fetal anomaly rate, Saskatchewan, annual, 2001-2005 
 
2001 2002 2003 2004 2005 
CA-specific IMR 1.4 0.8 1.4 1.4 1.7 
TOPFA rate 0.6 1.6 1.9 2 1.7 
0 
0.5 
1 
1.5 
2 
2.5 
R
at
e
 p
er
 1
,0
00
 li
ve
 b
ir
th
s 
/ 
p
re
gn
an
ci
es
 
Congenital anomaly-specific infant morality rate (per 1,000 live births) 
and termination of pregnancy for fetal anomaly rate (per 1,000 
pregnancies), Saskatchewan, 2001-2005 
 130 
 
Table 4.27 Congenital anomaly-specific infant mortality rate and termination of pregnancy 
for fetal anomaly rate, number of deaths and total births and pregnancies, Saskatchewan, 
annual, 2001-2005 
 2001 2002 2003 2004 2005 
Number of deaths due 
to congenital anomaly 
17 9 17 16 20 
Number of live births 12018 11611 11834 11845 11811 
CA-specific infant 
mortality rate (95% CI) 
1.4 
(0.9-2.3) 
0.8 
(0.4-1.5) 
1.4 
(0.9-2.3) 
1.4 
(0.8-2.2)  
1.7 
(1.1-2.6) 
Number of TOPFA 7 19 23 24 20 
Number of pregnancies 12097 11704 11912 11943 11884 
TOPFA rate (95% CI) 0.6 
(0.3-1.2) 
1.6 
(1.0-2.6) 
1.9 
(1.3-2.9) 
2.0 
(1.3-3.0) 
1.7 
(1.1-2.6) 
 
 4.6.3 Congenital anomaly-specific and crude infant mortality by mother's 
characteristics 
 Crude and CA-specific infant mortality rates were calculated for each age group and by 
RI status to explore variations in all-cause death and death related to congenital anomalies.
34
 
Crude rates of infant mortality declined with mother's age up to 34 years of age, then increased 
in the 35 years and over age group. Infant mortality rates due to CA exhibited a more J-shaped 
pattern with the highest rates in the oldest (1.9 deaths per 1,000 live births) and youngest age 
groups (1.4 deaths per 1,000 live births). Women aged 35 years and over had CA-specific infant 
mortality rates 72.7% higher than women aged 25-34.  
 
 
 
 
 
 
 
 
 
                                               
34 Due to suppression of health region of residence information, infant mortality rates could not be analyzed 
according to urban-rural residence of mother. There were 19 infant deaths where the mother's residence was 
withheld. 
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Figure 4.42 Crude and congenital anomaly-specific infant mortality rates, according to 
mother's age group, Saskatchewan, 2000-2005 (pooled)  
 
  
 The difference between infant mortality rates in RI women and non-RI women was 
substantial for all-cause and CA-specific deaths. The crude IMR was 102.1% higher in RI 
women compared to non-RI women, and the CA-specific IMR was 72.7% higher.  
 
Figure 4.43 Crude and congenital anomaly-specific infant mortality rates, according to 
Registered Indian status, Saskatchewan, 2000-2005 (pooled) 
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 4.6.4 Congenital anomaly-specific neonatal mortality by mother's characteristics 
 Congenital anomalies are an important cause of death during the first 27 days of life (or 
the neonatal period).(5) Rates of CA-specific neonatal mortality were calculated in order to 
assess any differences between population sub-groups (see table 4.26). Registered Indian women 
had rates almost twice as high as non-Registered Indian women. Similar to the pattern observed 
for CA-specific infant death, CA-specific neonatal mortality rates were highest in the 24 years & 
under and 35 years & over age groups (0.92 and 1.48 per 1,000 live births, respectively), 
although the difference between the groups was somewhat larger in this case. Rates could not be 
calculated for women living in rural and urban health regions due to suppression of residence.  
 
Table 4.28 Congenital anomaly-specific neonatal mortality rate (per 1,000 live births), by 
Registered Indian status, maternal age, and health region of residence, Saskatchewan, 
2000-2005 (pooled) 
 Congenital anomaly-specific neonatal 
mortality rate (per 1,000 live births) 
Registered Indian Status  
Registered Indian 1.41 
Non-Registered Indian 0.76 
Maternal age group  
24 years & under 0.92 
25-29 years 0.79 
30-34 years 0.75 
35 years & over 1.48 
Urban-Rural health region*  
Urban  
Rural  
Overall 0.90 
* Information suppressed.  
 
 
 4.6.5 Pregnancy terminations resulting in a birth 
 The fact that one pregnancy event may fall into more than one outcome category is 
important to consider. Equally important is the impact of dual classification on the calculation of 
rates and to the investigation of the impact of TOPFA on birth outcomes. In the case of fetuses 
aborted following the identification of a CA, events can be documented (and subsequently 
analyzed) as both a medical abortion and a birth (still or live). Whether or not a stillbirth or live 
birth record is created depends on the age and weight of the infant  - 20 weeks or more or more 
than 500 grams for stillbirths - and whether or not the infant breaths or has a heartbeat following 
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delivery. Between 2001-2005, 5.3% of all stillbirths and 2.9% of all infant deaths were the result 
of a TOPFA.  
 
Table 4.29 Proportion of stillbirths and infant deaths due to TOPFA, Saskatchewan, 2000-
2005 
 
Stillbirths Infant deaths 
Percent of deaths (95% CI) 5.3 (3.6-7.8) 2.9 (1.6-5.0) 
Deaths due to TOPFA 25 12 
Total events 469 420 
 
 Infant and perinatal mortality and stillbirth rates were calculated with and without 
TOPFA cases, in order to conduct a crude assessment of the impact of these cases on routinely 
reported indicators. Differences in annual rates were small for most years, with the largest 
difference observed in 2005 for both infant mortality (7.8 vs. 7.3 per 1,000 live births) and 
perinatal mortality (9.4 vs. 8.9 per 1,000 live births). The largest difference in regular compared 
to spontaneous (2) stillbirth rates was in 2004 (7.5 vs. 6.7 per 1,000 live births, respectively).  
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Table 4.30 Infant and perinatal deaths, with and without termination of pregnancy for fetal 
anomaly, Saskatchewan, 2000-2005 
 Missing 2000 2001 2002 2003 2004 2005 5-year 
Infant mortality 
Infant deaths (excluding 
TOPFA resulting in live 
births)  
  65 59 70 73 86 353 
Infant deaths  
(including TOPFA 
resulting in live births)   
  65 60 71 75 92 363* 
Live births   12018 11611 11834 11845 11805 59119 
Regular IMR   5.4 5.2 6.0 6.3 7.8 6.0 
IMR- no TOPFA   5.4 5.1 5.9 6.2 7.3 6.1 
Perinatal mortality 
Perinatal deaths 
(excluding TOPFA) 
1  118 116 106 112 119 572 
Perinatal deaths 
(including TOPFA) 
1  118 122 113 123 130 607 
Still- and live births 275  12043 11641 11846 11883 11827 59515 
Regular PMR† 43.6  9.8 10.5 9.5 10.4 11.0 10.2 
PMR- no TOPFA 43.6  9.8 10.0 8.9 9.4 10.1 9.6 
Stillbirth 
Spontaneous stillbirths 
(excluding TOPFA 
resulting in stillbirths) 
1 68 77 83 67 80 68 444 
Regular stillbirths 
(including TOPFA 
resulting in stillbirths)  
1 69 77 87 73 89 73 469 
Live and stillbirths 275 12007 12043 11641 11846 11883 11827 71522 
Regular stillbirth rate  5.8 6.4 7.5 6.2 7.5 6.2 6.6 
Spontaneous stillbirth 
rate (excluding 
TOPFA) 
 5.7 
 
6.4 7.1 5.7 6.7 5.7 6.2 
* Based on MOH year of death variable. 8 cases died in 2006 and were therefore removed from calculation. 
† Perinatal mortality: the total number of deaths of a fetus or infant between the end of the 20th week gestation and 
the end of the 6th day of life in a calendar year per 1,000 total births (live births and stillbirths) in the same calendar 
year. 
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CHAPTER 5: DISCUSSION 
 
5.1 Uptake and distribution of prenatal screening 
 5.1.1 Lower uptake in First Nations and rural women 
 Screening uptake often varies widely by geographic location and correlates to client and 
physician characteristics and value systems.(28-30, 173-176) Studies elsewhere have shown 
maternal age, religious background, ethnicity, and geographic location all predict MSS use. It 
was not known if similar factors influence utilization in Canada. There was some suggestion, 
however, that women of Aboriginal ethnicity have been less accepting of prenatal serum 
screening. In Ontario the decision not to implement MSS in specific aboriginal communities was 
due to both 'resistance to the concept by First Nations people' and 'geographical and logistical 
difficulties'.(177 p.1770) There was also the perception among Saskatchewan physicians that 
Aboriginal patients accept MSS less often.(32) This is the first detailed exploration, to my 
knowledge, of the predictors of MSS uptake in a Canadian population, while controlling for 
other covariates.  
 Prenatal screening uptake was much lower in First Nations women (9.6%) compared to 
non-First Nations (28.4%) and living in a rural health region exacerbated the difference. Even for 
women who lived in an urban health region, non-RI women were more than twice as likely to 
have had MSS than RI women (OR=2.56), when maternal age and year of pregnancy were held 
constant. This finding dispels the notion that uptake may simply be lower in rural and northern 
locations due to access barriers, where in some instance these populations comprise of higher 
proportions of First Nations women. However, living in a rural region still mattered when it 
came to use of prenatal screening, especially for RI women. First Nations women living in urban 
regions were also twice as likely to screen when compared to their rural counterparts. By far, the 
group most likely to screen was non-First Nations women age 35 years and over living in an 
urban region (54.2%).  
 Lower screening rates in First Nations and rural populations may reflect differences in 
the way prenatal care is accessed and delivered and/or in personal value systems. Dillon et al 
(1994) found resistance to the concept of prenatal screening in Aboriginal communities in 
Ontario, where some felt the medicalization of pregnancy was contrary to their cultural 
preference for the natural.(177) Nsiah-Jefferson (1989) theorized that women of different 
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cultures and of lower socioeconomic status are less accepting of prenatal screening for 
disabilities than women from the dominant culture, viewing them within a context of eugenic 
discrimination and medical exploitation.(178) Lower rates of TOPFA after prenatal diagnosis 
have also been observed in cultural minorities.(179) Aside from cultural and personal belief 
systems, another contributing factor may be that, on average, Aboriginal women are more likely 
to receive inadequate prenatal care and therefore may present to their care providers at a time 
when serum screening cannot be done.(180) While no national data exists to study this claim, in 
Manitoba an estimated 6.9% of women received inadequate prenatal care, with the figure being 
as high as 20.4% in neighbourhoods where the number of Aboriginal people was high.(180)
35
 A 
deeper investigation into this hypothesis was beyond the scope of the current study.  
 Risk increases with age for the most common congenital anomalies and younger, First 
Nations mothers may (rightly) view themselves as being at lower risk for the conditions 
detectable by serum screening and therefore view screening as unnecessary. The majority of 
Registered Indian women were under 25 years old (57.7%) and therefore were notably younger 
than the remaining pregnancy population in Saskatchewan (32.6%). This proposition cannot 
fully explain differences, as uptake rates were higher for non-First Nation women for all age 
groups studied. A multivariate analysis also found First Nation status to be an independent 
predictor of uptake (p<.000), even after controlling for maternal age. Follow-up by means of 
qualitative study or probing questionnaires will be important to elucidate factors responsible for 
low uptake in both First Nations and rural women.  
 The role of physicians and midwives with regard to uptake is uncertain, but differences in 
acceptance have been well-documented.(21, 32, 181-183) Permaul-Woods (1999) found that 
physicians in northern and rural Ontario were less likely to offer MSS than those in other 
regions.(173) Concerns about the social and cultural sensitivity of MSS and the availability of 
follow-up services affected use. In a 2005 survey, 48% of Saskatchewan physicians reported that 
fewer Aboriginal pregnant patients accepted MSS and likewise reported low access to resources 
necessary to deliver screening (ie. genetic counselling, abortion services and amniocentesis).(32) 
Many physicians had concerns generally, including about the performance of screening tests and 
creating unnecessary anxiety in women at low risk of having an affected pregnancy; findings 
                                               
35 Inadequate prenatal care referred to a low frequency of overall visits, as well as late presentation for first time 
prenatal care check-up.  
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similar to other Canadian studies (22, 175). Many physicians lacked sufficient knowledge about 
the test's performance, follow-up, and importantly, about the implications of having and raising a 
child with any of the conditions detected by screening. Poor provider understanding of complex 
screening protocols and inadequate follow-up resources has the potential to impact physician's 
practice, particularly in rural and remote communities.  
 
 5.1.2 The meaning of low uptake 
 Saskatchewan traditionally has had low rates of prenatal diagnosis compared to other 
provinces, and MSS rates are equally low, lending support to Renaud's (1993) theory of distinct 
provincial cultures when it comes to use of reproductive technologies.(181) Differential uptake 
across populations is important to monitor because MSS may lead to terminations of pregnancy; 
a practice with implications for CA birth incidence and infant/fetal mortality statistics. Like 
Saskatchewan, Newfoundland and Labrador have had a low rate of uptake (22%) relative to 
other provinces (eg. 63% in Ontario, 60% in Manitoba, 49% in British Columbia).(80, 133, 134, 
184) A study of women in that province found that screening uptake largely reflects values 
incongruent with the offer of MSS.(80) Uptake did not change appreciably over the study period 
in Saskatchewan (18.%-26.8%) and was similar in recent reporting (2006-2009).(135) 
 Prenatal screening rates are not always a straight-forward reflection of the population's 
preferences and values. Studies have shown that many women that had screening were not 
informed, engaged participants in these decisions.(185, 186) As such screening rates may be 
higher when informed consent is not a priority. In light of this fact, Vassy (2006) argues 
screening rates can give the erroneous impression that women want screening, which precipitates 
the investment of more resources and creates a cycle of expansion.(187) Seavilleklein (2009) 
adds that stopping the program, however, can be seen as removing choice even though women's 
wishes and wants were never established in the first place.(185) The more moderate uptake 
observed in Saskatchewan is not necessarily a negative finding, if utilization reflects women's 
own choices and values. A qualitative evaluation of women undergoing screening and those who 
did not would be an important contribution to our understanding of women's experience in the 
province.  
 One study in the United Kingdom found no sign of social inequalities in the uptake of 
prenatal screening (188), but another reported wide discrepancies (146). Unfortunately individual 
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data on mothers income and education levels are not available through Saskatchewan's 
administrative health databases; a future study may consider mapping MSS data using mother's 
postal code according to neighbourhood income level for some additional insights. In Northern 
Ireland, where access to abortion services are restricted, the reported offer and uptake of 
screening was found to be lower in women with less education.(83)  Similarly, Khoshnood 
(2004) found uptake in prenatal diagnostic testing was higher in more educated women in the 
United States, leading to a lower rate of age-related increase in the birth prevalence of DS.(146)  
 It is useful to consider the reasons that women choose to have screening and the role that 
women's need for reassurance may play. MSS is designed to predict just three types of 
conditions and in most cases provides little information about the fetus' overall wellbeing.(189) 
Women who opt for screening often desire to know more about the health of their baby and are 
wanting reassurance of the baby’s health.(80, 186) On the other hand, the most common reasons 
women refuse screening are because they would not terminate the pregnancy and the results are 
not definitive. Some feminist scholars reason that modern medicine has created a cycle of 
dependency ('medicalization') where women rely on medical experts to allay their fears and 
anxieties - fears and anxieties that are often created and reproduced by those in the medical 
profession.(190, 191) Women from certain cultural groups and those with lower levels of 
education may internalize medical risk to a lesser extent, and perhaps, may feel less compelled to 
screen.  
  
5.2 Utilization of Prenatal Diagnostic Testing 
 An estimated one percent of Saskatchewan pregnancies underwent prenatal diagnostic 
testing during the study. Reasons for testing over the five year period (2001-2005) shifted from 
'maternal age-related concerns' to 'abnormal MSS result', with the overall number of tests 
gradually decreasing (-13.2% overall from 2002 to 2004).
36
 This suggests that MSS is 
accomplishing one of its stated goals, which is to reduce the number of unnecessary invasive 
diagnostic tests.(157) Some women with screening results below the risk cut-off (or screen-
negative) still pursued amniocentesis, but there may have been other markers or risk factors 
driving those decisions. In 2011, the SOGC updated its clinical practice guidelines to say that 
                                               
36 Absolute numbers obtained from the Saskatoon Cytogenetics Lab reporting on all amniocenteses performed 
between 2006-2012 were only slightly lower than those reported here. Between 2002-2012 the total number of tests 
declined by 16.2%. 
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testing based solely on maternal age 'should be abandoned' and that women age 40 and over 
should not be offered an amniocentesis unless their screening result is above cut-off or they have 
another significant risk factor (eg. a previous child with a chromosomal anomaly).(157) The 
current dataset tells the story of prenatal screening and diagnosis in Saskatchewan prior to these 
new recommendations. In 2004, for example, 145 women aged 35 and over had an 
amniocentesis. Of those women, only 28.3% had received a positive MSS screening result and 
another 21.4% did not have MSS, which seems to contradict the SOGC's latest recommendation 
that testing should not be done solely based on age. Holding all other variables constant, women 
that were age 35 and over, non-RI status, and living in an urban health region were most likely to 
undergo diagnostic testing. These are the same groups most likely to utilize MSS. 
 Uptake of prenatal diagnostic testing may be viewed as a better marker of a population's 
preferences and values (as far women's views that abortion is an acceptable intervention 
following CA diagnosis) than MSS uptake, where many are seeking reassurance and do not 
pursue follow-up testing. Pregnancy termination rates following a prenatal CA diagnosis are 
high, but they can often be misleading as they are based on women who chose to proceed to 
prenatal diagnosis. In Saskatchewan, only one-third of women (32.7%) that received an 
increased- risk MSS result chose to follow-up with an amniocentesis. Compare this figure to 
France where 95% of women that received an increased-risk MSS result from 1997-1998 
underwent amniocentesis.(71) The fact that two-thirds of Saskatchewan women declined 
diagnostic testing, helps to put into context the finding that forty percent of women who received 
a prenatal diagnosis of a chromosomal anomaly terminated their pregnancy (74.1% of prenatally 
diagnosed Down syndrome or trisomy 18 cases and 18.6% cases of 'other' anomalies). Rates in 
some regions have been even higher (eg. 99.5% in France)(71, 98), although comparable figures 
are very difficult to locate. Women who accept prenatal diagnostic testing after an elevated MSS 
(or the identification of markers on the routine ultrasound scan) have been shown to have 
different views, values and beliefs regarding pregnancy investigation and  intervention compared 
to those who decline MSS or follow-up.(23, 25, 26, 30) Women who would not have an abortion 
more often refuse screening and follow-up testing.(17, 25, 30, 80) The personal risk-benefit 
analysis may favour refusal to screen and/or prenatal diagnostic testing. Women who are not 
willing to consider abortion might ask themselves - why risk pregnancy loss when nothing can 
be done to alter the outcome and when the likelihood of being truly affected is low? It is 
 140 
 
important to note that the majority of women that screened positive and opted for amniocentesis 
did not have a pregnancy affected by Down syndrome or trisomy 18 (96.1%) or any 
chromosomal anomaly (93.8%).  
 Few population-based studies in Canada have reported on the portion of CA cases that 
are diagnosed prenatally, and of these, the number that are aborted. Limited data on these 
outcomes precludes local comparisons. One BC study found that 86.1% of all NTD cases (1997-
1999) were diagnosed during pregnancy and that 73% were terminated, however, the current 
study was not designed to investigate outcomes for NTDs. Even surveillance reporting, for 
example from Alberta, fails to report on the proportion or number of CA-affected births or 
fetuses that resulted in pregnancy termination.(192) Smith et al (2011) found that 85% of all 
trisomy 18 and 84% of all trisomy 13 cases in areas of England and Wales were diagnosed 
during pregnancy (98); a substantially higher rate than found here. However, in that study 
antenatal detection included the identification of soft markers, which only signify an increased 
risk of anomaly and do not provide a definitive diagnosis (193). Saskatchewan data has shown 
that 63.2% of trisomy 18 cases, 13.9% of Down syndrome cases, and 27.4% of other 
chromosomal anomalies were diagnosed during pregnancy. More cases may have been suspected 
due to ultrasound markers but not confirmed by amniocentesis. Future research and surveillance 
would benefit from the electronic capture of diagnostic imaging findings and its linkage to the 
administrative health databases, as well as a national reporting of the rate of prenatal diagnoses 
of various conditions and associated termination rates.   
 The absence of ultrasound data and diagnostic information on stillbirths and fetal losses 
for non-chromosomal anomalies, such as neural tube defects, precluded our investigation of the 
prenatal detection rate for all CA types. In British Columbia, 86% of all NTDs occurring 
between 1997-1999 were detected during pregnancy and 73% of those pregnancies 
terminated.(11) Knowing the true NTD incidence rate in Saskatchewan would have provided 
exceptionally valuable information given that NTDs are largely preventable (up to 79%) with 
folic acid fortification and supplementation during pregnancy.(90) Knowledge of trends in NTD 
incidence would be an important contribution to public health planning. Live birth rates of spina 
bifida and anencephalus were reported and varied considerably year-to-year in Saskatchewan; 
for example the live birth prevalence of spina bifida dropped by 43% between 2000 and 2001, 
the same year the MSS program was formally introduced in the province. It is known that 
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amniotic AFP screening (requiring an amniocentesis) renders a very high detection rate for 
neural tube defects (99% and 0.3% false-positive rate), therefore most positive samples would 
identify a true case.(169, 170) Ten of the 54 TOPFA cases with an unknown diagnosis had 
positive amniotic fluid screens preceding a medical abortion. If these cases were presumed to 
have had an NTD, it would result in an incidence rate of 1.29 per 1,000 total births, which is 
15% higher than the known live birth rate of 1.10 per 1,000 live births. This would also suggest 
that TOPFA were responsible for the 15% reduction. If we presumed all TOPFA with unknown 
diagnoses were NTD-related (and diagnosed by ultrasound), the effect would be a 42.7% 
reduction. Van Allen (2006) reported a 60% difference in British Columbia's NTD live birth 
prevalence and incidence from 1997-1999 where 72% of all prenatally-diagnosed cases were 
terminated.(11) In Saskatchewan the difference could be as low as 5.4% (between the live birth 
prevalence and incidence rates) or as high as 43.1%, if all unknown cases were truly NTD-
related.  
 
5.3 Predictors of Termination of Pregnancy for Fetal Anomaly 
 A focal point of the current study was the identification of selective pregnancy 
terminations performed following the detection of a fetal anomaly. It was important to first 
explore characteristics of women ending their pregnancy in this manner, to consider differential 
effects between population subgroups. While we did not have detailed information on pertinent 
aspects of women's decision making, a few key personal and demographic variables were 
examined to gain some basic insights. Follow-up by qualitative inquiry on this highly sensitive 
topic would be valuable, as little is known about women's experience surrounding TOPFA in a 
largely rural and relatively more conservative province that has a growing First Nations 
population.  
  
 5.3.1 Registered Indian women 
 Registered Indian women had a considerably lower rate of uptake of prenatal screening 
and diagnostic testing than other Saskatchewan women, resulting in fewer pregnancy 
terminations for an anomaly in this population. Registered Indian women that received an 
increased-risk MSS result had lower rates of diagnostic testing, with only 18.5% having an 
amniocentesis after receiving an result above cut-off compared to 33.5% of non-RI women. It 
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may be that more First Nations women declined further testing, but problems accessing services 
may have also played a role. Apart from the reason, lower testing rates meant that Registered 
Indian women were less likely to obtain a prenatal diagnosis when the fetus had a chromosomal 
anomaly compared to other women (8.3% vs. 27.0%). The number of congenital anomalies 
diagnosed in RI women who screened-positive and then had amniocentesis was very small (but 
similar to the rate in non-RI women) and no TOPFA were identified. By comparison, the 
pregnancy termination rate was 66.7% for non-RI women that screened-positive, followed-up 
with amniocentesis, and received a diagnosis of a chromosomal anomaly. This resulted in 
TOPFA rates (per 1,000 total pregnancies) in RI women that were half as high as the rest of the 
population (0.64 vs. 1.34, per 1,000 pregnancies), although there was some sign that this 
difference was narrowing over the study period. Small numbers make a confident interpretation 
quite difficult, but this finding is consistent with RI women's tendency to screen less and also to 
have follow-up testing less often. This is not the first time ethnicity has been shown to predict 
this outcome. In England and Wales, women of Pakistani ethnicity had much lower rates of 
TOPFA than white British or Indian women.(98) It will be important that future research spans 
longer periods of time, given the relatively smaller population in Saskatchewan and the fact that 
congenital anomalies are rare, and TOPFA rarer still.  
 In the Smith et al (2011) study, prenatal detection of serious anomalies was higher and 
did not vary according to deprivation level or ethnicity (98); another study in the same region 
found no differences in screening uptake across these population sub-groups (194). However, the 
rate of TOPFA was significantly lower in the most deprived group compared to the least (63% 
vs. 79%, respectively), despite universal access to abortion services and prenatal diagnosis. This 
presents an interesting contrast to current findings where large differences between First Nations 
and non-First Nations women could be seen in both prenatal screening uptake and diagnosis, and 
ultimately, fewer TOPFAs. One important difference is the fact that the Smith et al (2011) study 
included anomalies detected by ultrasound (suspected cases), where use is much more universal, 
less invasive, and accepted by women as a standard component to prenatal care.(98) Another 
potential explanation is that uptake varies across ethnic groups, with each group applying its own 
views, values and cultural and religious norms to decision making. First Nation women may 
view MSS and prenatal diagnosis in a different light than women from other ethnic groups and 
the effect of ethnicity may be mediated by socioeconomic circumstances. The data released by 
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the Saskatchewan Ministry of Health did not allow for analysis across other ethnic groupings, 
which would have made for a very interesting and more refined analysis. 
  
 5.3.2 Maternal age 
 The study in England found no difference in TOPFA according to maternal age (98), but 
in Saskatchewan some differences were observed. Selective termination rates following a Down 
syndrome or trisomy 18 diagnosis were slightly lower in women 30 years and under compared to 
women over age 30 (71.4% vs. 75%), but were much higher when it came to "other" 
chromosomal anomalies (33.3% vs. 4.5%). At the population level, overall selective termination 
rates were more than four times as high (per 1,000 pregnancies) in the 35 years and over age 
group compared to those 24 years and under. This is a finding that reflects the higher rate of 
screening, prenatal diagnosis, and CA-risk in the highest age category, but not a greater 
propensity towards pregnancy termination in the case of a confirmed chromosomal anomaly. 
Women under 30 years of age were much less likely to receive a prenatal diagnosis when a 
chromosomal anomaly was present (18.4% vs. 31.8%). While risk for a chromosomal anomaly is 
considerably lower for younger mothers, 53.5% of all pregnancies with chromosomal anomalies 
and 40.7% of all DS pregnancies belonged to this group. This finding is consistent with what is 
known on the topic.(5) From 2001-2004, a notable rise in TOPFA rates (per 1,000 total 
pregnancies) could be seen for women aged 30 and over, but this rate dropped in 2005 and rose 
in those under 30 years, particularly those less than 25. Around this time the practice of offering 
to screening to women under age 35 was beginning to emerge. The 2007 prenatal screening 
guideline will have likely expanded the uptake of screening in younger populations further, as 
this study was done at a time when younger women were not a primary target of screening. 
Recent data on amniocentesis testing in Saskatchewan has shown that testing numbers due to 
'advanced maternal age' continued to fall up until 2012, while more and more tests are being 
done in response to abnormal MSS results and ultrasound findings. It also appears that the trend 
towards low amniocentesis uptake has continued, perhaps suggesting that the rate of TOPFA in 
Saskatchewan would be similar to the rate observed in the current study. It will be important to 
continue to monitor trends in TOPFA across maternal age, ethnicity, and geography as these may 
mirror changes in health service provision and access and in the views and values of different 
generations regarding pregnancy intervention and disability. 
 144 
 
 5.3.3 Timing of diagnosis 
 Timing of prenatal diagnosis has been shown to influence women's decisions to terminate 
or continue an affected pregnancy.(98, 195) Smith et al (2011) observed fewer pregnancy 
terminations with increasing gestational age: 75% of fetuses diagnosed (with select CA types) at 
less than 22 weeks and 19% after 23 weeks were aborted.(98) In the current analysis, the 
proportion of fetuses terminated following the diagnosis of a chromosomal anomaly was 58.3% 
at 12-16 weeks, 41.7% at 17-21 weeks, and 11.1% at 22 weeks or later. Many late diagnoses 
were cases where an abnormal ultrasound scan led to amniocentesis testing. It is possible that 
TOPFA rates may also be related to the type of anomalies diagnosed during each gestational 
period and to timing of diagnosis. In England women from higher deprivations areas were 
slightly less likely to receive an early diagnosis; a finding that attenuated, but did not eliminate, 
the differences in rates of pregnancy termination across socioeconomic groupings.(98) The 
number of First Nations women having amniocentesis was small in the current study, therefore it 
was not possible to investigate the timing of diagnosis in this population or its impact on TOPFA 
rates. 
 5.3.4 Type of anomaly 
 Rates of pregnancy termination vary widely according to the type of anomaly, with 
published rates at 80% and higher for chromosomal anomalies and neural tube defects.(6, 11, 98) 
Variations may reflect a clearer clinical picture around some diagnoses, as well as parents' 
understanding and concerns relating to raising a child with a chromosomal or nervous system 
anomaly.(98) The high rate of pregnancy termination following a prenatal diagnosis of Down 
syndrome was somewhat surprising given that survival is high and most children and adults 
enjoy a good quality of life, with increasing opportunities for participation in society. Largely 
due to increasing advocacy by individuals with Down syndrome ('self advocates') and their 
families, most people with Down syndrome will read, write and participate fully in their 
communities.(196) Advocates reject its medicalization, maintaining that "Down syndrome is a 
naturally occurring chromosomal arrangement and is not a disease, defect, or negative medical 
outcome of pregnancy (197 p.7)". Still termination of pregnancy rates following prenatal 
diagnosis were similar for both Down syndrome and trisomy 18 (73.3% and 75%, respectively), 
despite the fact that survival of infants with trisomy 18 is on average less than one month and 
94% of infants with Down syndrome live past their first year of life and well into their 50s and 
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60s (89, 196). Many women who received a positive MSS result for Down syndrome or trisomy 
18 opted not to pursue prenatal diagnosis (63.2% and 67.3%, respectively), suggesting that some 
women who would not end a DS-affected pregnancy likely remove themselves from the 
diagnostic pathway earlier on.  
 For women choosing to have prenatal diagnosis testing, perception of quality of life may 
be an important factor in their decision making about pregnancy termination, specifically, 
whether the child would suffer physically or emotionally.(198) Given the comparatively high 
pregnancy termination rate following detection of Down syndrome, one wonders if society has 
done enough to create awareness in general, and in particular, if counselling accurately portrays 
life with the condition. Lawson & Peters (2002) suggest that the social construction of disability 
plays a role in such decisions, given that "the inability [of people without a disability] to imagine 
the disability experience often translates into a collective mythology that a person with a 
disability lives a tragic life, marked by deprivation and suffering, a circumstances that should be 
resolutely avoided. This perception conflicts sharply with the view of many persons with 
disabilities who do not see themselves as different or abnormal and who hold society's attitudes 
responsible for disability-based discrimination."(59 p.6) Access to high-quality, accurate, and 
balanced counselling services is therefore imperative. Care must be taken not to oversimplify 
descriptions, portraying a life to be lived with deficits and illness, without counterbalancing the 
conversation with the joys and successes. Many Saskatchewan physicians admitted that they 
were not knowledgeable enough to counsel women on the implications of having a child with 
Down syndrome or trisomy 18. Given the immense challenge of providing fair, balanced, and 
value-neutral information to parents following a diagnosis, the CDSS (2007) maintains that 
increased investment in screening programs must be accompanied by funding to promote public 
awareness of Down syndrome and information materials to facilitate pre-test counselling about 
conditions being screened, which would support a more informed decision about screening.(197) 
Chapter 6 includes a more in-depth discussion on the topic of informed consent, non-directive 
counselling and the inherent challenges. 
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5.4 Termination of pregnancy for fetal anomaly and Population Health Outcomes 
 5.4.1 Congenital anomaly trends 
 A key objective of this study was to determine if the practice of termination of pregnancy 
for fetal anomaly led to decreases in the number of live births with a screenable congenital 
anomaly. Rate differences between live birth prevalence and incidence were observed for three 
outcomes - anencephalus, Down syndrome, and trisomy 18. In the case of both Down syndrome 
and trisomy 18, the prevalence and incidence lines both demonstrated an increasing trend over 
the study period, but the incidence line (accounting for pregnancy terminations) was steeper 
(10.0% for Down syndrome and 84.6% for trisomy 18, p>.05). The prenatal detection rate for 
trisomy 18 was higher than for Down syndrome (63.2% and 13.9%, respectively), which led to a 
greater difference in the number of infants born with trisomy 18 compared to the number of 
fetuses known to be affected. A difference could be seen for anencephalus for some years, but as 
discussed, the incidence will be an underestimate for this outcome due to lack of diagnostic 
information (in the study dataset) on fetal losses with non-chromosomal anomalies.  
 When six-year pooled birth prevalence and incidence rates were stratified by RI status 
and mother's age, the largest discrepancy was observed in women aged 35 years and over for 
Down syndrome, with the incidence being 29.6% higher than the live birth prevalence rate. In 
the case of trisomy 18, the rate differences were much larger and were observed across all age 
groups (144%-193%, increasing with age). Trisomy 18 is highly detectable during the routine 
screening ultrasound (199), which means that more cases in younger women would be detected 
without MSS, making ultrasound a pathway to prenatal diagnosis requiring further study. When 
examining rates according to RI status, the discrepancy between Down syndrome live birth and 
incidence rates was greater for non-RI women compared to RI women (13% vs. 5.2%, overall), 
reflecting both lower risk and lower utilization of screening/diagnosis and pregnancy termination 
in RI women. Close attention should be paid to CA rates in rural and First Nations mothers in 
future analyses, specifically watching for differences owing to pregnancy termination. Moreover, 
evaluation of primary prevention strategies or etiological research should not be undertaken 
unless TOPFA can be accounted for, as erroneous conclusions may result. 
 
 
 147 
 
 5.4.2 Impact of pregnancy termination for congenital anomaly on fetal and infant 
mortality  
  5.4.2.1 Infant mortality 
 Infant mortality is a powerful and commonly used indicator of the health of populations, 
largely due to the unique vulnerability of infants in harsh social and economic environments.(34)  
Less-than-optimal infant mortality rates are seen to reflect poorly on inequalities in societies and 
the tragic impact these have on the most vulnerable, in essence, "illuminating the machinery of 
social injustice (34 p.111)". Inequities between First Nations and non-First Nations, in Canada 
and Saskatchewan, have been well-documented, as have the health consequences.(38, 122, 200) 
Substantial disparities in infant mortality rates are known to exist and the current study set out to 
provide additional insights. In particular, I wondered if greater uptake of prenatal screening, 
diagnosis and pregnancy termination for CAs in non-First Nations women would enhance 
disparities in infant mortality rates, or at the very least maintain them in the wake of 
improvements in social and economic conditions over time.  
 Socioeconomic disparities in infant death are well-established, but there is still much to 
be learned about the causal pathways. Gortmaker and Wise (1997) mount a strong case for the 
need to recognize the influence that modern reproductive technologies exert on infant and fetal 
death in industrialized countries, often maintaining or escalating traditional socioeconomic 
disparities.(34) While these two sociologists were speaking specifically about breakthroughs in 
neonatal intensive care, differences in the uptake of prenatal screening, diagnosis, and TOPFA 
make it highly likely that the more recent generation of reproductive technologies have produced 
disparities of a distinctly different nature. Disparities potentially masked by difficulties in 
identifying and quantifying the impact of TOPFA and the extent to which this practice varies 
across social, economic, cultural and geographic lines. Central to this research was the 
hypothesis that TOPFA has consequences for infant mortality, shifting a number of deaths to the 
fetal period. 
 Limitations in the dataset precluded plans to model a 'TOPFA-adjusted infant mortality 
rate' and restricted analysis around fetal death in general. Similar to indicators like the well-used 
hospital standardized mortality ratio (HSMR), an adjusted IMR indicator could be designed to 
correct for TOPFA by estimating the likelihood that aborted fetuses would have resulted in a live 
birth, followed by a death within the first year. In the absence of such an indicator, we relied on 
the CA-specific infant and neonatal mortality rates, as well as the stillbirth rates. During the 
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study period, 20.8% of infant deaths (overall) were due to a CA; a figure that is lower than the 
proportion of deaths due to CA nationally, which was 30% in 1998 (1). This difference can likely 
be explained by Saskatchewan's higher overall rate of infant death (many of which were the 
result of non-CA related causes), since the overall CA-specific IMR (>=500 grams) in 
Saskatchewan was 37.8% higher than the national rate from 2000-2005.
37
 A clear trend in one 
direction or the other could not be seen in regards to CA-specific IMR. The 2002 rate was 42.9% 
lower than 2001 (p<.05), potentially pointing to an impact of the newly introduced MSS 
program, but the rates remained relatively unchanged (or even higher) during subsequent years 
studied (1.4, 0.8, 1.4, 1.4, and 1.7 CA-related deaths per 1,000 live births, respectively by year). 
These results span a relatively short time period and represent a significant decline from similar 
statistics dating back to 1985 (2.92 per 1,000 live births >=500 grams)(130), but they do not 
suggest a notable, or at least sustained, population impact attributable to the MSS program. One 
must also consider the (apparent) rise in the incidence rates of specific anomalies, including 
anencephalus (and similarly severe NTD), trisomy 18, and Down syndrome (average annual 
percent changes of 29.6%, 83.9%, and 10.0%).
38
 If more children are being born with 
vulnerabilities that cannot be effectively treated, despite improvements in medical and surgical 
care, the CA-specific IMR will rise. 
 A key consideration of the current study was how differences emerge along the pathway 
from prenatal serum screening through the first year of life. Smith et al (2011) found that 
socioeconomic variations in TOPFA resulted in socioeconomic inequalities in the rate of fetal 
loss, stillbirth, and live birth associated with an anomaly.(98) The effect was substantial, with the 
most deprived population experiencing a 20% higher rate of CA-related stillbirth, a 61% higher 
rate of live birth with a CA, and a 98% higher risk of CA-related neonatal mortality. After 
adjusting for maternal age, the disparities widened to 57%, 85%, and 123%, respectively. 
Comparing First Nations and non-First Nations in Saskatchewan, the CA-specific infant and 
                                               
37 Based on data from the Public Health Agency of Canada, the 6-year pooled (2000-2005) CA-specific IMR (in 
births 500 grams or more) was 1.11 per 1,000 live births for Canada (excluding Ontario) and 1.53 per 1,000 live 
births for Saskatchewan. Figures from the Public Health Agency of Canada were used here to compare 
Saskatchewan to the rest of the country because Canadian statistics for all deaths (not just those 500 grams or more) 
were not available at the time of writing, and to ensure better comparability. 
38 A portion of the observed increase in chromosomal anomalies may be due to under ascertainment of cases in 2000 
and 2001, thereby making the change over time appear to be greater than it was. Nonetheless increases in the 
incidence of Down syndrome and Trisomy were detected between 2002-2005 (average annual percent change was 
19.0% and 6.4%, respectively). 
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neonatal mortality rates were 42.1% and 85.5% higher (respectively) in the First Nations 
population. Higher levels of infant death due to a CA in the children of First Nations women may 
be somewhat unexpected given the fact that rates of congenital anomalies (combined) were 
lower in this population (140.5 vs. 101.2 per 10,000 pregnancies, p<.000) and rates of 
chromosomal anomalies were substantially lower (44.5 vs. 22.8 per 10,000). Increased uptake of 
prenatal screening, diagnosis and higher rates of TOPFA in non-First Nations women will 
explain some of this observed difference, but there are other factors that could be studied (eg. 
differences in the survival of infants born with a congenital anomaly).  
 Looking at infant mortality risk across maternal age groups, it was found that infants of 
both the youngest and oldest mothers were at greater risk of dying during the first year of life. 
The crude IMR generally declined with age of mother and was 30.9% higher in mothers under 
age 25 compared to those age 35 and over (7.2 vs. 5.5 deaths per 1,000 live births, respectively). 
However, the higher frequency of deaths due to a CA in children of mothers age 35 and over 
(34.1% of deaths in this age group were due to a CA compared to 19.3% in those under 25 years) 
led to a higher crude rate for this age group. When the analysis was restricted to the first 27 days, 
the CA-specific neonatal mortality rate was 61%-97% higher in infants born to women age 35 
and over compared to younger age groups, which may be explained by the much higher 
incidence of chromosomal anomalies in the older age group (97.2 per 10,000 pregnancies
39
 for 
women aged 35 and over vs. 31.0 per 10,000 pregnancies in women under 25 years). The overall 
congenital anomaly incidence increased significantly with age as well (11.0% of women under 
age 25 vs. 12.9% of women aged 35 and over, p<.000). The trend towards delayed childbearing 
may have a direct impact on provincial and regional infant mortality, depending on older 
mothers' use of prenatal screening, diagnosis and decisions to terminate or continue affected 
pregnancies. In the current study, TOPFA was more common with increasing maternal age (2.78 
per 1,000 pregnancies in women aged 35 and over vs. 0.61 per 1,000 pregnancies in those under 
age 25) and future research and surveillance efforts investigating pregnancy outcomes according 
to maternal characteristics (ie. age group, ethnicity, and geography) should take into 
consideration these differences.  
                                               
39 Here pregnancies refers to those that resulted in a live or stillbirth, or spontaneous abortions or elective abortions 
that underwent prenatal diagnostic testing. 
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 The interrelationship between pregnancy termination and infant death is not entirely 
straightforward. In Canada, there is no gestational age limit at which a termination of pregnancy 
can be legally performed for a serious anomaly.(201) If an abortion is done in the second or third 
trimester when the fetus is viable, the possibility of a live birth increases. Even if the baby is not 
born alive, all infants born at 20 weeks or later (or weighing 500 grams or more) must be 
registered as a stillbirth in Saskatchewan according to the Vital Statistics Act.(202) A central 
hypothesis to this research was that TOPFA may lower the perinatal and infant mortality rates, 
however, this oddity in coding and birth registration practices complicates the association given 
that it may actually increase the number of infant deaths and stillbirths depending on the CA and 
the timing of the abortion. An unexpected finding was that 5.3% of all stillbirths and 2.9% of all 
infant deaths were the result of TOPFA, even though the death certificate only identified five 
cases as being 'termination of fetus or newborn' (the ICD code used to denote a TOPFA). When 
TOPFA were removed from indicator calculations, the difference between regular and 
spontaneous rates were small for infant mortality (6.0 vs. 6.1 per 1,000 live births), but 
somewhat wider for stillbirths (6.6 vs. 6.2 per 1,000 total births). The largest difference in annual 
rates was 6.4% (in 2005) for infant deaths and 10.7% (in 2004) for stillbirths. In settings where 
this practice is more prevalent, the impact is likely to be sizeable. In the case of the termination 
of a Down syndrome fetus, the likelihood of a fetus/infant with DS dying naturally as a stillbirth 
or live birth in the first year is low, so the practice of TOPFA, depending on its timing, can lead 
to an increase in the number of infant deaths or stillbirths. In the case of anencephalus and 
trisomy 18, the impact on mortality rates would be neutral or a decrease, if the termination was 
performed before 20 weeks and the fetus weighed less than 500 grams and no heartbeat or 
breath, as most babies born die within the first year. Because there is no simple calculation able 
to add or subtract such cases, there is need for a more sophisticated TOPFA-adjusted IMR.  
 Initially the hope was to model an adjusted infant mortality rate and to explore the impact 
of TOPFA on perinatal mortality. However, the absence of stillbirth diagnostic data and ICD 
codes that enable the identification of TOPFA less than 20 weeks and less than 500 grams from 
the hospital data file precluded such analysis. Year of infant death was not included in the dataset 
for all CAs detectable by the MSS program, therefore making it impossible to investigate the 
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contribution of these outcomes to the annual IMR.
40
 Congenital anomaly research is often 
limited by the absence of accurate and complete diagnostic data for whole populations. To model 
an adjusted-IMR, complete, detailed diagnostic information would be required, and even still, a 
larger dataset necessary in order to estimate survival of affected fetuses into infancy. Once 
survival-to-infancy rates were calculated, one would need to model the likelihood that each 
infant would survive beyond the first year of life. There were just 289 cases of screenable 
anomalies in Saskatchewan over this 6-year period, or an average of 48 cases per year. Even with 
a much larger population dataset, estimating survival for different CA types may be a challenge. 
When it comes to survival estimates for CA-affected fetuses and infants, national figures from 
the Public Health Agency of Canada only contain births and are therefore biased by the 
exclusion of many TOPFA cases over the period. Earlier data from PHAC or another provincial 
registry, predating prenatal screening programs, may underestimate survival amongst vulnerable 
infants due to advances in neonatal intensive care over time. If survival data could be pooled 
from multiple CA surveillance systems and a system created for categorizing the severity of 
TOPFA cases, estimates could be applied to local level TOPFA data to estimate adjusted infant 
and fetal mortality rates. 
 Some progress has been made in regards to congenital anomaly surveillance in 
Saskatchewan. A Congenital Anomaly Surveillance System is being piloted in the Saskatoon 
Health Region (CASS-S), and it is hoped that it will expand to the rest of Saskatchewan. Still the 
administrative health databases contain a wealth of data not available in such systems. If 
timeliness and access could be improved, linking of both administrative health data and the 
CASS-S would be necessary to capture information on non-CA births, CA outcomes, and data on 
health care utilization patterns for the entire population. In recent years health information 
coding practices in the Discharge Abstract Database (hospital file) have improved, which should 
enable better capture of TOPFA and spontaneous loss due to fetal anomaly.(37) Given the 
concerns described in detail here regarding the IMR and the differential impact of TOPFA, 
another option might be to report on 'IMR excluding CA-specific deaths' and 'CA-specific IMR' 
separately for international and interprovincial comparisons. These rates can be easily calculated 
and allow for consideration of differences in CA and non-CA related death in infancy. 
                                               
40 Access to the full dataset was permitted on one occasion at the Ministry of Health's offices in Regina, making 
some analysis possible.  
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 Pregnancy terminations for fetal anomaly are likely much less common in Saskatchewan 
compared to provinces where MSS uptake is considerably higher. Adjusted fetal and infant 
mortality rates would be very valuable for other regions/provinces to apply to their own 
populations, in particular, when TOPFA is prevalent or rates vary across key sub-populations.  
Liu et al (15) found that provinces and territories with higher rates of fetal death due to 
pregnancy termination and/or congenital anomalies at 20-23 weeks gestation had lower CA-
specific IMR.(15) Moreover, they reported that the fetal death rate due to pregnancy termination/ 
congenital anomalies at 20 to 23 weeks' gestation was almost eight times higher in Nova Scotia 
(16.7 per 100,000 fetuses at risk in Saskatchewan vs. 131.4 per 100,000 fetuses at risk in Nova 
Scotia). Analysis of the CA-specific stillbirth rate was not possible here, but would have made a 
valuable contribution to our understanding in this province. Nationally the proportion of 
stillbirths <500g due to CA/TOPFA constituted 11.6% of all stillbirths <500g in 1985 and it 
increased to 40.4% in 200. (37) The proportion of neonatal deaths <500g that were due to 
CA/TOPFA increased from 3.6% in 1985 to 19.7% in 2003. In Saskatchewan, 13.6% of neonatal 
deaths < 500g were due to CA/TOPFA from 2000-2005; a figure lower than the national rate in 
2003.
41
 All signs point to a large and increasing impact of TOPFA on population-based birth and 
mortality statistics nationally, whereas in Saskatchewan, the effect appears to be less 
pronounced.  
 
  5.4.2.2 Fetal mortality 
 A recent study by Joseph et al (2013)(2) found that increases in stillbirth rates from 2000- 
2010 were due to increases in pregnancy terminations, resulting in subsequent declines in CA 
live birth rates. The observed increase was predominantly due to stillbirths weighing less than 
500 grams. The authors emphasize the importance of differentiating between spontaneous 
stillbirths and those resulting from pregnancy terminations. For instance, in British Columbia 
(BC), the rate of spontaneous stillbirths decreased non-significantly by 16% between 2000-2010 
and the same rate declined non-significantly by 5.7% in Saskatchewan between 2000-2005. In 
comparison, the rate of stillbirths (overall) increased in BC by 31% over the same period, 
                                               
41 This number would be 11.3% if only using Vital Statistics death certificate data to identify CA-related cause of 
death (as the previously reported PHAC figures did). The 3.6%-19.7% figure for Canada likely represents an 
underestimate as not all provinces submitted stillbirth cause of death data for the entire period and due to the 
limitations of coding of stillbirths.  
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whereas a much smaller increase of just 3.3% was observed in Saskatchewan between 2000-
2005. Two important differences to note are that the increasing stillbirth trend in BC only 
emerged in 2006-2010 (the rate was stable during 2000-2005) and that the overall rate was 
22.7% higher than Saskatchewan's rate during the study period (2000-2005). The BC study also 
found that the rate of TOPFA (resulting in a live or stillbirth) increased by 133% (from 2.4 per 
1000 total births in 2000-2002 to 5.7 per 1000 total births in 2008-10). While the same rate 
increased by 67% in Saskatchewan from 2002-2005 (0.51 to 0.93 per 1,000 total births)
42
, rates 
in BC were more than four times higher. This finding makes sense given the higher rate of 
maternal serum screening in that province (recall that rates were two times higher than for 
Saskatchewan in 2006) and potentially higher prenatal detection rate (although there is no data 
available to confirm this). In the context of a provincial evaluation of an increasing stillbirth 
trend, Joseph et al (2013) recognize the importance of reporting separately on spontaneous 
stillbirths and those due to pregnancy termination.(2) Similarly it is easy to see how important 
this distinction will be for comparisons between and within provinces, where variations have 
been shown to exist in the acceptance and use of prenatal screening and pregnancy termination. 
 Early spontaneous fetal losses resulting from congenital anomalies are an important 
outcome, but one that administrative databases are not well-designed to capture. A small number 
could be seen in the current dataset (n=7), but only those where an amniocentesis was completed 
prior to loss or where physicians reported a detected anomaly to the provincial MSS program. A 
number of early fetal losses known to be affected by a CA will have been missed due to absence 
of O35/655 codes, in addition to those never recognized (eg. spontaneous abortions not 
investigated). The current investigation focused on the impact of TOPFA on fetal-infant 
mortality, and not spontaneous loss, due to the fact that the latter should occur at fairly similar 
rates across populations, while we see here that TOPFA does not. First trimester screening 
techniques raise the importance of surveillance for early losses, which can only be captured in 
the hospital data and not through Vital Statistics reporting.  
 
 
 
                                               
42 2000 and 2001 data was omitted from comparison due to the number of TOPFAs that were shown to have been 
missed, based on comparisons with CIHI data. The rate of TOPFA (resulting in live or stillbirth) was 0.08 per 1,000 
total births for these two years combined. 
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5.5 Amniocentesis-related fetal loss 
 Amniocentesis is the "gold standard" test used to diagnosis chromosomal anomalies and 
neural tube defects in Saskatchewan (as CVS is not available), with high levels of accuracy (98-
99%) (203). The fetal loss rate following amniocentesis is a contentious question and the answer 
is vital to informed decision-making. The “First and Second Trimester Evaluation of Risk for 
Aneuploidy” (FASTER) trial suggested fetal loss was substantially lower than previously 
reported, prompting the SOGC to review studies dating back to 1986.(171) Their conclusion 
(2007) was  
"There is no single percentage (or odds ratio) that can be quoted as the risk of 
pregnancy loss following midtrimester amniocentesis in singleton pregnancies. 
The risk is unique to the individual and is based on multiple variables including 
....patient factors (eg. maternal age, reproductive history, pre-existing maternal 
conditions, pregnancy-related factors such as placental location, multiples, or 
use of assisted reproductive techniques); procedure factors (eg. needle size, 
operator experience, ultrasound guided or freehand, and maternal BMI); and 
post procedure factors (eg. infection) (p. 588-9)." (171)  
 Even still the SOGC puts forth 0.6-1.0% as the best estimate of increased rate of 
pregnancy loss attributable to amniocentesis. Studies may estimate the procedure-related 
pregnancy loss rate separate from the background pregnancy loss rate, in order to quantify the 
additional risk imposed on the pregnancy by the procedure. Based on amniocentesis data and 
linked outcomes in Saskatchewan, the stillbirth rate was 2.2% in tested pregnancies and 0.61% in 
those not having amniocentesis. When restricting the analysis to stillbirths less than 24 weeks, 
the stillbirth loss rate dropped to 0.95% in the tested group and 0.12% in the control group. This 
finding is consistent with the SOGC's estimate above. During the process of informed consent, 
the SOGC recommends sharing the combined overall risk with the patient.(171) 
 
5.6 Consideration of the MSS program in relation to screening principles 
 5.6.1 Acceptable treatment 
 What makes a screening program worthwhile? To answer this question I draw upon 
Wilson & Junger's influential principles for evaluation of screening programs.(204) 
 The principle that Wilson and Junger (1968) proposed as being most important was the 
existence of an acceptable treatment for patients with recognized disease.(204) In the case of 
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prenatal screening, the choice is to either continue or terminate the pregnancy, however, its 
acceptability is more morally problematic than interventions associated with other screening 
programs. Whether or not abortion is an acceptable option will depend on a multitude of factors, 
including the couple's beliefs, values, and understanding of the condition. In countries where 
abortion is not permitted, prenatal serum screening programs would not meet Junger's criterion. 
Abortion is permitted in Canada, although abortion services are perhaps not easily accessible 
throughout. In Saskatchewan, current and past abortion trends clearly show a lower demand for 
elective medical abortion, presumably revealing less demand or support for abortion generally. 
The current study found that rates of pregnancy terminations following prenatal diagnosis are 
close to those in Australia and British Columbia (6, 205), if not slightly lower (73% of prenatally 
diagnosed cases of Down Syndrome and 75% of trisomy 18 were aborted), but the rate of 
prenatal diagnosis was considerably lower than in Europe (8). An absence of good, comparable 
data on prenatal detection rates across provinces and countries makes interpretation of these 
figures difficult. Women who would not terminate most likely refused amniocentesis, therefore 
uptake of prenatal diagnostic testing rates tell us more about a population's views and 
preferences and comparable data across regions would provide additional insights. 
 Prior to its implementation, opposition was raised to the MSS program on the premise 
that it discriminated against unborn children with disabilities and due to its link to abortion, 
raising the question of whether it met the proposed principle that the test should be acceptable to 
the population. In the most recent release of guidelines on prenatal screening programs, the 
SOGC echoes this belief stating "the screen must be acceptable to the population being screened 
(p. 738)."(48) Prenatal screening programs have emerged in several Canadian provinces, but it is 
unlikely that any of these have made efforts to engage the population to determine its level of 
acceptability. While certainly ideal, the question is how best this might be accomplished. This 
line of thinking will be explored further in Chapter 6.    
 While treatment options are limited, the program allows some women with affected 
pregnancies to receive a diagnosis prior to delivery, which may help prepare mothers 
emotionally. This claim has been used to promote screening but there is little evidence 
supporting this notion, therefore more research is needed to compare any differences in the 
experience of mothers who learn about their child's condition before delivery and those that are 
told after. Given that most prenatally diagnosed cases are aborted, the number would be small. In 
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addition, many women that would not abort, do not proceed to diagnostic testing due to the risk 
to the fetus. Looking at the results from the current study, only seven out of the 27 confirmed 
cases of Down syndrome and trisomy 18 detected over a five-year period might have benefited 
from the information in this way. Ninety-three women did not know that their baby had either 
Down syndrome or trisomy 18 until after delivery. In the case of Down syndrome, 22.4% of 
women with an affected pregnancy had MSS and 70.8% received a "screen-positive" result, of 
those, 41.1% chose to follow-up with an amniocentesis and 85.7% aborted.
43
 For the most part, 
in the case of Down syndrome and trisomy 18, most women who choose amniocentesis also 
choose to have an abortion.(185) It is not known if women benefit from the awareness that they 
are at increased risk, even when they do not pursue diagnostic testing to know for certain.  
  
 5.6.2 An important health problem 
 Wilson & Junger contend that the condition being screened for must be an important 
health problem.(204) Important, by their definition, does not necessarily depend on prevalence 
only, but also should be considered from the point of view of individuals and communities. 
Often program materials, the media, and academic articles declare that MSS screens for 'serious' 
or 'severe' health conditions in the fetus. In the case of anencephalus and trisomy 18, this is 
certainly true as the majority of infants with such conditions will die within the first year of life, 
if not shortly after birth.(206) However, this label can be problematic when it comes to children 
born with Down syndrome or spina bifida; conditions that have increasingly good survival rates 
and quality of life.(207, 208) The variation from child-to-child, as well as the medical system's 
inability to predict outcomes using information available during the prenatal period, makes 
assessing severity difficult and subject to the biases and limited perspectives of providers. Most 
people have no prior knowledge of individuals with such conditions; therefore will base their 
understanding on what is shared by their physicians, pamphlets, and the internet. Similarly, 
pregnant women often rely on friends and the internet to answer their questions about 
screening.(209) In a 2005 survey of Saskatchewan physicians, just half of physicians who 
offered MSS to their patients said they had enough knowledge to explain the implications of 
raising a child affected by spina bifida or Down syndrome to a women with an affected 
                                               
43 The termination of rate of 85.7% is higher than the previously reported 73.3%, however, the latter includes cases 
that did not have MSS initially but went directly to amniocentesis. 
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pregnancy.(32) Many (85%) agreed that having an affected child presents a considerable burden 
for parents and fewer (59%) felt that people with Down syndrome or spina bifida have the 
potential to lead full lives and make important contributions to our communities. Congenital 
anomalies (both minor and major) affected an estimated 11.8% of pregnancies in Saskatchewan 
and only a small portion have known primary prevention strategies.(79) The question of what 
conditions should be screened for is a complex moral question and the debate will only become 
more complex as other tests are added to the screening arsenal.  
  
 5.6.3 Diagnostic follow-up testing 
 Wilson & Junger emphasized the importance of a test to determine whether the person 
with a positive screen truly has the condition, and the need for facilities for diagnosis and 
treatment.(204) Amniocentesis or chorionic villa sampling (CVS) are the two prenatal diagnostic 
tests used to confirm chromosomal anomalies and neural tube defects, however, only 
amniocentesis is available in Saskatchewan. While amniocentesis is generally performed 
between 15-18 weeks gestation, CVS can be performed at 10-12 weeks (although the fetal loss 
rate is higher). The challenge for Saskatchewan is that the newer generation screens, which can 
be done earlier in the pregnancy, will require earlier diagnostic testing to detect an anomaly. The 
benefit, it is argued, is that women can receive an earlier diagnosis and may be more accepting of 
an abortion. Since CVS is not available, most will still need to wait until 15-18 weeks for a 
diagnosis. 
 Such is the case with many specialized techniques, amniocentesis presents a special 
challenge in a province with a widely dispersed and relatively small population. Few rural health 
regions have obstetricians willing to perform the test, perhaps due to the fact that the skill of the 
practitioner is linked to procedure-related fetal loss.(171) Women wanting amniocentesis will 
usually need to travel to Saskatoon or Regina for testing and all samples are currently processed 
through the Saskatoon cytogenetics laboratory. While the procedure-related risk to the fetus may 
seem small (0.5-1.0%), the risk of having a child with a CA is also small for most women. First 
trimester screening methods are most sensitive when they incorporate a nuchal translucency 
measurement, which is a specialized ultrasound scan that few practitioners in Saskatchewan are 
certified to collect. Even in the two largest cities, access is not always timely. As testing 
continues to evolve, disparities in access should be monitored.    
 158 
 
 5.6.4 SOGC guidelines 
 While the Saskatchewan MSS program has taken up the SOGC's recommendation to 
routinely offer MSS to all pregnant women, there are other key recommendations that have not 
been adopted. For instance, the SOGC guideline states that "performance of the screen should be 
substantiated by annual audit (48 p.737)", yet the first audit performed by the MSS program was 
completed in 2012 and covers the same period as the current study (May 2001- March 2005). 
The program would certainly receive a failing grade as far as timely audits. It is important to 
note, however, that this is largely due to poor data access and the difficulty around linking MSS 
results to population outcomes, which rely on administrative data from the province. Next, the 
SOGC recommended that the nuchal fold and fetal nasal bone measurements only be taken by 
sonographers trained and accredited for this service and when there is ongoing quality assurance; 
it is unclear if this type of evaluation has been built-in to the current system. Ultrasound dating in 
the first trimester is important to accurate determination of gestational age, and as such, the 
SOGC recommends that it be available when there is uncertainty or for any abnormal screen 
calculated on the basis of menstrual dates. Some rural Saskatchewan hospitals have not been able 
to perform ultrasound dating due to resource challenges and travel distance can significantly 
hinder access for women, particularly in northern communities. The SOGC recommends that 
maternal weight, ethnicity, insulin-dependent diabetes mellitus, and use of assisted reproduction 
technologies (ART) should be incorporated into the screen in order to improve the accuracy of 
testing. Currently maternal weight is used as part of risk calculation, but ethnicity, diabetes status 
and ART history are not.(135) Finally, the SOGC makes a general recommendation that 
sufficient resources be available for genetic counselling services, patient and health care provider 
education, as well as resources for annual clinical audit and data management. Genetic 
counselling services are situated in Saskatoon, and are not well-integrated within the current 
MSS program. While genetic counsellors do some post-test counselling prior to amniocentesis, 
the majority is done by physicians and midwives. Given the centrality of genetic counselling to 
most prenatal screening programs, this is an area that merits further exploration. 
  
 5.6.5 Practice implications 
 The provincial MSS program fares poorly on some criteria, and better on others. Based 
on its performance during the time period from 2002-2005, the MSS program was a moderate 
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detective when it came to Down syndrome and trisomy 18. Data limitations precluded 
assessment of its performance for neural tube defects. Even though the detection rate was 
moderate, performance at the population level is largely dependent on how many women utilize 
screening. A highly sensitive test that is used by very few may not justify its existence. The 
current study estimates that 22 cases of congenital anomalies in Saskatchewan were diagnosed 
after a screen-positive MSS result that was followed by amniocentesis (2001-2005), many of 
which may not have been in the absence of such screening.
44
 Having said this, false-positive tests 
have been an important point of contention for MSS programs generally. The patient finds 
themselves in a position where they accept the offer of a test designed to help them know more 
about the health of their baby, only to often worry unnecessarily. In Saskatchewan, 958 women 
during the study period received a "screen positive" result, but very few had an affected 
pregnancy (eg. 2.1% of those who screened positive had a baby with DS). Research has shown a 
clear increase in maternal anxiety in the face of a false-positive screening result (186, 210, 211) 
and this rate must be monitored closely. 
 The question of whether or not the Saskatchewan MSS program, or any similar prenatal 
screening program, optimizes outcomes for those who chose to have screening is a difficult one 
to answer. Screening is argued to improve the following outcomes: lowering the live birth rate of 
infants with DS, trisomy 18, or a neural tube defect; reducing the number of unnecessary 
amniocentesis tests in pregnant women wanting to (or perceiving themselves to need to) undergo 
diagnostic testing; giving pregnant women a choice of whether to carry an affected child or 
terminate when a CA is confirmed; and for women who will deliver an affected child, helping 
them to prepare emotionally and practically. The current study is the first to provide evidence on 
prenatal serum screening in Saskatchewan, shedding some light on important measures that may 
help planners judge if it is indeed a worthwhile program. The extent to which the live birth rate is 
impacted depends largely on the uptake of MSS in the population and the number of diagnosed 
cases that are terminated. In Saskatchewan, MSS uptake was low over the course of the study 
(topping out at 26.8%) and more recent data from the Provincial Laboratory has not shown a 
                                               
44 In total, there were 70 CA cases diagnosed by amniocentesis over the study period. Forty-seven of these women 
had MSS testing prior to undergoing amniocentesis, but only 22 of these women received an increased-risk or 
"screen-positive" result. 
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discernible increase since that time.
45
(135) There was a 13.2% decrease in the number of 
amniocenteses performed from 2002-2004. The proportion of testing due to 'advanced maternal 
age' fell from 74.5% to 39.0% during the study period, while the proportion of tests performed 
due to 'abnormal MSS result' increased from 7.5% to 38.2%.
46
 While the proportion of tests 
performed in the oldest age group (women aged 35 and over) dropped, it increased in all other 
younger age groups as a result of increased screening and 'increased risk' results.   
 Low precision is a well-documented limitation of the triple test. The problem of false-
positives should not be downplayed. False-positive results can lead to increased anxiety during a 
vulnerable time, inconvenience, expensive follow-up, and perhaps most important, increased risk 
for fetal loss associated with amniocentesis.(186, 212) In Saskatchewan, out of 9909 women 
screened for DS or trisomy 18 between 2001-2005, 754 experienced a false-positive (7.6%), and 
273 of those women (36.2%) underwent amniocentesis and were later found not to have an 
affected pregnancy, with four fetal losses following the procedure (1.5%). The fact that one out 
of every 13 women screened for DS or trisomy 18 received a false-positive result is concerning. 
A subsequent increase in anxiety has been well-documented, and most concerning is research 
that shows this anxiety often does not abate (ie. residual anxiety), even after confirmation by 
diagnostic testing.(186, 213, 214) Newer tests including the quadruple screen, NT measurements, 
and first trimester testing have been incorporated into the province's protocols and have a higher 
detection rate (~80%) with a slightly lower false-positive rate (5%). While the performance 
should be somewhat better than the triple test, false-positive results remain a concern.  
 Research is lacking on other potential negative consequences of screening. Very little is 
known about the long term impact of abortion in the case of a diagnosed anomaly. For instance, 
a certain proportion of fetuses affected by a serious anomaly would be lost naturally between 
diagnosis and term; but I could not locate any research exploring the psychological, emotional, 
and spiritual costs to families when they chose to intervene/terminate compared to continuing the 
pregnancy. Are there benefits to allowing nature to 'take its course', even when the prognosis is 
grim, or do families and mothers fare better when the pregnancy is ended. Another potential 
source of harm is to individuals living with these conditions. The existence of a population-based 
                                               
45 With the addition of integrated screening, aggregate reports on the number of MSS specimens processed no longer 
enable one to calculate an estimated rate of uptake. This is because some that provide a first trimester sample did not 
present for a second trimester sample, and vice versa.  
46More recent data from the Saskatoon Cytogenetics Laboratory shows that 'advanced maternal age' accounted for 
just 13.1% of all tests in 2012; abnormal ultrasound findings for 25.8%; and abnormal MSS for another 56.6%. 
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screening program clearly expresses the thinking that it is morally, legally, and socially 
acceptable to end the lives of fetuses with such conditions through government-sanctioned health 
programs. Chapter 6 explores this question further. 
 Absence of concrete guidelines, policies or laws governing screening programs and 
interventions is glaring. The task of policy-making in the arena of reproductive screening, testing 
and interventions is a daunting one, which is almost certainly why such decisions remain in the 
hands of women (and their families) and health care providers to negotiate. While this may seem 
to be the best available option, resolution of ethical dilemmas within the confines of the clinical 
encounter can have important limitations that will be discussed.  
 Finally, the finding that MSS and amniocentesis uptake is low in Saskatchewan is not 
necessarily a negative one. It may reflect greater acceptance of the possibilities inherent in any 
pregnancy and a tendency away from medicalization. Many women who opt for screening often 
do so for reassurance of the baby’s health, not necessarily intending to intervene on the 
pregnancy.(80) The most common reasons women refuse screening is because they would not 
terminate the pregnancy and the results obtained are not definitive. If progress continues to be 
made - developing new treatments, refining therapies, adapting environments for those with 
challenges - living with a disability will not be the same today as it is ten years from now. Just as 
life for a child with Down syndrome looks very different today than it did a few decades ago. 
Those advocating for the rights of individuals with disabilities fear that eliminating children with 
such characteristics from society will lead to diminished resources and research efforts geared 
towards improving quality of life for those with disabilities. It is typically parents and families of 
affected individuals that advocate and lobby for greater social inclusion and against 
discriminatory policies and attitudes. Fewer families raising children with a disability, means a 
smaller lobby effort. In addition, research has found that women that give birth to affected 
infants were more often of low socioeconomic status or part of an ethnic minority, meaning that 
infants requiring greater social and medical support are disproportionately being born into 
families with the fewest resources.(98, 110) Unique from other screening programs, MSS 
presents women with an opportunity to learn more about the health of their fetus, with the 
possibility that pregnancy termination will result. The gravity of such decisions cannot be 
underestimated and reinforces the importance of the intent, design and delivery of any program 
including the MSS.    
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5.7 Surveillance: the missing pieces 
 A wealth of information is contained in Saskatchewan's administrative health databases, 
which is naturally exciting to those wishing to undertake research, evaluation, or surveillance. 
Even so, compiling data for the current study was a gruelling and cumbersome process taking 
more than five years to complete. Pregnancies and congenital anomalies are two especially 
challenging outcomes to study in the absence of perinatal and congenital anomaly surveillance 
systems. Women may experience multiple, consecutive pregnancy outcomes, some of which 
require hospital care and others physician care. While hospital data has been well-validated for 
pregnancy events, physician data has not. Physician data does, however, provide an opportunity 
for greater capture of events. There may have been a slight trade-off as far as sensitivity and 
specificity go.  
 While our study was able to identify some interesting trends and patterns, it is only a 
snapshot in time. On-going, regular evaluation and surveillance are integral to our understanding 
of risks encountered during the prenatal period, those threatening healthy pregnancies and 
ultimately healthy infants and children. Key to the production of useful surveillance is timely 
information. The current system is not timely, nor is it user-friendly for researchers, health 
regions or governments. A provincial overhaul is warranted in both the mechanism by which 
researchers access data and in the handling of data. Classification experts, well-versed in the 
intricacies of coding standards and data systems, would be invaluable. While researchers 
typically possess important analytical and methodological skills, it is unrealistic to expect they 
have expert knowledge of how health information is coded and where each variable is contained 
within a number of disparate databases.  
 Even when well-designed, sophisticated surveillance systems are in place, variations in 
registration and coding present challenges as far as the validity and reliability of indicators, and 
often where rankings are concerned.(36) In the case of infant and perinatal mortality, variations 
in the registration of extremely small babies and of births affected by lethal congenital 
anomalies, accurate assignment of cause of death, and differences in the modality of 
ascertainment of gestational age are known problems. Variations across countries may present 
more of a challenge than those within, but even in Canada with a definition-based birth 
registration system, regional variations exist.(37) Registration of TOPFA births vary across 
health regions, further complicating assessment of the growing, and evolving, impact of prenatal 
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diagnosis. Internationally there is disagreement about the birth registration of pregnancy 
terminations even when they constitute a live birth or stillbirth (36), further challenging 
comparisons across countries. The Better Outcomes Registry & Network (BORN) in Ontario is 
an innovative perinatal and congenital anomaly surveillance system worthy of modelling.(3) 
Characterized by its high-quality data, research embrace, and capacity for knowledge translation, 
BORN Ontario links data on prenatal screening, congenital anomalies, and maternal-newborn 
outcomes. In contrast, the Saskatchewan Ministry of Health has never released a report on 
congenital anomalies and limited work has been done to further study the problem of high infant 
mortality. In 2010 the World Health Assembly adopted a resolution and called all Member States 
to promote primary prevention and the health of children living with congenital anomalies 
through the development of strong registration and surveillance systems, building capacity and 
expertise, and more research on causal factors, diagnosis and prevention.(215) Efforts have been 
made nationally to meet some of these goals and this will be an important direction for 
Saskatchewan in the future.  
 Abortion data has become increasingly politicized in Canada, leading to underreporting 
of its prevalence, timing and causes. A number of private clinics, though publicly funded, have 
refused to report even aggregate figures to the national Therapeutic Abortion Database. Starting 
in 2010 CIHI assumed responsibility from Statistics Canada to manage data collection and 
publish statistical reports on therapeutic abortions data.(129) Private abortion clinics do not 
operate in Saskatchewan, therefore provincial estimates should be accurate. Estimates from 
Manitoba, British Columbia, and New Brunswick are the most affected. Abortion data are 
integral for the calculation of teen pregnancy rates, understanding the problem of untimely 
pregnancy and contraceptive use, identifying TOPFA, and studying the shift in provision of 
abortion services from hospital to clinic (eg. 21.8% of all abortions in Canada were performed in 
a clinic in 1990 and 45.6% were in 2003). Because of the debate that persists around the ethics of 
elective medical abortion, some may be hesitant to report on this issue for fear of inciting 
controversy. For instance, the Association of Public Health Epidemiologist of Ontario (APHEO) 
goes as far as to say "Given the sensitive nature of therapeutic abortion data, extra care should be 
given when presenting this information. Consider presenting pregnancy rates only to the public 
and providing specific therapeutic abortion information internally for public health staff."(216) 
Whether the result of an untimely pregnancy or in the case of the identification of a CA, the topic 
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of abortion is morally contentious and socially divisive in Canada. Recognition of this fact is 
important to research involving pregnancy outcomes, with the expectation that it should be 
treated equal to other events and not be concealed given its relevance to research, policy, 
planning, and even moral and ethical debate. Consideration should be given to mandatory 
reporting by private clinics to their respective provincial governments, or at minimum, 
government reporting of physician claims for abortion services to CIHI.     
 
5.8 Study strengths 
 The strengths of the Maternal-Fetal-Infant dataset lie in its population-based and 
longitudinal design, large sample size, comprehensive ascertainment of pregnancy outcomes, and 
its ability to link several important datasets. The study sample included 93,171 pregnancies 
spanning a six-year period (2000-2005). Because the study population included all pregnancies, 
and not a sample of pregnancies, there were fewer concerns regarding selection bias. While the 
inability to account for confounding factors can introduce a level of bias to a cohort study design, 
a number of confounders (eg. maternal age, RI status, and RHA) were available for inclusion in 
analysis. Follow-up was very high, with a small number of participants lost to follow-up due to 
moving outside the province (n=1645 or 1.8%). Both Vital Statistics, hospital and physician 
services data were used to identify pregnancy outcomes and should capture nearly all pregnancy 
events involving Saskatchewan residents. Confidence is strong in the validity and reliability of 
Vital Statistics birth and death certificate data (217), which represents a census of events and is a 
legal requirement in each province and territory. Based on a comparison of hospital births 
reported in the DAD and Vital Statistics birth registrations (Statistics Canada), CIHI estimated 
that 98.9% of all births in 2008 were captured in the DAD (218), making Vital Statistics the gold 
standard for birth data. Physician data was also used in this study to capture congenital anomalies 
in live born infants. While Saskatchewan data has not been validated for such purposes, a 
Quebec study found physician data on congenital anomalies to be reasonably reliable.(219) 
Parents of infants diagnosed with a CA were contacted to assess the accuracy of codes in RAMQ 
database and there was 60% (or higher) agreement with very high specificity. An important 
benefit of the cohort design, coupled with the ability to link clinical testing data with 
administrative databases, was that the time-order of 'exposure' (ie. testing) and pregnancy 
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outcomes were clear and linked; much of the surveillance and research performed to date has not 
been able to directly link screening to outcomes in populations. 
 The current study was designed to detect cases of TOPFA following amniocentesis that 
were terminated prior to 20 weeks, which is a crucial component missing from the Canadian CA 
Surveillance System (CCASS) and a limitation in many studies. A study done in South Australia 
found that 79% of TOPFA (1980-1998) were done before 20 weeks gestation.(131) This figure 
was estimated to be lower (61.1%) in the current study, but still represents an important share of 
these events that would otherwise have been missed. Even with greater awareness of coding 
standards amongst health coders (ie. to apply O35 codes to flag TOPFA), the ICD-10 codes are 
still too general for an accurate accounting of the types of CAs in fetuses being aborted.  
 Screening data from the Provincial Laboratory and cytogenetics data from the two 
tertiary centres was necessary to investigate factors related to MSS and amniocentesis utilization, 
as well as to assist in the identification of TOPFA. A common methodological limitation of 
previous studies and the Canadian CA surveillance system has been the inability to link 
screening and diagnostic practices to pregnancy outcomes. Covariates such as mother's age, 
health region of residence, and Registered Indian status were available for the entire population, 
and through use of appropriate statistical modelling strategies and interaction assessment, a 
detailed analysis was conducted and relationships explored. Most studies on predictors of MSS 
to date have been descriptive in nature and none have done a thorough exploration of the 
relationship between First Nations ethnicity and screening.  
 
5.9 Study limitations 
 Limitations encountered during the course of this study are described below. 
Consideration of the type and nature of these limitations is important in validating the study's 
findings.  
 
 5.9.1 Exposure measurement  
 Screening and cytogenetics laboratory data is expected to be of high quality, given its 
importance in risk estimation and diagnosis of anomalies. While MSS and amniocentesis data 
was fairly complete, a small number of cases may have been missed where patients sought out 
testing in a neighbouring province and for those that had double marker serum screening in 2000 
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and 2001 before a formal screening was launched in the province.
47
 By restricting the 
investigation of MSS predictors to 2002-2004, there is no concern of misclassifying those that 
had double marker screening as non-screeners. In some cases blood was taken more than once 
when screening was done outside the 15-20 week period or sometimes if the result was positive. 
It was also not uncommon for a woman to have submitted a sample, to have received an 
increased-risk result, then for the Provincial Laboratory to request that the doctor confirm the 
gestational age and recalculate that woman's risk based on the revised age. Most cases where 
there was more than one sample, the physician ordered the blood draw too early, requiring a 
second sample. Given that one patient may have had multiple screens, and the complexity of 
examining more than one result, the final result was used here. The last result was deemed to be 
the most accurate risk estimate, but we may be underestimating the occurrence of interim false-
positive results and their associated impact. Some 'screen negatives' will have actually screened 
positive initially, potentially explaining at least some of the follow-up diagnostic tests observed 
in those at decreased risk.   
 The timeframe spanned by some components of the dataset was less-than-ideal, but was 
due to data availability. Data from the screening program and the Cytogenetics laboratories were 
not available for the entire study period, which meant that analysis was largely restricted to 
2002-2004 when investigating predictors of screening and diagnostic testing uptake. For infant 
mortality outcomes, the study period was 2001-2005 due to the fact that study was designed to 
only include births occurring in 2000; this meant that some deaths to infants born in 1999 would 
have been excluded from the 2000 death data. Because the provincial MSS program was 
implemented in May of 2001, a decision was made to request data back to 2000 and forward to 
2005 (the most recent year as of the date of request). Data compilation took more than five years 
and we requested the study period be extended, but were informed by the Ministry of Health that 
the inclusion of more recent data would create further delays. Finally, the lack of amniocentesis 
data for 2000, and from January - September of 2001 for the southern half of the province, 
complicated interpretation. Cases of chromosomal anomalies that ended through pregnancy 
termination during this time would have been missed (discussed in more detail in 5.9.2).
 Demographic information collected on women and infants for this study came from the 
                                               
47 Prior to program implementation, some blood samples were sent out-of-province for double marker screening. 
Data was not available for the current study.  
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provincial Person Registry System (PRS). While data from the PRS is of high quality and is 
updated routinely, information on health region of residence and Registered Indian status will be 
affected by people who moved and did not report their change of address to the Ministry of 
Health and by those who chose not to declare themselves to be Registered Indian. Registered 
Indians are Saskatchewan Health beneficiaries registered under Section 6 of the Indian Act and 
assigned a ten-digit number in the Indian Registry.(220) Declaration of RI status to the Ministry 
of Health is voluntary, meaning that not all individuals who have RI status will be identified in 
the PRS. Based on a comparison of federal government RI population figures and the 
Saskatchewan Ministry of Health's covered population reports, we estimated that 85% of RI 
people declared themselves to the Ministry of Health. Non-status Aboriginal people are not 
identified as such in the PRS.  
 
 5.9.2 Outcome ascertainment 
 Determining the cause of death for infants can be complex, leaving one to question the 
accuracy of the underlying (or primary) cause on the death record. Exact causes of death are not 
always clear, resulting in somewhat subjective primary causes of death being listed on death 
certificate.(37) The reported cause of death may also be influenced by the social or legal 
conditions surrounding the death and by the level of medical investigation. The ICD-10-CA was 
used to code causes of death for all infants dying during the study period, which has the benefit 
of lending consistency. Canadian data quality for ICD-10 coding is high.(221)   
 As described in the section on 'study strengths', the use of both Vital Statistics birth data 
and physician claims data enabled better capture of pregnancy events. However, physician 
claims data have not been validated for this purpose and there appeared to be errors in the use of 
the 'other abortion' code. Hospital and Vital Statistics data were available in many cases to 
ensure the most accurate categorization of pregnancy events, but not for all. 
 A potential source of bias in cohort studies comes from the degree of accuracy with 
which subjects have been classified with respect to their exposure or disease status.(212) While 
our confidence was high in the data on exposure (ie. screening and diagnosis), there were 
unavoidable limitations as far as ascertaining congenital anomaly outcomes. In particular, the 
absence of CA diagnoses for stillbirths inevitably resulted in an underestimation of cases. Cause 
of death for stillbirths is coded in both the DAD and on the Vital Statistics birth record. 
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Regrettably the DAD diagnostic data was omitted from the study request by the Ministry of 
Health (due to lack of awareness of its existence) and from the Vital Statistics data. Until 
recently the Ministry of Health did not have Vital Statistics cause-of-death data available for 
stillbirths in an electronic format (220). Ultimately we were not able to analyze trends in the 
causes of fetal deaths, which would have been measured through indicators like CA-related 
stillbirth rate and CA-related perinatal mortality. Pregnancies that underwent amniocentesis, then 
ended in stillbirth, did have diagnostic information pertaining to chromosomal anomalies. 
Stillbirths that were not tested would not have been identified as having a CA, even where one 
was known or suspected. The biggest gap would be for non-chromosomal anomalies. 
Availability of ultrasound diagnostic information would have been incredibly valuable given that 
many affected pregnancies will be screened, and some diagnosed, using this screening modality. 
Fetuses with anencephaly can be identified through high-resolution ultrasound examination (222, 
223), therefore many affected cases will have been missed. In the Smith et al (2011) study in 
England and Wales, 90% or more of all spina bifida and anencephaly cases were detected during 
pregnancy  either by serum screening or ultrasound.(98) It is likely that many known or 
suspected cases of NTDs resulting in spontaneous abortion or stillbirth have been missed in the 
current study, which is why NTD outcomes were not explored in detail. Most important to this 
piece of research are fetuses with an NTD that were terminated following prenatal diagnosis. 
Because likelihood of pregnancy termination is high for this category of anomaly, in particular 
for anencephalus and similarly severe conditions, these pregnancies are important to our 
understanding of prenatal ultrasound and serum screening and the pathway to diagnosis and 
pregnancy outcome.(109, 110)    
 Identification of pregnancies that were aborted following a CA diagnosis were not 
directly coded in the data. Rather we relied on the observation that prenatal screening or 
diagnosis was followed by a medical abortion, or a live birth or stillbirth (with or without a 
termination of newborn or fetus code) was preceded by a medical abortion. After applying these 
broad criteria, all diagnostic and procedural codes relating to the pregnancy were examined to 
confirm that there was high likelihood of a TOPFA. Pregnancies where a CA was diagnosed 
solely by use of an ultrasound, then terminated, would have been missed unless it resulted in a 
live birth. However, we suspect that very few women or physicians would proceed with an 
abortion without first having ordered MSS or an amniocentesis, but it is still possible that some 
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cases bypassed serum screening and invasive testing. In an effort to remedy this data gap, a 
request was submitted to the Canadian Institute for Health Information for aggregate counts of 
cases in Saskatchewan where an induced abortion code was accompanied by a 655/O35 code, 
indicating the abortion was the result of a fetal anomaly.
48
 While consistency of coding for 
TOPFA may have been less accurate in the DAD during the early years (1990s), the number of 
TOPFA identified in the current study were close to the CIHI figures from 2001-2005. For the 
period from 2000-2005, the aggregate data from CIHI identified 115 pregnant women that had a 
TOPFA compared to 94 identified in the current dataset. Most of the missing TOPFA cases 
occurred in 2000; a year that was intentionally omitted from many of the analyses due to the 
absence of amniocentesis information and the recognition that most TOPFA would be missed, as 
described earlier. The divergence in live birth prevalence and incidence of Down syndrome and 
trisomy 18 from 2002 will reflect true differences, while rates in 2000 and 2001 may be the 
result poor case capture. As such, the emergence of the disparity between CA incidence and 
prevalence cannot be attributed to the MSS program with confidence. Having said that, the 
requested CIHI data (for the province of Saskatchewan) also showed a slight increasing trend in 
TOPFA rates from 2000-2010. 
  The classification of congenital anomaly covers a broad range of conditions from the 
relatively minor to those with an exceptionally poor prognosis. While analyses pertaining to 
MSS-detectable conditions (ie. Down syndrome, NTD, and trisomy 18) were highly specific, 
reporting on the 'other CA' or 'congenital heart defect' categories included the grouping of a 
range of conditions with varying severities, especially given the use of physician claims data 
where less severe anomalies are more likely to be captured. These categories of outcomes, while 
included in the dataset, were not a focus of this study.  
 Some key sources of information were unavailable for inclusion in the study dataset. 
Stillbirth diagnoses, ICD codes (O35/655) detailing the reason for pregnancy terminations when 
a CA is known or suspected, and variables from the reproductive abstract in the DAD (eg. 
gestational age) would have all supplied valuable information better-enabling the dataset to meet 
the needs of this piece of research. Nonetheless the current study is the first comprehensive 
investigation examining the use of prenatal screening, diagnosis, and their combined impact on 
                                               
48 Before making this request, we asked the Ministry of Health to provide these codes, however our request was 
denied. 
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several important pregnancy outcomes in Saskatchewan, even if only for a six-year period. It is 
unique in that it incorporates data from multiple sources, with a wide-range of information 
collected for each pregnancy.  
 
 5.9.3 Assumption of independence  
 Because pregnancies were not linked in the dataset, it was impossible to account for 
repeat observations (or multiple pregnancies involving individual women over the study period). 
Logistic regression models assume that all observations are independent from one another, which 
was not the case for the MSS uptake and amniocentesis testing models. When such a scenario 
cannot be avoided, it is ideal that a small percent of data is affected. The lack of independence 
will primarily impact the statistical significance of the parameter estimates in the model, but may 
affect the strength of the association. To further investigate the number of women appearing 
more than once in the MSS model, the Ministry of Health ran a report on their copy of the 
dataset and found that 31,628 out of 35,537 (89%) cases represented discrete individuals. In 
total, 3899 pregnancies were second and third pregnancies. The effect of pregnancy-specific 
factors such as age are less of a concern, as these change from pregnancy-to-pregnancy and will 
be less correlated. Parameter estimates around person-specific factors that do not vary with time 
have greater potential for error. For instance, First Nations ethnicity is constant and this sub-
group has a higher fertility rate, which may have slightly elevated the effect of Registered Indian 
status in the models. To test the robustness of the MSS model, only one year of data was used to 
fit the model, which eliminated repeat pregnancies. Using the midpoint year (2003), the final 
model was nearly identical to the three-year model, with the exception of the Registered Indian 
status and mother's age interaction term, which became borderline non-significant (p=.061). This 
may have been due to the diminished power of the model given its smaller sample size. Given 
the very similar models produced using the two time periods, confidence in the final model is 
restored.  
  
5.10 Summary 
 This study was carried out to produce an epidemiological profile of birth outcomes in 
Saskatchewan, including the termination of pregnancies for congenital anomaly. Ninety-four 
women terminated their pregnancy following detection of a fetal anomaly, which led to a lower 
live birth prevalence of infants with Down syndrome, trisomy 18, and anencephalus. When 
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pregnancy terminations were included in the analysis, a steeper increase in the incidence of those 
anomalies could be seen in Saskatchewan. Women that were not Registered Indian, those age 35 
and over, and those living in the Saskatoon or Regina Qu'Appelle health regions were more 
likely to have MSS during their pregnancy. Due to lower MSS uptake and use of amniocentesis, 
the difference between the live birth prevalence and incidence of Down syndrome and trisomy 
18 was smaller for Registered Indian women than for the rest of the population. Chromosomal 
anomalies were also less common in Registered Indian infants and fetuses. At the population 
level, selective termination rates were more than four times as high (per 1,000 pregnancies) in 
the 35 years and over age group compared to those 24 years and under. This finding reflects the 
higher rate of screening, prenatal diagnosis, and risk in the highest age category. 
 Since the implementation of the provincial MSS program, amniocentesis testing numbers 
declined slightly, but more women in the younger age groups are now testing due to abnormal 
MSS results and fewer women are testing due to age-related concerns alone. The majority of 
women that opted to have an amniocentesis and received confirmation of a CA diagnosis chose 
to terminate the pregnancy. The rate of pregnancy termination was similar for Down syndrome 
(73.3%) and trisomy 18 (75%), but was much lower for 'other chromosomal anomalies' (18.3%). 
Women under 30 years of age were much less likely to receive a prenatal diagnosis when a 
chromosomal anomaly was present (18.4% vs. 31.8%). While risk for a chromosomal anomaly is 
considerably lower amongst younger mothers, 53.5% of all pregnancies with a chromosomal 
anomaly belonged to this group. In total, 37 cases of pregnancy termination resulted in live or 
stillborn infants, which had consequences for mortality statistics.  
 Strong surveillance systems and reasonable access to research datasets will be an on-
going challenge for the province of Saskatchewan and should be looked at as a priority. Trends 
in infant and fetal mortality are important to our understanding of the health of our populations. 
As per the SOGC's guidelines, performance of the MSS program must be monitored on an on-
going basis, which will require data linkage and dedicated resources. Beyond surveillance and 
research, the field of prenatal screening and diagnosis is advancing at a rapid pace and the 
provincial government would be wise to engage citizens and experts on the profound ethical 
dilemmas raised by the termination of select pregnancies. Following along with protocols 
developed by other centres and organizations will not ensure that programming reflects local 
values, as these pertain to prenatal screening and intervention.  
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Chapter 6: ETHICAL, SOCIAL, AND POLICY INQUIRY 
6.1 Introduction to the Dilemma 
This chapter is dedicated to describing some of the ethical and moral challenges 
provoked by prenatal screening, both in its current and prospective forms. Much has been written 
in the ethics literature on this topic, with the occasional controversy popping up in abbreviated 
form in the news media. Academic papers in non-ethics' journals typically focus on the technical 
or programmatic aspects of screening and do not effectively alert the reader to the complex, 
profound, and intensely debated moral dilemmas raised by the practice. The current dissertation 
explored some of the more technical aspects of screening, but also investigated factors 
influencing individual uptake and the impact of pregnancy terminations on population outcomes. 
A discussion of ethics was felt necessary to ensure a well-rounded portrayal of the issue, putting 
findings into context and helping to ensure their moral relevance did not remain hidden behind 
the scientific complexities. Here I lay out the themes of the major arguments in a descriptive 
manner, recognizing that volumes have been written on the ethics of both screening and abortion. 
My goal is not to highlight all the particulars of the debate as they are numerous and complex, 
but instead to think about prenatal screening from a broader sociopolitical framework and 
consider what this approach might offer. A major ethical tension arising within the context of 
population based prenatal screening is the tension between community morality and the principle 
of respect for personal autonomy. Western medicine has framed prenatal screening and selective 
termination as a personal moral dilemma, thereby deemphasizing the social context in which the 
practice has materialized and the importance of community values. I will consider how a broader 
sociological perspective, one that takes into account the relevance of community values and 
limitations of the clinical encounter, could inform key practice and policy issues involving 
prenatal screening. It is my position that the community's voice must be invited to the 
conversation and public engagement processes should occur prior to any additional expansion in 
programming. I end with a look at how the community’s voice might be better heard on key 
issues, even those issues that at first glance seem to be the problems of individuals. 
Since the introduction of a formal prenatal screening program in Saskatchewan in 2001, it 
has remained a self-regulating program, with the Provincial Laboratory and a small group of 
Obstetricians making decisions about its design, test offerings, and physician education. Locally 
there has been no move to address ethical issues in an organized, comprehensive way, nor is 
 173 
 
there a clear description of the specifics of these concerns. In November 1993, the Royal 
Commission on New Reproductive Technologies released its final report, consisting of several 
volumes, which included the topic of prenatal genetic diagnosis and the now out-dated maternal 
serum alpha-fetoprotein screen.(102) The report helped guide the creation of the Assisted 
Reproduction Act, passed many years later in 2004, but the Act fell short of legislating any 
parameters around prenatal screening.(224) The Act did not ban or control any activities relating 
to prenatal screening, diagnosis, or the use of termination of pregnancy for identified conditions, 
despite several recommendations by the Commission to ban sex selection abortions and prenatal 
genetic testing for multifactorial disorders and to restrict presymptomatic testing (eg. for 
conditions like Huntington disease) to genetic centres. The Act did, however, prohibit sex 
selection as part of assisted reproduction activities (eg. the selection of embryo based on gender). 
Much has changed in the field of reproductive screening and medicine since its writing, yet it is 
unclear what policy mechanisms exist for updating this legislation and how future policy 
decisions will be made. It must also be noted that much of the Act has been struck down, 
although the initial prohibitions remain in effect. The legislation was successfully challenged 
through the judicial process based on the fact that health falls within the jurisdiction of each 
province and territory, further challenging policy creation and standardization across Canada. At 
the same time, it presents an opportunity for legislation to be better-tailored to local norms and 
values.  
 In comparison, the United States has made a more concerted effort to engage the public 
(including experts) and has introduced legislation around screening. The National Human 
Genome Research Institute supports a scholarly program on the ethical, legal and social 
implications (ELSI) of genetics research. The ELSI inquiry examines the values underlying the 
use of new genetic technology, ideally before being implemented.(155). In 1999, the ELSI 
program was expanded to specifically address issues arising when genetics is used to advance the 
public's health, resulting in PHELSI. While Canadian scholars have contributed to the work 
being done as part of the ELSI research program, there does not appear to be a formal 
mechanism by which this work is connected to Canadian policymaking processes for 
consideration of implications for citizens in this country. In the United States, the 'Prenatally and 
Postnatally Diagnosed Conditions Awareness Act' was enacted into federal law in 2008 in 
response to growth in this field.(225) This piece of legislation mandates the creation and 
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expansion of services to better educate women who receive a diagnosis confirming the existence 
of a congenital anomaly, using the best current evidence relating to Down syndrome and other 
diagnosed conditions. In addition, it requires formal programs that link women having testing to 
groups that specialize in children living with disabilities; enhanced awareness and education 
programs for health providers providing pre- or post-test counselling; and has even mandated the 
establishment of a national registry of families willing to adopt newborns with Down syndrome. 
I will argue that the absence of a well-defined mechanism for community and expert 
engagement, linked to policy creation, leaves Canadians poorly equipped to discuss and debate 
the sociopolitical and moral implications that accompany scientific and technological adaptations 
in the field of reproductive medicine and genetics. 
 In the past five years, several new developments have together reshaped the landscape of 
prenatal screening in Canada, lending urgency to the need for dialogue on the salient ethical 
questions. The four most notable developments include: a 2007 recommendation from the 
Society of Obstetricians and Gynaecologists of Canada (SOGC) to expand the offer of screening 
to routinely include all pregnant women (48); testing techniques enabling earlier and better 
detection (eg. first trimester screening and non-invasive prenatal diagnosis) (45, 47, 226); recent 
evidence suggesting that sex selection abortions have skewed the male-female birth ratio in 
Canada (56); and the latest technologies (ie. preimplantation genetic diagnosis) that bypass the 
fetus all together and select against congenital anomalies or particular traits before the embryo 
meets the womb. In the past two decades, the pace of change in the fields of genomics and 
prenatal screening has accelerated, exceeding society's capacity to integrate this science into 
coherent public policy.  
 Two important ethical dilemmas lie at the heart of the moral debate regarding prenatal 
screening. First, is the use of abortion to avoid the birth of children (with disabilities) morally 
permissible? This dilemma has roots in the abortion debate, but also brings to light special 
concerns about discrimination and eugenic practices. Second, if we think this practice is 
acceptable (at least in some instances) should all decisions about when abortions can be 
performed remain with the individual or should the broader society be part of the conversation 
about parameters of screening and terminations of pregnancy when fetal anomalies are detected 
(TOPFA)? While the current approach to screening in Canada is described as non-discriminatory 
while prioritizing personal autonomy, there has been no coherent, organized debate on this moral 
 175 
 
stance. Within these two broad questions, the ethical arguments made are multi-faceted and 
numerous. The role that science and technology and social and cultural systems play in the 
evolution of prenatal screening and diagnosis also warrants our attention, and will be interwoven 
into the current analysis. 
 
6.2 Re-examining the Autonomy-only Perspective  
In Western societies, respect for personal autonomy is the operative ethical paradigm 
governing the use of prenatal screening.(227) Autonomy is the idea that we must protect an 
individual’s ability to act independently and to make his or her own moral decisions.(228)  When 
one hears it said, “it’s her choice”, or “she’ll do what is right for her”, the principle of autonomy 
is being employed. Some ethicists view autonomy as being a key element in making morality 
possible, therefore underlying all other ethical decision-making theories. Others have critiqued 
the absolute focus on autonomy as excessive and limiting.(156) A focus on autonomy has 
presented a seemingly straightforward way to resolve ethical dilemmas around prenatal 
screening. 
Both prenatal screening and abortion are often framed as measures that support women's 
reproductive choices. In the case of prenatal screening, autonomy provides a powerful argument 
for women’s rights to make decisions about screening and subsequent termination of the 
pregnancy. Autonomy is also a strong argument used in the abortion debate generally. However, 
as Callahan argues, it is limited both in its ability to provide a good rationale for why we should 
accept prenatal screening and in its power to ensure ethically sound decision-making.(156) Most 
arguments based on this line of thinking propose that a woman, as an independent moral agent, 
has the right to additional information about her pregnancy based on available technology and 
the right to make autonomous choices about termination based on her own values and life 
situation. Interestingly many feminist scholars have challenged the common claims put forth in 
support of prenatal screening programs - that women want screening and that screening supports 
women's autonomy.(185, 191, 229) An exclusive focus on autonomy is limiting in so far as it 
blinds us to the broader social forces at play, and precludes consideration of why screening is 
widely available and endorsed by particular groups within the medical profession.  
When it comes to the delivery of prenatal screening the ethical focus has been primarily 
on informed consent and non-directive counseling.(227) Both factors are seen as integral in 
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allowing women to guide their own autonomous decisions. The most recent clinical practice 
guideline released by the Society of Obstetricians and Gynaecologists of Canada (2007) states 
that counselling must be non-directive, respecting a woman's right to accept or decline any and 
all testing.(157) Non-directive counselling is commonly viewed as the proper way to delivery an 
offer to screen, providing women with necessary information in an unbiased manner to help them 
make decisions about prenatal screening and follow-up. In theory, following these guidelines is 
crucial to helping the patient make the right decision, which means her own decision. However, 
evidence has shown that many factors external to the patient, and specific to the clinical 
encounter, can impact the choice she will make. Factors such as how information is provided; 
who provides the information; and the provider’s expectation that the patient will act (i.e. abort); 
all play a role in women's decisions whether or not to screen and to pursue diagnostic testing.(21, 
32, 138, 230, 231) Non-directive counselling requires the provider to remove their own personal 
values from the counselling episode, even when their own views and values are incongruent with 
the offer of screening. In practice, non-directive counselling is difficult to deliver. Studies of 
midwives have found many experience personal and professional conflicts when they offer 
screening, in particular for those who had experience of Down's syndrome.(232-234) In a 
random survey of physicians providing counselling to women following a prenatal diagnosis of 
Down syndrome, Wertz (2000) found that 63% of doctors tried to remain neutral in their advice, 
while 23% admitted urging parents to terminate or emphasizing the negative aspects of DS to 
favour pregnancy termination and 14% emphasized the positive aspects of DS to favour 
continuation of pregnancy or actively urged parents to continue the pregnancy.(231) Marteau et 
al (1994) also found that obstetricians tend to be more directive in their advice and more likely to 
advocate pregnancy termination compared to geneticists and genetic counsellors.(235) By 
maintaining that the counseling process is value-neutral, there is risk of misleading the patient by 
denying and hiding the existence of such biases. As a result, the evidence suggests that 'non-
directive counseling' is a misnomer and fraught with hidden biases. Its moral superiority to 
overtly paternalistic approaches remains questionable.(185, 227) Arthur Caplan (1993) explains 
that the adoption of non-directive counseling was an attempt to adhere to an ethic of value 
neutrality, which has enabled the field of clinical genetics to distance itself from historical 
abuses.(236) However, he argues that with the expanding possibilities and availability of testing 
 177 
 
that the time has come to start a new debate about what ethos should replace this approach, as the 
endeavor for value neutrality is “no longer healthy” for clinical practice or public policy.   
Seavilleklein (2009) makes a strong case for why we should be concerned that women's 
autonomy is not being protected or promoted by the routine offer of screening.(185) Among her 
concerns is the finding that the information necessary to achieve informed consent is often 
disclosed incorrectly, not at all, or a discussion does not take place. All of these violate the 
assumption that all pregnant women receive and adequately understand the pertinent information 
being provided. Marteau and Dormandy (2001) critique the counseling process as flawed by 
inadequate information, being directive, and too complex.(237, 238) In a small study in England, 
they found that 57% of women screened were not sufficiently informed to make decisions about 
screening.(238) Seavilleklein cites a body of research showing that most women do not fully 
understand the basics of testing; a failing that does not appear to differ among those who opt for 
testing or those who decline, and is common even among women with high educational 
levels.(185) The current confines of the prenatal visit may be partly responsible, given the 
limited amount of time available to adequately discuss all the information that would be 
necessary to achieve informed consent.  
Some have raised concerns that the offer of MSS is disproportionately focused on the 
process of screening, rather than on actual details about the conditions being screened for and the 
potential results.(232, 239) Grant & Flint (2007) echoed these concerns, questioning physicians’ 
knowledge regarding people who live with a disability.(197) They call for greater awareness of 
these conditions when speaking to prospective parents, which includes the sharing of appropriate 
resources with women and their families (eg. parent support groups, genetic counselling, early 
intervention and developmental clinics, and relevant specialists). They go as far to say that "if 
front line health care providers lack this information, telling a pregnant woman about a fetal 
Down syndrome karyotype is prejudicial and contrary to the SOGC's recommendation that 
'screening programs should show respect for the needs and quality of life of persons with 
disabilities.' "(197 p.581)
49
 Many health care providers have never had experience with 
individuals with the conditions being screened and there is a high-level of variation in provider's 
capabilities when it comes to counselling.(239)  Several studies in Canada and beyond have 
                                               
49 The line referenced by the Canadian Down Syndrome Society in a commentary on the SOGC's revised 
screening guidelines was later removed from the guideline.  
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documented insufficiencies in physician knowledge about prenatal screening, and importantly, 
the conditions being screened for.(22, 32, 240) In a 2005 survey, Saskatchewan physicians 
acknowledged limitations in their knowledge of prenatal screening and the conditions being 
screened for, and about one-quarter of respondents expressed concerns about future 
developments and additions to testing protocols.(32)  
One wonders if it is realistic to think that physicians can continue to be responsible for 
counselling as screening possibilities expand along with the knowledge base needed to support 
informed consent. Physicians and midwives in Saskatchewan and elsewhere are currently handed 
the responsibility for much of the pre- and post-test counseling; many of whom see small 
numbers of pregnant patients each year, and even fewer screening test results that show an 
increased-risk. According to 2002-2004 statistics from the Provincial Laboratory, 81.1% of 
physicians ordering a MSS test ordered fewer than seven tests on average each year.(135) Out of 
the 635 physicians that ordered a MSS test during this three-year period, fewer than 50 
physicians ordered 50% of all MSS tests and six physicians ordered 20% of all tests in the 
province. Together, the complexities of testing and infrequent experiences with MSS for most 
physicians raise questions about the appropriateness of physicians being made responsible for the 
majority of counselling. This concern is likely to grow as the number, types, and complexity of 
genetic tests increases. If patients are not fully aware of the implications and risks associated 
with screening and follow-up diagnosis, any hope for autonomous decision-making is greatly 
jeopardized. 
 It is commonly accepted that population-based programs offering prenatal serum 
screening must be optional or voluntary to preserve woman's autonomy, as opposed to being 
routinely ordered by the physician. This is a necessary caveat to avoid the implementation of 
potentially eugenic policies. Studies have shown that many women tested are not aware 
screening is voluntary, as it may at times be presented as being routine.(213, 241). The offer of 
prenatal screening may also occur at the same time as other routine tests, giving the impression 
that screening is routine and therefore should be accepted. While the thinking is that women 
make their own decisions, a reoccurring theme in qualitative research on this topic has been that 
they often look to the health care provider for guidance. How testing is offered by health care 
providers is an important factor in the acceptance or refusal of testing.(230) In a qualitative study 
by McNeil (2009), women who screened and those who did not both reported that health 
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professional’s attitudes and opinions affected their decision.(242), compounding concerns that 
informed consent and the counselling process is not sufficient to resolve inherent ethical 
dilemmas. It makes sense that the opinion of one's physician or midwife holds significant weight, 
but it should be noted that no studies could be found directly linking provider's approach to 
counselling to women's decision-making process or pregnancy outcomes. Given the obstacles to 
truly informed consent, Seavilleklein recommended that the expansion of screening to include all 
women (as per the SOGC's guideline), regardless of risk, be reconsidered.(185) It is debatable 
whether or not individual decisions can truly be autonomous, but clear that the current situation 
faces real challenges that should be addressed. 
  Some fear that the decision to have screening may become an expectation more than a 
choice.(243) Women who test may be viewed by others as doing the responsible thing for 
herself, her family and her baby, and this may create a sense of obligation for them to accept. 
Women who do not accept testing or those who continue a pregnancy known or likely to be 
affected by a disability may be viewed by others as irresponsible and selfish.(243) The fact that 
such births can be prevented may increase the expectation that they are. Screening and TOPFA 
have the potential to become normalized, and therefore expected, in which case women who do 
not make 'proper' use of screening may be blamed for their decisions.(103) One survey found 
that 75% of pregnant women found it too difficult to refuse diagnostic testing when a physician 
recommends it.(244) Moreover, 78% believed they would not receive sympathy or support if 
they knowingly gave birth to an affected infant or after refusing diagnostic testing. These 
concerns may be reasonable given studies that have found community members and physicians 
assign greater levels of blame to women who give a birth to a baby with a disability after 
refusing screening compared to those who were not offered testing.(245, 246) Lawson (2003) 
found the general public and physicians judged women who continued a pregnancy despite a 
CA diagnosis as less deserving of financial aid and sympathy. Findings such as these force us to 
ask whether new technologies will serve to further marginalize those living with congenital 
anomalies and other genetic conditions, conditions that may increasingly be viewed as 
"preventable".
50
  
                                               
50 Screening and prenatal testing is one means whereby the fetus may be assessed for anomalies or genetic risk. 
However, preimplantation genetic diagnosis (PGD) has a much greater capacity for evaluating and removing 
embryos with unwanted markers. Mykitiuk and Nisker (2010) argue that the biomedical determinations of embryo 
'health' through PGD have important consequences for our (changing) definition of health, and put forth the concept 
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While there is great concern that MSS be voluntary, some worry that the distinction 
between routine and optional testing may be no more than a shift from public to private eugenics. 
Duster (1990) raises the possibility that the application of new genetic technologies could lead to 
a return of eugenics through the 'back door'.(248) Some disability rights groups agree and have 
argued the current individualistic approach to selective termination allows discriminatory
 
and 
covertly eugenic attitudes to flourish.(227) Shakespeare (1998) views current prenatal screening 
practices as 'weakly eugenic' because they operate at a level of individual choice rather than state 
population policy, but cautions that screening could become 'strongly eugenic' if applied to entire 
populations and if framed in terms of cost savings to society.(227) One solution, I argue 
throughout this chapter, is to open up the debate to wider scrutiny and invite the values of more 
stakeholders, in particular those most affected (ie. people with disabilities and women). 
In the absence of published data regarding general awareness about prenatal screening 
and TOPFA, it is difficult to know how many people are aware of its existence and the nuances 
to the debate. Outside of women who were offered screening during pregnancy and those 
directly affected, basic awareness might be quite low and more in-depth knowledge of this 
technical field lower yet. This may be due to the fact that discussions about the morality of 
screening and TOPFA have been largely restricted to the individual and the clinical encounter, at 
the point where women are often hearing about prenatal screening for the first time. As such the 
invitation to have screening can come at an unanticipated moment, one where the pregnant 
mother is looking for reassurance of her growing fetuses' health, but instead is sensitized to the 
possibility of a health dilemma. Accordingly, reassurance of the baby's health is one of the most 
common reasons given by women who accept testing.(80) 
 Screening uptake and the impact of TOPFA on population rates were explored in earlier 
chapters, giving the impression that some populations of women are less interested in testing of 
this nature. Burgess and William-Jones caution that the aggregate social impact of the actions of 
many individuals may be significant, but do not necessarily reflect the intentions of those making 
the individual decisions.(249) For instance, women opting for termination of a fetus with a 
                                                                                                                                                       
of social determinants of health of embryos as a means of identifying the social factors (eg. poverty, poor nutrition) 
that impact the embryos health, and distinguish these factors from the social context through which health is 
constructed (eg. parent's perceptions as to the meaning of genetic markers for their lives and their potential child's 
life).247. Mykitiuk R, Nisker J. Social determinants of 'health' of embryos. In: Nisker J, Baylis F, Karpin I, 
McLeod C, Mykitiuk R, editors. The 'Healthy' Embryo: social, biomedical, legal and philosophical perspectives. 
New York: Cambridge University Press; 2010. p. 116-35. 
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disability may be seen as rejecting the condition itself, and not the social circumstances (eg. 
financial cost, prejudice), which may encourage others to act in the same way.(250) Individual 
women's decisions about prenatal selection might affect the way society views pregnancy and 
fetuses and children with disabilities, by suggesting criteria with which we judge humans to be 
worthy of respect and consideration. Fewer people being born with these conditions may 
diminish our comfort and awareness of such conditions. The increasing number of participants in 
prenatal screening and prenatal selection might also reduce the pressure on governments and 
institutions to affect change, because change would increasingly involve challenging the norm.  
Some scholars, writing on the topic of medicalization of pregnancy and women's health, 
critique the social construction of pregnancy in modern times as a high-risk event, requiring a 
high degree of medical and technological intervention.(251, 252) Even normal, non-complicated 
pregnancies have become medically problematic as opposed to being viewed as normal, natural 
processes and events. While increased medical intervention and monitoring have undeniably had 
benefits for the health of pregnant women and their infants, the medical gaze in combination 
with new prenatal genetic testing technologies have important consequences for women and 
children's health and their definitions (247). Abby Lippman (1999) argues that the genetics 
model frames the individual as the agent of prevention, thereby eliminating society's obligation 
to remove adverse social circumstances damaging to health - transforming illness into a private 
event.(253) With mother and fetus as the focal point of prevention and personal responsibility, it 
inherently downplays the broader influences on women's and children's health. It also may act as 
an impetus for a particular standard of health.(253) In the case of prenatal screening, where there 
are no medical cures for screenable conditions, the only way to eliminate the condition, is to 
eliminate the fetus through a medical abortion. With abortion as the principle solution to genetic 
test result 'problems', it has the power to devalue certain kinds of human life and trivialize the 
use abortion as a powerful method of prevention.(226)  
Mykitiuk and Nisker (2010) consider the ways in which disability and health are 
medicalized through the application of reproductive technologies, heavily shaping future 
conceptions of health and sharpening the focus on the embryo and fetus as a determinant.(247) 
As the science advances, it is likely that both will come under greater scrutiny and that our 
conception of health and disease will stem from what can be known or forecasted based on the 
embryo. Lippman (1998) cautions that technologies are problematic when advanced under the 
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pretence that they are trying to improve lives by creating more options and freedom, if at the 
same time they are actually preserving gender, class, and racial disparities.(253) Furthermore, 
she asserts "the extent to which geneticization will lead to further devaluation of specific groups 
of people is vast; it would be naive to think that developing genetic analyses in a society that is 
already hierarchically gendered, racist, and classist and that systematically discriminates against 
those with disabilities can do other than reflect and reinforce these attitudes."(253 p.65) 
Moreover, as expectations shift, choosing may not be a straightforward concept when it comes to 
deciding whether or not to intervene.  
The new fields of Public Health and Community Genetics (PHG and CHG) have called 
for the reframing of current genetic practices and controversies as population health or 
community health issues.(254) On the one hand, the emergence of these fields represents a 
movement away from the traditional clinical perspective in genetics, which may increase the 
potential for consideration of broader research, policy and practice issues. On the other hand, it 
might result in an expansion from individual test offering to population-based initiatives 
targeting whole groups, which raises concerns about the growing support for genomics at the 
population level, in spite of major deficiencies in our ability to grapple with these issues.    
 
6.3 Birth defects: A Personal Trouble or Public Issue 
The prevailing view that prenatal screening and selective termination are the decisions of 
individuals is evident. The way screening is provided in the health care system and the type of 
ethical inquiry that occurs in the literature both reflect a strong predilection towards seeing 
abnormal pregnancies as problems for individual women. This is comparable to how most 
medical conditions have traditionally been viewed.
51
 At the same time, a shift is occurring where 
people are recognizing the wisdom of looking at the broader context of health, well-being and 
illness. The ushering in of the population health paradigm has challenged researchers, health care 
professionals and lay people to go beyond the individual risk factors to consider the social, 
environmental, and political determinants of health.
52
 While there remains a strong inclination 
                                               
51 This line of thinking, concerned with the framing of health as a personal issue and potentially diminishing the role 
of the social context, applies to current conversations on personalized medicine as well. 
52 Population health is an approach that aims to improve the health of the whole population and reduce health 
inequities among population groups. It focuses on health outcomes, patterns of health determinants, and policies and 
interventions that link these two. 85. Kindig D, Stoddart G. What is population health? American journal of 
public health. 2003 Mar;93(3):380-3. PubMed PMID: 12604476. Pubmed Central PMCID: 1447747. 
 183 
 
towards individualized approaches, a call for a broader way of thinking about prenatal screening 
and its ethical basis will bring about a richer exploration of the many nuances to this debate.  
Partly owing to medicine’s paternalistic roots, health care issues typically focus 
exclusively on individuals (i.e. the doctor as expert and the individual patient as health care 
recipient). Health care ethics by extension is guilty of the same way of framing problems.(156) 
Callahan (2003) critiques the dominant focus on individual-as-moral decision-maker as the 
“complete triumph of liberal individualism in bioethics."(156 p.498) He views liberal 
individualism as a Western ideology, as opposed to a moral theory, which powerfully determines 
what ideas and ways of framing issues are acceptable. Issues arising in health care ethics today, 
by default, are often framed as individual issues, which then require individual responses. This is 
not unexpected seeing that health care providers work at the 'micro-level' on a day-to-day basis 
and require practical tools for resolving sensitive dilemmas. An added pressure is physicians’ 
liability if they do not offer prenatal screening. For example, in Canada, there have been an 
increasing number of 'wrongful birth' lawsuits filed against physicians who did not offer 
screening or who may have misinterpreted the woman’s risk for an affected pregnancy.(255, 
256) Therefore the only prudent option for the physician is to offer the test and guide the patient 
through an individualized process of ethical decision-making within their own constraints of 
time, knowledge and individual values. A logical consequence is that physicians, midwives, and 
genetic counsellors may then see their roles as limited to assisting the patient to make the best 
decision based on the patient’s values, priorities and life circumstances, without either the 
physician or the patient giving full consideration to the social context in which these options 
have come about. The provider may also bring his or her own biases and assumptions into the 
encounter, yet may not fully be aware of them and their impact. Callahan states, “…it is [not] 
easy for any of us to see how our tacit political and social ideologies, lurking just below the 
surface, are pulling the strings of our 'rational' thought.”(156 p.501) Health care providers cannot 
be held responsible for the fact that ethical discussions are limited to the clinical encounter, but it 
is the accepted, and generally uncontested, way in which ethical dilemmas are resolved today. It 
is also a practice with inherent and strong limitations. 
It is useful to consider that health care ethics occur at the micro (individual), meso 
(organizational) and macro (societal) levels (257); all interconnected, but requiring different 
types of questions and decision-making strategies. Many issues like prenatal screening cut across 
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all three planes, but because health care ethics is tailored to guiding clinical decisions for medical 
professionals, it has emerged largely as a way of thinking about individual ethical dilemmas. The 
clinical encounter is wrought with challenges - time constraints, less than optimal clinician 
understanding, information bias, personal value differences - which call into question who is the 
most appropriate and best-equipped person to assist in this ethical decision-making process. The 
intent of this analysis is not to find fault in well-intentioned health professionals who must act 
and react within the current system, but to question the wisdom of leaving patients and providers 
to navigate through these ethical minefields, when issues could, and perhaps should, first be 
openly discussed in the public realm to create greater awareness of the complexities. Such an 
approach would also enable the inclusion of the 'disabled voice' in screening policy (227) - a 
group that has not been consulted in regards to prenatal screening practices in Canada. There is a 
recognizable appeal in using more easily applied ethical principles at the individual level rather 
than engaging in major public controversies, which may partly explain why ethical dilemmas are 
often deferred to individuals and practitioners. This way of resolving issues has become the norm 
in medical practice despite its limitations. Drawing from the social sciences may help place 
individual experiences in the broader, sociopolitical context and to consider the importance of  
community dialogue.  
 Much can be learned about the roots of individual and social morality from Sociology’s 
prominent theorists. In The Sociological Imagination (1959), C Wright Mills points to the value 
of thinking about personal troubles as public issues and supports a critical examination of how 
such issues are framed.(258) Most interesting and relevant to the current discussion is Mill’s 
notion that any issue must be considered simultaneously at the level of the individual and 
society, since they are interrelated and indivisible. Mills thoughtfully writes, 
“Know that many personal troubles cannot be solved merely as troubles, but must be 
understood in terms of public issues - and in terms of the problems of history making. 
Know that the human meaning of public issues must be revealed by relating them to 
personal troubles - and to the problems of the individual life.  Know that the problems of 
social science, when adequately formulated, must include both troubles and issues, both 
biography and history, and the range of their intricate relations. Within that range the life 
of the individual and the making of societies occur; and within that range the sociological 
imagination has its chance to make a difference in the quality of human life in our 
time.”(258 p.226)  
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Drawing from Mill’s work, a fuller understanding of the intricate connections between the 
individual and public spheres is needed to appreciate how individual choices around prenatal 
screening are inextricably linked to the social, political and shared moral values of the larger 
society. Recall the eugenic philosophies that flourished throughout North America in early 
1900’s culminated in the atrocities of Nazi Germany, where millions of Jewish people, the 
disabled and the mentally ill were exterminated.(259) Most academics and researchers, although 
initially active participants, quickly disassociated themselves from this way of thinking. It has 
often been misunderstood that this dangerous ideology originated with the Nazi regime, when 
medicine and science built the foundation.(259) Following the war, many concentration camp 
victims were scorned by other citizens and the crimes against them were often not 
acknowledged, demonstrating the same prevailing attitudes that led up to the murder of millions. 
Canada was not exempt from the eugenic mindset. Sterilization laws were implemented in 
British Columbia and Alberta where official government policy allowed sterilization of people 
who were mentally ill and those with disabilities – the former requiring 'consent' from the 
individual.(259) Once legal, involuntary sterilization is now considered battery under Canadian 
law; a tremendous shift in definition over a relatively short period of time (this practice occurred 
in Alberta all the way up to the early 1970s). This is but one recent and local example of how 
social conceptions of worth and respect shape the values and actions of individuals. In the same 
way, public eugenic policies did not emerge in a vacuum, but rather came about through the 
actions of individuals over time, leading to their normalization (even if temporarily). Applying a 
critical analysis to current screening practices will be important if we are to avoid serious 
consequences and violations similar to tragedies throughout history. 
 
6.4 The Contribution of a Communitarian Perspective 
While individualism has become a popular ideology in Western societies, ethicists from 
the communitarian tradition critique the notion of the individual as the focal point of moral 
concern.(228) Callahan (2003) argues that an absolute focus on the individual blocks what he 
calls 'serious ethical inquiry'.(156) Due to the relentless focus on autonomy, deeper ethical 
inquiry must yield to individuals’ notions of right and wrong. In this way of thinking, individual 
rights take precedence over the interests of the larger society, and the society must not impose 
any notions about good and value. Communitarianism counters this perspective, responding that 
 186 
 
history, tradition and moral communities are the true sources of moral thought and action.(228) 
Communitarians also believe public controversies cannot be resolved by focusing on the well-
being of one person at a time, but rather discussion needs to happen around community values 
and what a 'good society' would look like. From a communitarian perspective, the first question 
then that needs to be asked should focus on the social and cultural impact of a decision. 
Communitarians object to the preoccupation with the individual and its lack of recognition of the 
individual as a social being. Both the choices afforded to individuals and the thinking used to 
make decisions about these choices are a result of the larger society we live within.(156) Prenatal 
screening and selective termination is only an option for individuals to the extent that society 
permits this option and social institutions have created the means to make it optional at all.   
 
6.5 A Technoethical Inquiry Perspective 
The biotechnology revolution is a powerful social force that has quietly yet dramatically 
changed the way we think, value, live and relate to one another. Science and the market appeal of 
its new technologies are social forces that have an incalculable impact on our way of 
thinking.(156) As Callahan points out, due to our view of biotechnology, if something is 
available and some individuals want it, then it is thought it should be released and only 
prohibited when scientifically proven to be harmful.(156) This is often referred to as the 
'technological imperative (260)'. The mere availability of prenatal screening has become a 
justification for its provision. Because technologies must be used in order to gauge whether they 
are harmful or not, by the time it is found to be harmful, its use is often normalized and expected. 
To remove prenatal screening services from the slate of tests currently offered to pregnant 
women, screening would need to proven to be harmful, ineffective, and costly (or a combination 
of these). However, society’s working definition of harm is narrow and often does not include 
social, moral and political consequences.(156) Furthermore, science is often framed as a value-
free activity, a view that seems to support the unrestrained development of new prenatal 
screening tools. Shakespeare (1998) disagrees, arguing that science is a social activity and 
scientists
 
must take responsibility for its application.(227)  
Prenatal screening is a good example of a cluster of reproductive technologies that are 
reshaping the way society views childbirth, disability, and genetics. Similar to most technologies, 
prenatal screening was created and implemented with virtually no input from the broader 
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community, including women or people living with disabilities. Because prenatal screening leads 
to fewer children born with these conditions, these groups, and society generally, have major 
stakes in how this technology plays out. Its unilateral release is evidence that it is not the public 
that guides policy around the introduction of new technology; for the most part, technology leads 
us.  
Technoethical inquiry is an interdisciplinary framework with an explicit focus on the role 
of technology in society and the interplay between technology and other social systems (261), 
and it has much to offer to the current conversation. Using this perspective, the transformative 
power of technology is recognized as one that plays an intermediary role in all human activity, 
and to some extent, has replaced nature. Luppicini (2009) maintains that 
"The rise of the technological society is accompanied by a social and ethical crisis that 
society is now struggling to deal with. Because of the tremendous power and impact of such 
technological intertwinements, social and ethical considerations are now at the forefront of 
public concern and academic interest. However, due to the complexity and multiplicity of 
human-technological intertwinements that arise, it is an ongoing challenge for social 
scientists to keep up with changes that occur in so many areas. What further complicates the 
situation is that many of these changes are not directly observable and require sophisticated 
strategies to discern. ...Reflecting on the complex character of our contemporary world 
defined by technology is perhaps the most challenging problem of the 21
st 
century. What 
makes this challenging is not due to technology (in itself), but rather, the elusive character of 
technology within society. As some new technologies become accepted and integrated in 
society (i.e., cell phones, Internet), they tend to become invisible to individuals and disappear 
into the background of everyday life (Volti, 2009). The main consequence of this is that the 
powerful intermediating role of technology is poorly understood because it is not noticed. 
This blocks any efforts to provide responsible decision making about which technologies to 
nurture, which to suppress, and in what contexts."(261 p.6-7) 
As new reproductive technologies like prenatal screening become increasingly integrated into 
our societies, they too will become less noticed, less contested. Perhaps the greatest value of the 
current dissertation is that it begins to describe the social impact of a new individually applied 
technology - prenatal screening in Saskatchewan - a practice that cannot be understood without 
rigorous, in-depth study and data access.  
Prenatal screening today is not what it will be tomorrow, and it is almost certain that as 
our ability to screen changes, so too will our sensibilities about what is acceptable. With this in 
mind then, we (as a society) must recognize that each new wave of technology is gradually 
redefining the maternal-child relationship (as conditional on the child's health and/or parental 
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preferences
53
); the nature of human reproduction; and our definitions of health.(247, 262) We 
must also question how future decisions will be made given the current direction (or lack 
thereof) in Canada, and evaluate if this is consistent with how they ought to be made. Currently 
there is no legal regulation of prenatal screening or selective abortions, which means that each 
individual is asked to decide for herself, with all the biases and limitations of the current clinical 
process and all the outside pressures and expectations weighing down on her. It is unclear what a 
more regulated screening practice might look like. At one end of the spectrum could be a 
situation where the government regulates which tests are offered and who provides and receives 
the offer, with heavy restrictions on when and for which reasons a fetus can be aborted or even 
prohibiting abortions for this reason. Given prevailing political and social ideologies, a more 
moderate approach might better appeal to the general population. This could include elements 
where public and expert engagement help to create some legislative controls (eg. which 
screening tests are offered in Canada; how to handle new tests as they become available), while 
still allowing women the decision to terminate a pregnancy affected by fatal anomalies.  
New reproductive technologies can place governments, providers and women in difficult 
positions when forced to reject or turn away "progress", or when they take a "wait and see" 
approach. Saskatchewan took this very approach to the implementation of the MSS program, yet 
was viewed by some as being behind the times or not current with evidence-based medical 
practice. Central to this dilemma is the notion of personal responsibility on the part of the 
inventor of the technology who creates new possibilities in the first place. Mario Bunge (1977), 
the first to coin the term technoethics, argued that technologists and engineers must be held both 
technically and morally responsible for what they design and implement.(263) Moreover, the 
invention should not be harmful, but beneficial, in both the short and long term. Harm, according 
to Callahan (2003), should be conceived of in the broadest sense of what truly harms people (eg. 
threats to their values, social relationships).(156)  
The current way of thinking conveys that what the inventors of prenatal screening 
technologies have created are essentially value-neutral until a woman applies them to her own 
circumstance. Still Seavilleklein (2009) reminds us that women's choices are determined by 
                                               
53 In her book, Rothman (1986) describes how modern medicine, with its new capacity for prenatal screening/ 
diagnosis, preimplantation genetic diagnosis, surrogacy, has promoted a situation where pregnancy is viewed as 
tentative.262. Rothman BK. The tenative pregnancy: prenatal diagnosis and the future of motherhood. New 
York: Viking; 1986.  
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whichever options are available and that these options are the result of broader contextual factors 
such as political and economic interests, historical circumstance, and research agendas.(185) 
Vassy (2006), for instance, argued that prenatal screening in the United Kingdom did not come 
about in response to women's demands, but as a result of particular interests (eg. medical supply 
industry, sectors of the medical profession, and government organizations).(187) Tests are 
brought to market by private companies, who are intrinsically profit-driven and therefore have a 
vested interest in expanding testing technologies. In the case of prenatal screening, testing 
reduces costs associated with caring for affected individuals throughout their life course; a fact 
that has been highlighted and studied in many cost-benefit analyses.(264-267) As more women 
are tested (whether they have provided informed consent or not), those involved in screening 
interpret this as women wanting more testing and use it as evidence to support expanded testing 
services.(187)  Callahan (2003) cautions that the power and profit of technology can effectively 
control and manipulate, but is very difficult to see, much less retaliate against.(156) 
A key challenge in a world with a global economy and access to the internet is that tests 
banned in one country can be easily shipped from another country, and then an abortion 
performed in the woman's home country or in a country where this type of abortion is permitted. 
Reproductive tourism, as it has sometimes been called, presents challenges to creating policies 
and legislation to prevent activities judged to be unethical and undesirable. This has been seen in 
the case of sex-selection abortions (which are similar in nature to pregnancy terminations for 
fetal anomaly in that, for some individuals, a particular sex is an undesirable outcome) where 
Canadian couples have accessed services in the United States.(268) While sex selection 
abortions are not illegal in Canada, it is almost impossible to find a physician who would 
perform one or a hospital that would knowingly allow one.(269) A good sign that social and 
moral consensus can be achieved in Canada on particular controversies. Because abortion is 
generally permitted for unwanted pregnancies in Canada and sex determination by ultrasound is 
exceedingly common, sex selection abortions invariably do occur unbeknownst to the physician 
and are not as rare as one might think.(56) Luppicini (2008) tells us that "one of the overarching 
guiding principles of Technoethics, referred to as the Law of Technoethics, asserts that ethical 
rights and responsibilities assigned to technology and its creators increases as technological 
innovations increase their social impact (p. 16)." (261) In the case of prenatal screening and 
selective abortions for sex selection, the social impact can be profound. In the case of sex 
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selection abortions, many regions in countries like India and China are disproportionately male - 
a situation that has further exacerbated abuse of female children (eg. feticide by families and 
infanticide when a female child is born) and has obvious repercussions for fertility and women's 
equality.(57) In societies where underlying biases and prejudices prevail, the use of abortion to 
remove marginalized groups of individuals may exacerbate the existing problem. It is unclear 
what the current expectations are for those researching and creating new reproductive testing 
technologies. If these individuals indeed have responsibilities to the larger society, a challenge 
will be helping them identify which of their creations will be largely benevolent and which might 
be too problematic.  
  Science and medicine are not the only stakeholder groups that should take responsibility 
for regulating the field of prenatal screening and selective abortion in Canada. Muller-Hill 
reflects on the holocaust and concludes, “medicine and science should never again be trusted 
when they promise to deliver their own ethical values; these values have to come from other 
sources (p.49).” (259 p.49) Citizens, interest groups, religious organizations, and  politicians, 
along with experts from medical and non-medical fields, all can and should play an important 
role in setting policy directions. Where possible, individuals with disabilities and carriers of 
genetic disease should be engaged directly, recognizing that even family members will 
sometimes have different views.(227) At present, obstetricians, medical geneticists and genetic 
counsellors, and laboratories have almost exclusive influence on practice and policy, which 
should be recognized as being problematic. And while prenatal screening is almost universally 
available throughout Canada, it does not mean current practice should not be reevaluated.  
The emergence of prenatal ultrasound screening has opened a window to the womb, 
allowing women to better-bond with their child before birth, lowering maternal anxiety, and 
reducing risk behaviours.(270) Ultrasound has become particularly ingrained into the prenatal 
care experience, with most women waiting with anticipation until the time they can 'see their 
baby', enabling mothers to bond in a way not possible before the introduction of this technology. 
On the other hand, it has consequences for pre-birth discrimination, value judgements about what 
constitutes a life worth living, transformation of the pregnancy experience, and potentially 
repealing the hard-won victories of the disability rights movement. Luppicini (2009) refers to 
this as the 'paradox of technology', where a technology provides opportunities to improve human 
life and society, while simultaneously having "anti-human consequences against which 
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individuals ought to defend and protect themselves."(261 p.15) In the case of prenatal screening, 
it may for some individuals redefine their relationship with their fetus/baby as conditional based 
on his or her health, functionality, and normalcy. Even for those who refuse screening there are 
unavoidable consequences, namely that society is repositioning itself in relation to individuals 
with disabilities and health risks, in which case having a child with a CA may inadvertently 
increase the burden for families. Seveilleklein (2009) explains how new choices can soon 
become the socially expected choice, and can have unexpected consequences that include the 
disappearance of previous options.(185) In France, a country where screening and diagnosis is 
remarkably common and pregnancy termination high, it may not be long until the population of 
people with Down syndrome disappears. From 1983-2002, 71% of all Down syndrome cases in 
Parisian mothers were detected prenatally and 95% were terminated (31), effectively making the 
decision to birth and raise a child with Down syndrome socially inconceivable and practically 
much more difficult without community support groups and programming. Having a child with a 
disability in a society where fewer and fewer are granted entrance, runs the risk for lower levels 
of practical support and less positive regard for people living with these conditions. It eliminates 
others from the population that may have acted together as a community of support and kinship. 
It also limits the range of human experience and the richness inherent in the diversity of 
experience. As such, it is important that we further study and remedy such imbalances that 
favour one option, without enabling the other option to remain a viable alternative (eg. similar to 
the earlier discussed conditions attached to the Postnatally Diagnosed Awareness Act in the 
United States).  
Part of the challenge in technoethical inquiry is to identify sub-system imbalances, 
explain why they are so, and consider their impact on the lives and choices of individuals.
54
 
Social inequalities are produced by sub-system operations and must be analyzed at that level. It 
could be argued for example that reproductive technologies (falling within the medical sub-
                                               
54 Under the technoethical inquiry approach, sub-systems include law, politics, religion, economy, science, 
communication, culture, medicine, and education; each with their own core operations and values. Law has as its 
core operation, the production of social norms and regulation of conflict and justice as its core value. Religion's core 
operation is the production of spiritual guidance, and faith is its core value. While each system has separate and 
mutually exclusive operations, they are open to the environment and each other. Luppicini describes that "each 
subsystem has its own set of perspectives by which it observes the other subsystems. For example, politics can 
observe the other sub-systems from a political standpoint and interpret society in political terms... economics .... in 
economic terms (p.9)".261. Luppicini R. Technoethical inquiry: from technological systems to society. 
Global Media Journal - Canadian Edition. 2009;2(1):5-21. 
 192 
 
system) produce social inequalities. The current study and others have provided data suggesting 
that greater uptake of screening by more educated, wealthy women and certain ethnic 
communities means CAs might disproportionately affect lower income and First Nation 
families.(31, 83, 98) This may represent an inequity in a context wherein community resources 
and social support for women is insufficient to support the decision to continue an affected 
pregnancy. Within the technoethical systems perspective, social change is achieved when society 
reacts to changes in its sub-system operations involving human agents (eg. changing medical 
norms), not by human agency directly.(261) Using this way of thinking any significant change in 
prenatal screening practice would not only require individuals to act differently, but also require 
changes in sub-system operations. This may be in the form of professional guidelines, 
legislation, legal precedent, or increasingly through collective action orchestrated through social 
media campaigns (also part of the technological sub-system). The focus of the technoethical 
paradigm is on knowledge acquisition and understanding the system under inquiry.(261) 
Technoethical inquiry can help us to better evaluate the ethical responsibilities that accompany 
new inventions, which can help us navigate the system in ways that reduces these tensions. A 
successful analysis occurs when a shared understanding is achieved in regards to the key ethical 
dilemmas, but does not require consensus.(261)  
 
6.6 Screening for Any Condition or Only the 'Severe' 
The existence of prenatal screening programs, in contexts where abortion is permitted, is 
associated with the belief that abortion of fetuses with certain traits is socially and morally 
acceptable. Often it is said that screening detects 'severe conditions', however severe is a relative 
term and used in this context includes Down syndrome and spina bifida. Alone these conditions 
are not severe, many would argue, but could be if there were other co-morbidities. The Canadian 
Down Syndrome Society (CDSS) views "Down syndrome [as] a naturally occurring 
chromosomal arrangement that has always been part of the human condition, seeing it as neither 
a disease nor a negative medical outcomes of pregnancy." (197 p.580) The severity of the 
condition is likely to influence people's beliefs about when abortion should be permitted, 
therefore is an important component to the debate. If certain parameters were set within which 
fetuses could be aborted, what might those parameters be? Some working in the field of prenatal 
diagnosis and fetal medicine have been skeptical that a consensus on what constitutes severe 
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could be achieved in a general way. The SOGC states "screening for a disorder should be 
undertaken only when the disorder is considered to be serious enough to warrant intervention 
(157 p.738)", but does not go as far as to define what constitutes a serious disorder. A challenge 
will be determining how we (as a society) decide which disorders are serious. For the most 
severe cases, those that are predictably fatal, it could be argued that the practice simply shifts the 
timing of death, intervening earlier in a dying process that is inevitable. For a truly terminal 
condition, like anencephalus, this could very well be true.  
Claims are often made that people with disabilities are valued (or should be), similarly to 
those without but one cannot help notice the apparent inconsistency when we have population-
based programs aimed at the prenatal detection of such fetuses with the offer to prevent their 
birth. The fact that some or all women may choose to intervene not only means that future 
persons with these conditions may be removed from our society, but it also implies that their 
value as a human being in this world hinges on that identifiable trait or condition. In essence, it 
creates entrance requirements for humanity.(4) Seavilleklein (2009) favours the use of a 
relational autonomy framework to encourage a deeper look at the options made available through 
prenatal screening and to consider why some options and not others are available.(185) For 
instance, a woman may screen for Down syndrome and abort, but cannot choose to abort based 
on fetal sex. Looking to future possibilities, society may find it unsettling if programs expanded 
the offer of screening to include the identification of fetuses at-risk for less severe or late-onset 
conditions (eg. BRCA mutations for breast cancer or at-risk APOE alleles for Alzheimer's 
disease). Heterogeneity is part of the human condition and a large segment of the population will 
have an increased likelihood of experiencing one condition or another. Some of the problems are 
that there is subjectivity in the interpretation of 'risk', limited ability to predict degree of 
impairment, as well as varying abilities to understand and imagine a future child (unknown to 
you as yet) living with any given condition or risk. Already in Saskatchewan and other 
jurisdictions women are having their pregnancies prenatally tested for Cystic Fibrosis, which 
given its frequency in the general population may be the next condition approved for screening.  
One might posit that population-based screening for other, less serious conditions, is 
unlikely, however, the potential integration of new genomic technologies into non-invasive 
testing techniques is thought to be inevitable.(226) This would mean that a plethora of conditions 
and risks could be detected in the first trimester, without immediate risk to the fetus, and by way 
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of a simple blood draw. Such a development would have irrevocable and vast implications for 
the field of prenatal detection and ultimately the filtering of fetuses affected by such conditions. 
A chief concern is that children could then be born with a pre-mapped genome, without having 
given their own consent for testing, which could have repercussions for care and treatment for 
those with 'at-risk' genomes, as well as infringing on their right to not know.(226) Parental 
consent for testing for conditions viewed by the parents as severe with immediate consequences 
is one thing, but non-consensual complete genome mapping is far more problematic. Taken 
alone one condition or another may not dissuade a parent from giving birth, but multiple risks 
together may have a more powerful impact on their choice. The timing of testing has also been 
shown to impact the decision to have an abortion or not. de Jong (2010) notes that a majority of 
people in western countries view the moral significance of the fetus and embryo as something 
that increases with development.(226) The fact that earlier testing enables earlier abortions might 
make this option more acceptable to women, as well as altering their views about new testing 
possibilities.   
 
6.7  Baby or Fetus: Complex Implications for Word Choice  
During the writing of this thesis, seemingly simple decisions about word choice often 
became agonizing selections for someone wanting to give a reasonably balanced perspective on 
the topics. Describing and discussing the subject matter in a way that was accurate and 
straightforward was not always an easy task. Often the easier way to phrase an event led to 
reliance on the common clinical terminologies, which some view as value-neutral or objective 
language. Others, like the Canadian Down Syndrome Society (CDSS), take exception with much 
of the language used to describe the process of screening to patients who are potentially carrying 
a fetus with Down syndrome.(197) The CDSS argues that terminology can send implicit 
messages about the desirability of having a child with the condition or any other condition. 
Nondirective language is a fundamental principle of genetic counseling. The decision to use the 
term 'risk' instead of 'likelihood or chance' or 'diagnosis' instead of 'determination' when speaking 
about screening results, as the CDSS and others argue, denotes an undesired outcome.(197, 271) 
Another example is the use of 'normal' when speaking about unaffected children, as opposed to 
saying 'children without a congenital anomaly or disability'. Skotko (2006) notes that this type of 
partiality is built into the educational materials of many programs, thereby often biasing parents 
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early on towards particular choices.(271) Saskatchewan MSS program patient brochures use a 
mix of word choices, with very little information on the conditions being screened in the regular 
brochure and no information on conditions screened in the low literacy version.   
Aside from the language used to describe screenable conditions, care must also be taken 
in describing abortion and the developing fetus in an academic paper. Words like 'termination of 
pregnancy' or 'pregnancy interruption' are recent examples of new word choices, perhaps with 
the intention of creating distance from the term 'abortion' (ie. medical or therapeutic abortion). 
The term 'fetus', widely used in academic contexts, may be referred to as an 'unborn child', 'child 
in utero', or 'baby' depending on the contexts. Feticide is a less common reference to abortion. 
Another attempt at reframing contentious practices by means of a language change is the recent 
substitution of  'after-birth abortion' in place of 'infanticide', although the ethicists who chose to 
use this term also insert "killing of newborn" in brackets.(272) The authors admit their language 
choice was intentional and meant to emphasize their view that "the moral status of the individual 
killed is comparable with that of a fetus (on which ‘abortions’ in the traditional sense are 
performed) rather than to that of a child."(273 p.2) One term that was used often in this 
dissertation is "termination of pregnancy for fetal anomaly", which was sometimes abbreviated 
to TOPFA to make reading easier. The short form was used with hesitation, recognizing that it is 
inherently reductionist and downplays the significance of a complex, painful, moral and personal 
dilemma with far-reaching societal implications.  
 
6.8 Abortion and the Moral Status of the Fetus 
  Today in North America and most developed nations, the general acceptance of abortion 
has allowed supporters to sidestep the issue of human rights, given that most unborn children 
have not been conferred formal, legally enforced rights. The usual argument goes that the fetus, 
although human, alive, and having its own unique DNA, does not meet the legal criteria for 
personhood. Still the fact that the fetus is not viewed as a person by legal systems in many 
countries does not preclude the fetus from possessing what ethicists call moral status.
55
 
                                               
55 Dwyer (2010) defines moral status as "a characteristic that we human moral agents attribute to entities, by virtue 
of which they matter morally for their own sake, so that we must pay attention to their interests or integrity when we 
consider actions that might affect them, regardless of whether other beings are concerned about them. When an 
entity has moral status, I may not act toward it in any way I please, disregarding its well-being, preferences, or 
continued existence. I owe some moral obligations to that entity itself. As a moral agent, I must care to some degree 
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Intuitively, and increasingly as a result of our ability to study and view the fetus via new 
technologies, we recognize the importance of this phase of growth to achieving personhood. 
Some, like Gillon (1988), view people (from embryo to elder) as existing on different points in 
the life continuum and being the same human being (biological) that they were as embryos and 
as fetuses.(275) Some argue that human life, however it exists, is inviolable, while others view 
the fetuses right to protection as increasing with development. This latter line of thinking 
supports the concept of the fetus as a patient, in which case, Chervenak & McCullough (1995, 
1996) argue that before viability it is up to the pregnant woman to confer moral status, but after 
viability the fetus becomes a patient to whom doctors have duties.(276, 277) In this case 
directive counselling for fetal benefits is ethically justified. The physician caring for a pregnant 
woman has two patients, not one.  
  Countless arguments have been made in support of abortion, including that human 
persons may have been human embryos and fetuses, but that human persons, embryos, and 
fetuses are not the same.(275) The three most ethically significant factors used to determine the 
fetus' moral standing seem to be: whether the mother wants the fetus to be born; fetal viability 
outside the womb; and the health of the fetus. Those that accept abortion as morally 
unproblematic often accept the view that the killing of embryos and fetuses is permissible in the 
interests of the pregnant mother.(275) Therefore while the fetus may have moral status, this 
status is secondary to what is deemed to be in the mother's (or family's) best interests. As 
Shakespeare (1998) observes, peoples' views about abortion in the case of a fetal anomaly are 
often more complex than being 'pro-choice' or 'pro-life'.(227) For example, some people who 
oppose social abortions support abortion in the case of fetal anomaly, while some disability 
rights activists argue for abortion rights except where an anomaly is diagnosed. The threat of an 
anomaly is also sometimes used to justify abortion rights in general.   
  Concerning the morality of terminating a pregnancy due to a known or suspected fetal 
anomaly, the common dilemma is whether we can morally justify limiting abortion for 
particular reasons, when we do not limit abortion for any reason. That is, in North America 
women do not need to provide justification for early abortions, which typically are the result of 
unwanted or untimely pregnancies. In a legal sense, abortions for all reasons are treated equally, 
                                                                                                                                                       
about what it wants or needs, or simply what it is; this imposes some limitations on how I may act toward it."274.
 Dwyer JG. Moral status and human life: Cambridge University Press; 2010. 
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even if ethically many do differentiate between an abortion due to a rape and one due to the 
mother's career.(227) The feminist argument is that women have the fundamental right to make 
their own decisions about their bodies, which is necessary for their full participation in 
society.(278) Here the fetus is viewed as having no moral status, or a moral status subordinate to 
its mother's interests. An important difference between abortions for any of these reasons and 
abortions following a CA diagnosis is that the mother in the latter instance had the intention of 
carrying the child to term, to bring it into personhood. It was not that the mother did not want to 
bear a child, but she did not want to bear that particular child.(279) Gillon (1988) makes the case 
that "any embryo or fetus that is intended to be kept alive and allowed to develop normally and 
become a human person nothing should be done to it that would harm the person it will become 
which would not be accepted if done to a 'fully fledged' person." (later called "The Actual Future 
Principle" by Harman 1999) (275 p.4). In essence, the fetus should be treated as having the 
moral standing of a person, not because it is a person, but because it is intended to be one.(280) 
This thinking is reflected in public health prenatal programming that aims to optimize outcomes 
for infants, and to a large extent, holds women responsible for their choices and behaviours once 
they have made the commitment to carry the child.  
  Those that oppose the selective termination of fetuses with an anomaly may or may not 
favour abortion for other reasons. However, writers in the field of disability equality have 
concerns about the push women may feel towards choosing abortion after a prenatal diagnosis. 
Because many physicians and genetic counsellors view selective termination as a favourable 
option (281-283) and biases exist that frame disabled lives as those not worth living (278), 
women may feel compelled to abort. Disability rights activists object to the notion that these 
lives are less valuable, distinguishing between 'impairment' (the physical condition) and 
'disability' (social consequences of impairments). Sharp and Earle (2002) explain this position 
further saying "... it may be that in the current social and economic environment, disabled lives 
are not [viewed by the medical establishment as] worth living; however, that is not a 
consequence of impairment itself, but instead of prevailing social and economic conditions 
which militate against impaired individuals leading full and satisfying lives (p.140)".(278 p.140) 
While Shakespeare accepts the notion that women should have the right to choose, he does not 
see their choices as currently being truly free due to the broader forces at play in any decision. 
While Shakespeare views the ethical tensions between the feminist and disability rights 
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discourses as reconcilable, Sharp & Earle (2002) mount an interesting case as to why they are 
fundamentally in opposition.(278) 
 Prenatal selection, the termination of a fetus affected by a condition undesirable to the 
mother and/or posing serious threats to the quality of life of the child, is allowed in our society 
because it involves a fetus. That is, the current mindset and value system of most Canadians 
would likely not permit the euthanizing of children or adults with cystic fibrosis, Down 
syndrome or spina bifida. This is not to say that this cannot change. Consider the Netherlands, 
where the Groningen Protocol was designed for the euthanasia of sickly newborns.(284) Two 
medical ethicists from Oxford University incited controversy following a paper published in the 
Journal of Medical Ethics that argued 'after-birth abortion' is not inherently different than late 
termination of pregnancy because the moral status of the infant is similar to a fetus, saying 
"neither is a 'person' in a morally relevant sense."(273 p.2) The concept of postnatal abortion is 
quite relevant to the current analysis, in that it may be viewed by some as a justifiable extension 
of pregnancy terminations for congenital anomaly (eg. when a prenatal diagnosis is not made and 
the parents are given the choice to end the infant's life shortly after birth). In Saskatchewan, the 
current study identified 12 cases where the pregnancy termination resulted in a live birth. Such 
cases can be quite traumatic for health care staff and parents, who then must witness the infant 
die over the course of minutes, hours, or even days.(285) While these early births are the result 
of an abortion procedure, the question of the healthcare teams' duty to the born-alive infant 
becomes another difficult ethical dilemma.
56
 
 Women today are increasingly aware of early risk exposures and most treat themselves, and 
by extension treat their growing fetuses, with care. A large and growing body of evidence has 
shown that the quality of life inside the womb (ie. the uterine environment and the interaction 
between mother-child) has a substantial impact on future health and development, making the 
prenatal period a critical determinant of the lives most hope to experience. There is, at times, an 
uncomfortable contradiction inherent in society's treatment of the growing unborn child. There 
is immense concern for the life within and anticipation of its birth. People will lay hands on 
                                               
56 In January of 2013, Canadian Members of Parliament for the Conservative party asked the RCMP to initiate a 
homicide investigation of an estimated 491 cases of fetuses 'born alive' following an abortion procedure between the 
years 2000-2009. They note that these cases appear to meet the criminal code definition of a homicide, which is 
someone causing a child to die after birth by causing an injury during or before birth. 286. Hopper T. Birth 
of a legal quandry: live-birth abortions a perilous grey zone in Canada's criminal code. National Post. February 1, 
2013. 
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pregnant mothers' stomachs waiting to sense the movement from within; mothers will worry 
about the chemicals they are exposed to and the vitamins and nutrients they consume; some will 
plan to preserve the cord blood stem cells, to document the pregnancy in beautiful artwork; day-
to-day accounts of the experience may be detailed via social media; and most mothers will visit 
their care providers routinely to ensure that everything possible is done to increase the chance of 
having a healthy child. Virtually no mother refers to her growing child as a "fetus", but rather it 
is a "baby" and the family's longing to meet the child is often palpable.  
  When it happens, the diagnosis of a fetal anomaly can be devastating for the mother and 
family and a sudden shift may occur when the fetus is suspected to have health concerns. 
Barbara Rothman (1986, 1993) powerfully describes women's painful experiences and the shift 
where they begin to try and conceal their pregnancy (while awaiting a diagnosis), deny fetal 
movements, and the immense pressure to act swiftly before the fetus grows further, assuming an 
earlier abortion will be easier.(287) She laments the lack of full consideration of the toll that the 
prenatal screening and diagnostic process, as well as the decision to continue or terminate, take 
on the pregnant woman. Emphasizing the inability of genetic testing information to provide a 
true picture of the condition, its consequences (ie. level of impairment), and future quality of 
life, Rothman is concerned about the decisions that women are faced with. In line with 
Shakespeare's argument, she is also skeptical about women's true ability to choose. "When a 
woman 'chooses' aborting rather than bringing to birth a child with a particular condition or 
predisposition, she is doing so in a world that sets the parameters of that child's life just as surely 
as genes do. Abortion can be the right choice, the moral choice, the only choice, but it, like 
birthing the child, is always a choice in a context."(287 p.267)  
 The key controversy here may well be the question of when and under which 
circumstances abortion is ethically permissible, if at all. If we believe it is moral to allow women 
to terminate pregnancies when they are untimely and therefore likely to impact the quality of a 
woman's life, then can we argue it is morally wrong to terminate any specific kind of pregnancy? 
Is it unethical to terminate pregnancies based on sex, race, sexual orientation, intelligence, or 
other aesthetic qualities? There seems to be fairly widespread consensus in the medical 
community that prenatal sex selection should be prohibited in Canada.
57
 Hence we are faced with 
                                               
57 Interestingly, the practice is also illegal in India, where it has become widespread, particularly in many rural 
communities. 
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a distinction between prenatal screening for the purpose of selecting fetuses based on sex as 
opposed to selection based on disability and future quality of life. Ethical analyses find 
similarities between the two and question whether different recommendations (i.e. for the 
prohibition of prenatal sex selection and the acceptance of prenatal selection due to disability) 
are more a result of better-developed social pressures against sex discrimination than disability 
discrimination.(249) The fact that both the public and medical profession reject the notion that 
abortion is morally permissible in certain circumstances (ie. female gender or aesthetic 
characteristics), suggests that traditional rationale supporting abortion (as a woman's individual 
choice) does not extend to all situations. Similarly, feminists have struggled with the concept of 
sex selection abortion, generally opposing this practice, but have difficulty morally reconciling it 
against the claim that it is each woman's right to have an abortion for whatever reason she 
chooses.(288)   
  Here in Canada, many would argue our society values a woman’s ability to decide 
whether or not she carries her pregnancy to term, but there is no clear social consensus on the 
question of abortion, when it should be permitted, and under which circumstances.(289) Support 
for abortion varies across provinces, with individuals polled in British Columbia and Quebec 
showing greater support than those polled from the prairies. No information is available on 
Canadians' views of the termination of fetuses with varying conditions or traits. Given that we 
also know that support can change when dialogue is guided by evidence, it is unclear what 
abortion policies Canadians would be willing to support. More in-depth investigation in this area 
would be valuable and may be guided by the Genetic Town Hall model that was successfully 
utilized in the United States (described in section 6.12). 
 
6.9 The Moral Ideal: Embracing Diversity and Respecting Disability 
  A more idealized approach to moral controversies such as prenatal selection may move 
us beyond what some describe as libertarianism's 'selfish ethos' to more fully consider others 
(156). Emmanuel Kant wrote about the duty of beneficence, which means acting in a way that 
furthers the happiness or welfare of another.(290) Three interesting studies that looked at 
parents and siblings of children with Down syndrome found overwhelming life satisfaction and 
pride in their family member with Down syndrome.(291-293) When surveying those with the 
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condition, Stoyko (2011) found that almost 99% of people with DS said they were happy with 
their lives, 97% liked who they are, and 96% liked how they look. For those with direct 
experience of life with Down syndrome, the diagnosis is not the tragedy that some may 
perceive. Interestingly, studies using a community sample have found that parenting a child with 
DS was thought to be less rewarding, more costly, and result in less family continuity, yet the 
majority of respondents within these studies had no personal experience of persons with DS or 
any other intellectual disability.(294) Those with negative views of parenting a child with a 
disability were also more likely to say they would terminate an affected pregnancy. Parents' 
perceptions are important to screening decisions and may be unrealistic. Given the mostly 
positive reports from families with someone who has Down syndrome and the fact that most of 
these pregnancies are wanted pregnancies prior to diagnosis, more must be done to ensure 
women have a full understanding of the conditions about which they are making vital decisions 
for their pregnancy. Parens and Asch (2003) remind us that the disability is one aspect of the 
individual not the sum total.(295)  Still Asch (1999) laments that "once a prospective parent 
knows of the likely disability of a future child, there is nothing else to know or imagine about 
who the child might become: disability subverts parental dreams."(p.1652)" 
 The International Convention on Disability Rights is a covenant guaranteeing people living 
with disabilities equal human rights, fundamental freedoms, and respect for their inherent 
dignity.(296) The Convention, signed by 155 states in 2006 and put into force in 2008, places a 
heavy emphasis on the prevention of discrimination and awareness raising to foster greater 
respect for those living with disabilities, including combating stereotypes and prejudices and 
promoting awareness of their capacities and contributions. Canada has signed and ratified this 
agreement, but one cannot help to recognize the incongruence between respect for disability and 
population-based screening programs that aim to prevent their entry into our society. It seems 
disingenuous for Canada and other developed national to affirm the rights of those living with 
disabilities and to speak against discrimination, yet to continue to leverage sophisticated 
technologies to seek out those fetuses who show signs of potential disability and to utilize 
various, invasive techniques to remove them from the trajectory of human existence. Even if we 
concede that this population does not yet meet the moral requirements of personhood and 
therefore ending their lives cannot be viewed as an infringement of their human rights, the act of 
measuring, evaluating, and destroying affected fetuses might still be seen as a hostile, uncaring 
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act that blocks certain types of fetuses from coming to enjoy life within the world community. 
Several Members of Parliament in the United Kingdom share similar concerns about legislation 
that allows late pregnancy termination in the case of a CA only, in the face of laws protecting 
people with disability from being treated less favourably.(297) As such, a parliamentary inquiry 
was launched (report published July 17th, 2013) to seek out evidence from parents, medical 
practitioners, academia, support groups, disability groups, lawyers and other interested 
individuals to help inform possible new legislation. 
 
6.10 Current Regulatory Environment 
 Not all provinces in Canada currently offer prenatal screening as part of a comprehensive 
and centrally organized provincial program, but nearly all offer maternal serum and ultrasound 
screening and prenatal diagnosis through amniocentesis or chorionic villus sampling. Policy 
creation and implementation of practice guidelines appear to vary across jurisdictions, often 
occurring in a rather disjointed way. Decisions about prenatal screening are made predominantly 
by professional medical groups, which then are implemented by provincial health departments, 
and become mandatory and routine aspects of prenatal care delivery by physicians and 
midwives. Currently the SOGC, and more recently the Canadian College of Medical Geneticists 
(CCMG), consisting almost entirely of medical doctors in these specialties, review the scientific 
literature and make recommendations for the implementation of new testing possibilities. The 
SOGC has released recommendations on prenatal screening as it pertains to those conditions 
currently tested through serum screening (i.e. Down syndrome, trisomy 18, and neural tube 
defects), cystic fibrosis carrier screening and sex selection abortion. No open discussion of ethics 
is visible in any of these documents, calling into question the adequacy of the analysis and the 
suitability of the SOGC to make decisions with such far-reaching social consequences. 
Practicing physicians and midwives are primarily used as agents to deliver testing, which has 
helped legitimize the practice, but arguably, their authentic voices have not been heard either. A 
2005 survey of Saskatchewan physicians found that physicians held diverse views regarding 
prenatal screening, selective termination, and disability.(32) Many expressed concerns about the 
increasing capacity for genetic testing of fetuses and the social, ethical and clinical implications. 
With the forward momentum of screening, it was perhaps surprising when the SOGC stated in 
August of 2002 that population-based prenatal screening for cystic fibrosis for all pregnant 
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women could not be recommended at this time. While this could be described as a prudent 
course of action, there was no mention of ethical uncertainties, but rather practicalities of clinical 
implementation. The predicament is that the SOGC and other health care policy makers either 
support or oppose the implementation of new testing regimens based on clinical and scientific 
evidence, which does not contemplate their ethical significance and societal implications. 
Webster and Baylis (2000) note that it is not uncommon for ethical issues arising in the clinical 
setting to be camouflaged and portrayed as ordinary by using familiar nonmoral language.(298) 
The end result is that the technology is essentially unevaluated in terms of its ethical merit. 
 
6.11 Public Engagement as an Ethical Issue 
Prenatal screening has been framed as a purely private or medical matter, where the focus 
is on procedural solutions when substantive debate is actually what is required (156). Academic 
publications compare one screening method against another and debate the cost-effectiveness of 
population-based screening; however less is published in the medical literature about the ethical 
merits of the practice generally. Debates around the morality of prenatal screening still rage, but 
typically within the refuge of ethics' journals. The health care community owns the practice of 
prenatal screening and diagnosis, yet its focus largely rests on the 'how', overlooking its moral 
underpinnings. The fact that the much-needed ethics debates have been excluded from the 
mainstream media is also concerning. Public awareness and inquiry may be one means of 
helping to promote accountability, and ensuring medical practice reflects a spectrum of values 
and perspectives. It may also invite others from outside the healthcare community to contribute 
and even lead the much-needed debate.  
Prenatal screening today is framed as a legitimate practice exempt from moral scrutiny 
(largely due to the claim that it is the individual’s choice), therefore impeding further dialogue 
about its parameters, delivery and the social consequences today and in the future. It is my 
position that the public must be engaged on the topic of prenatal screening and the availability of 
abortion for affected pregnancies. One might ask if broad public engagement around prenatal 
screening, or any major moral issue in society, will result in a more ethical outcome than if only 
a select group of experts had been consulted. In health care, the structure and culture of the 
clinical setting can be constraining.(298) Inadequate space exists where ethical issues can be 
openly and fully explored, rather there may be “tremendous pressure to get along by going along 
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(299 p.298)”. Increasingly there is recognition (by policymakers, scholars, scientists, and the 
public) of the importance of hearing from 'citizens', which may be a means of increasing the 
public's trust in both policy and scientific technologies.(300)  
What is it about public debate and consultation that will help to ensure deeper ethical 
inquiry? While the health care setting, as a workspace, is also a 'moral community' where ethical 
dilemmas can be openly discussed; it removes the recipients (mothers being offered testing) of 
care and those with invested interests (people with disabilities) from the deeper and broader 
dialogue. It also does not allow input from other citizens and groups with an interest in the 
outcomes (eg. focuses on 'patients'). For the same reasons moral communities within health care 
settings are supported, moral communities are necessary in a broader sense. Intentional dialogue 
that includes the views and knowledge of a variety of persons, from a mix of backgrounds and 
social circumstances, will bring about a fuller analysis than is possible in a clinical encounter. It 
may also sensitize women to the nature of the issue before the offer of screening, giving them 
time to consider their own personal views and values before making a decision. Decisions with 
wide-ranging social implications that have the ability to change who we are, how we relate to 
one another and the type of world we live in. Already we may be greatly disadvantaged in our 
ability to critically evaluate the offering of prenatal screening as the practice has to a large extent 
become normalized (at least for a handful of conditions).  
Consider a hypothetical scenario where a pregnant mother is offered a noninvasive 
screening test during her 10th week of pregnancy and receives a genetic profile that identifies a 
genetic risk factor that has important implications for the child's future health and survival -- the 
BRCA genetic mutation for breast cancer. The mother then requests that her pregnancy be 
terminated, fearing for her daughter's future wellbeing and her own pain and suffering living 
with this knowledge. In this hypothetical case, the mother may find it consistent with her 
personal and family values to carry through with the termination, but as a society we must reflect 
on the sentiment underlying this decision and the social impact if such decisions were to become 
common. This dilemma calls into question the limits of personal autonomy. While society has 
been conditioned to believe it should remain silent about the choices individual women make 
about their own bodies, that silence has come with a price; the sacrifice of reasoned societal 
debate and formulation of a coherent social morality with respect to genetic testing. These 
concerns are beyond the realm of personal ethical dilemmas and are serious society-wide moral 
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controversies. As Rayna Rapp (2000) poignantly observed, women today are 'moral pioneers' not 
by choice, but by necessity.(4) 
 
6.12 The Task of Involving the Public  
 Using a model similar to that employed in the Genetic Town Halls in the United States 
or the use of theatre in Canada (300, 301), broad public consultation can be conducted that will 
offer citizens the opportunity to deeply engage on the morality of prenatal screening and its 
parameters. Cox and Nisker (2010) advocate for novel strategies that can be used for "broad and 
inclusive public participation in genetic policy development."(300 p.153) With a knowledge 
translation plan in place, finding from such consultations could effectively be used by decision-
makers to shape public policy. At present the public has not been well-engaged in ongoing 
ethical debate around biotechnology. The introduction of the Canadian Biotechnology Strategy 
(CBS) has created opportunities for greater public engagement (eg. Consulting with Canadians 
website) and may prove to have benefits as far as delving into the deeper ethical and social 
inquiry needed. A renewed sense of public empowerment over decision-making may encourage 
community members to become engaged about what decisions provide the most good for 
society. As much as personal empowerment promotes health and well-being, engagement in 
policy debates may be empowering in a moral and social sense, potentially alleviating the 
powerlessness people feel when they must submit to social practices contrary to their own 
morality, which may be thought of as a form of social 'moral residue (290)'.  
More attention should be paid to innovative and comprehensive strategies for eliciting 
public input on issues like prenatal screening and diagnosis. Rosalee Starzomski suggests that 
first a space must be created for the public to critically evaluate the use of genetic 
technologies.(290) In order to engage people in a meaningful way, at minimum, there is a need 
for increased awareness; a mechanism for feedback; accountability of government, industry and 
science; legitimization of lay knowledge; transparency; and a way to engage all types of people, 
especially people with disabilities and cultural groups who traditionally have been 
underrepresented (and less interested) in genetics.(290, 302) The CBS covers some of these 
components, but it's scope is wide and the link between its research and policy uncertain. No 
public consultations have been conducted on prenatal genetic screening or testing to date. 
Starzomski (2004) presents another interesting example of public participation in decision-
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making around new technology in Canada.(290) The Canadian Public Health Association 
(CPHA) used mixed methods to connect with a variety of Canadians on xenotransplantation. 
Most interesting, the process revealed significantly different opinions depending on how much 
information respondents were given. If people knew less, there were more likely to support the 
new technology than if they were well informed. This has important implications for future 
processes designed to gather public feedback, especially on complex and not well understood 
issues. It also underscores the limitations of public polling or surveys where many respondents 
may not have an adequate understanding to provide an informed opinion at that time. Education 
is a crucial component to developing meaningful engagement processes that are designed to 
inform policy.(300, 303, 304) A key aspect of the CPHA’s process is that lay knowledge was 
valued and used to formulate a broad policy. Because new technologies, directly or indirectly, 
impact us all, input from a broad range of stakeholders will be important. 
In 2005, Jeffrey Nisker led a novel approach whereby Canadians in Vancouver, 
Edmonton and Toronto were engaged on the topic of preimplantation genetic diagnosis.(300) 
Using a theatre presentation of a play called Orchids that presents two women in a fertility clinic 
for in vitro fertilization - one leaving it to chance if her child will inherit the genetic condition 
she has and the other requesting PGD to ensure her child does not carry that same condition. 
Participant discussion followed the performance in the form of either a large group discussion or 
a focus group. Discussions were taped, transcribed, and results were shared with Health Canada 
for policy development on the topic of PGD. Cox and Nisker (2010) note that "Canadians attach 
enormous importance to opportunities such as this to engage in dialogue and contribute to health 
policy development."(300 p.157) Feedback was also positive in regards to using this medium to 
educate, engage and arouse discussion. While some of the discussion that occurred during the 
course of this project could be applied to prenatal screening/testing and genetics generally, public 
engagement specifically on the topic of prenatal screening would be most valuable for policy 
guidance. In addition, broad-based participation is an important guiding principle for public 
engagement efforts and must include other citizens outside large metropolitan centres, as the 
current study highlights variations that likely reflect distinct geographical and cultural values and 
norms.    
In 2004, a unique public engagement model, called Genetic Town Halls: Making Every 
Voice Count, was used in six cities across the United States.(301) Over a focused 3.5 hour 
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session, participants learned, debated, and voted in a series of polling questions and provided 
their opinions during facilitated small- and large-group discussions. With the intention of going 
beyond basic focus groups, the Genetics and Public Policy Center (at the Phoebe R. Berman 
Bioethics Institute, Johns Hopkins University) prepared and shared videos that provided 
grounding in the science of reproductive genetic testing, including carrier testing, 
preimplantation genetic diagnosis, and prenatal testing. Interviews were also videotaped that 
provided various viewpoints about genetic testing from experts in fields ranging from medicine 
to theology. On-site experts were available to clarify any issues that came up during discussions. 
Local community members shared their views during panel discussions, and often included 
clergy, parents having experience with genetic testing, medical professionals, community 
activists, elected officials, and those from the biotech industry. The sessions were open to all 
interested individuals and the participants (n=536) came from various demographics groupings, 
political and religious affiliations, and varied experiences with testing. However, there was no 
mention of recruiting individuals with first-hand experience with disability or carriers of 
particular genetic conditions. The majority of participants rated the experience positively. During 
the sessions, participants expressed the desire to be better informed, to contribute to the broader 
discussion, and to have input into the implementation and development of these technologies on 
an on-going basis.  
The Town Hall model was motivated by the recognition that public opinion research 
through surveys, focus groups and interviews falls short due to individual's limited knowledge on 
complex technologies.(301) The Genetic Town Hall approach was designed to gather opinions 
from and facilitate debate amongst a better-informed group of citizens. Three major issues were 
considered: acceptable uses of testing/ limits; safety and accuracy of testing; and effects of 
reproductive genetic testing on individuals, families, and societies. The majority (89%) felt there 
should be limits set on testing, with many supporting the ability to test for fatal childhood 
diseases (81.9%) and fewer supporting testing for adult-onset disease (56.4%) or hypothetical 
genes for intelligence or strength (21.3%). A major theme that emerged was the need for 
diversity in society and the fear of the loss of diversity and discrimination against those with a 
condition, however, many also agreed that reproductive genetic testing helps parents make 
informed choices and have healthy babies. At the same time that the Genetic Town Halls were 
being held, the same issues were being discussed online. Using this format, participants met 
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three times for one-hour, were sent the videos to watch in advance of the session, and sessions 
were moderated by a content expert in order that questions were answered immediately. Findings 
were largely the same using both approaches and were shared with decision-makers in hopes of 
contributing to public policy. A subsequent session was held in 2008 on the topic of biobanking. 
The Genetic Town Hall represents an ambitious and novel undertaking capable of successfully 
educating and engaging citizens on complex and ethically contentious technologies. It is a model 
worthy of consideration here in Saskatchewan and Canada to better engage citizens on 
technically complex ethical dilemmas, in order to create policy that is better-aligned with the 
community's values while simultaneously raising awareness.  
 
6.13 Concluding Thoughts   
 An extensive body of research spanning many years has explored the challenges to informed 
consent in the context of prenatal screening and identified hurdles that are difficult to resolve. 
Less-than-optimal provider knowledge, directive counseling, involuntary screening, time 
constraints of the clinical visit, the complexity of information, and poor patient understanding all 
present challenges to autonomous decision making. A better alternative will require changes to 
ensure more ethical patient-provider encounters and public participation in policymaking and 
agenda setting. Very little information has been provided to the public to increase awareness 
about the practice of prenatal screening or its ethical controversies. The same is true when 
screening is offered to a pregnant woman; there is no mention of moral concern, despite the fact 
that the practice of TOPFA is highly debated. A pregnant woman may have a nagging sense that 
the practice is ethically sensitive, but when her physician does not broach these topics it may 
erroneously leave the impression that there is social and moral consensus around its use. There is 
also very little, if any, engagement of the local community by governments or screening 
programs, despite the SOGC and CCMG having recommended that local values be taken into 
consideration prior to implementation of a program.(48) Largely due to its intimate link to 
abortion, the provincial government and health system appears reticent to engage the public on 
the topic of prenatal screening. Yet any meaningful social critique must open itself up to the 
larger society, which extends beyond academic journals and medical texts.  
 A more open clinical encounter may be just as important as more open public debate. In 
response to the inherent limitations in the operationalization of informed consent and non-
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directive counseling, Wyatt (2001) suggests an approach where the patient-provider relationship 
is characterized by openness and transparency about the provider’s personal values and morals, 
not manipulated by masking personal biases.(305) Such an approach should be considered 
whether or not meaningful public debate occurs. Social critiques must occur at all levels (micro-, 
meso-, and macro-), bringing to light the factors influencing available options.  
 We must recognize that greater public input does not necessarily mean drastic restrictions 
would be imposed on current practice, although possible, but instead it might be decided that 
personal choice is the best approach within certain limits. Creation of ethical boundaries in a 
society are important, as limits help reaffirm collective beliefs, values, and preferences. 
Engagement of this nature should occur before the next new prenatal screening test hits the 
market. Recently, the SOGC reviewed the prenatal screen for cystic fibrosis, eventually 
recommending that it not be implemented at a population level yet, but rather be reserved for 
high-risk parents. It is useful to have the educated opinions of a group of experts from the field 
reviewing this technology, however it is not enough. Cystic fibrosis may well be the next 
condition added to the accepted list for screening and prenatal selection; this will qualitatively 
change the prenatal screening environment as it would represent a shift from conditions with 
immediate and notable health ramifications to those that are relatively less severe and associated 
with much longer life expectancies. It is not hard to imagine how screening practice will expand 
from severe and immediately terminal conditions like anencephalus; to the less predictable and 
less serious such as Down syndrome; to the questionably severe, unpredictable and often 
undiagnosed until later in life, including cystic fibrosis and BRCA mutations. The key question 
is: will the decision makers be willing to consult the public? If the SOGC had recommended 
mass screening for cystic fibrosis, the weight of this recommendation likely would have trickled 
down to the local level, where provincial health departments (lacking the knowledge needed to 
fully evaluate such a request) would feel compelled to offer the best care possible. Eventually lay 
people would discover this technology was being used, well-after its implementation, but many 
would presume that someone evaluated the practice for its moral and social consequences. 
Opposing voices would have little hope of influencing policy after implementation.     
 Not only do prevailing social norms shape individual's way of thinking, but individual 
choices also shape the society we live in. Individuals make decisions for themselves, but they are 
also making political and social decisions that have the potential to indisputably change the 
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world we live in.(156) In her review of xenotransplantation, Starzomski explains how one 
individual seeking out treatment in another country where the technology is legal can lead to 
catastrophic implications for the home community and even the world, given the potential for 
new viruses to emerge.(290) The consequences of prenatal screening are less obvious and require 
more investigation, but are similarly profound. It is difficult to discern if there are fewer 
individuals living with Down syndrome in our communities without large and sophisticated 
research able to accurately identify cases of TOPFA and the factors contributing to observed 
trends. Still the disappearance of such individuals represents an important loss, especially to 
other families within the Down syndrome community and to those living with other disabilities. 
If we hope to genuinely optimize reproductive options for women, it will be important that we 
attend to any systematic imbalances that favour TOPFA over socially supportive environments 
and a culture that embraces all individuals equally. Further qualitative research should be done in 
Saskatchewan to deepen our understanding of the reasons that women choose to screen or not, 
and their experiences along the prenatal screening pathway, including the decision to continue or 
terminate a pregnancy following prenatal diagnosis.  
 While screening, in its current form, is limited to a small number of conditions, de Jong 
et al (2010) warn that the new non-invasive prenatal diagnosis (NIPD) exacerbates the moral 
challenges presented by traditional prenatal serum screening.(226) Because NIPD is easier, safer, 
and can occur earlier in the pregnancy, the fear is that informed consent may become harder to 
achieve and selective abortion normalised. However, there is a real likelihood that this 
technology will expand to include testing for a much broader range of abnormalities, genetic 
risks and non-medical traits. In this case, informed consent might be nearly impossible to 
achieve, given the herculean challenge of explaining to women the implications of numerous 
conditions and the inability to predict outcomes with any degree of certainty. de Jong et al (2010) 
put forth an urgent call for proactive analysis of the implications of NIPD in an expanded form, 
and further ethical dilemmas that will emerge.(226) We cannot foretell what form future testing 
will take, but we can appreciate the urgent need to be prepared with an engagement process and 
decision-making framework able to respond to the next controversy. 
Individual autonomy is an important principle that supports individual freedom, but it is 
not enough to justify a practice that will profoundly change the way we live together as a society 
and our treatment of a most vulnerable sector of our population (the fetus). The social 
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implications of prenatal screening today, and even more so tomorrow as technology advances, 
are too immense to force upon individuals who may or may not be aware of their social and 
historical embeddedness. It is our moral obligation to seek authentic input from individuals and 
communities within a well-informed context, not only on specific issues but common values. 
When controversial issues are dealt with strictly on an individual basis, there is greater risk that 
other voices from the broader society will be ignored and potentially reshaped by those of 
science and markets. As public health professionals, practitioners, academics, and citizens, it is 
our responsibility to move forward debates about public involvement and call for a culture of 
public consultation, where all Canadians are invited to shape policies around prenatal screening 
and genomics, helping to shape the scientific and medical agenda early on. 
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APPENDIX A - 
TECHNICAL DESCRIPTION, SASKATCHEWAN MINISTRY OF HEALTH 
 
 
Examination of Population-Based Outcomes of a 
Provincial Prenatal Screening Program (SR 05-011) 
N. Muhajarine and B. Winquist (Ph.D. Candidate), University of Saskatchewan 
 
 
GENERAL FEATURES 
 
1. Time Period: Subject inclusion:  January 1, 2000 to December 31, 2005 
History:  January 1, 2000 to December 31, 2006 
2. Databases: Person registry 
Hospital separation data 
Physician services data 
Vital Statistics (birth registration data) 
Vital Statistics (death registration data) 
Provincial Lab maternal serum screening test data (May 1, 2001 to March 31, 2005 
only)   
RHA amniocentesis data (January 1, 2001 to December 31, 2005 for Saskatoon 
Health Region data; October 1, 2001 to December 31, 2005 for Regina 
Qu’Appelle Health Region data)  
3. Sex:   Females 
Babies – both males and females 
4. Age:   Women – all ages 
Babies – 0 to 365 days old 
5. Population: Saskatchewan Health covered population 
 
 
OBJECTIVES 
 
Maternal serum screening (MSS) is a screening method used to identify women at an increased risk for 
pregnancies with congenital anomalies and offer these women follow-up diagnostic testing.  The 
Saskatchewan MSS program first became available to all pregnant women throughout the province early 
in 2001.  The first MSS tests recorded were in May 2001. 
 
While Saskatchewan’s infant mortality rate has traditionally been higher than the national average, it is 
hypothesized that at least part of this difference is due to Saskatchewan’s lower uptake of prenatal 
screening technologies.  For the same reason, infant mortality rates and rates of congenital anomalies may 
vary across health regions within Saskatchewan.  The primary objective of this Study is to assess whether 
or not Saskatchewan’s prenatal screening program has a measurable impact on population health 
outcomes.  There are four broad research questions being examined: 
 What effect, if any, does the MSS program have on the population? Specifically, has the program 
resulted in measurable decreases in the live birth prevalence of infants with congenital 
anomalies?  Has the program resulted in a change to annual infant mortality rates?   
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 What are the patterns of utilization of prenatal screening by Saskatchewan women?  Might 
differences in uptake help to explain variations in the live birth prevalence of congenital 
anomalies or infant mortality rates? 
 Are there unique characteristics of the province (e.g., large rural population, challenges in care 
accessibility) and its people (e.g., aboriginal culture, values) that contribute to or detract from the 
program utilization? 
 What are the social, legal and ethical implications for current and future policy and practice?   
 
STUDY OUTLINE 
 
The population-based cohort for this Study is all female residents, eligible for Saskatchewan Health 
benefits coverage, who either delivered a baby (live or stillborn) or experienced a pregnancy termination 
(spontaneous, medical and/or “other or unspecified” abortion) between January 1, 2000 and December 31, 
2005, inclusive.  Women will be identified using the Vital Statistics (live birth and stillbirth data), person 
registry, hospital separation, and physician services files as described below.  
 
Identification of women with births and stillbirths during the study period 
Saskatchewan Health beneficiaries who delivered a live born or stillborn baby in Saskatchewan between 
January 1, 2000 and December 31, 2005 will be identified using the Vital Statistics birth registration file. 
Vital Statistics birth and stillbirth registration data for out-of-province births/stillbirths to Saskatchewan 
residents will be included where the data are available. Adoptions will be excluded because it is not 
possible to link the baby with his/her birth mother. (From 1999 to 2003, public adoptions dropped from 
66 to approximately 20 per year.) For birth and stillbirth events, the index date for the mothers will be 
defined as the date of baby birth or stillbirth. 
 
Identification of women with abortions during the study period 
Saskatchewan Health beneficiaries who had a spontaneous, medical or other/unspecified abortion during 
the study period of January 1, 2000 and December 31, 2005 will be identified using hospital separation 
and physician services data as follows. 
 
Spontaneous abortion subjects will be identified as female Saskatchewan Health beneficiaries who had 
one or more physician service or hospital separation record with any of the following diagnostic and/or 
procedure codes during the study period: 
 
Spontaneous abortion codes 
ICD-9 code ICD-10-CA code Fee-for-Service code 
632 O02.1 350P 
634.x O03.x  
 
Medical abortion subjects will be identified as female Saskatchewan Health beneficiaries who had one 
or more hospital separation record with any of the following ICD-9 or ICD-10-CA diagnostic codes 
during the study period. In Saskatchewan, medical abortions are performed as day surgery or inpatient 
procedures. Subjects who had a medical abortion in Saskatchewan will, therefore, be identified only 
through the hospital separation data using the ICD-9 or ICD-10-CA codes listed below. 
 
Subjects who had a medical abortion outside Saskatchewan will be identified using both hospital 
separation data (using the ICD-9 and ICD-10-CA codes listed below) and physician services data. 
Physician services data with the following ICD-9 and/or fee-for-service codes will used only to identify 
medical abortions performed outside Saskatchewan. Physician services data will not be used to identify 
medical abortions performed in Saskatchewan. 
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Medical abortion codes 
ICD-9 code ICD-10-CA code Fee-for-Service code 
635.x O04.x 50P 
  250P 
 
Other and unspecified abortion subjects will be identified as female Saskatchewan Health beneficiaries 
who had one or more physician services or hospital separation records with any of the following 
diagnostic codes during the study period: 
 
Other and unspecified abortion codes 
ICD-9 code ICD-10-CA code Fee-for-Service code 
636.x O05.x  
637.x    
 
The three types of abortion events (i.e., spontaneous, medical and other/unspecified) will first be 
identified separately and will then be combined into a single “abortion event file” as described below. 
 
Spontaneous (SA), medical (MA) and other/unspecified (OA) abortion records from the physician 
services and hospital separation data will be processed separately using a “90-day rule” to collapse 
records into MA, SA, and OA episodes. The 90-day rule will be applied as follows: if a woman has two 
or more physician service and/or hospital separation records for a given type of abortion, the record with 
the earliest service date is identified as the index date and all records for the same type of abortion (MA, 
SA, or OA) within 90 days following the index date will be considered part of the same episode. 
 
The resulting three abortion episode files (i.e., one file each for SA, MA and OA episodes) will then be 
combined into a single abortion event file using a 90 day rule to collapse overlapping episodes. The 90-
day rule will be applied as follows: if a woman has two or more abortion episodes, the episode with the 
earliest index date will be considered the “index abortion event” and any other episodes occurring 
within the following 90 days will be considered part of that abortion event. In these cases, flags on the 
subject file will indicate that one or more abortion episodes were identified in the 90 day period following 
the “index abortion event” (i.e., flags will identify the type of abortion, number of days after the index 
date and data source (physician service record vs. hospital separation record). 
 
The abortion event file will then be combined with the birth/stillbirth file as follows to create a 
comprehensive subject file. In instances where an abortion event for a woman occurs within 180 days 
before or 90 days after the date of birth/stillbirth, the abortion will be considered part of the birth/stillbirth 
event. In these cases, the abortion event will be included in the abortion subject file, but it will have the 
same study identification number as the corresponding birth/stillbirth record for that woman. 
 
Preparation of subject files 
The comprehensive subject file will then be used to create two subject files for women: one file relating to 
women who had birth/stillbirth events and one file relating to women who had abortion events during the 
study period. Note that a woman may be included in the study more than once (e.g. for two or more birth, 
stillbirth, or abortion events). Women included in the study more than once will have a different study 
identification number assigned for each event. The exception to this is abortion events that occur up to 
180 days before or 90 days after the date of birth/stillbirth. In these cases, the abortion record is 
considered likely to be part of the birth/stillbirth event and is assigned the same study identification 
number as the corresponding birth/stillbirth event. 
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For women, the study entry date will be the later of January 1, 2000 or health coverage initiation date up 
to December 31, 2005.  A study exit date will be set to the index date of the livebirth, stillbirth, or 
abortion event. As noted above, women with more than one event during the study period are included 
once for each qualifying event. In these cases, a study exit date corresponding to the index date of each 
event is assigned and the study entry date for the second event will be set to the later of 90 days after the 
first event or the health coverage initiation date, the study entry date for the third event will be set to the 
later of 90 days after the second event or the health coverage initiation date, and so on. 
 
A baby subject file containing demographic and birth/stillbirth information for the liveborn and stillborn 
infants will also be created. For babies, a study exit date is set to the earliest of the date of death, date of 
emigration from the province, or one year after birth. 
 
Compilation of service information 
For women, hospital separation, physician services, and MSS test data will be compiled from the study 
entry date to the study exit date.  Amniocentesis data from the Cytogenetic Laboratory, Saskatoon Health 
Region and from the Regina General Hospital, Regina-Qu’Appelle Health Region will also be compiled 
from January 1, 2001 to December 31, 2005 and from October 1, 2001 to December 31, 2005, 
respectively. A flag will be included on the mother’s subject file to indicate a mother’s registered Indian 
status. MSS test data to be provided are shown in Table 3. Residence information to be compiled for 
subjects will be based on the Regional Health Authority (RHA) of mother's residence as of December 31 
of the year of the subject’s study exit date. 
 
For babies, hospital separation, physician services and vital statistics data will be compiled for the period 
beginning on the date of birth and ending on their study exit date.  For babies whose study exit is due to 
death, cause of death will be determined from the death registration file.   
 
For both women and babies, diagnoses of interest are reported by specific codes or grouped (Table 1). All 
other codes or records will be suppressed. 
 
For women, specific hospital procedure codes that may affect pregnancy outcome (CCP and CCI), and, 
for both women and babies, physician fee-for service (FFS) codes of interest are reported by specific 
codes or grouped (Table 2). All other records are suppressed.  
 
 
Note:   
- Not all services provided by Saskatchewan physicians are captured in the Medical Services Branch 
data.  Some physicians are on contract and/or alternative payment arrangements and either do not 
submit claims at all or do not consistently submit shadow/dummy claims. 
 
 
DATA TO BE RELEASED TO THE RESEARCHER 
Note: 
- Release of any information for analyses off-site is dependent on cell size issues being addressed 
to comply with legislation and departmental policies and procedures.  Depending on small 
number issues, aggregation of certain variables (e.g., mother’s age group, residence, diagnoses, 
etc.) will be carefully considered.  These issues will be assessed and discussed at the time when 
data are being compiled. 
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Aggregate Data  
Aggregate data on congenital anomalies will be compiled in order to provide information on trends in the 
birth prevalence of congenital anomalies and how rates naturally fluctuate overtime.  The aggregate data 
will be at the RHA and provincial level and will be compiled by year from 1990 to 2005 for live births 
and from 2000 to 2005 for stillbirths with the following categories of congenital anomalies:  Down 
syndrome, neural tube defects, oral facial clefts, congenital heart defects, and limb reduction defects.  
Data on live births will be based on hospital separation data during the first year of life.  Data on 
stillbirths will be based on hospital delivered stillbirths identified in hospital separation data. (Stillbirths 
have only been coded in hospital data since the 1999/00 fiscal year.)   
 
Person-Level Research Datasets 
Subject file #1 – women – birth and stillbirth events 
Unique Mother Study ID number
58
 
Unique Baby Study ID number
1
 
Count (number of times mother in study; may be grouped) 
Age Group [calculated as of the exit date and grouped (e.g., <20, 20-24, 25-29, 30-34, 35-39, 40+)] 
RHA of residence as of December 31 of the year of the exit date (may need to be grouped) 
Study days (This field reports the number of days from the study entry date to the study exit date. The 
study entry date is defined as the later of January 1, 2000 or actual coverage initiation; for 
women with more than qualifying event in the study, the study entry date for the second event is 
set to the later of 90 days after the first event or the health coverage initiation date, the study 
entry date for the third event is set to the later of 90 days after the second event or the health 
coverage initiation date, and so on.) 
Study exit date (reported as the year of the birth/stillbirth event) 
Registered Indian Flag (1=yes) 
Event flag (B=birth,S= stillbirth) 
MSS test flag (1=yes) 
 
Subject file #2 – women – abortion events 
Unique Mother Study ID number
1
 
Count (number of times mother in study; may be grouped) 
Age Group [calculated as of the exit date and grouped (e.g., <20, 20-24, 25-29, 30-34, 35-39, 40+)] 
RHA of residence as of December 31 of the year of the exit date (may need to be grouped) 
Study days (This field reports the number of days from the study entry date to the study exit date. The 
study entry date is defined as the later of January 1, 2000 or actual coverage initiation; for 
women with more than qualifying event in the study, the study entry date for the second event is 
set to the later of 90 days after the first event or the health coverage initiation date, the study 
entry date for the third event is set to the later of 90 days after the second event or the health 
coverage initiation date, and so on.) 
Study exit date (reported as the year of the abortion event) 
Registered Indian Flag (1=yes) 
MSS test flag (1=yes) 
                                               
58
 The study ID numbers are sequential study reference number assigned for this study by the Epidemiology and 
Research Unit. The study ID numbers bear no resemblance to an individual's HSN. For women with more than one 
event included in the study, a new Study ID number will be generated for each qualifying event. There will be no baby 
ID for those pregnant women whose pregnancy ends in an abortion. 
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Index abortion type (M=medical; S=spontaneous; O=other/unspecified) 
Source (D=physician services; H=hospital separation) 
Days1 (date of first overlapping abortion episode; reported as the number of days after the date of 
the index abortion event) 
Source1 (D=physician services; H=hospital separation) 
Abortion type1 (M=medical; S=spontaneous; O=other/unspecified) 
Days2 (date of second overlapping abortion episode; reported as the number of days after the date of 
the index abortion event) 
Source2 (D=physician services; H=hospital separation) 
Abortion type2 (M=medical; S=spontaneous; O=other/unspecified) 
 
Hospital discharge file - women 
Unique Mother Study ID number
1
 
Admission date (reported as the number of days before the study exit date) 
Discharge date (reported as the number of days before the study exit date) 
Diagnostic code (all available) 
Diagnostic type (0=optional, 1=pre-admit comorbidity, 2=post-admit comorbidity, 3=secondary, 
6=asterisk code, 9=external cause of injury) 
Procedure categories (all available) 
Diagnosis flag (ICD-9/ICD-10-CA) 
Day surgery flag 
Physician services file - women 
Unique Mother Study ID number
1
 
Service date (reported as the number of days before the study exit date) 
Diagnostic code  
Fee-for-service code 
 
MSS lab file - women – see Table 3. 
 
Amniocentesis file - women 
Unique Mother Study ID number
1
 
Date tested (reported as the number of days before the study exit date) 
Indication (Reason for test: Abnormal Ultrasound [AUS], Advanced Maternal Age [AMA], fetal 
anomaly, positive maternal screen, etc.) 
Gestational age (at test date; only available on SHR data) 
Fetus sex (male, female; only for RQHR data, SHR provides this in the Karyotype field) 
Cytogenetic result (normal or abnormal - only available on RQHR data) 
Amniocentesis diagnosis (e.g., Trisomy 21, Trisomy 18, etc. Provided only if cytogenetic result was 
abnormal; only available on RQHR data) 
Karyotype (Amnio. result; e.g., 46XX-female normal, 46XY-male normal, 47XX+18, 47XY+18, 
47XX+21, 47XY+21, etc.; only available on SHR data) 
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Subject file - babies (Vital Statistics birth/stillbirth information included in this file) 
Unique Baby Study ID number
1 
Date of birth/stillbirth (provided as year; may need to be grouped or not provided) 
Stillbirth flag (1=Yes) 
Sex (male or female) 
Study exit date (reported as the number of days after baby’s date of birth; blank for stillbirths) 
Exit flag (0=study exit, 1=death, 2=coverage termination; blank for stillbirths) 
Birth weight (grouped as <500, 500-999, 1000-1499, 1500-2499,2500-3999, 4000+ grams) 
Gestational age (duration of pregnancy in weeks; grouped) 
Mother’s parity (number of previous births (live & stillbirths) including current birth; grouped) 
Plurality (single or multiple births) 
 
Hospital discharge file - babies (age 0-365 days) 
Unique Baby Study ID number
1 
Admission date (reported as the number of days after baby’s date of birth) 
Discharge date (reported as the number of days after baby’s date of birth) 
Diagnostic code (all available) 
Diagnostic type (0=optional, 1=pre-admit comorbidity, 2=post-admit comorbidity, 3=secondary, 
6=asterisk code, 9=external cause of injury) 
Diagnosis flag (ICD-9/ICD-10-CA) 
Day surgery flag 
 
Physician services file - babies 
Unique Baby Study ID number
1 
Service date (reported as the number of days after baby’s date of birth) 
Diagnostic code 
Fee-for-service code 
 
Death registration file - babies 
Unique Baby Study ID number
1 
Age at death (grouped as 0 days, 1-6 days, 7-27 days, 28-364 days, 365 days) 
Underlying cause of death  
Multiple causes of death (all available) 
Autopsy flag 
Autopsy used (identifies whether or not autopsy finding was used in determining the cause of death) 
RHA of mother’s residence 
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APPENDIX B –  
TABLE OF DIAGNOSTIC AND PROCEDURAL CODES  
Table 1: Diagnostic reporting: The following ICD-9 and ICD-10 codes will be reported for specific codes of 
interest or grouped as specified; all others will be suppressed. 
Category MSP 
Assigned 
Codes* 
ICD-9** ICD-10-CA Description 
Infants:     
DG01  740.x, 742.0 Q00-Q01.x Anencephalus & encephalocele  
DG02  741.x Q05.x Spina bifida  
DG03  758.0 Q90.0-Q90.2; 
Q90.9 
Down's syndrome - Trisomy 21  
DG04  758.2 Q91.0-Q91.3 Edwards' syndrome - Trisomy 18  
DG05  745-747.x Q20-Q28.x Congenital malformations of circulatory system 
DG06  752.x Q50-Q56.x Congenital malformations of genital organs 
DG07  742.1-742.9 Q02-Q04.x, 
Q06.x, Q07.x 
All other congenital anomalies of nervous 
system 
DG08  758.1, 758.3-
758.9 
Q91.4-Q99.x All other chromosomal anomalies 
DG09  743-744.x, 748-
751.x, 753-
757.x, 759.x 
Q10-Q19.x, 
Q30-Q45.x, 
Q60-Q89.x 
All other congenital anomalies 
DG10  779.6 P96.4 Other conditions originating in the perinatal 
period - termination of pregnancy, fetus and 
newborn 
DG11  761.8 P01.8 Fetus and newborn affected by other maternal 
complications of pregnancy - spontaneous 
abortion, fetus 
DG12   P95 Stillbirth 
DG13   760-761.7, 
761.9-779.5, 
779.8, 779.9 
P00-P01.7, 
P01.9-P94.9, 
P96-P96.3, 
P96.5-P96.9 
Other fetus or newborn conditions originating in 
the perinatal period (i.e., the time period around 
birth up to 7-10 days after birth) 
*Medical Services assigns codes for the identification of specific conditions that are grouped within 
general categories within the International Classification of Diseases. Available on the physician services 
file only. 
**Four digit ICD-9 codes are only available on the hospital file; physician file has only three digit 
diagnoses. Therefore, on the physician file, four digit codes will have to be grouped (e.g., ICD-9 742.0 
will be grouped in DG07; ICD-9 758.0 and 758.2 will be grouped into DG08; ICD-9 761.8 and 779.6 will 
be grouped in DG13; 656.4 will be grouped in DG22; DG21 will include all of V28 on the physician file). 
Note also that V27 is not a valid code in the Medical Services data. V26 will not be provided on the 
physician file because the three-digit code is too broad to fit into either DG21 or DG23. 
***DG19 Antenatal screening: ICD-9 codes - flag that screening was done; ICD-10-CA codes - flag for 
abnormal findings on antenatal screening of mother. 
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Category MSP 
Assigned 
Codes* 
ICD-9** ICD-10-CA Description 
Women:     
DG14 Z62 656.4, V27.1, 
V27.3, V27.4, 
V27.6, V27.7 
O36.42, O36.43, 
O36.49, Z37.1, 
Z37.3-Z37.4, 
Z37.6-Z37.7x 
Stillbirth 
    Pregnancy with Abortive Outcome 
(pregnancy termination): 
DG15  630, 631, 633 O00.x, O01.x, 
O02.0, O02.8 - 
O02.9 
Non-viable pregnancy 
DG16  632, 634.x O02.1, O03.x Spontaneous abortion/miscarriage 
DG17  635.x O04.x Medical/Therapeutic or other 
abortion  
DG18  636.x, 637.x O05.x Other or unspecified abortion 
DG19  638 O07.x Failed attempted abortion 
DG20   O31.1, O31.2 Continuing pregnancy after 
abortion or intrauterine death of one 
fetus or more 
DG21  V26.3, V28.0-
V28.2, V28.8-
V28.9, V83-V84.x 
O28.x, Z36.x, 
Z31.5 
Antenatal screening & abnormal 
findings*** 
DG22  639-656.3, 656.5-
676.x, 678-679.x, 
V23.x 
O08-O27.x, O29-
O31.0, O31.8-
O36.41, O36.5-
O99.x, Z35.x 
All other pregnancy/childbirth 
related complications 
DG23  V26.1, V26.8 Z31.1, Z31.2, 
Z31.3 
Assisted reproductive therapy 
DG24 Z22       Pregnancy exam 
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Table 2:  Hospital procedures and physician fee-for-service codes of interest to be grouped and 
reported; all others will be suppressed. 
Category CCP CCI FSC* Description 
Women only:    
PG01   241P Stillbirth 
PG02   350P Spontaneous abortion 
PG03 81.21, 
86.3 
5.CA.93.^^ 48P, 248P Ectopic gestation removal 
PG04 86.4x, 87-
87.2x 
5.CA.88.^^, 
5.CA.89.^^, 
5.CA.90.^^ 
50P, 250P Therapeutic/medical abortion 
PG05 87.56 5.FG-5.FM.^^ n/a Surgical repair of Fetus 
PG06 87.3 5.AB.02.^^ 57P, 58P, 59P, 
44W 
Amniocentesis 
PG07 84-86.2x, 
86.8-
86.9x, 
87.4-
87.55, 
87.57-
87.99 
5.AB-5.AB.01.^^, 
5.AB.03.x--
5.AD.14.^^, 5.FB-
5.FD.^^, 5.FT-
5.MD.^^ 
3B, 9B, 5P, 8B, 8P, 
13P, 40P-47P, 49P, 
51P-55P, 118P, 
200P-218P, 246P, 
258P, 269P, 279P, 
580P 
Other obstetric-related procedures 
PG08   149W Nuchal translucency screen 
PG09 n/a n/a 40W, 47W, 48W, 
41W, 45W, 46W, 
446W, 50W 
Other diagnostic procedures related 
to pregnancy 
PG10 81.92 1.RM.83.^^, 
1.RB.57.^^ 
108P Assisted reproductive therapy 
          
Women and infants:    
PG11 n/a n/a 5G, 7G, 9G, 11G, 
13G, 38G, 39G, 
40G, 50G 
Genetic assessment** 
*Data from physician FFS’s has now been added to provide some information on numbers of tests 
performed for subjects included.  Only counts of tests performed, NOT results, can be provided from the 
above databases.  Some of the amniocentesis test results available in Saskatchewan will, instead, be 
obtained directly from the Saskatoon Health Region.  In addition, since pregnancy outcomes are of 
interest, it was thought that FFS codes related to terminations and complications related to pregnancy 
could be added. Information would be beneficial. 
**Data on whether genetic assessments were ordered for infants for up to 1 year after birth could be 
compiled if desired, so this has also been included in the FFS codes (as for the amniocentesis information 
based on physician claim data, these data will NOT include results). 
[Website for FFS codes: http://www.health.gov.sk.ca/ic_pub_2005oct1_pps.html] 
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Table 3. Maternal serum screening test data for release (May 2001 to March 2005): Two files - 
Patient and Results 
MSS Test Field/Variable 
Description 
MSS Evaluation PRA DB V29Jul05 Loc. 
Variable Name Table Name Field # 
MSS PATIENT TABLE       
Unique mother study ID 
number 
STUDYID n/a n/a 
Was the fetus affected with 
anencephaly? (0,1) ** 
ANENCEPH_RESULT FETUS 32 
Was the fetus affected with 
Cleft Lip? (0,1) ** 
CLEFT_LIP_RESULT FETUS 37 
Was the fetus affected with 
Closed Spina Bifida? (0,1) 
** 
CSB_RESULT FETUS 34 
Was the newborn infant 
affected with Down 
Syndrome? (0,1) ** 
DS_RESULT FETUS 14 
Was the fetus affected with 
encephalocele? (0,1) ** 
ENCEPHALOCELE_RESULT FETUS 40 
Gravida (number of times 
patient has been pregnant) 
GRAVIDA PREGNANCY 4 
Last menstrual period 
(reported as the number of 
days prior to study exit 
date) 
LMP_DATE PREGNANCY 5 
How many fetuses are 
there? (Multiple pregnancy: 
-1 to 5) 
MULTIPLE (-1 TO 5) PREGNANCY 12 
Was the newborn infant 
affected with Neural Tube 
Defect? (0,1) ** 
NT_RESULT FETUS 15 
Delivery type code (0-13) 
** 
OUT_DELIVERY FETUS 23 
Karyotype of the fetus (1-8) OUT_KARYOTYPE FETUS 28 
Gestational age in weeks at 
date of delivery ** 
OUT_WEEKS FETUS 25 
Para (number of live 
children the patient has) 
PARA PREGNANCY 3 
Gestational age as of the 
date of physical exam 
(reported in days) 
PE_GA PREGNANCY 8 
Pregnancy outcome (result 
of pregnancy) ** 
PREG_OUTCOME PREGNANCY 20 
Race Flag (for racial origin; 
Aboriginal 1 = Yes; all 
others suppressed) 
RACE_FLG RACE 4 (PK) 
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Was the fetus affected with 
Trisomy 13? (0,1) ** 
T13_RESULT FETUS 36 
Was the newborn infant 
affected with Trisomy 18? 
(0,1) ** 
TRI18_RESULT FETUS 16 
Ultrasound gestational age 
(reported in days) 
US_GA FETUS 4 
 ** Data are not complete 
for these fields. 
      
        
MSS RESULTS TABLE       
Unique mother study ID 
number 
STUDYID n/a NEW 
Patient age at expected date 
delivery (grouped) 
AGE_EDC INTERPRETATION 16 
Age equivalent risk - the 
maternal age that is 
equivalent to the calculated 
risk after screening 
AGEEQUIV INTERPRET_CONDITION  9 
Is this an amended result? AMENDED     
The risk before screening: 
for DS, and T18, this is the 
age-based risk; for OSB, 
this is the population 
prevalence.  
BACKGROUND_RISK INTERPRET_CONDITION 11 
Condition ID # (1 = Down 
Syndrome (DS); 2 = Open 
spina bifida (OSB) or 
neural tube (NT) defect; 3 = 
Trisomy 18 (T18)) 
COND_ID INTERPRET_CONDITION 4 (K) 
Screening results for current 
interpretation version 
CURRENT_RESULT INTERPRETATION 49 
Gestational age as of the 
specimen date (reported in 
days) 
GA INTERPRETATION 10 
Gestational age 
determination date 
(reported as the number of 
days prior to the study exit 
date) 
GA_DET_DATE INTERPRETATION 42 
Method of estimation of 
gestational age (0-9) 
GA_EST_METHOD INTERPRETATION 5 
Initial screening status 
(First screen result) (0-19) 
INIT_SCRNSTAT INTERPRETATION 33 
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The interpretative message 
number related to the test 
result(s) for physician - 
OSB, T18, DS (look up 
codes in Message Table to 
be included in the file 
layout document) 
MSGID INTERPRET_CONDITION 14 
Version of the interpretive 
message 
MSGVER     
Reference MOM (i.e., user 
defined MoM cut-off for 
OSB) 
REFMOM INTERPRET_CONDITION 16 
Reference risk (i.e., user 
defined cut-off for OSB, DS 
& T18; Results above will 
be positive) 
REFRISK INTERPRET_CONDITION 13 
Requisition identifier 
number 
REQ_ID     
Calculated risk after 
screening 
RISK INTERPRET_CONDITION 10 
Risk qualifier printed on the 
report (OSB 0-4; DS 0-6; 
T18 0-4) 
RISKFLAG INTERPRET_CONDITION 7 
Risk qualifier printed on the 
report for age-based risk of 
DS (0-5) 
RISKFLAG4 INTERPRET_CONDITION 8 
Screen Result for OSB, DS, 
T18 (0-4) 
SCREEN INTERPRET_CONDITION 12 
Current screening status 
(Initial sample, 
repeat…etc.; 0-19)   
SCRNSTAT INTERPRETATION 32 
Date of MSS specimen 
collection (reported as the 
number of days prior to 
study exit date) 
SPEC_DATE SPECIMEN 5 
Specimen flag for number 
of specimens taken per 
requisition per patient 
SPEC_FLG [created] NEW 
Specimen type (1= serum; 2 
= amniotic fluid)  
SPEC_TYPE SPECIMEN 4 
Date of ultrasound (reported 
as the number of days prior 
to study exit date) 
US_DATE INTERPRETATION 53 
Ultrasound gestational age 
in days  (reported if 
available) 
  n/a n/a 
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APPENDIX C-  
SPECIFICATIONS SHEET, CANADIAN INSTITUTE FOR HEALTH INFORMATION 
 
Canadian Institute for Health Information              
Data Request Specifications Form                                            Date: April 19, 2012 
Aggregate Data                                                   Prepared By:  Decision Support Services   
       
 
Specifications Status: FINAL 
 
Requestor’s Organization:  University of Saskatchewan 
Requestor’s Name (GSDAP student):  Brandace Winquist 
Requestor’s Supervisor:  Dr. Nazeem Muhajarine 
Project Title:  Population-based outcomes of a provincial prenatal screening program: examining impact, 
uptake and ethics. 
 
Database(s):   
 Discharge Abstract Database (DAD) 
 Hospital Morbidity Database (HMDB) 
 National Ambulatory Care Reporting System (NACRS) 
  
Level(s) of Care (facility type):   
 DAD/HMDB 
o Acute Care (All submitting provinces/territories) 
o Day Surgery (All submitting provinces/territories) 
 NACRS (All submitting provinces/territories) 
 
Calendar Year(s):  
 DAD/HMDB: 2000 to 2010 
 NACRS: 2003 to 2010 
 
Scope:   
 All acute inpatient and day surgery Therapeutic Abortions (TA) records associated with 
Saskatchewan residents submitted to the DAD/HMDB during the study period. 
 All Therapeutic Abortions (TA) records associated with Saskatchewan residents submitted to NACRS 
during the study period. 
 
Output Format:   
 Excel format. 
 
Details of Data Request: 
 
Inclusions: 
 
 All acute inpatient and day surgery Therapeutic Abortions records (including Deaths) associated with 
Saskatchewan residents regardless of the submitting province/territory. 
 
o DAD/HMDB Records 
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 Acute Inpatient / Day Surgery – ICD-10-/CA/CCI  
 Diagnosis Code = O04.^^ AND 
 Diagnosis Type = M, 1, 2, W, X, Y, or C  
CODED IN CONJUNCTION WITH 
 Intervention Code = 5.CA.88.^^, 5.CA.89.^^, 5.CA.20.^^, or 5.CA.24^^ 
Additional diagnoses codes to identify those records where Congenital Anomaly was 
recorded.  
 Diagnosis Code = O35.^^ AND 
 Diagnosis Type = Any 
 Analytical Institution Type = Acute Inpatient / Day Surgery 
 Submitting Province/Territory = All 
 Calendar Year = 2001 to 2010 
 
 Acute Inpatient / Day Surgery – ICD-9/CCP 
 Diagnosis Code = 635.^^ AND 
 Diagnosis Type = M, 1, 2, W, X, or Y  
CODED IN CONJUNCTION WITH 
 Intervention Code = 10.56, 87.0, 81.93, 87.1, 87.21, 85.5, 87.29, 86.41, 86.42, or 81.7 
Additional diagnoses codes to identify those records where Congenital Anomaly was 
recorded.  
 Diagnosis Code = 655.^^ AND 
 Diagnosis Type = Any 
 Analytical Institution Type = Acute Inpatient / Day Surgery 
 Submitting Province/Territory = All 
 Calendar Year = 2000 to 2006 
 
 Saskatchewan Residents 
 Province/Territory Issuing Health Care/Card Number = Saskatchewan  
OR 
 Province/Territory Issuing Health Care/Card Number = CA or 99 AND 
 Postal Code = Saskatchewan postal code or Mini-Code (SK) 
 
 
o NACRS Records 
 Therapeutic Abortions (TA) – ICD-10-CA/CCI 
 Diagnosis Code = O04.^^ AND 
CODED IN CONJUNCTION WITH 
 Intervention Code = 5.CA.88.^^, 5.CA.89.^^, 5.CA.20.^^, or 5.CA.24^^ 
Additional diagnoses codes to identify those records where Congenital Anomaly was 
recorded.  
 Diagnosis Code = O35. ^^ 
 MIS Functional Centre = All 
 Submitting Province/Territory = All 
 Calendar Year = 2003 to 2010 
 Saskatchewan Residents 
 Province/Territory Issuing Health Care/Card Number = Saskatchewan  
OR 
 Province/Territory Issuing Health Care/Card Number = CA or 99 AND 
 Postal Code = Saskatchewan postal code or Mini-Code (SK) 
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Exclusions:   
 Exclude stillbirths and cadaveric donations. 
 Exclude records where the specified intervention was cancelled, abandoned, previous or performed 
out of hospital (OOH). 
 
Groupings: 
 Gestational Age: <=11 weeks, 12-14 weeks, 15-19 weeks, and 20+ weeks (provided by B. Winquist) 
 Congenital Anomalies (CA):  ICD-10-CA: O35.^^, ICD-9: 655.^^ 
 
Format of Output: 
 The two reports will be presented in excel worksheets and formatted as shown below: 
o Report 1 – TAs performed in Saskatchewan (Saskatchewan residents only) 
o Report 2 – TAs performed in Canada (Saskatchewan residents only) 
 Each Classifications System (ICD-9/CCP, ICD-10-CA/CCI) will have its own report(s). 
 
Number of SK Residents that had a TA performed and had a CA diagnosis recorded 
Gestational 
Age 
CA 
Diagnosis Code 
Calendar Year 
2000 … 2010 
<=11 wks. O35.00    
 …    
 Other    
12-14 wks. O35.00    
 …    
 Other    
15-19 wks. O35.00    
 …    
 Other    
20+ wks. O35.00    
 …    
 Other    
 
METHODOLOGICAL NOTES AND DATA LIMITATIONS 
 
 If several abstracts for one patient meet the selection criteria and occurred within 28 days, only the 
first one is retained.  This avoids counting the same termination of pregnancy multiple times. 
 The findings are limited by the availability of the input data. 
 
NOTES: 
 
To comply with CIHI’s Privacy and Confidentiality Policies, in instances in which there are fewer than 5 
cases to report in a cell, Decision Support Services will review the output and determine whether or not 
the number of cases will be suppressed. 
 
Description of Diagnosis Types 
 
Diagnosis Types:  Diagnosis type is a one-digit code used to indicate the relationship of the diagnosis to 
the patient’s stay in hospital. 
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 M – Most Responsible Diagnosis: The one diagnosis or condition that can be described as being the 
most responsible for the patient’s stay in hospital.  In the event that multiple diagnoses are listed, the 
most responsible diagnosis from the condition associated with the longest length of stay or most 
resource intensity will be designated as the Most Responsible. 
 1 – Pre-admit Comorbidity: A diagnosis or condition that existed prior to the patient’s admission to 
hospital, and which satisfies the requirements for determining comorbidity (see note below on 
comorbidities). 
 2 – Post-admit Comorbidity:  A diagnosis or condition that arises post-admission and satisfies the 
requirements for determining comorbidity (see note below on comorbidities).  If a post-admit 
comorbidity also becomes Most Responsible Diagnosis, it will be recorded twice: once as the MRDx 
and once a diagnosis type 2. 
 3 – Secondary Diagnosis: A diagnosis or condition for which a patient may or may not have received 
treatment and does not satisfy the requirements for determining comorbidity. 
 4 – Morphology code: Diagnosis type (4), morphology codes describe the type and behaviour of 
neoplasm. 
 6 – Asterisk Code (as of 2005-2006): Assigned to an asterisk code on the second line of the 
diagnosis field of the abstract whenever the manifestation rather than the underlying cause is 
responsible for the greatest length of stay and or resources used during hospitalization. 
 9 - External cause of injury code: A diagnosis type (9) is an external cause of injury code.  
 0 – Optional diagnoses (newborns): restricted to Newborn codes only. 
 5, 6 (prior to 2005-06), 7, 8  - Optional diagnoses: Optional diagnosis data 
 W – Diagnosis Associated with First Service Transfer  
 X - Diagnosis Associated with Second Service Transfer 
 Y - Diagnosis Associated with Third Service Transfer 
 
Co-morbidities 
Co-morbidities are all conditions that co-exist at the time of admission or develop subsequently and 
demonstrate at least one of the following: 
 significantly affects the treatment received 
 requires treatment beyond maintenance of the pre-existing condition 
 increases the length of stay by at least 24 hours. 
 
 DEFINITION OF A THERAPEUTIC ABORTION 
 
1. Diagnosis code 635 – Legally induced abortion in ICD-9/ICD-9-CM at the 3rd level digit or 
Diagnosis code O04 – Medical abortion at the 3rd digit level  
AND 
2. Diagnosis type of M, 1, 2, W, X, Y, or C  
 AND 
3. At least one of the following CCP, ICD-9-CM or CCI Intervention codes in any position, not just 
the principal intervention. Any intervention with a status attribute of ‘A’ (procedure abandoned after 
onset) should not be included. 
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INTERVENTION CODES  
 
CCP ICD-9-CM CCI* (at the 5th digit level) 
10.56 – Other genitourinary 
instillation 
96.49 – Other genitourinary 
instillation 
5CA88^^ – Pharmacological 
termination of pregnancy 
87.0 – Intra-amniotic injection 
for termination of pregnancy 
75.0 – Intra-amniotic injection 
for abortion 
5CA89^^ – Surgical termination 
of pregnancy 
81.93 – Insertion of laminaria  69.93 – Insertion of laminaria 5CA20^^ – Pharmacotherapy (in 
preparation for), termination of 
pregnancy 
87.1- Vacuum aspiration for 
termination of pregnancy 
69.01 – Dilation and curettage 
for termination of pregnancy 
5CA24^^ – Preparation by 
dilating cervix (for), termination 
of pregnancy 
87.21 – Dilation and curettage 
for termination of pregnancy 
69.51 – Aspiration curettage of 
uterus 
 
85.5 – Medical induction of 
labour 
73.4 – Medical induction of 
labour 
 
87.29 – Other termination of 
pregnancy NEC 
74.91- Hysterotomy to terminate 
pregnancy 
 
86.41 – Hysterotomy to 
terminate pregnancy 
69.6 – Menstrual extraction or 
regulation 
 
86.42 - Hysterectomy to 
terminate pregnancy 
68.3 – Subtotal abdominal 
hysterectomy 
 
81.7 – Menstrual extraction or 
regulation 
68.4 – Total abdominal 
hysterectomy 
 
 68.51- Laparoscopically assisted 
vaginal hysterectomy (LAVH) 
 
 68.59 – Other abdominal 
hysterectomy 
 
 68.6 – Radical abdominal 
hysterectomy 
 
 68.7 – Radical vaginal 
hysterectomy 
 
 68.9 – Other and unspecified 
hysterectomy 
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CONGENITAL ANOMALIES CODES 
 
ICD-9/ICD-9-CM ICD-10-CA 
655.0^ - Central nervous system malformation in 
fetus.  Includes:  fetal or suspected fetal: 
anencephaly hydrocephalus spina bifida (with 
myelomeningocele) 
O35.00^ - Maternal care for (suspected) fetal 
anencephaly  
 
655.0^ - Central nervous system malformation in 
fetus.   
O35.01^ - Maternal care for (suspected) fetal spina 
bifida  
655.0^ - Central nervous system malformation in 
fetus.   
O35.02^ - Maternal care for (suspected) fetal 
hydrocephalus  
655.0^ - Central nervous system malformation in 
fetus.   
O35.03^ - Maternal care for (suspected) fetal spina 
bifida with hydrocephalus  
655.0^ - Central nervous system malformation in 
fetus.   
O35.08^ - Maternal care for (suspected) other 
neural tube defects in fetus  
655.0^ - Central nervous system malformation in 
fetus.   
O35.09^ - Maternal care for (suspected) central 
nervous system malformation in fetus, unspecified  
655.1^ - Chromosomal abnormality in fetus 
 
O35.1^ - Maternal care for (suspected) 
chromosomal abnormality in fetus 
655.2^ -  Hereditary disease in family possibly 
affecting fetus 
O35.2^ - Maternal care for (suspected) hereditary 
disease in fetus  
655.3^ -  Suspected damage to fetus from viral 
disease in the mother 
Includes:  suspected damage to fetus from maternal 
rubella 
O35.3^ - Maternal care for (suspected) damage to 
fetus from viral disease in mother (maternal 
cytomegalovirus infection, maternal rubella, etc) 
 
655.4^ - Suspected damage to fetus from other 
disease in the mother Includes: suspected damage 
to fetus from maternal: alcohol addiction, 
listeriosis, toxoplasmosis 
O35.4^ - Maternal care for (suspected) damage to 
fetus from alcohol 
 
655.5^ -  Suspected damage to fetus from drugs 
 
O35.5^ - Maternal care for (suspected) damage to 
fetus by drugs (damage to fetus from drug 
addiction) 
655.6^ -  Suspected damage to fetus from radiation O35.6^ - Maternal care for (suspected) damage to 
fetus by radiation 
655.8^ -  Other known or suspected fetal 
abnormality, not elsewhere classified Includes:  
suspected damage to fetus from: environmental 
toxins, intrauterine contraceptive device 
O35.7^ - Maternal care for (suspected) damage to 
fetus by other medical procedures (damage to fetus 
by amniocentesis, biopsy procedures, 
haematological investigation, intrauterine 
contraceptive device, intrauterine surgery) 
655.8^ -  Other known or suspected fetal 
abnormality, not elsewhere classified Includes:  
suspected damage to fetus from: environmental 
toxins, intrauterine contraceptive device 
O35.8^ - Maternal care for other (suspected) fetal 
abnormality and damage (damage to fetus from 
maternal listeriosis, from maternal toxoplasmosis) 
 
655.9^ -  Unspecified 
 
O35.9^ - Maternal care for (suspected) fetal 
abnormality and damage, unspecified 
 
 
 
 
